<SEC-DOCUMENT>0001144204-14-066530.txt : 20141110
<SEC-HEADER>0001144204-14-066530.hdr.sgml : 20141110
<ACCEPTANCE-DATETIME>20141110163253
ACCESSION NUMBER:		0001144204-14-066530
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20140930
FILED AS OF DATE:		20141110
DATE AS OF CHANGE:		20141110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		141209118

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v393002_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended September 30,
2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-decoration: underline; text-align: center"><B><U>Florida</U></B></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-decoration: underline; text-align: center"><B><U>65-0643773</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization)</B></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-decoration: underline; text-align: center"><B><U>20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;large accelerated filer&rdquo;
and &ldquo;accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 45%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 5%; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;(Do not check if a smaller
    reporting company)</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-align: center; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;Yes  &nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>
&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 1, 2014, approximately 93,672,564 shares of the
Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 2pt double"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 79%">&nbsp;</TD>
    <TD STYLE="width: 12%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><B><A HREF="#a_002">PART I &ndash; FINANCIAL INFORMATION</A></B></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><A HREF="#a_001"><B>Cautionary Statement Regarding Forward-Looking Statements</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">ii</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003">Financial Statements (Unaudited)</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_004">Condensed Consolidated Balance Sheets &ndash;<BR> As of September 30, 2014 and December 31, 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_005">Condensed Consolidated Statements of Operations &ndash;<BR> For the Nine Months and the Three Months Ended September 30, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_006">Condensed Consolidated Statement of Changes in Capital Deficiency &ndash;<BR> For the Nine Months Ended September 30, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">3</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><A HREF="#a_007">Condensed Consolidated Statements of Cash Flows &ndash;<BR> For the Nine Months Ended September 30, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.3in"><A HREF="#a_008">Notes to Condensed Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">10</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 3.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">16</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011">Controls and Procedures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_012"><B>PART II &ndash; OTHER INFORMATION</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013">Legal Proceedings</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;1A.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_014">Risk Factors</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_015">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_016">Defaults Upon Senior Securities</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_017">Mine Safety Disclosures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Item&nbsp;5.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_018">Other Information</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;6.</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_019">Exhibits</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_020">Signatures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">20</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms,
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics,
Inc. and its consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix
Ltd., our wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;, and other statements
included elsewhere in this Quarterly Report on Form 10-Q, which are not historical, constitute &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the
future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking
statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with
respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy
of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement
is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking
statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil,
                                         Canada, Australia and other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the supply of drug product pursuant to our supply arrangement with Funda&ccedil;&atilde;o
                                         Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian
                                         MOH;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         the compliance by Fiocruz with its purchase obligations under our supply and technology
                                         transfer agreement which may result in the termination of such agreement which may have
                                         a material adverse effect on our company;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk of significant
                                         delays in the commercial introduction of taliglucerase alfa in the United States, Brazil,
                                         Israel, Canada, Australia and other markets as planned;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to
                                         the acceptance and use of taliglucerase alfa or any of our product candidates, if approved,
                                         by physicians, patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we
                                         will not be able to develop a successful sales and marketing organization for taliglucerase
                                         alfa in Israel or for any other product candidate in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay
                                         in the commencement or completion of our preclinical studies and clinical trials which
                                         may be caused by several factors, including: unforeseen safety issues; determination
                                         of dosing issues; lack of effectiveness during clinical trials; slower than expected
                                         rates of patient recruitment; inability to monitor patients adequately during or after
                                         treatment; inability or unwillingness of medical investigators and institutional review
                                         boards to follow our clinical protocols; or lack of sufficient funding to finance our
                                         clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the
                                         results of our clinical trials will not support the applicable claims of safety or efficacy,
                                         that our product candidates will not have the desired effects or include undesirable
                                         side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on
                                         performance by third party providers of services and supplies, including without limitation,
                                         clinical trial services;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the approval
                                         or the potential rejection of any application filed with or submitted to the regulatory
                                         authorities reviewing taliglucerase alfa outside of the United States, Israel, Brazil,
                                         Canada, Australia and other countries in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish
                                         and maintain strategic license, collaboration and distribution arrangements, and to manage
                                         our relationships with Pfizer Inc., Fiocruz and any other collaborator, distributor or
                                         partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         our ability to make scheduled payments of the principal of, to pay interest on or to
                                         refinance our 2018 convertible notes, or any other indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         our ability to finance our research programs, the expansion of our manufacturing capabilities
                                         and the ongoing costs in the case of delays in regulatory approvals for taliglucerase
                                         alfa outside of the United States, Israel, Brazil, Canada, Australia and other countries
                                         in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation
                                         and filing of applications for regulatory approval of our other product candidates in
                                         the United States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations
                                         with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products
                                         that are competitive to our product candidates may be granted orphan drug status in certain
                                         territories and, therefore, will be subject to potential marketing and commercialization
                                         restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development
                                         of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress
                                         of our research and development activities and our clinical activities with respect to
                                         any product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks
                                         and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product
                                         liability risks, and risks of securing adequate levels of product liability and clinical
                                         trial insurance coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of
                                         infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of
                                         obtaining patents covering our products and processes and in successfully enforcing our
                                         intellectual property rights against third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                         biosimilar legislation and/or healthcare reform in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption
                                         of our operations due to terrorist activities and armed conflict, including as a result
                                         of the disruption of the operations of regulatory authorities, our subsidiaries, our
                                         manufacturing facilities and our customers, suppliers, distributors, collaborative partners,
                                         licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed
under the heading <FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&quot;
</FONT>in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013, and are described from time to time in
the reports we file with the U.S. Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_003"></A>Item&nbsp;1. Financial
Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="a_004"></A><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT><BR>
(U.S. dollars in thousands)<BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">December 31, 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">60,317</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">86,398</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts receivable - Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,091</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,830</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,846</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">DEFERRED CHARGES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,795</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,073</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,620</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,384</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,696</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Liability in connection with collaboration operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,371</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">132,489</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">140,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CAPITAL DEFICIENCY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(47,694</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,946</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,795</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="a_005"></A>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except share data)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">11,517</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,116</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,396</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,284</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">COMPANY&rsquo;S SHARE IN COLLABORATION
    AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,075</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,476</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,798</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,587</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,515</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,909</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">RESEARCH AND DEVELOPMENT EXPENSES
    (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,467</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,052</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,723</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 27pt">Less &ndash; grants and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,146</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,049</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,947</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,086</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">RESEARCH AND
    DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,418</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,637</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">SELLING, GENERAL
    AND ADMINISTRATIVE EXPENSES (2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,289</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,065</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,012</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,780</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,645</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,490</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(153</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,851</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL INCOME</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">216</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL INCOME
    (EXPENSES) &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,351</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(102</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">NET LOSS
    FOR THE PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(21,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">NET LOSS
    PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">WEIGHTED
    AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE &ndash; BASIC AND DILUTED:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,828,851</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,307,170</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,971,572</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,433,502</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">(1) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,198</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">173</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">609</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">(2) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(81</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,255</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN CAPITAL DEFICIENCY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<BR>
    shares</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="15" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 43%; font-weight: bold">Balance at December 31, 2012</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">93,489,809</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">93</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">180,145</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(183,595</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(3,357</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Changes during the nine-month period ended September 30, 2013:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to restricted stock
    award, net of forfeitures of 1,667 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,667</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Exercise of options granted to
    employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2013</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,552,910</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">183,700</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(200,500</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(16,706</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,551,098</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">94</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">184,345</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(211,385</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(26,946</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Changes during the nine-month period ended September 30, 2014:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to restricted stock
    award, net of forfeitures of 1,834 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,834</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Exercise of options granted to
    employees (includes net exercise)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,474</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,474</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2014</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,663,064</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">185,071</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(232,859</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(47,694</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">*</FONT> Represents
amount less than $1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common
Stock, $0.001 par value; Authorized &ndash; as of September 30, 2014 and 2013 - 150,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of the condensed
consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Nine
    Months Ended</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">September
    30, 2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">September
    30, 2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">(21,474</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">(16,905</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Adjustments required
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,453</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Depreciation and write down of fixed assets</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,418</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,689</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Financial expenses (income), net (mainly
    exchange differences)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">869</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(140</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Changes in accrued liability for employee rights
    upon retirement</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">149</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">145</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Gain on amounts funded in respect of employee
    rights upon retirement</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(25</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(26</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Amortization of debt issuance costs and debt
    discount</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">332</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Changes in operating assets and liabilities:</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Decrease in deferred revenues (including
    non-current portion)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6,172</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,393</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Increase in accounts receivable and other
    assets</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(578</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(798</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Decrease (increase) in inventories</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,127</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,538</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in; text-indent: -0.125in">Decrease in accounts payable
and accruals (including long term )</TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,736</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(5,413</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net cash used in operating
    activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(24,407</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(25,911</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Purchase of property and equipment</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(617</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,668</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Investment in restricted deposit</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(93</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Amounts funded in respect
    of employee rights upon retirement, net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(122</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(121</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net cash used in investing
    activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(832</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,831</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net proceeds from issuance of convertible notes</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,930</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Exercise of options</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net cash provided by financing
    activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">66,960</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">EFFECT
    OF EXCHANGE RATE CHANGES ON CASH</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(885</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">144</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0in"><FONT STYLE="font-size: 10pt">NET INCREASE (DECREASE) IN
    CASH AND CASH EQUIVALENTS</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(26,081</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39,362</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">BALANCE
    OF CASH AND CASH <B>EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT BEGINNING OF PERIOD</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">86,398</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">52,035</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">BALANCE
    OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">60,317</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">91,397</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">122</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">187</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Issuance cost related to convertible note offering not
    yet paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">73</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix BioTherapeutics, Inc. (collectively with its
subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused
on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;
</SUP>protein expression system (&ldquo;ProCellEx&rdquo;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary
under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application
process in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On May 1, 2012, the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement
therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase
alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase
alfa was also approved by the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012, by the Brazilian Ministry
of Health (the &ldquo;Brazilian MOH&rdquo;) in March 2013 and by the applicable regulatory authorities of certain other countries,
including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved
by the FDA or any other major regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In August 2014, the FDA approved taliglucerase alfa
for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia
and Canada but in no other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Taliglucerase alfa is being marketed in the United
States under the brand name ELELYSO&trade; by Pfizer Inc. (&ldquo;Pfizer&rdquo;), the Company&rsquo;s commercialization partner,
as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &ldquo;Pfizer Agreement&rdquo;).
The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. granted Pfizer an exclusive, worldwide
license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since
2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities
for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million
in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related
milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&rsquo;s
approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits
or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with
respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive
marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts
that may be deducted from gross sales for certain expenses and costs of goods sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On June 18, 2013, Protalix Ltd. entered into a Supply
and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;),
an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term
of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete
the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz
the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense,
and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has
committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement.
In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year.
Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at
least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">During the nine months ended September 30, 2014, the
Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In September 2014, CONITEC, the National Commission
for Incorporation of Technologies in Brazil&rsquo;s Unified Healthcare System, announced that it had decided to give a positive
funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established
that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil. The Company anticipates that CONITEC&rsquo;s resolution will be implemented around the end of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">To facilitate the arrangement with Fiocruz, Pfizer
amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization
and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as
defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil
on Protalix Ltd.&rsquo;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. is required to pay a fee equal to 5%
of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement
pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to
the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approvals from the FDA, the Israeli
MOH and the Brazilian MOH, marketing approval has been granted to ELELYSO in Canada, Australia, Mexico, Chile, Uruguay and Albania.
In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional
countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements
or named patient provisions in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to taliglucerase alfa, the Company is working on the development of certain other products
using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approval of taliglucerase alfa for
marketing in the United States, Israel, Brazil and other countries, successful completion of the Company&rsquo;s development programs
and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products
internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its
operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process
for each of its product candidates during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Obtaining marketing approval with respect to any product
candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required
to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K
for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance
sheet at December 31, 2013 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS does not include 7,879,601 and 18,781,572
shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion
of the convertible notes (issued in September 2013) for the nine months ended September 30, 2013 and 2014, respectively, and 8,817,090
and 18,661,182 shares of Common Stock for the three months ended September 30, 2013 and 2014, respectively, because the effect
would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Inventory at September 30, 2014 and December&nbsp;31,
2013 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">September 30,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Raw materials</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,660</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,342</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,830</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES </B>(continued)<B>: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">During the nine months ended September 30, 2014,
the Company recorded approximately $1.6 million for write-down of inventory under cost of revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to
Level 1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The fair value of the convertible notes as of September
30, 2014 is approximately $59.4 million based on a level 2 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">During the nine months ended September 30, 2014, the
Company issued a total of 113,800 shares of Common Stock in connection with the exercise of a total of 116,801 options by certain
employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On July 24, 2014, the Company&rsquo;s
                                                                                 Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase 150,000
                                                                                 shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $3.37 per share.
                                                                                 The                                                                                  options vest over a three-year period;
                                                                                 the first 50,000 shares vest on the first anniversary of the grant date and the
                                                                                 remaining shares vest in eight equal quarterly increments over the subsequent two year period. Vesting of the options will
                                                                                 be                                                                                  accelerated in full upon a Corporate
                                                                                 Transaction or a Change in Control, as those terms are defined in the
                                                                                 Company&rsquo;s 2006 Stock Incentive Plan. The Company estimated the fair value of the option on the date of  board approval
                                                                                 using the                                                                                  Black-Scholes option-pricing model
                                                                                 to be approximately $293,000.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">On September 28, 2014, the Company&rsquo;s Board of Directors approved, subject to certain
                                                                                 terms and conditions, the grant of a 10-year option to purchase 900,000 shares of Common Stock to its newly appointed
                                                                                 President                                                                                  and Chief Executive Officer with
                                                                                 an exercise price of $2.37 per share. The options vest over a four-year period in 16 equal
                                                                                 quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in
                                                                                 Control,                                                                                  as those terms are defined in the
                                                                                 Company&rsquo;s 2006 Stock Incentive Plan. The Company estimated the fair value of the
                                                                                 option on the date of    board approval
                                                                                 using the Black-Scholes option-pricing model to be approximately $1,236,490.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_009"></A>Item&nbsp;2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated
financial statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the
year ended December 31, 2013. Some of the information contained in this discussion and analysis, particularly with respect to
our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.
You should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2013 for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter and biosimilar versions
of recombinant therapeutic proteins, based on our plant cell-based expression technology, that primarily target large, established
pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex
therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We
believe ProCellEx will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to
existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent
versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process
is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic
proteins. We are now also applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins,
with the first two product candidates being glucocerebrosidase and antiTNF fusion protein, and we are performing research focused
on the expression, and subsequently the oral delivery, of antibodies in plant cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the U.S. Food and Drug Administration, or the
FDA, approved for sale our first commercial product, taliglucerase alfa for injection, which is being marketed in the United States
and Israel under the brand name ELELYSO, as an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients
with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved by the Brazilian National
Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria, or ANVISA) in March 2013, by the Israeli Ministry of Health,
or the Israeli MOH, in September 2012, by the Australian Therapeutic Goods Administration (TGA) in May 2014, by Health Canada
in May 2014 and by the applicable regulatory authorities in Uruguay, Mexico and Chile. Taliglucerase alfa is being marketed under
the name UPLYSO<FONT STYLE="font-size: 10pt"> </FONT>in Brazil and certain other Latin American countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2014, the FDA approved ELELYSO for injection for pediatric patients. Prior to this approval,
ELEYSO was approved for pediatric indications in Australia and Canada but in no other jurisdictions. In September 2014, CONITEC,
the National Commission for Incorporation of Technologies in Brazil&rsquo;s Unified Healthcare System, announced that it had decided
to give a positive funding recommendation for UPLYSO in the treatment of adult patients with types 1 and 3 Gaucher disease, and
established that UPLYSO will be the first choice for treatment for new adult Gaucher patients in Brazil. We anticipate that CONITEC&rsquo;s
resolution will be implemented around the end of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taliglucerase
alfa is our proprietary, recombinant form of glucocerebrosidase, or GCD, that is produced or expressed through ProCellEx. Taliglucerase
alfa is the first plant cell-based recombinant therapeutic protein to be approved by the FDA or by the regulatory authorities
with jurisdiction over any substantial market. Gaucher disease is a rare and serious lysosomal</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">storage
disorder with severe and debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that
is naturally found in human cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement
by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer
an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those
rights in Israel and in Brazil. We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities
for the continued development efforts for taliglucerase alfa outside of Israel. Protalix Ltd. has been marketing taliglucerase
alfa in Israel since 2013 and in Brazil since January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2013, we entered into a Supply and Technology Transfer
Agreement, or the Brazil Agreement, with Fiocruz, for taliglucerase alfa. The agreement became effective in January 2014. The
technology transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and skills
required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable,
high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the technology transfer is seven years. Under
the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first
two years of the term. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase
alfa per year. Additionally, we are not required to complete the final stage of the technology transfer until Fiocruz purchases
at least approximately $280 million worth of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to naive and switch studies in adults which were successfully completed, we conducted a 12-month clinical trial of na&iuml;ve
and switchover pediatric patients, which was successfully completed in 2012. The application for our approved pediatric indication
was based on the data from this study</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif"> Patients in the extension
trials are still being treated with taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, Brazil, Israel and Chile. In France, Gaucher patients are being treated with taliglucerase
alfa through an Autorisation Temporaire d&rsquo;Utilisation (ATU), or Temporary Authorization for Use, a regulatory mechanism
used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine
public health need exists. In addition taliglucerase alfa is currently being provided to Gaucher patients under special access
agreements or named patient provisions in certain countries. Hundreds of patients, in the aggregate, have been treated with taliglucerase
alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) PRX-102, a therapeutic protein candidate for the treatment
of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in a phase I/II clinical trial. We expect to complete
patient recruitment and report interim results around year end, and to report final results during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) PRX-112, an orally administered glucocerebrosidase enzyme
for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot
cells, currently the subject of a phase IIa clinical trial treating 10 Gaucher patients for 28 days. Enrollment of required patients
for this trial has been completed and we expect to report results by the end of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
PRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-administered treatment for immune mediated disorders using plant cells as a natural capsule for the expressed
protein. We are currently conducting preclinical studies on oral antiTNF for several attractive indications, and we expect to
initiate a phase I clinical trial of oral anti TNF for the oral treatment of autoimmune diseases around year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1 under development for the treatment of cystic fibrosis, to be administered by inhalation. We have already held a pre-IND meeting
with the FDA regarding this product candidate, and plan to file an IND with the FDA following the completion of toxicology studies
around year end, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold
the worldwide commercialization rights to all of our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
We have built an internal marketing team designed to serve the Israeli and Brazilian market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union
and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition,
we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and
results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting
principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements,
as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and
judgments, including those described in greater detail below. We base our estimates on historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September 30, 2014 compared to the
three months ended September 30, 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $2.4&nbsp;million during the three
months ended September 30, 2014, an increase of approximately $112,000, or 5%, compared to revenues of $2.3&nbsp;million for
the three months ended September 30, 2013. Revenues for the three months ended September 30, 2014 included $1.3 million of sales
of ELEYSO in Israel. Revenues
also represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million in each quarterly
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.3 million as our share of net income
from the collaboration under the Pfizer Agreement during the three months ended September 30, 2014, compared to revenues of $1.1
million for the three months ended September 30, 2013. Our share in the collaboration agreement recorded during the three months
ended September 30, 2014 represents our 40% share of the net income generated during the period, which was primarily the result
of revenues generated by Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions
of the Pfizer Agreement, we record income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa
and related expenses incurred based on reports we receive from Pfizer summarizing the results of the collaborative activities
under the Pfizer Agreement for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $1.8 million for the three months ended
September 30, 2014, an increase of approximately $211,000, or 13%, compared to $1.6 million for the three months ended September
30, 2013. Cost of revenues for the three months ended September 30, 2014 and September 30, 2013 consists mainly certain fixed
costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser
extent, the direct cost of products we sold in Israel for which revenues were recognized during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $6.1&nbsp;million for
the three months ended September 30, 2014, an increase of $468,000, or 8%, from $5.6&nbsp;million for the three months ended September
30, 2013. The increase resulted primarily from an increase of $1.2 million in expenses related to subcontractors and consultants
in connection with preclinical and clinical activities, which was partially offset by a decrease of $399,000 in costs related
to materials and a decrease in $181,000 in salaries expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and administrative expenses
were $2.0&nbsp;million for the three months ended September 30, 2014, an increase of $232,000, or 13%, from $1.8&nbsp;million
for the three months ended September 30, 2013. The increase resulted primarily from marketing expenses of approximately $539,000
which was partially offset by a decrease of approximately $385,000 in salaries expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses, net, was
$1.8 million for the three months ended September 30, 2014, compared to financial expense of $102,000 for the three months
ended September 30, 2013. Financial expenses resulted primarily from interest expense of 888,000 for the 4.5% convertible
note and as a result of the devaluation of the New Israeli Shekel against the U.S. dollar during the period in the amount of
$913,000, which was partially offset by financial income which resulted primarily from interest earned on short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nine months ended September 30, 2014 compared to the
nine months ended September 30, 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $11.5&nbsp;million during the nine
months ended September 30, 2014, an increase of $3.4 million, or 42%, compared to revenues of $8.1&nbsp;million for the nine months
ended September 30, 2013. Revenues for the nine months ended September 30, 2014 include $3.8 million of products sold in Israel,
$3.5 million in Brazil and $1.4 million in connection with products we delivered at cost to Pfizer under the Pfizer Agreement.
Revenues also represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million
in each quarterly period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $2.3 million as our share of net income
from the collaboration under the Pfizer Agreement during the nine months ended September 30, 2014 and September 30, 2013. Our
share in the collaboration agreement recorded during the nine months ended September 30, 2014 represents our 40% share of the
net income generated during the period, which was primarily the result of revenues generated by Pfizer in the United States which
exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement, we record income or loss equal
to 40% of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive
from Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $7.5 million for the nine months ended
September 30, 2014, an increase of $3.6 million, or 93%, compared to cost of revenues of $3.8 million for the nine months ended
September 30, 2013. Cost of revenues for the nine months ended September 30, 2014 consists of the costs of the $1.0 million of
products we delivered at cost to Pfizer under the Pfizer Agreement, write-down of inventory of $1.6 million, and certain fixed
costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser
extent, the direct cost of products we sold in Israel and Brazil for which revenues were recognized during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $17.1&nbsp;million for
the nine months ended September 30, 2014 and $17.4 million for the nine months ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses for our various
development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and administrative expenses
were $7.3&nbsp;million for the nine months ended September 30, 2014, an increase of $1.2 million, or 20%, from $6.1&nbsp;million
for the nine months ended September 30, 2013. The increase resulted primarily from sales and marketing expenses of approximately
$1.8 million, primarily in connection with sales in Brazil, which was partially offset by a decrease of $491,000 in salaries expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses were $3.4 million for
the nine months ended September 30, 2014, compared to financial income of $63,000 for the nine months ended September
30, 2013. Financial expenses resulted primarily from interest expense of $2.7 million for the 4.5% convertible note and from
the devaluation of the New Israeli Shekel against the U.S. dollar in the amount of $800,000, which was partially offset by financial
income which resulted primarily from interest earned on short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures which supersedes our product sales revenue, we have not been profitable and have generated operating
losses since our inception with the exception of the quarter ended June 30, 2012 due to the $25.0 million milestone payment we
received from Pfizer in connection with FDA approval of taliglucerase alfa in that period. To date, we have funded our operations
primarily with proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and ordinary shares of Protalix
Ltd., and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with the sale of such
shares, through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection
with an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we generated gross
proceeds of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September 18, 2013, we completed
a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including
$9.0 million aggregate principal amount of Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option,
which was exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
November 2009, Pfizer paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement
and subsequently paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.&rsquo;s meeting a certain milestone. Protalix
Ltd. also received a milestone payment of $25.0 in connection with the FDA&rsquo;s approval of taliglucerase alfa in May 2012.
Protalix Ltd. is also entitled to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase
alfa (except in Israel and Brazil). In calculat</FONT>ing net profits there are certain agreed upon limits on the amounts that
may be deducted from gross sales for certain expenses and costs of goods sold. Pfizer has also paid Protalix Ltd. $8.3 million
in connection with the successful achievement of certain milestones under the Clinical Development Agreement between Pfizer and
Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was
$24.4&nbsp;million for the nine months ended September 30, 2014. The net loss for the nine months ended September 30, 2014 of
$21.5 million was further increased by a decrease of $6.2 million in deferred revenues, and a decrease of $1.7 million in
accounts payable and accruals, but was partially offset by depreciation expense of $2.4 million and a decrease of $1.1
million in inventories. Net cash used in investing activities for the nine months ended September 30, 2014 was $832,000 and
consisted primarily of purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations
was $25.9&nbsp;million for the nine months ended September 30, 2013. The net loss for the nine months ended September 30,
2013 of $16.9 million was further increased by a decrease of $5.4 million in deferred revenues, a decrease of $5.4 million
in accounts payable and accruals and an increase of $3.5 million in inventories, but was partially offset by share based
compensation of $3.5 million and $2.7 million in depreciation. Net cash used in investing activities for the nine months
ended September 30, 2013 was $1.8 million and consisted primarily of purchases of property and equipment. Net cash provided
by financing activities was $67.0 million, consisting primarily of net proceeds from our offering of 2018 4.5% convertible
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in
the near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer&rsquo;s commercialization
efforts for taliglucerase alfa in the United States and as our commercialization efforts for taliglucerase alfa in Brazil and
Israel progress, and as taliglucerase alfa is launched by Pfizer in other countries in which taliglucerase alfa was recently approved.
We also anticipate that we will generate additional revenues after additional anticipated marketing approvals of taliglucerase
alfa are granted in new countries. We expect to continue to incur significant research and development expenses, including expenses
related primarily to the clinical trials of PRX-102 and oral glucocerebrosidase and the advancement of PRX-106 and our other product
candidates into clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required
to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated
with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital
outlays and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer&rsquo;s commercialization efforts for taliglucerase alfa in the United States
and other countries, the progress of our commercialization efforts for taliglucerase alfa in Brazil and Israel and, if anticipated
marketing approvals of taliglucerase alfa are granted in other jurisdictions, the progress of Pfizer&rsquo;s global commercialization
efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review
of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims
and other intellectual property rights, the number and development requirements of other product candidates that we pursue and
the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through public or private equity offerings, debt financings, corporate collaboration, licensing arrangements or through other
means. We currently do not have any commitments for future external funding. We may need to raise additional funds more quickly
if one or more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly
than we presently anticipate. We may also decide to raise additional funds even before we need them if the conditions for raising
capital are favorable. Any sale of additional equity or debt securities will likely result in dilution to our shareholders. The
incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict
our operations. Additional equity or debt financing, grants or corporate collaboration and licensing arrangements may not be available
on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate
our research and development programs, reduce our planned commercialization efforts or obtain funds through arrangements with
collaborators or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to
develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the nine and three months ended September 30, 2014 or the nine and three months ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine and three months ended September 30, 2014 or the nine and three months ended
September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September 30, 2014 and September 30, 2013.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the
currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50%
of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided
in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are
remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical
exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which
they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our costs, including salaries, expenses and office
expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in
Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended <BR>September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 0">Average rate for period</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3.491</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3.639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3.611</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Rate at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects
due to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve
principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances
primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes
in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains
may decline in the future as a result of changes in the financial markets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the
effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this
Quarterly Report on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management,
including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures
designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this
Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation,
our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified
by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to
their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within
a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty
and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of
some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls
is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness
to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration
in the degree of compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September 30,
2014 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B><A NAME="a_012"></A>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_013"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_014"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the three months ended September 30, 2014. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_018"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_019"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Incorporated by Reference</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit</B><BR>
    <B>Number</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit Description</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: Black 1pt solid; text-align: center"><B>Form</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: center"><B>File<BR>
 Number</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Date</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Filed</B><BR>
    <B>Herewith</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended and Restated Articles of Incorporation of the
        Company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        June 9, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        December 13, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        December 26, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        February 26, 2007</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">February 28, 2013</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement with Moshe Manor dated September 28, 2014</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">September 29, 2014</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">31.1</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section
    302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive
    Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial
    Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 41%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 10, 2014</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 10, 2014</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer, Treasurer and Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v393002_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 10, 2014</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">President and Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v393002_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 10, 2014</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v393002_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2014 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 10, 2014</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Moshe Manor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">President and Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v393002_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2014 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 10, 2014</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Vice President and Chief Financial
        Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20140930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:plx="http://www.protalix.com/20140930">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20140930.xsd" />
  <xbrli:context id="I20140630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014_3M">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013_3M">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014_3M_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013_3M_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014_3M_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013_3M_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q1_1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20130630_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20130630_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20130630_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20130630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014Q1_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20140630_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20140630_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20140630_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_3M">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009_3M_ScenarioTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_6M_ScenarioThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">plx:ScenarioThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20140630_ProtalixBioTherapeuticsIncorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20140630_PfizerIncorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I20130618_ProtalixLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013_1M_ProtalixLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>
      <xbrli:endDate>2013-06-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q2YTD_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014Q2YTD_EmployeeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">plx:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-23</xbrli:startDate>
      <xbrli:endDate>2014-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-27</xbrli:startDate>
      <xbrli:endDate>2014-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>plx:item</xbrli:measure>
  </xbrli:unit>
  <us-gaap:LongTermDebtNoncurrent id="Tag1" contextRef="I20140630" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies id="Tag2" contextRef="I20140630" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingencies id="Tag3" contextRef="I2013" unitRef="USD" xsi:nil="true" />
  <us-gaap:InventoryNet id="Tag4" contextRef="I20140630" unitRef="USD" decimals="-3">6830000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="Tag5" contextRef="I2013" unitRef="USD" decimals="-3">7957000</us-gaap:InventoryNet>
  <us-gaap:AssetsCurrent id="Tag6" contextRef="I20140630" unitRef="USD" decimals="-3">71208000</us-gaap:AssetsCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="Tag7" contextRef="I20140630" unitRef="USD" decimals="-3">2069000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="Tag8" contextRef="I2013" unitRef="USD" decimals="-3">1457000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:StockholdersEquity id="Tag9" contextRef="I2013" unitRef="USD" decimals="-3">-26946000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag10" contextRef="I20140630" unitRef="USD" decimals="-3">84795000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag11" contextRef="I2013" unitRef="USD" decimals="-3">113333000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag12" contextRef="I2013" unitRef="USD" decimals="-3">86398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="Tag13" contextRef="I20140630" unitRef="USD" decimals="-3">1992000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="Tag14" contextRef="I2013" unitRef="USD" decimals="-3">2091000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag15" contextRef="I20140630" unitRef="USD" decimals="-3">108105000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="Tag16" contextRef="I2013" unitRef="USD" decimals="-3">113583000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities id="Tag17" contextRef="I20140630" unitRef="USD" decimals="-3">132489000</us-gaap:Liabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag18" contextRef="I20140630" unitRef="USD" decimals="-3">60317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Liabilities id="Tag19" contextRef="I2013" unitRef="USD" decimals="-3">140279000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity id="Tag20" contextRef="I20140630" unitRef="USD" decimals="-3">-47694000</us-gaap:StockholdersEquity>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag21" contextRef="I2013" unitRef="USD" decimals="-3">67048000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag22" contextRef="I20140630" unitRef="USD" decimals="-3">38373000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag23" contextRef="I2013" unitRef="USD" decimals="-3">41796000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag24" contextRef="I2013" unitRef="USD" decimals="-3">2371000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag25" contextRef="I20140630" unitRef="USD" decimals="-3">2373000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Tag26" contextRef="I2013" unitRef="USD" decimals="-3">2368000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag27" contextRef="I2013" unitRef="USD" decimals="-3">12073000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag28" contextRef="I20140630" unitRef="USD" decimals="-3">6620000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag29" contextRef="I2013" unitRef="USD" decimals="-3">9369000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag30" contextRef="I20140630" unitRef="USD" decimals="-3">24384000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag31" contextRef="I2013" unitRef="USD" decimals="-3">26696000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="Tag32" contextRef="I20140630" unitRef="USD" decimals="-3">67359000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredCosts id="Tag33" contextRef="I2013" unitRef="USD" decimals="-3">141000</us-gaap:DeferredCosts>
  <us-gaap:Assets id="Tag34" contextRef="I20140630" unitRef="USD" decimals="-3">84795000</us-gaap:Assets>
  <us-gaap:Assets id="Tag35" contextRef="I2013" unitRef="USD" decimals="-3">113333000</us-gaap:Assets>
  <us-gaap:AccountsPayableTradeCurrent id="Tag36" contextRef="I20140630" unitRef="USD" decimals="-3">3578000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="Tag37" contextRef="I2013" unitRef="USD" decimals="-3">5254000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="Tag38" contextRef="I20140630" unitRef="USD" decimals="-3">14186000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AssetsCurrent id="Tag39" contextRef="I2013" unitRef="USD" decimals="-3">97903000</us-gaap:AssetsCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag40" contextRef="I20140630" unitRef="USD" decimals="-3">1621000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Tag41" contextRef="I2013" unitRef="USD" decimals="-3">1578000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag42" contextRef="I20140630" unitRef="USD" decimals="-3">11846000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag43" contextRef="I2013" unitRef="USD" decimals="-3">13711000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredCosts id="Tag44" contextRef="I20140630" unitRef="USD" decimals="-3">120000</us-gaap:DeferredCosts>
  <us-gaap:Revenues id="Tag45" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">11517000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag46" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">8116000</us-gaap:Revenues>
  <plx:OtherGainsLosses id="Tag47" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">2259000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="Tag48" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">2275000</plx:OtherGainsLosses>
  <us-gaap:CostOfRevenue id="Tag49" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">7476000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag50" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">3876000</us-gaap:CostOfRevenue>
  <us-gaap:OtherNonoperatingIncome id="Tag51" contextRef="D2013_3M" unitRef="USD" decimals="-3">29000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingExpense id="Tag52" contextRef="D2013_3M" unitRef="USD" decimals="-3">131000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:Revenues id="Tag53" contextRef="D2014_3M" unitRef="USD" decimals="-3">2396000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag54" contextRef="D2013_3M" unitRef="USD" decimals="-3">2284000</us-gaap:Revenues>
  <plx:OtherGainsLosses id="Tag55" contextRef="D2014_3M" unitRef="USD" decimals="-3">1311000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="Tag56" contextRef="D2013_3M" unitRef="USD" decimals="-3">1075000</plx:OtherGainsLosses>
  <us-gaap:OtherNonoperatingIncome id="Tag57" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">216000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingExpense id="Tag58" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">153000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag59" contextRef="D2014_3M" unitRef="Shares" decimals="0">92971572</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag60" contextRef="D2013_3M" unitRef="Shares" decimals="0">92433502</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag61" contextRef="D2014_3M_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">173000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag62" contextRef="D2013_3M_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">609000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag63" contextRef="D2014_3M_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">-67000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag64" contextRef="D2013_3M_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">345000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag65" contextRef="D2014_3M" unitRef="USD" decimals="-3">-1802000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag66" contextRef="D2013_3M" unitRef="USD" decimals="-3">-102000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag67" contextRef="D2014_3M" unitRef="USD" decimals="-3">-8010000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag68" contextRef="D2013_3M" unitRef="USD" decimals="-3">-5747000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag69" contextRef="D2014_3M" unitRef="USDPerShare" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag70" contextRef="D2013_3M" unitRef="USDPerShare" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag71" contextRef="D2014_3M" unitRef="USD" decimals="-3">2012000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag72" contextRef="D2013_3M" unitRef="USD" decimals="-3">1780000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag73" contextRef="D2014_3M" unitRef="USD" decimals="-3">-6208000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag74" contextRef="D2013_3M" unitRef="USD" decimals="-3">-5645000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="Tag75" contextRef="D2014_3M" unitRef="USD" decimals="-3">1851000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag76" contextRef="D2014_3M" unitRef="USD" decimals="-3">49000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag77" contextRef="D2014_3M" unitRef="USD" decimals="-3">8052000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag78" contextRef="D2013_3M" unitRef="USD" decimals="-3">7723000</us-gaap:ResearchAndDevelopmentExpense>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag79" contextRef="D2014_3M" unitRef="USD" decimals="-3">1947000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag80" contextRef="D2013_3M" unitRef="USD" decimals="-3">2086000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag81" contextRef="D2014_3M" unitRef="USD" decimals="-3">6105000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag82" contextRef="D2013_3M" unitRef="USD" decimals="-3">5637000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag83" contextRef="D2014Q2YTD_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">-81000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag84" contextRef="D2013Q2YTD_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">1255000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:CostOfRevenue id="Tag85" contextRef="D2014_3M" unitRef="USD" decimals="-3">1798000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="Tag86" contextRef="D2013_3M" unitRef="USD" decimals="-3">1587000</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit id="Tag87" contextRef="D2014_3M" unitRef="USD" decimals="-3">1909000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="Tag88" contextRef="D2013_3M" unitRef="USD" decimals="-3">1772000</us-gaap:GrossProfit>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag89" contextRef="D2014Q2YTD" unitRef="USDPerShare" decimals="2">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag90" contextRef="D2013Q2YTD" unitRef="USDPerShare" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag91" contextRef="D2014Q2YTD" unitRef="Shares" decimals="0">92828851</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag92" contextRef="D2013Q2YTD" unitRef="Shares" decimals="0">92307170</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag93" contextRef="D2014Q2YTD_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">764000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag94" contextRef="D2013Q2YTD_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">2198000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherNonoperatingExpense id="Tag95" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">3490000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag96" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">139000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NonoperatingIncomeExpense id="Tag97" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-3351000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag98" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">63000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag99" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-21474000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag100" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-16905000</us-gaap:NetIncomeLoss>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag101" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">17134000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="Tag102" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">17418000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag103" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">7289000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag104" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">6065000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="Tag105" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-18123000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag106" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-16968000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GrossProfit id="Tag107" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">6300000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="Tag108" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">6515000</us-gaap:GrossProfit>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag109" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">23280000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag110" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">23467000</us-gaap:ResearchAndDevelopmentExpense>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag111" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">6146000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="Tag112" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">6049000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag113" contextRef="I20140630" unitRef="USD" decimals="-3">1660000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="Tag114" contextRef="I2013" unitRef="USD" decimals="-3">2342000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag115" contextRef="I20140630" unitRef="USD" decimals="-3">0</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Tag116" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;Inventory at September 30, 2014 and December 31, 2013 consisted of the following:&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;table align="center" cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; clear: both; margin-left: 1in; width: 85%; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&lt;strong&gt;September&amp;#160;30&lt;/strong&gt;,&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&lt;strong&gt;December&amp;#160;31&lt;/strong&gt;,&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; width: 70%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" align="center" valign="bottom" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" align="center" valign="bottom" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="6" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;(U.S. dollars in thousands)&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Raw materials&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;1,660&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;2,342&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Work in progress&lt;/td&gt;
&lt;td style=" font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;92&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Finished goods&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;5,170&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;5,523&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Total inventory&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;6,830&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;7,957&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryDisclosureTextBlock id="Tag117" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;Inventory at September 30, 2014 and December 31, 2013 consisted of the following:&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;table align="center" cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; clear: both; margin-left: 1in; width: 85%; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&lt;strong&gt;September&amp;#160;30&lt;/strong&gt;,&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&lt;strong&gt;December&amp;#160;31&lt;/strong&gt;,&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; width: 70%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" align="center" valign="bottom" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;strong&gt;2014&lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2" align="center" valign="bottom" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="6" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;(U.S. dollars in thousands)&lt;/td&gt;
&lt;td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Raw materials&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;1,660&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;2,342&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Work in progress&lt;/td&gt;
&lt;td style=" font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;92&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Finished goods&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;5,170&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;5,523&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;tr style=" vertical-align: bottom; font-size: 10pt;"&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;Total inventory&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;6,830&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"&gt;&lt;font&gt;7,957&lt;/font&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;"&gt;During the nine months ended September 30, 2014, the Company recorded approximately $&lt;font&gt;1.6&lt;/font&gt; million for write-down of inventory under cost of revenues.&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="Tag118" contextRef="I2013" unitRef="USD" decimals="-3">92000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag119" contextRef="I20140630" unitRef="USD" decimals="-3">5170000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag120" contextRef="I2013" unitRef="USD" decimals="-3">5523000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryWriteDown id="Tag121" contextRef="D2014Q2YTD" unitRef="USD" decimals="-5">1600000</us-gaap:InventoryWriteDown>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag122" contextRef="D2013Q2YTD" unitRef="Shares" decimals="0">7879601</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag123" contextRef="D2014Q2YTD" unitRef="Shares" decimals="0">18781572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag124" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;strong&gt;NOTE 3 &amp;#150; FAIR VALUE MEASUREMENT&lt;/strong&gt;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into &lt;font&gt;three&lt;/font&gt; broad levels, which are described below:&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;Level &lt;font&gt;1&lt;/font&gt;: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level &lt;font&gt;1&lt;/font&gt; inputs.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;Level &lt;font&gt;2&lt;/font&gt;: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;Level &lt;font&gt;3&lt;/font&gt;: Unobservable inputs are used when little or &lt;font&gt;no&lt;/font&gt; market data is available. The fair value hierarchy gives the lowest priority to Level &lt;font&gt;3&lt;/font&gt; inputs.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"&gt;&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;The fair value of the convertible notes as of &lt;/font&gt;September 30, 2014 is approximately $&lt;font&gt;59.4&lt;/font&gt; million based on a level 2 measurement.&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag125" contextRef="I20140630" unitRef="USD" decimals="-5">59400000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <dei:TradingSymbol id="Tag126" contextRef="D2014Q2YTD">PLX</dei:TradingSymbol>
  <plx:NumberOfSubsidiaries id="Tag127" contextRef="D2014Q2YTD" unitRef="Pure" decimals="0">2</plx:NumberOfSubsidiaries>
  <us-gaap:ProceedsFromCollaborators id="Tag128" contextRef="D2009_3M" unitRef="USD" decimals="-5">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="Tag129" contextRef="D2009_3M_ScenarioTwoMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromCollaborators>
  <plx:MilestonePayment id="Tag130" contextRef="D2012_6M_ScenarioThreeMember" unitRef="USD" decimals="-5">25000000</plx:MilestonePayment>
  <plx:CollaborativeArrangementProfitSharePercentage id="Tag131" contextRef="I20140630_ProtalixBioTherapeuticsIncorporationMember" unitRef="Pure" decimals="2">0.40</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="Tag132" contextRef="I20140630_PfizerIncorporationMember" unitRef="Pure" decimals="2">0.60</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:SupplyCommitmentPerYear id="Tag133" contextRef="I20130618_ProtalixLtdMember" unitRef="USD" decimals="-6">40000000</plx:SupplyCommitmentPerYear>
  <us-gaap:ProceedsFromSaleOfOtherAssets1 id="Tag134" contextRef="D2014Q2YTD" unitRef="USD" decimals="-5">3500000</us-gaap:ProceedsFromSaleOfOtherAssets1>
  <plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits id="Tag135" contextRef="D2013_1M_ProtalixLtdMember" unitRef="USD" decimals="-5">12500000</plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag136" contextRef="I20140630" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Tag137" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;strong&gt;NOTE &lt;font&gt;1&lt;/font&gt; - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" ; font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top; font-size: 10pt;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top;"&gt;
&lt;td style=" text-align: right; width: 6%;"&gt;&lt;font style=" font-size: 10pt;"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style=" width: 94%;"&gt;&lt;strong&gt;&lt;font style=" font-size: 10pt;"&gt; &amp;#160;&amp;#160;&amp;#160;General&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&lt;sup&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#147;ProCellEx&amp;#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's &lt;font&gt;two&lt;/font&gt; subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type &lt;font&gt;1&lt;/font&gt; Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &amp;#147;Israeli MOH&amp;#148;) in September 2012, by the Brazilian Ministry of Health (the &amp;#147;Brazilian MOH&amp;#148;) in  March 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.&lt;/font&gt;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;#153; by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &amp;#147;Pfizer Agreement&amp;#148;). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO&amp;#153;.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since &lt;font&gt;2014&lt;/font&gt;, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $&lt;font&gt;60.0&lt;/font&gt; million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $&lt;font&gt;5.0&lt;/font&gt; million clinical development-related milestone payment. The Company received during &lt;font&gt;2012&lt;/font&gt; an additional $&lt;font&gt;25.0&lt;/font&gt; million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a &lt;font&gt;40&lt;/font&gt;% and &lt;font&gt;60&lt;/font&gt;% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt;



&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is &lt;font&gt;seven&lt;/font&gt; years and the agreement may be extended for an additional &lt;font&gt;five&lt;/font&gt;-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in &lt;font&gt;four&lt;/font&gt; stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa during the first &lt;font&gt;two&lt;/font&gt; years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of &lt;font&gt;2014&lt;/font&gt;.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;During the nine months ended September 30, 2014, the Company recorded revenues of approximately $&lt;font&gt;3.5&lt;/font&gt; million from the sale of products to Fiocruz.&lt;br/&gt;
&lt;br/&gt;
In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil. The Company anticipates that CONITEC's resolution will be implemented around the end of 2014.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $&lt;font&gt;12.5&lt;/font&gt; million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix Ltd. is required to pay a fee equal to &lt;font&gt;5&lt;/font&gt;% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to &lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;ELELYSO&lt;/font&gt; in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;br/&gt;
&lt;br/&gt;
&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/font&gt;&lt;/p&gt;



&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;/div&gt;

&lt;div&gt;

&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top; font-size: 10pt;"&gt;
&lt;td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"&gt;&lt;strong&gt; &amp;#160;&amp;#160;Basis of Presentation&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#147;GAAP&amp;#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;/div&gt;

&lt;div&gt;

&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top; font-size: 10pt;"&gt;
&lt;td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"&gt;&lt;strong&gt; &amp;#160;&amp;#160;Net loss per share&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Diluted LPS does not include &lt;font&gt;7,879,601&lt;/font&gt; and &lt;font&gt;18,781,572&lt;/font&gt; shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2013 and &lt;font&gt;2014&lt;/font&gt;, respectively, and &lt;font&gt;8,817,090 &lt;/font&gt;and &lt;font&gt;18,661,182 &lt;/font&gt;shares of Common Stock for the three months ended September 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;/div&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Tag138" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top; font-size: 10pt;"&gt;
&lt;td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"&gt;&lt;strong&gt; &amp;#160;&amp;#160;Basis of Presentation&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#147;GAAP&amp;#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag139" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">140000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag140" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">149000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="Tag141" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">145000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag142" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top; font-size: 10pt;"&gt;
&lt;td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt;
&lt;td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"&gt;&lt;strong&gt; &amp;#160;&amp;#160;Net loss per share&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Basic and diluted loss per share (&amp;#147;LPS&amp;#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $&lt;font&gt;0.001&lt;/font&gt; per share (the &amp;#147;Common Stock&amp;#148;) outstanding for each period.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Diluted LPS does not include &lt;font&gt;7,879,601&lt;/font&gt; and &lt;font&gt;18,781,572&lt;/font&gt; shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2013 and &lt;font&gt;2014&lt;/font&gt;, respectively, and &lt;font&gt;8,817,090 &lt;/font&gt;and &lt;font&gt;18,661,182 &lt;/font&gt;shares of Common Stock for the three months ended September 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <plx:NatureOfOperationsPolicyTextBlock id="Tag143" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div class="CursorPointer"&gt;
&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;"&gt;
&lt;tr style=" vertical-align: top;"&gt;
&lt;td style=" text-align: right; width: 6%;"&gt;&lt;font style=" font-size: 10pt;"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style=" width: 94%;"&gt;&lt;strong&gt;&lt;font style=" font-size: 10pt;"&gt; &amp;#160;&amp;#160;&amp;#160;General&lt;/font&gt;&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#147;Company&amp;#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&lt;sup&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#147;ProCellEx&amp;#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&amp;#147;EMA&amp;#148;) application process in the European Union. The Company's &lt;font&gt;two&lt;/font&gt; subsidiaries are referred to collectively herein as the &amp;#147;Subsidiaries.&amp;#148;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;On May 1, 2012, the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type &lt;font&gt;1&lt;/font&gt; Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &amp;#147;Israeli MOH&amp;#148;) in September 2012, by the Brazilian Ministry of Health (the &amp;#147;Brazilian MOH&amp;#148;) in  March 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.&lt;/font&gt;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;#153; by Pfizer Inc. (&amp;#147;Pfizer&amp;#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &amp;#147;Pfizer Agreement&amp;#148;). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO&amp;#153;.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since &lt;font&gt;2014&lt;/font&gt;, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $&lt;font&gt;60.0&lt;/font&gt; million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $&lt;font&gt;5.0&lt;/font&gt; million clinical development-related milestone payment. The Company received during &lt;font&gt;2012&lt;/font&gt; an additional $&lt;font&gt;25.0&lt;/font&gt; million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a &lt;font&gt;40&lt;/font&gt;% and &lt;font&gt;60&lt;/font&gt;% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt;



&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &amp;#147;Brazil Agreement&amp;#148;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#147;Fiocruz&amp;#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is &lt;font&gt;seven&lt;/font&gt; years and the agreement may be extended for an additional &lt;font&gt;five&lt;/font&gt;-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in &lt;font&gt;four&lt;/font&gt; stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa during the first &lt;font&gt;two&lt;/font&gt; years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $&lt;font&gt;40&lt;/font&gt; million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $&lt;font&gt;280&lt;/font&gt; million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of &lt;font&gt;2014&lt;/font&gt;.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;During the nine months ended September 30, 2014, the Company recorded revenues of approximately $&lt;font&gt;3.5&lt;/font&gt; million from the sale of products to Fiocruz.&lt;br/&gt;
&lt;br/&gt;
In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil. The Company anticipates that CONITEC's resolution will be implemented around the end of 2014.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $&lt;font&gt;12.5&lt;/font&gt; million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Protalix Ltd. is required to pay a fee equal to &lt;font&gt;5&lt;/font&gt;% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to &lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;ELELYSO&lt;/font&gt; in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;br/&gt;
&lt;br/&gt;
&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/font&gt;&lt;/p&gt;



&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;"&gt;&amp;#160;&lt;/p&gt;

&lt;p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;

&lt;p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights id="Tag144" contextRef="I20130618_ProtalixLtdMember" unitRef="USD" decimals="-6">280000000</plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag145" contextRef="D2013_3M" unitRef="Shares" decimals="0">8817090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag146" contextRef="D2014_3M" unitRef="Shares" decimals="0">18661182</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag147" contextRef="D2014Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag148" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">25000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <us-gaap:StockholdersEquity id="Tag149" contextRef="I2013Q1_RetainedEarningsMember" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag150" contextRef="I2013Q1_1" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag151" contextRef="D2013Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag152" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag153" contextRef="D2013Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2558000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag154" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">2558000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag155" contextRef="D2013Q2YTD_CommonStockMember" unitRef="Shares" decimals="INF">64768</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag156" contextRef="D2013Q2YTD_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag157" contextRef="D2013Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">102000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag158" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag159" contextRef="D2013Q2YTD_RetainedEarningsMember" unitRef="USD" decimals="-3">-16905000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag160" contextRef="I20130630_CommonStockMember" unitRef="Shares" decimals="INF">93552910</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag161" contextRef="I20130630_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag162" contextRef="I20130630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">183700000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag163" contextRef="I20130630_RetainedEarningsMember" unitRef="USD" decimals="-3">-200500000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag164" contextRef="I20130630" unitRef="USD" decimals="-3">-16706000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Tag165" contextRef="I2014Q1_CommonStockMember" unitRef="Shares" decimals="INF">93551098</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag166" contextRef="I2014Q1_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag167" contextRef="I2014Q1_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">184345000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag168" contextRef="I2014Q1_RetainedEarningsMember" unitRef="USD" decimals="-3">-211385000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag169" contextRef="D2014Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag170" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag171" contextRef="D2014Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">522000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag172" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">522000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag173" contextRef="D2014Q2YTD_CommonStockMember" unitRef="Shares" decimals="INF">113800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag174" contextRef="D2014Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag175" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="Tag176" contextRef="D2014Q2YTD_RetainedEarningsMember" unitRef="USD" decimals="-3">-21474000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="Tag177" contextRef="I20140630_CommonStockMember" unitRef="Shares" decimals="INF">93663064</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag178" contextRef="I20140630_CommonStockMember" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag179" contextRef="I20140630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">185071000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag180" contextRef="I20140630_RetainedEarningsMember" unitRef="USD" decimals="-3">-232859000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Tag181" contextRef="I2013Q1_CommonStockMember" unitRef="Shares" decimals="INF">93489809</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Tag182" contextRef="I2013Q1_CommonStockMember" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag183" contextRef="I2013Q1_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag184" contextRef="D2013Q2YTD_CommonStockMember" unitRef="Shares" decimals="INF">-1667</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="Tag185" contextRef="D2013Q2YTD" unitRef="Shares" decimals="INF">1667</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag186" contextRef="D2014Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesAuthorized id="Tag187" contextRef="I20140630" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag188" contextRef="D2014Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag189" contextRef="D2014Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag190" contextRef="D2014Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag191" contextRef="D2014Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag192" contextRef="I20130630" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:NetIncomeLoss id="Tag193" contextRef="D2013Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag194" contextRef="D2013Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag195" contextRef="D2013Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag196" contextRef="D2013Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesAuthorized id="Tag197" contextRef="I20130630" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Tag198" contextRef="D2013Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Tag199" contextRef="D2013Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag200" contextRef="D2014Q2YTD_CommonStockMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Tag201" contextRef="D2013Q2YTD_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:NetIncomeLoss id="Tag202" contextRef="D2014Q2YTD_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Tag203" contextRef="D2014Q2YTD_CommonStockMember" unitRef="Shares" decimals="INF">-1834</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited id="Tag204" contextRef="D2014Q2YTD" unitRef="Shares" decimals="INF">1834</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag205" contextRef="D2014Q2YTD" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromConvertibleDebt id="Tag206" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">66930000</us-gaap:ProceedsFromConvertibleDebt>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="Tag207" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">150000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:CashlessExerciseOfStockOptions id="Tag208" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">73000</plx:CashlessExerciseOfStockOptions>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag209" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">42000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:ShareBasedCompensation id="Tag210" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">683000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag211" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">3453000</us-gaap:ShareBasedCompensation>
  <plx:DepreciationAmortizationAndAssetImpairment id="Tag212" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">2418000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="Tag213" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">2689000</plx:DepreciationAmortizationAndAssetImpairment>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag214" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-869000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Tag215" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">26000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <us-gaap:AmortizationOfFinancingCosts id="Tag216" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">332000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag217" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-6172000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag218" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-5393000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag219" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">578000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag220" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">798000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories id="Tag221" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-1127000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="Tag222" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">3538000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag223" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-1736000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag224" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-5413000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag225" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-24407000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag226" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-25911000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag227" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">617000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag228" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">1668000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag229" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">93000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag230" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">122000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Tag231" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">121000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag232" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-832000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag233" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">-1831000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag234" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">43000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag235" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">43000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag236" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-885000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag237" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">144000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag238" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">-26081000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag239" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">39362000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag240" contextRef="I2013Q1_1" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag241" contextRef="I20130630" unitRef="USD" decimals="-3">91397000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag242" contextRef="D2014Q2YTD" unitRef="USD" decimals="-3">122000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Tag243" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">187000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <us-gaap:AmortizationOfFinancingCosts id="Tag244" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">15000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag245" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">30000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag246" contextRef="D2013Q2YTD" unitRef="USD" decimals="-3">66960000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="Tag247" contextRef="D2014Q2YTD_EmployeeMember" unitRef="Shares" decimals="INF">116801</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag248" contextRef="C60">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements id="Tag249" contextRef="C59" unitRef="Item" decimals="INF">8</plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag250" contextRef="D2014Q2YTD_EmployeeMember" unitRef="USD" decimals="0">43000</us-gaap:ProceedsFromStockOptionsExercised>
  <plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements id="Tag251" contextRef="C60" unitRef="Item" decimals="INF">16</plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue id="Tag252" contextRef="C60" unitRef="USD" decimals="0">1236490</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
  <plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently id="Tag253" contextRef="C59">P2Y</plx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag254" contextRef="C60" unitRef="Shares" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Tag255" contextRef="C59">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag256" contextRef="C60" unitRef="USDPerShare" decimals="2">2.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag257" contextRef="D2014Q2YTD_EmployeeMember" unitRef="Shares" decimals="INF">113800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Tag258" contextRef="C59">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Tag259" contextRef="C60">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag260" contextRef="C59" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag261" contextRef="C59" unitRef="USDPerShare" decimals="2">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Tag262" contextRef="C59" unitRef="Shares" decimals="INF">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue id="Tag263" contextRef="C59" unitRef="USD" decimals="0">293000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
  <dei:EntityRegistrantName id="Tag264" contextRef="D2014Q2YTD">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag265" contextRef="D2014Q2YTD">0001006281</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag266" contextRef="D2014Q2YTD">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag267" contextRef="D2014Q2YTD">2014-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag268" contextRef="D2014Q2YTD">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag269" contextRef="D2014Q2YTD">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="Tag270" contextRef="D2014Q2YTD">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="Tag271" contextRef="C58" unitRef="Shares" decimals="INF">93672564</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="Tag272" contextRef="D2014Q2YTD">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag273" contextRef="D2014Q2YTD">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag274" contextRef="D2014Q2YTD">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"&gt;&lt;strong&gt;NOTE &lt;font&gt;4&lt;/font&gt; &amp;#150; STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt;

&lt;p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"&gt;
&lt;tr style=" vertical-align: top; text-align: justify;"&gt;
&lt;td style=" width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" width: 0.25in; text-align: left;"&gt;&lt;br/&gt;
a.&lt;/td&gt;
&lt;td style=" text-align: justify;"&gt;
&lt;p style=" font: 10pt Times New Roman, Times, Serif; text-indent: 0in;"&gt;During the nine months ended September 30, 2014, the Company issued a total of &lt;font&gt;113,800&lt;/font&gt; shares of Common Stock in connection with the exercise of a total of &lt;font&gt;116,801&lt;/font&gt; options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $&lt;font&gt;43,000&lt;/font&gt;.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;

&lt;p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"&gt;
&lt;tr style=" vertical-align: top; text-align: justify;"&gt;
&lt;td style=" width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" width: 0.25in; text-align: left;"&gt;b.&lt;/td&gt;
&lt;td style=" text-align: justify;"&gt;On July 24, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a &lt;font&gt;10&lt;/font&gt;-year option to purchase &lt;font&gt;150,000&lt;/font&gt; shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $&lt;font&gt;3.37&lt;/font&gt; per share. The options vest over a &lt;font&gt;three&lt;/font&gt;-year period; the first &lt;font&gt;50,000&lt;/font&gt; shares vest on the first anniversary of the grant date and the remaining shares vest in &lt;font&gt;eight&lt;/font&gt; equal quarterly increments over the subsequent &lt;font&gt;two&lt;/font&gt; year period. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's &lt;font&gt;2006&lt;/font&gt; Stock Incentive Plan. The Company estimated the fair value of the option on the date of board approval using the Black-Scholes option-pricing model to be approximately $&lt;font&gt;293,000&lt;/font&gt;.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;

&lt;p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"&gt;&amp;#160;&lt;/p&gt;

&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"&gt;
&lt;tr style=" vertical-align: top; text-align: justify;"&gt;
&lt;td style=" width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style=" width: 0.25in; text-align: left;"&gt;c.&lt;/td&gt;
&lt;td style=" text-align: justify;"&gt;&lt;font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;&lt;font style=" font-size: 10pt;"&gt;On September 28, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a &lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;10&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt;-year option to purchase &lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt; shares of Common Stock to its newly appointed President and Chief Executive Officer with an exercise price of $&lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;2.37&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt; per share. The options vest over a &lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;&lt;font&gt;four&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt;-year period in &lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;16&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt; equal quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's &lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;2006&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt; Stock Incentive Plan. The Company estimated the fair value of the option on the date of board approval using the Black-Scholes option-pricing model to be approximately $&lt;/font&gt;&lt;font&gt;&lt;font style=" font-size: 10pt;"&gt;1,236,490&lt;/font&gt;&lt;/font&gt;&lt;font style=" font-size: 10pt;"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="value8" xlink:href="#Tag147" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote8" xlink:role="http://www.xbrl.org/2003/role/footnote">Represents amount less than $1</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value8" xlink:to="footnote8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="8" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20140930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:plx="http://www.protalix.com/20140930" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.protalix.com/20140930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20140930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20140930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20140930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20140930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/plx-daei" id="plx-daei">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccbs" id="plx-ccbs">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsoo" id="plx-ccsoo">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsoop" id="plx-ccsoop">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocisecd" id="plx-ccsocisecd">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocisecdp" id="plx-ccsocisecdp">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-ccsocf" id="plx-ccsocf">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sap" id="plx-sap">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-i" id="plx-i">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvm" id="plx-fvm">
        <link:definition>103 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-st" id="plx-st">
        <link:definition>104 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapp" id="plx-sapp">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-it" id="plx-it">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sapd1" id="plx-sapd1">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-isoicd" id="plx-isoicd">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-std" id="plx-std">
        <link:definition>40401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-fvmd" id="plx-fvmd">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-se" id="plx-se">
        <link:definition>105 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/plx-sed" id="plx-sed">
        <link:definition>40501 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/XLink" schemaLocation="http://www.xbrl.org/2003/xl-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="SupplyCommitmentPerYear" id="plx_SupplyCommitmentPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseAmountToBeSatisfiedToReceiveEntitledRights" id="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScenarioThreeMember" id="plx_ScenarioThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProtalixLtdMember" id="plx_ProtalixLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonemployeeMember" id="plx_EmployeeAndNonemployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScenarioFourMember" id="plx_ScenarioFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" id="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" id="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20140930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccbs" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoo" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsoo" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocf" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-isoicd" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-isoicd" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_AssetsCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Calculation : us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" xlink:title="Calculation : us-gaap_Assets to us-gaap_DeferredCosts" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:title="us-gaap_OtherReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_OtherReceivablesNetCurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_InventoryNet" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableTradeCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableOtherCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_DeferredRevenueCurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_CommitmentsAndContingencies" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_LongTermDebtNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="4" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesNoncurrent" order="1" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to us-gaap_ConvertibleDebtNoncurrent" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_Revenues" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="plx_OtherGainsLosses" xlink:title="Calculation : us-gaap_GrossProfit to plx_OtherGainsLosses" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_CostOfRevenue" order="3" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_OperatingIncomeLoss" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_NonoperatingIncomeExpense" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingExpense" order="1" weight="-1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_GrossProfit" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="3" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Calculation : plx_ResearchDevelopmentAndEngineeringExpenseNet to plx_GrantsAndReimbursementsReceivedOrReceivable" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncome" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetIncomeLoss" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="3" weight="1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="plx_DepreciationAmortizationAndAssetImpairment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to plx_DepreciationAmortizationAndAssetImpairment" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_AmortizationOfFinancingCosts" order="6" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInInventories" order="9" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromStockOptionsExercised" order="11" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="11" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInRestrictedCash" order="3" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromConvertibleDebt" order="1" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-isoicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20140930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoop" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsoop" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocisecd" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsocisecd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd1" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sapd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-std" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-std" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sed" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sed" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoop">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_1" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocisecd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="arc" order="6.5" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Definition : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="arc" order="7.5" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerIncorporationMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerIncorporationMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="Definition : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixLtdMember" xlink:label="plx_ProtalixLtdMember" xlink:title="plx_ProtalixLtdMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixLtdMember" xlink:title="Definition : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixLtdMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioThreeMember" xlink:label="plx_ScenarioThreeMember" xlink:title="plx_ScenarioThreeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioThreeMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioThreeMember" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioFourMember" xlink:label="plx_ScenarioFourMember" xlink:title="plx_ScenarioFourMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioFourMember" xlink:title="Definition : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioFourMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_1" xlink:title="Definition : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="Definition : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SignificantAccountingPoliciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Definition : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="3.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="us-gaap_ProceedsFromSaleOfOtherAssets1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Definition : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" xlink:type="arc" order="4.65625" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-std">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="7.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="Definition : us-gaap_OptionIndexedToIssuersEquityEquityAxis to us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="Definition : us-gaap_OptionIndexedToIssuersEquityEquityAxis to us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeAndNonemployeeMember" xlink:label="plx_EmployeeAndNonemployeeMember" xlink:title="plx_EmployeeAndNonemployeeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="plx_EmployeeAndNonemployeeMember" xlink:title="Definition : us-gaap_OptionIndexedToIssuersEquityTypeDomain to plx_EmployeeAndNonemployeeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" xlink:title="plx_EmployeeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="plx_EmployeeMember" xlink:title="Definition : us-gaap_OptionIndexedToIssuersEquityTypeDomain to plx_EmployeeMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" use="optional" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" use="optional" order="38" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="48" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" use="optional" order="58" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="Definition : us-gaap_ClassOfStockLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:type="arc" use="optional" order="68" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" use="optional" order="88" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="Definition : us-gaap_ClassOfStockLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:type="arc" use="optional" order="78" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" use="optional" order="98" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_ScheduleOfStockByClassTable to us-gaap_TitleOfIndividualAxis" xlink:type="arc" use="optional" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:title="us-gaap_ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:title="Definition : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" use="optional" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="108" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" use="optional" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" use="optional" order="70" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="Definition : us-gaap_SubsequentEventLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:type="arc" use="optional" order="90" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_SubsequentEventTable" xlink:type="arc" use="optional" order="20" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" use="optional" order="20" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20140930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent">Accounts receivable - Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_1">Accounts Receivable, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent_1" xlink:title="Label : us-gaap_AccountsReceivableNetCurrent to label_us-gaap_AccountsReceivableNetCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:title="us-gaap_OtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US" id="label_us-gaap_OtherReceivablesNetCurrent">Other Receivables, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="label_us-gaap_OtherReceivablesNetCurrent" xlink:title="Label : us-gaap_OtherReceivablesNetCurrent to label_us-gaap_OtherReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherReceivablesNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherReceivablesNetCurrent_1" xml:lang="en-US" id="label_us-gaap_OtherReceivablesNetCurrent_1">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="label_us-gaap_OtherReceivablesNetCurrent_1" xlink:title="Label : us-gaap_OtherReceivablesNetCurrent to label_us-gaap_OtherReceivablesNetCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryNet" xml:lang="en-US" id="label_us-gaap_InventoryNet">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryNet_1" xml:lang="en-US" id="label_us-gaap_InventoryNet_1">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_1" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_InventoryNet_2" xml:lang="en-US" id="label_us-gaap_InventoryNet_2">Total inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="label_us-gaap_InventoryNet_2" xlink:title="Label : us-gaap_InventoryNet to label_us-gaap_InventoryNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent_1" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xlink:title="Label : us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent to label_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredCosts" xml:lang="en-US" id="label_us-gaap_DeferredCosts">Deferred Costs, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredCosts_1" xml:lang="en-US" id="label_us-gaap_DeferredCosts_1">DEFERRED CHARGES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="label_us-gaap_DeferredCosts_1" xlink:title="Label : us-gaap_DeferredCosts to label_us-gaap_DeferredCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Assets_1" xml:lang="en-US" id="label_us-gaap_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets_1" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent">Long-term Debt, Excluding Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_1">Liability in connection with collaboration operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_1" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies">COMMITMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies_1" xlink:title="Label : us-gaap_CommitmentsAndContingencies to label_us-gaap_CommitmentsAndContingencies_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent">Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableTradeCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableTradeCurrent_1">Accounts Payable, Trade, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="label_us-gaap_AccountsPayableTradeCurrent_1" xlink:title="Label : us-gaap_AccountsPayableTradeCurrent to label_us-gaap_AccountsPayableTradeCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableOtherCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableOtherCurrent_1">Accounts Payable, Other, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="label_us-gaap_AccountsPayableOtherCurrent_1" xlink:title="Label : us-gaap_AccountsPayableOtherCurrent to label_us-gaap_AccountsPayableOtherCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueCurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueCurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueCurrent_1">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="label_us-gaap_DeferredRevenueCurrent_1" xlink:title="Label : us-gaap_DeferredRevenueCurrent to label_us-gaap_DeferredRevenueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_1" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent">Convertible Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtNoncurrent_1">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="label_us-gaap_ConvertibleDebtNoncurrent_1" xlink:title="Label : us-gaap_ConvertibleDebtNoncurrent to label_us-gaap_ConvertibleDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRevenueNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DeferredRevenueNoncurrent_1">Deferred Revenue, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="label_us-gaap_DeferredRevenueNoncurrent_1" xlink:title="Label : us-gaap_DeferredRevenueNoncurrent to label_us-gaap_DeferredRevenueNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1">Liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent to label_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrent_1">Total long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrent to label_us-gaap_LiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Liabilities_1" xml:lang="en-US" id="label_us-gaap_Liabilities_1">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities_1" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity">CAPITAL DEFICIENCY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_1" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_StockholdersEquity_2" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_2">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_2" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_StockholdersEquity_3" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_3">Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_3" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_1">Total liabilities net of capital deficiency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Revenues" xml:lang="en-US" id="label_us-gaap_Revenues">REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues" xlink:title="Label : us-gaap_Revenues to label_us-gaap_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Revenues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Revenues_1" xml:lang="en-US" id="label_us-gaap_Revenues_1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="label_us-gaap_Revenues_1" xlink:title="Label : us-gaap_Revenues to label_us-gaap_Revenues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfRevenue" xml:lang="en-US" id="label_us-gaap_CostOfRevenue">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_GrossProfit" xml:lang="en-US" id="label_us-gaap_GrossProfit">GROSS PROFIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GrossProfit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GrossProfit_1" xml:lang="en-US" id="label_us-gaap_GrossProfit_1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit_1" xlink:title="Label : us-gaap_GrossProfit to label_us-gaap_GrossProfit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_1">OPERATING LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_1" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense">Other Nonoperating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingIncome" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome">Other Nonoperating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncome_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingIncome_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncome_1">FINANCIAL INCOME</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="label_us-gaap_OtherNonoperatingIncome_1" xlink:title="Label : us-gaap_OtherNonoperatingIncome to label_us-gaap_OtherNonoperatingIncome_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_1">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_1" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_NetIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_1" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NetIncomeLoss_2" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_2">Net loss for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_2" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLoss_3" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_3">NET LOSS FOR THE PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_3" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_1">BASIC AND DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">BASIC AND DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense_1">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis" xlink:title="Label : us-gaap_IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseMember">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Label : us-gaap_GeneralAndAdministrativeExpenseMember to label_us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="label_us-gaap_StatementEquityComponentsAxis" xlink:title="Label : us-gaap_StatementEquityComponentsAxis to label_us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsMember" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsMember_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember_1" xlink:title="Label : us-gaap_RetainedEarningsMember to label_us-gaap_RetainedEarningsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_SharesOutstanding" xml:lang="en-US" id="label_us-gaap_SharesOutstanding">Beginning Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_SharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_1">Ending Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_1" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharesOutstanding_2" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="label_us-gaap_SharesOutstanding_2" xlink:title="Label : us-gaap_SharesOutstanding to label_us-gaap_SharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1">Share-based compensation related to stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercise of options granted to employees (includes net exercise) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of options granted to employees (includes net exercise)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockMember" xml:lang="en-US" id="label_us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember" xlink:title="Label : us-gaap_CommonStockMember to label_us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember">Additional paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember" xlink:title="Label : us-gaap_AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember_1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember_1" xlink:title="Label : us-gaap_AdditionalPaidInCapitalMember to label_us-gaap_AdditionalPaidInCapitalMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare">Common Stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_2">Common stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_2" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized">Common Stock, Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized_1" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensation_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_1">Share based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation_1" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense">Pension and Other Postretirement Benefit Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" xlink:title="Label : us-gaap_PensionAndOtherPostretirementBenefitExpense to label_us-gaap_PensionAndOtherPostretirementBenefitExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts">Amortization of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCosts_1">Amortization of debt issuance costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="label_us-gaap_AmortizationOfFinancingCosts_1" xlink:title="Label : us-gaap_AmortizationOfFinancingCosts to label_us-gaap_AmortizationOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Decrease in accounts payable and accruals (including long term)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash">Increase (Decrease) in Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised">Exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_1" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_2">Cash proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised_2" xlink:title="Label : us-gaap_ProceedsFromStockOptionsExercised to label_us-gaap_ProceedsFromStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_BasisOfAccountingPolicyPolicyTextBlock to label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromCollaborators" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators">Pfizer Agreement, upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromCollaborators_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromCollaborators_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromCollaborators_1">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="label_us-gaap_ProceedsFromCollaborators_1" xlink:title="Label : us-gaap_ProceedsFromCollaborators to label_us-gaap_ProceedsFromCollaborators_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="us-gaap_ProceedsFromSaleOfOtherAssets1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfOtherAssets1" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfOtherAssets1">Proceeds from Sale of Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:to="label_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="Label : us-gaap_ProceedsFromSaleOfOtherAssets1 to label_us-gaap_ProceedsFromSaleOfOtherAssets1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfOtherAssets1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfOtherAssets1_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfOtherAssets1_1">Revenue from sale of products</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:to="label_us-gaap_ProceedsFromSaleOfOtherAssets1_1" xlink:title="Label : us-gaap_ProceedsFromSaleOfOtherAssets1 to label_us-gaap_ProceedsFromSaleOfOtherAssets1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementScenarioAxis" xml:lang="en-US" id="label_us-gaap_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="label_us-gaap_StatementScenarioAxis" xlink:title="Label : us-gaap_StatementScenarioAxis to label_us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="label_us-gaap_TypeOfArrangementAxis">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="label_us-gaap_TypeOfArrangementAxis" xlink:title="Label : us-gaap_TypeOfArrangementAxis to label_us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureTextBlock_1">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="label_us-gaap_InventoryDisclosureTextBlock_1" xlink:title="Label : us-gaap_InventoryDisclosureTextBlock to label_us-gaap_InventoryDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfInventoryCurrentTableTextBlock to label_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryRawMaterialsNetOfReserves_1">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="label_us-gaap_InventoryRawMaterialsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryRawMaterialsNetOfReserves to label_us-gaap_InventoryRawMaterialsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves">Inventory, Work in Process, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryWorkInProcessNetOfReserves_1">Work in process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="label_us-gaap_InventoryWorkInProcessNetOfReserves_1" xlink:title="Label : us-gaap_InventoryWorkInProcessNetOfReserves to label_us-gaap_InventoryWorkInProcessNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xml:lang="en-US" id="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" xlink:title="Label : us-gaap_InventoryFinishedGoodsNetOfReserves to label_us-gaap_InventoryFinishedGoodsNetOfReserves_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_InventoryWriteDown" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown">Inventory write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryWriteDown_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryWriteDown_1" xml:lang="en-US" id="label_us-gaap_InventoryWriteDown_1">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="label_us-gaap_InventoryWriteDown_1" xlink:title="Label : us-gaap_InventoryWriteDown to label_us-gaap_InventoryWriteDown_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock_1">FAIR VALUE MEASUREMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock">STOCK TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">Common stock issued in connection with exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US" id="label_us-gaap_OptionIndexedToIssuersEquityEquityAxis">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="label_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="Label : us-gaap_OptionIndexedToIssuersEquityEquityAxis to label_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentFlag" xml:lang="en-US" id="label_dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag" xlink:title="Label : dei_AmendmentFlag to label_dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate" xlink:title="Label : dei_CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentPeriodEndDate" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate" xlink:title="Label : dei_DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Label : us-gaap_ArrangementsAndNonarrangementTransactionsMember to label_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_TradingSymbol" xml:lang="en-US" id="label_dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="label_dei_TradingSymbol" xlink:title="Label : dei_TradingSymbol to label_dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityFilerCategory" xml:lang="en-US" id="label_dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory" xlink:title="Label : dei_EntityFilerCategory to label_dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityRegistrantName" xml:lang="en-US" id="label_dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName" xlink:title="Label : dei_EntityRegistrantName to label_dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCentralIndexKey" xml:lang="en-US" id="label_dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey" xlink:title="Label : dei_EntityCentralIndexKey to label_dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding" xlink:title="Label : dei_EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalYearFocus" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus" xlink:title="Label : dei_DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus" xlink:title="Label : dei_DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentType" xml:lang="en-US" id="label_dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType" xlink:title="Label : dei_DocumentType to label_dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract" xlink:title="Label : us-gaap_AccountingPoliciesAbstract to label_us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">Accounts payable and accruals:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to label_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1">Common stock issued for cash, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" xlink:title="Label : us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts to label_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="label_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Label : us-gaap_AntidilutiveSecuritiesNameDomain to label_us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_1">CURRENT ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract_1" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract_1" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="label_us-gaap_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="label_us-gaap_ClassOfStockLineItems" xlink:title="Label : us-gaap_ClassOfStockLineItems to label_us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CostOfSalesMember" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember">Cost of Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfSalesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostOfSalesMember_1" xml:lang="en-US" id="label_us-gaap_CostOfSalesMember_1">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="label_us-gaap_CostOfSalesMember_1" xlink:title="Label : us-gaap_CostOfSalesMember to label_us-gaap_CostOfSalesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock">Convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock_1">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock_1" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to label_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="us-gaap_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="label_us-gaap_EarningsPerShareAbstract">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="label_us-gaap_EarningsPerShareAbstract" xlink:title="Label : us-gaap_EarningsPerShareAbstract to label_us-gaap_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareAbstract_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareAbstract_1">NET LOSS PER SHARE OF COMMON STOCK:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="label_us-gaap_EarningsPerShareAbstract_1" xlink:title="Label : us-gaap_EarningsPerShareAbstract to label_us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EquityComponentDomain" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="label_us-gaap_EquityComponentDomain" xlink:title="Label : us-gaap_EquityComponentDomain to label_us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="label_us-gaap_FairValueDisclosuresAbstract" xlink:title="Label : us-gaap_FairValueDisclosuresAbstract to label_us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract" xlink:title="Label : us-gaap_IncomeStatementAbstract to label_us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain" xlink:title="Label : us-gaap_IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_InventoryDisclosureAbstract">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="label_us-gaap_InventoryDisclosureAbstract" xlink:title="Label : us-gaap_InventoryDisclosureAbstract to label_us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract">CURRENT LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesNoncurrentAbstract_1">LONG TERM LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesNoncurrentAbstract to label_us-gaap_LiabilitiesNoncurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US" id="label_us-gaap_OptionIndexedToIssuersEquityTypeDomain">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="label_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="Label : us-gaap_OptionIndexedToIssuersEquityTypeDomain to label_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_us-gaap_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="label_us-gaap_ScenarioUnspecifiedDomain" xlink:title="Label : us-gaap_ScenarioUnspecifiedDomain to label_us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="label_us-gaap_ScheduleOfStockByClassTable" xlink:title="Label : us-gaap_ScheduleOfStockByClassTable to label_us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xml:lang="en-US" id="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">Supply Commitment, Remaining Minimum Amount Committed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="Label : us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted to label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_1" xml:lang="en-US" id="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_1">Total supply commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_1" xlink:title="Label : us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted to label_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementTable" xml:lang="en-US" id="label_us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="label_us-gaap_StatementTable" xlink:title="Label : us-gaap_StatementTable to label_us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementLineItems" xml:lang="en-US" id="label_us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems" xlink:title="Label : us-gaap_StatementLineItems to label_us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfStockholdersEquityAbstract">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="label_us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="Label : us-gaap_StatementOfStockholdersEquityAbstract to label_us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract" xlink:title="Label : us-gaap_StatementOfCashFlowsAbstract to label_us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:title="Label : us-gaap_StatementOfFinancialPositionAbstract to label_us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues">Common stock issued for cash (net of issuance costs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueNewIssues to label_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteAbstract">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="label_us-gaap_StockholdersEquityNoteAbstract" xlink:title="Label : us-gaap_StockholdersEquityNoteAbstract to label_us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_1">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CashlessExerciseOfStockOptions" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions">Cashless Exercise Of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CashlessExerciseOfStockOptions_1" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_1">Cash due from broker assisted exercises of employee stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_1" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CashlessExerciseOfStockOptions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CashlessExerciseOfStockOptions_2" xml:lang="en-US" id="label_plx_CashlessExerciseOfStockOptions_2">Exercise of options granted to employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="label_plx_CashlessExerciseOfStockOptions_2" xlink:title="Label : plx_CashlessExerciseOfStockOptions to label_plx_CashlessExerciseOfStockOptions_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage_1" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage_1">Collaborative arrangement profit sharing percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage_1" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_CollaborativeArrangementProfitSharePercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_CollaborativeArrangementProfitSharePercentage_2" xml:lang="en-US" id="label_plx_CollaborativeArrangementProfitSharePercentage_2">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="label_plx_CollaborativeArrangementProfitSharePercentage_2" xlink:title="Label : plx_CollaborativeArrangementProfitSharePercentage to label_plx_CollaborativeArrangementProfitSharePercentage_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="plx_DepreciationAmortizationAndAssetImpairment" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment">Depreciation Amortization And Asset Impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment_1" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment_1">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment_1" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_DepreciationAmortizationAndAssetImpairment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_DepreciationAmortizationAndAssetImpairment_2" xml:lang="en-US" id="label_plx_DepreciationAmortizationAndAssetImpairment_2">Depreciation and write down of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="label_plx_DepreciationAmortizationAndAssetImpairment_2" xlink:title="Label : plx_DepreciationAmortizationAndAssetImpairment to label_plx_DepreciationAmortizationAndAssetImpairment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_plx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_plx_DocumentAndEntityInformationAbstract">Document And Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="label_plx_DocumentAndEntityInformationAbstract" xlink:title="Label : plx_DocumentAndEntityInformationAbstract to label_plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeAndNonemployeeMember" xlink:label="plx_EmployeeAndNonemployeeMember" xlink:title="plx_EmployeeAndNonemployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeAndNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeeAndNonemployeeMember" xml:lang="en-US" id="label_plx_EmployeeAndNonemployeeMember">Employee And Nonemployee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeAndNonemployeeMember" xlink:to="label_plx_EmployeeAndNonemployeeMember" xlink:title="Label : plx_EmployeeAndNonemployeeMember to label_plx_EmployeeAndNonemployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeAndNonemployeeMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeeAndNonemployeeMember_1" xml:lang="en-US" id="label_plx_EmployeeAndNonemployeeMember_1">Employee And Nonemployee [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeAndNonemployeeMember" xlink:to="label_plx_EmployeeAndNonemployeeMember_1" xlink:title="Label : plx_EmployeeAndNonemployeeMember to label_plx_EmployeeAndNonemployeeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeAndNonemployeeMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EmployeeAndNonemployeeMember_2" xml:lang="en-US" id="label_plx_EmployeeAndNonemployeeMember_2">Certain Employees and Non-employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeAndNonemployeeMember" xlink:to="label_plx_EmployeeAndNonemployeeMember_2" xlink:title="Label : plx_EmployeeAndNonemployeeMember to label_plx_EmployeeAndNonemployeeMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" xlink:title="plx_EmployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_EmployeeMember" xml:lang="en-US" id="label_plx_EmployeeMember">Employee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="label_plx_EmployeeMember" xlink:title="Label : plx_EmployeeMember to label_plx_EmployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_EmployeeMember_1" xml:lang="en-US" id="label_plx_EmployeeMember_1">Employee [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="label_plx_EmployeeMember_1" xlink:title="Label : plx_EmployeeMember to label_plx_EmployeeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_EmployeeMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_EmployeeMember_2" xml:lang="en-US" id="label_plx_EmployeeMember_2">Certain Employee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="label_plx_EmployeeMember_2" xlink:title="Label : plx_EmployeeMember to label_plx_EmployeeMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable">Grants And Reimbursements Received Or Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xml:lang="en-US" id="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2">Less - grants and reimbursements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" xlink:title="Label : plx_GrantsAndReimbursementsReceivedOrReceivable to label_plx_GrantsAndReimbursementsReceivedOrReceivable_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1">Increase in liabilities for property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xml:lang="en-US" id="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" xlink:title="Label : plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment to label_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xml:lang="en-US" id="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2">License and supply agreement potential future payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:to="label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" xlink:title="Label : plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits to label_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_MilestonePayment" xml:lang="en-US" id="label_plx_MilestonePayment">Milestone Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_MilestonePayment_1" xml:lang="en-US" id="label_plx_MilestonePayment_1">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_1" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_MilestonePayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_MilestonePayment_2" xml:lang="en-US" id="label_plx_MilestonePayment_2">Milestone payment triggered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePayment" xlink:to="label_plx_MilestonePayment_2" xlink:title="Label : plx_MilestonePayment to label_plx_MilestonePayment_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock">Nature Of Operations [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_1" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_1">The accounting policy related to the nature of operations of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_1" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NatureOfOperationsPolicyTextBlock_2" xml:lang="en-US" id="label_plx_NatureOfOperationsPolicyTextBlock_2">General</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="label_plx_NatureOfOperationsPolicyTextBlock_2" xlink:title="Label : plx_NatureOfOperationsPolicyTextBlock to label_plx_NatureOfOperationsPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_NumberOfSubsidiaries" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries">Number Of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_NumberOfSubsidiaries_1" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_1">Number of subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_1" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_NumberOfSubsidiaries_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_NumberOfSubsidiaries_2" xml:lang="en-US" id="label_plx_NumberOfSubsidiaries_2">Number of Subsidiaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfSubsidiaries" xlink:to="label_plx_NumberOfSubsidiaries_2" xlink:title="Label : plx_NumberOfSubsidiaries to label_plx_NumberOfSubsidiaries_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_OtherGainsLosses" xml:lang="en-US" id="label_plx_OtherGainsLosses">Other Gains Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_OtherGainsLosses_1" xml:lang="en-US" id="label_plx_OtherGainsLosses_1">The Company's share in collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses_1" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_OtherGainsLosses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_OtherGainsLosses_2" xml:lang="en-US" id="label_plx_OtherGainsLosses_2">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="label_plx_OtherGainsLosses_2" xlink:title="Label : plx_OtherGainsLosses to label_plx_OtherGainsLosses_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PfizerIncorporationMember" xml:lang="en-US" id="label_plx_PfizerIncorporationMember">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PfizerIncorporationMember_1" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_1">Pfizer Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_1" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PfizerIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PfizerIncorporationMember_2" xml:lang="en-US" id="label_plx_PfizerIncorporationMember_2">Pfizer Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerIncorporationMember" xlink:to="label_plx_PfizerIncorporationMember_2" xlink:title="Label : plx_PfizerIncorporationMember to label_plx_PfizerIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_1">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_1" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xml:lang="en-US" id="label_plx_ProtalixBioTherapeuticsIncorporationMember_2">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="label_plx_ProtalixBioTherapeuticsIncorporationMember_2" xlink:title="Label : plx_ProtalixBioTherapeuticsIncorporationMember to label_plx_ProtalixBioTherapeuticsIncorporationMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixLtdMember" xlink:label="plx_ProtalixLtdMember" xlink:title="plx_ProtalixLtdMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ProtalixLtdMember" xml:lang="en-US" id="label_plx_ProtalixLtdMember">Protalix Ltd [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixLtdMember" xlink:to="label_plx_ProtalixLtdMember" xlink:title="Label : plx_ProtalixLtdMember to label_plx_ProtalixLtdMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixLtdMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ProtalixLtdMember_1" xml:lang="en-US" id="label_plx_ProtalixLtdMember_1">Protalix Ltd [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixLtdMember" xlink:to="label_plx_ProtalixLtdMember_1" xlink:title="Label : plx_ProtalixLtdMember to label_plx_ProtalixLtdMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ProtalixLtdMember_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_plx_ProtalixLtdMember_2" xml:lang="en-US" id="label_plx_ProtalixLtdMember_2">Protalix Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixLtdMember" xlink:to="label_plx_ProtalixLtdMember_2" xlink:title="Label : plx_ProtalixLtdMember to label_plx_ProtalixLtdMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">Purchase Amount To Be Satisfied To Receive Entitled Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1">The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xml:lang="en-US" id="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2">Supply commitment for entitled rights to be received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:to="label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" xlink:title="Label : plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights to label_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet">Research Development And Engineering Expense Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1">Research and development expenses, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioFourMember" xlink:label="plx_ScenarioFourMember" xlink:title="plx_ScenarioFourMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioFourMember" xml:lang="en-US" id="label_plx_ScenarioFourMember">Scenario Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioFourMember" xlink:to="label_plx_ScenarioFourMember" xlink:title="Label : plx_ScenarioFourMember to label_plx_ScenarioFourMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioFourMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioFourMember_1" xml:lang="en-US" id="label_plx_ScenarioFourMember_1">Scenario Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioFourMember" xlink:to="label_plx_ScenarioFourMember_1" xlink:title="Label : plx_ScenarioFourMember to label_plx_ScenarioFourMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioFourMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioFourMember_2" xml:lang="en-US" id="label_plx_ScenarioFourMember_2">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioFourMember" xlink:to="label_plx_ScenarioFourMember_2" xlink:title="Label : plx_ScenarioFourMember to label_plx_ScenarioFourMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioOneMember" xml:lang="en-US" id="label_plx_ScenarioOneMember">Scenario One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioOneMember_1" xml:lang="en-US" id="label_plx_ScenarioOneMember_1">Scenario One [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_1" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioOneMember_2" xml:lang="en-US" id="label_plx_ScenarioOneMember_2">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioOneMember" xlink:to="label_plx_ScenarioOneMember_2" xlink:title="Label : plx_ScenarioOneMember to label_plx_ScenarioOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioThreeMember" xlink:label="plx_ScenarioThreeMember" xlink:title="plx_ScenarioThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioThreeMember" xml:lang="en-US" id="label_plx_ScenarioThreeMember">Scenario Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioThreeMember" xlink:to="label_plx_ScenarioThreeMember" xlink:title="Label : plx_ScenarioThreeMember to label_plx_ScenarioThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioThreeMember_1" xml:lang="en-US" id="label_plx_ScenarioThreeMember_1">Scenario Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioThreeMember" xlink:to="label_plx_ScenarioThreeMember_1" xlink:title="Label : plx_ScenarioThreeMember to label_plx_ScenarioThreeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioThreeMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioThreeMember_2" xml:lang="en-US" id="label_plx_ScenarioThreeMember_2">Upon FDA Approval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioThreeMember" xlink:to="label_plx_ScenarioThreeMember_2" xlink:title="Label : plx_ScenarioThreeMember to label_plx_ScenarioThreeMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ScenarioTwoMember" xml:lang="en-US" id="label_plx_ScenarioTwoMember">Scenario Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ScenarioTwoMember_1" xml:lang="en-US" id="label_plx_ScenarioTwoMember_1">Scenario Two [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_1" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ScenarioTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ScenarioTwoMember_2" xml:lang="en-US" id="label_plx_ScenarioTwoMember_2">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScenarioTwoMember" xlink:to="label_plx_ScenarioTwoMember_2" xlink:title="Label : plx_ScenarioTwoMember to label_plx_ScenarioTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" xlink:title="Label : plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares to label_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesLineItems">Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="label_plx_SignificantAccountingPoliciesLineItems" xlink:title="Label : plx_SignificantAccountingPoliciesLineItems to label_plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SignificantAccountingPoliciesTable" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable">Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_plx_SignificantAccountingPoliciesTable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SignificantAccountingPoliciesTable_1" xml:lang="en-US" id="label_plx_SignificantAccountingPoliciesTable_1">Significant Accounting Policies [Table].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="label_plx_SignificantAccountingPoliciesTable_1" xlink:title="Label : plx_SignificantAccountingPoliciesTable to label_plx_SignificantAccountingPoliciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember">Stock Options And Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_1" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_1">Stock Options And Restricted Shares [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_1" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_StockOptionsAndRestrictedSharesMember_2" xml:lang="en-US" id="label_plx_StockOptionsAndRestrictedSharesMember_2">Options and Restricted Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockOptionsAndRestrictedSharesMember" xlink:to="label_plx_StockOptionsAndRestrictedSharesMember_2" xlink:title="Label : plx_StockOptionsAndRestrictedSharesMember to label_plx_StockOptionsAndRestrictedSharesMember_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplyCommitmentPerYear" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear">Supply Commitment Per Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplyCommitmentPerYear_1" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_1">The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_1" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplyCommitmentPerYear_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplyCommitmentPerYear_2" xml:lang="en-US" id="label_plx_SupplyCommitmentPerYear_2">Supply agreement maximum consideration payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyCommitmentPerYear" xlink:to="label_plx_SupplyCommitmentPerYear_2" xlink:title="Label : plx_SupplyCommitmentPerYear to label_plx_SupplyCommitmentPerYear_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1">Share-based compensation related to restricted stock award, forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited to label_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures">Convertible Debt, Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xml:lang="en-US" id="label_us-gaap_ConvertibleDebtFairValueDisclosures_1">Fair value convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="label_us-gaap_ConvertibleDebtFairValueDisclosures_1" xlink:title="Label : us-gaap_ConvertibleDebtFairValueDisclosures to label_us-gaap_ConvertibleDebtFairValueDisclosures_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract">SUBSEQUENT EVENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="label_us-gaap_SubsequentEventsAbstract" xlink:title="Label : us-gaap_SubsequentEventsAbstract to label_us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_1">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock_1" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CostOfRevenue_1" xml:lang="en-US" id="label_us-gaap_CostOfRevenue_1">COST OF REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue_1" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_1">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense_1">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense_1" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingExpense_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense_1">FINANCIAL EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense_1" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1">Financial expense (income), net (mainly exchange differences)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1">Increase in accounts receivable and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInInventories_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories_1">Decrease (increase) in inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories_1" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash_1">Investment in restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash_1" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostOfRevenue_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_CostOfRevenue_2" xml:lang="en-US" id="label_us-gaap_CostOfRevenue_2">COST OF REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue_2" xlink:title="Label : us-gaap_CostOfRevenue to label_us-gaap_CostOfRevenue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SellingGeneralAndAdministrativeExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_SellingGeneralAndAdministrativeExpense_2" xml:lang="en-US" id="label_us-gaap_SellingGeneralAndAdministrativeExpense_2">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="label_us-gaap_SellingGeneralAndAdministrativeExpense_2" xlink:title="Label : us-gaap_SellingGeneralAndAdministrativeExpense to label_us-gaap_SellingGeneralAndAdministrativeExpense_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_OtherNonoperatingExpense_2" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingExpense_2">FINANCIAL EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="label_us-gaap_OtherNonoperatingExpense_2" xlink:title="Label : us-gaap_OtherNonoperatingExpense to label_us-gaap_OtherNonoperatingExpense_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2">Financial expenses (income,), net (mainly exchange differences)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2" xlink:title="Label : us-gaap_ForeignCurrencyTransactionGainLossUnrealized to label_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_3" xml:lang="en-US" id="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_3">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_3" xlink:title="Label : plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement to label_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_3" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable_2" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_2">Increase in accounts receivable and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_2" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInInventories_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInInventories_2" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInInventories_2">Decrease (increase) in inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="label_us-gaap_IncreaseDecreaseInInventories_2" xlink:title="Label : us-gaap_IncreaseDecreaseInInventories to label_us-gaap_IncreaseDecreaseInInventories_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInRestrictedCash_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInRestrictedCash_2" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInRestrictedCash_2">Investment in restricted deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="label_us-gaap_IncreaseDecreaseInRestrictedCash_2" xlink:title="Label : us-gaap_IncreaseDecreaseInRestrictedCash to label_us-gaap_IncreaseDecreaseInRestrictedCash_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2" xlink:title="Label : us-gaap_PaymentsForProceedsFromOtherInvestingActivities to label_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_2">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_2" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense_2" />
    <link:label xlink:type="resource" xlink:label="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_3" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_3" xml:lang="en-US" id="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_3">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="label_plx_ResearchDevelopmentAndEngineeringExpenseNet_3" xlink:title="Label : plx_ResearchDevelopmentAndEngineeringExpenseNet to label_plx_ResearchDevelopmentAndEngineeringExpenseNet_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Forfeited (Deprecated 2012-01-31)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodForfeited" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements">Sharebased Compensation Arrangement by Sharebased Payment Award Options Vested Number of Equal Quarterly Increments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_1" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_1">Number of equal quarterly increments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_1" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_2" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_2">Represents the number of equal quarterly increments for remaining shares vest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_2" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently">Sharebased Compensation Arrangement by Sharebased Payment Award Options Vested Period of Equal Quarterly Increments Subsequently</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_1" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_1">Subsequent vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_1" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_2" xml:lang="en-US" id="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_2">Represents the subsequent vesting period of equal quarterly increments for remaining shares vest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:to="label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_2" xlink:title="Label : plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently to label_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_1" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_1">Estimated fair value of option on the date of grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_1" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_2" xml:lang="en-US" id="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_2">Represents the estimated fair value of option on the date of grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_2" xlink:title="Label : plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue to label_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1">Term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1">Option granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1">Information by vesting schedule for share-based compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:title="Label : us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTable" xml:lang="en-US" id="label_us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="label_us-gaap_SubsequentEventTable" xlink:title="Label : us-gaap_SubsequentEventTable to label_us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="label_us-gaap_SubsequentEventTypeAxis" xlink:title="Label : us-gaap_SubsequentEventTypeAxis to label_us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="label_us-gaap_SubsequentEventTypeDomain" xlink:title="Label : us-gaap_SubsequentEventTypeDomain to label_us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventMember" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember" xlink:title="Label : us-gaap_SubsequentEventMember to label_us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="label_us-gaap_SubsequentEventLineItems" xlink:title="Label : us-gaap_SubsequentEventLineItems to label_us-gaap_SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventMember_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember_1">Subsequent Events [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember_1" xlink:title="Label : us-gaap_SubsequentEventMember to label_us-gaap_SubsequentEventMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventLineItems_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems_1">Subsequent Events [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="label_us-gaap_SubsequentEventLineItems_1" xlink:title="Label : us-gaap_SubsequentEventLineItems to label_us-gaap_SubsequentEventLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US" id="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="Label : us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction to label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromConvertibleDebt_1">Net proceeds from issuance of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="label_us-gaap_ProceedsFromConvertibleDebt_1" xlink:title="Label : us-gaap_ProceedsFromConvertibleDebt to label_us-gaap_ProceedsFromConvertibleDebt_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xml:lang="en-US" id="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1">Issuance cost related to convertible note offering not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xlink:title="Label : us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction to label_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Exercise of options granted to employees (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised to label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualAxis" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualAxis">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="label_us-gaap_TitleOfIndividualAxis" xlink:title="Label : us-gaap_TitleOfIndividualAxis to label_us-gaap_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Label : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to label_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US" id="label_us-gaap_BoardOfDirectorsChairmanMember">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="label_us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Label : us-gaap_BoardOfDirectorsChairmanMember to label_us-gaap_BoardOfDirectorsChairmanMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:title="us-gaap_ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US" id="label_us-gaap_ChiefExecutiveOfficerMember">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="label_us-gaap_ChiefExecutiveOfficerMember" xlink:title="Label : us-gaap_ChiefExecutiveOfficerMember to label_us-gaap_ChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BoardOfDirectorsChairmanMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BoardOfDirectorsChairmanMember_1" xml:lang="en-US" id="label_us-gaap_BoardOfDirectorsChairmanMember_1">Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="label_us-gaap_BoardOfDirectorsChairmanMember_1" xlink:title="Label : us-gaap_BoardOfDirectorsChairmanMember to label_us-gaap_BoardOfDirectorsChairmanMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ChiefExecutiveOfficerMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ChiefExecutiveOfficerMember_1" xml:lang="en-US" id="label_us-gaap_ChiefExecutiveOfficerMember_1">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="label_us-gaap_ChiefExecutiveOfficerMember_1" xlink:title="Label : us-gaap_ChiefExecutiveOfficerMember to label_us-gaap_ChiefExecutiveOfficerMember_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_1">Issuance cost related to convertible note offering not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_1" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xml:lang="en-US" id="label_plx_SupplementalOfferingAndStockIssuanceCosts_2">Supplemental offering and stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="label_plx_SupplementalOfferingAndStockIssuanceCosts_2" xlink:title="Label : plx_SupplementalOfferingAndStockIssuanceCosts to label_plx_SupplementalOfferingAndStockIssuanceCosts_2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20140930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protalix.com/role/plx-daei" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-daei" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapd1" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sapd1" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sapp" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sapp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sap" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sap" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccbs" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccbs" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocf" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsocf" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-std" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-std" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoo" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsoo" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsoop" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsoop" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocisecd" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsocisecd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvmd" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-fvmd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-fvm" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-fvm" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-isoicd" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-isoicd" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-i" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-i" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-it" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-it" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-ccsocisecdp" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-ccsocisecdp" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-st" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-st" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-se" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-se" />
  <link:roleRef roleURI="http://www.protalix.com/role/plx-sed" xlink:type="simple" xlink:href="plx-20140930.xsd#plx-sed" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-daei">
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xlink:title="plx_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_TradingSymbol" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : plx_DocumentAndEntityInformationAbstract to dei_DocumentType" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapd1">
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" xlink:title="plx_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_NumberOfSubsidiaries" xlink:label="plx_NumberOfSubsidiaries" xlink:title="plx_NumberOfSubsidiaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfSubsidiaries" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_NumberOfSubsidiaries" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_MilestonePayment" xlink:label="plx_MilestonePayment" xlink:title="plx_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePayment" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_MilestonePayment" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="plx_CollaborativeArrangementProfitSharePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_CollaborativeArrangementProfitSharePercentage" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SupplyCommitmentPerYear" xlink:label="plx_SupplyCommitmentPerYear" xlink:title="plx_SupplyCommitmentPerYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SupplyCommitmentPerYear" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_SupplyCommitmentPerYear" order="4.65625" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:label="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" order="4.53125" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:label="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" order="4.5625" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_CommonStockParOrStatedValuePerShare" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="us-gaap_ProceedsFromSaleOfOtherAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromSaleOfOtherAssets1" order="4.6875" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:title="us-gaap_ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_ProceedsFromCollaborators" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:title="Presentation : plx_SignificantAccountingPoliciesLineItems to us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" xlink:title="plx_SignificantAccountingPoliciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to plx_SignificantAccountingPoliciesLineItems" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:title="us-gaap_StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_StatementScenarioAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:title="us-gaap_TypeOfArrangementAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="Presentation : plx_SignificantAccountingPoliciesTable to us-gaap_TypeOfArrangementAxis" order="3.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixBioTherapeuticsIncorporationMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_PfizerIncorporationMember" xlink:label="plx_PfizerIncorporationMember" xlink:title="plx_PfizerIncorporationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerIncorporationMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_PfizerIncorporationMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ProtalixLtdMember" xlink:label="plx_ProtalixLtdMember" xlink:title="plx_ProtalixLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ProtalixLtdMember" xlink:title="Presentation : us-gaap_ArrangementsAndNonarrangementTransactionsMember to plx_ProtalixLtdMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_SignificantAccountingPoliciesTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_SignificantAccountingPoliciesTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesNameDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:label="plx_StockOptionsAndRestrictedSharesMember" xlink:title="plx_StockOptionsAndRestrictedSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_StockOptionsAndRestrictedSharesMember" xlink:title="Presentation : us-gaap_AntidilutiveSecuritiesNameDomain to plx_StockOptionsAndRestrictedSharesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:title="us-gaap_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioTwoMember" xlink:label="plx_ScenarioTwoMember" xlink:title="plx_ScenarioTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioTwoMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioTwoMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioThreeMember" xlink:label="plx_ScenarioThreeMember" xlink:title="plx_ScenarioThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioThreeMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioThreeMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioFourMember" xlink:label="plx_ScenarioFourMember" xlink:title="plx_ScenarioFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioFourMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioFourMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ScenarioOneMember" xlink:label="plx_ScenarioOneMember" xlink:title="plx_ScenarioOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="plx_ScenarioOneMember" xlink:title="Presentation : us-gaap_ScenarioUnspecifiedDomain to plx_ScenarioOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:title="Presentation : us-gaap_StatementScenarioAxis to us-gaap_ScenarioUnspecifiedDomain" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="Presentation : us-gaap_TypeOfArrangementAxis to us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sapp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" xlink:title="plx_NatureOfOperationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to plx_NatureOfOperationsPolicyTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtPolicyTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sap">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccbs">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:title="us-gaap_AccountsPayableTradeCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableTradeCurrent" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:title="us-gaap_AccountsPayableOtherCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" xlink:title="Presentation : us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableOtherCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AccountsReceivableNetCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_InventoryNet" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:title="us-gaap_OtherReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_OtherReceivablesNetCurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:title="us-gaap_DeferredCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DeferredCosts" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:title="us-gaap_DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DeferredRevenueCurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:title="us-gaap_ConvertibleDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_ConvertibleDebtNoncurrent" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:title="us-gaap_DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_DeferredRevenueNoncurrent" order="1.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_LongTermDebtNoncurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_CommitmentsAndContingencies" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_Liabilities" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesNoncurrentAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquity" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocf">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="plx_DepreciationAmortizationAndAssetImpairment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_DepreciationAmortizationAndAssetImpairment" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to plx_DepreciationAmortizationAndAssetImpairment" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:title="us-gaap_AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AmortizationOfFinancingCosts" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_PensionAndOtherPostretirementBenefitExpense" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInDeferredRevenue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInInventories" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:title="us-gaap_ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromConvertibleDebt" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromStockOptionsExercised" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_IncreaseDecreaseInRestrictedCash" order="1.875" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2.375" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetIncomeLoss" order="1" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="8.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions" xlink:title="plx_CashlessExerciseOfStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="plx_CashlessExerciseOfStockOptions" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to plx_CashlessExerciseOfStockOptions" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="plx_SupplementalOfferingAndStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to plx_SupplementalOfferingAndStockIssuanceCosts" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-std">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements" use="optional" priority="0" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" use="optional" priority="0" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" use="optional" priority="0" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromStockOptionsExercised" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" use="optional" priority="0" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" use="optional" priority="0" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="0" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" use="optional" priority="0" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:title="Presentation : us-gaap_OptionIndexedToIssuersEquityEquityAxis to us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" xlink:title="plx_EmployeeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="plx_EmployeeMember" xlink:title="Presentation : us-gaap_OptionIndexedToIssuersEquityTypeDomain to plx_EmployeeMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_EmployeeAndNonemployeeMember" xlink:label="plx_EmployeeAndNonemployeeMember" xlink:title="plx_EmployeeAndNonemployeeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="plx_EmployeeAndNonemployeeMember" xlink:title="Presentation : us-gaap_OptionIndexedToIssuersEquityTypeDomain to plx_EmployeeAndNonemployeeMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:title="us-gaap_ScheduleOfStockByClassTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_ClassOfStockLineItems" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_OptionIndexedToIssuersEquityEquityAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:title="us-gaap_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_ScheduleOfStockByClassTable to us-gaap_TitleOfIndividualAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfStockByClassTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : us-gaap_TitleOfIndividualAxis to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="us-gaap_BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_BoardOfDirectorsChairmanMember" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:title="us-gaap_ChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:title="Presentation : us-gaap_TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_ChiefExecutiveOfficerMember" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoo">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareAbstract to us-gaap_EarningsPerShareBasicAndDiluted" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses" xlink:title="plx_OtherGainsLosses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_OtherGainsLosses" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_OtherGainsLosses" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_GrantsAndReimbursementsReceivedOrReceivable" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="plx_ResearchDevelopmentAndEngineeringExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to plx_ResearchDevelopmentAndEngineeringExpenseNet" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_CostOfRevenue" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareAbstract" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_GrossProfit" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpense" order="10.96875" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:title="us-gaap_OtherNonoperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingExpense" order="10.875" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:title="us-gaap_OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingIncome" order="10.9375" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ResearchAndDevelopmentExpense" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_Revenues" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_SellingGeneralAndAdministrativeExpense" order="8.5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsoop">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:title="us-gaap_CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_CostOfSalesMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" order="1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" order="1.5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocisecd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:title="us-gaap_RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:title="Presentation : us-gaap_StatementLineItems to plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_NetIncomeLoss" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquity" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvmd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_ConvertibleDebtFairValueDisclosures" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-fvm">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-isoicd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryNet" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryFinishedGoodsNetOfReserves" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryRawMaterialsNetOfReserves" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWriteDown" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWorkInProcessNetOfReserves" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-i">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-it">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-ccsocisecdp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_CommonStockParOrStatedValuePerShare" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_CommonStockSharesAuthorized" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-st">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-se">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/plx-sed">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventTable" use="optional" priority="0" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventLineItems" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" use="optional" priority="0" order="10" />
    <link:loc xlink:type="locator" xlink:href="plx-20140930.xsd#plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:label="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently" use="optional" priority="0" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" use="optional" priority="0" order="10" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!1PT*[H0$``!@-```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,EUUOPB`4AN^7[#\TW"Z6
MXC;G%JL7^[C<3.9^`"NGEDB!`#K]]Z/XD<5T&C.3<5-2X)SW*4G?O`Q&RUHD
M"S"6*YDCDF8H`5DHQN4T1Q^3ETX?)=91R:A0$G*T`HM&P\N+P62EP2:^6MH<
M5<[I!XQM44%-;:HT2+]2*E-3YU_-%&M:S.@4<#?+>KA0TH%T'=?T0,/!$Y1T
M+ESRO/33:Q(#PJ+D<;VQT<H1U5KP@CI/BA>2[:ET-@JIKPQ[;,6UO?(8"+<J
M-"N_"VSJWOS1&,X@&5/C7FGM,?!2X"]E9I]*S=+#35HH55GR`I@JYK4_@=1J
M`Y39"L#5(@UC6E,NM]P'],-FB\-`S@S2?%]H?")'-Q*.ZT@X;B+AN(V$HQ<)
MQUTD'/U(..XCX2!9+""Q."J)Q5))+)Y*8C%5$HNKDEALE?R7KSJ?.P&'Y]]_
MW-#F2/"Q;B7`GMFLUDV/*5?4`'MWQB?TLP/\['V(P^?7L5':^B1OX/13V$;U
MIKJC?2,PCL,NK+>%WIVBOP6<+KB7NJ&Y9S!@+=HXW&N&WP```/__`P!02P,$
M%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`
M).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?
M5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61
M,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,
M0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@
M\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`
M"````"$`T45'SVP!``"="P``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````O);+
M:L,P$$7WA?Z#T;Z1Y21.4F)G4PK9MND'"'O\(+9D)/61O^]@@M-`F&8AM#%(
MPC.'<^7!V]U/WT5?8&RK5<;$+&81J$*7K:HS]G%X?5JSR#JI2MEI!1D[@66[
M_/%A^P:==/B2;=K!1EA%V8PUS@W/G-NB@5[:F1Y`X4FE32\=+DW-!UD<90T\
MB>.4F[\U6'Y5,]J7&3/[$OL?3@-V_K^VKJJV@!==?/:@W(T6_%N;HVT`'!:5
MI@:7L6G+\O%D/4-BQF_#B'E@&C$G<;S*<1@:7,2,2SX^!0416@EI9!4XGQ5E
M1B2!:41"XH26(T@[H>70;M+04:545`F.87]3SS;20/GN#`YUBX7/D^]JFZ(1
M/F&F>7L!F;;.(Y@<-Z&#(G,2P=60;I:!@UJ2MR8TC:!QO'Y2TY4E;G%,VMGX
MS,JZ4X<_9I=/>UQ3_1<^V]]A8T'!>'5Q!\R&@A&AU8C)#;_ZJ<Y_`0``__\#
M`%!+`P04``8`"````"$`)I=ME&\"``!K!@``#P```'AL+W=O<FMB;V]K+GAM
M;)2577.B,!2&[W=F_P.3^RT?]GNJ'8K8S=1B1]!>,BE$R30D#,2J_WX/N-(H
MG8Z]@B3DR7G?\QKO[C<Y-SYH63$I^L@^LY!!12)3)I9]-(M&?ZZ142DB4L*E
MH'VTI16Z'_S^=;>6Y?N;E.\&`$351YE2Q:UI5DE&<U*=R8(*6%G(,B<*AN72
MK(J2DK3**%4Y-QW+NC1SP@3:$6[+4QARL6`)'<IDE5.A=I"2<J*@_"IC184&
M=PO&Z7RGR"!%$9`<ZMYP9'!2*3]EBJ9]=`%#N:8'$^6J>%@Q#JLW/:N'S$$K
M\J4T4KH@*ZXBD+>G@U_.N>-<UE_65LP975>?F^JAL7EE(I7K^E.P=MN.>E#`
MNEEZ9:G*8-VRK';N+V7+3.TG`6]J_,9!.*=Y&J*1MW<DAD[%OE!,;6,L=NXS
M"2VL7<>@S$9&><O@I<2I71>N4[Q),/2#T!_&\!9.QGCH1C!X<,=NX/DZ!5+1
M8IP3,6$$M&<=T],HC=\G%/.?`CI:3><:YOQGQ3@:!MQO-5W\#`-"VFHN-4P3
MC=-%@9`6<Z5AKHZK"?%C@$?8<X,H=CUO,@LB'#S&+]`R#^L.VS<:YOH8@X.Y
M'T23*?9#[>0ZJ*T1-\=[1BZ>QG-W///C9]\-9U-H:1#IVP\B9AWO#Z.)]Q1'
M4S<(72_"D#-]+_2C/=KNY/-[V7HD'#U:=B>AFO`X(F\<+K5/YQT]3W8GE]\7
MH0?*T1-E=Y*I%Q$F&4U7G,9R`;_;#[C;M(+L`TXGFE]W)!Y211@_$*9'T^YD
ML]N9KQAZ+NTFF&:36;B0$L(3N"GK1WW5-*TW]_\3@W\```#__P,`4$L#!!0`
M!@`(````(0#WUB6S-`,``'<*```8````>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&ULG%9=;YLP%'V?M/^`>`\$$B")DE0ET*W2)DW3/IX=,,$J8&0[3?OO=XU#
M@DD+U5X2\#WWX.-S[>OUW4M9&,^8<4*KC>E84]/`54)34ATVYN]?#Y.%:7"!
MJA05M,(;\Q5S\V[[^=/Z1-D3SS$6!C!4?&/F0M0KV^9)CDO$+5KC"B(99242
M\,H.-J\91FF35!:V.YWZ=HE(92J&%?L(!\TRDN"()L<25T*1,%P@`?/G.:EY
MRU8F'Z$K$7LZUI.$EC50[$E!Q&M#:AIELGH\5)2A?0&Z7YPY2EKNYN6&OB0)
MHYQFP@(Z6TWT5O/27MK`M%VG!!3(93<8SC;FO;.*%Z:]73?K\X?@$^\\&SRG
MIR^,I-](A6&QP29IP)[2)PE]3.40)-LWV0^-`3^8D>(,'0OQDYZ^8G+(!;CM
M@2"I:Y6^1I@GL*!`8[F>9$IH`1.`7Z,DLC)@0=!+\W\BJ<@WYLRWO&`Z<P!N
M[#$7#T12FD9RY(*6?Q7(.5,I$O=,`AEG$L>UW(7G>/XXBZUFU`B,D$#;-:,G
M`XH&OLEK)$O060%SJTS-XZ+U/:F@49+<2Y:&"U1PL.=Y&WAK^QF6-#E#0@4)
M3.,"\7P=LFLA<@$E;=0.7',</25N$=(]4'21!8O5ES4#V]\VK%4ADW05;J!_
M+WP#HB-VMPBO1Q+=0ER=)+Y%=$@TH;/_$2J3-B9\Y.)%T/,B5)!Y!](S=#>*
MB$81\1!"DPD3Z?LY?W<#MG[*)-AJ'0U!SXI0089DCB*B440\A-!D@J2NS.%R
ME>">BPN]CD(%630[T@EF>G37C?K3I1Z-NM'`G^O1N!MUG>7UPYH>7]<C3Y?Q
M;2B3>KIZ<PL59,BV440TBHB'$)I,.-6ZMDF9X]4IDT:J4T&&9(XBHE%$/(30
M9,K;3*=7#%>G!/=<O!9)<[R'"J*J<^+WMN:N&YW->Z=/U(U.%OVVT(U"C[TF
M*SVJT:L^6&)VP#M<%-Q(Z%$V<1>VRV54W2]"9P7="9I,;SR">T<S;E\"T/=K
M=,#?$3N0BAL%SH!R:@6P89BZ.:@70>NFU^RI@([?/.9PP</0]Z86@#-*1?LB
MN]OERKC]!P``__\#`%!+`P04``8`"````"$`GW47>P$#``!W"```&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6R45EUOFS`4?9^T_V#YO7PX@9`HI&I2
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M7^TB[&[6K3]_.#NJP3-2A3A^D3S]QFL&9D.:3`+V0CP8Z'UJ7L%D]\7LNS8!
M/R1*648/I?XICE\9SPL-V0X@(!/7*GV^92H!0X'&(8%A2D0)`N"**FXJ`PRA
M3^W]R%-=Q'@6.L'"F_D`1WNF]!TWE!@E!Z5%]=>"_!.5)2$G$KB?2/S`F9-@
M$7V$979B@7O'0AP2!7X0_E^+:^-J;;JEFF[64AP1E!XH5PTUA>RO@+GSQT;3
M._:68>"4(;DQ+#%>8`1>*$CRXX80;^T^0F:2$V9K,7#M,?X8L>L0)J$@K]<(
MO@TUOIZ[3HH!&RDFET;;UKX8KDLFZ[Z"B'K(2`DX=+D2`X9Z&08<3I;>6LQ\
M@`GZE5OYN_<0(VU`<KDV`XXQ!'Y.1GB.V1IG,5&;3C\,/?A-M`T19#:'UG9&
MC+3!7KE<FP&/M1$R*96MQ<Q;;><UK6/V6]A^6[ZM*?R()@,>:_(74TT68]<-
M_,4K?HT0`9F]Z1?LI,O],N"IMFF=68S5%D9FX:EK0\1B"2UN@!CETIR,@X[Q
M_FXTX+$V0J;:+*:K,R-MJLTBH-KZ:CWO$JO-'@"VLU5,YFS'RE*A1!Q,<_>A
M%OJW_;ES0]JCH_\`?;^A.?M.9<YKA4J6P53/64`]27MRV($63=LW]T)#QV\?
M"SC@&30;SP%P)H3N!J:5]7\9-O\```#__P,`4$L#!!0`!@`(````(0##F<2&
M60(``#\%```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)14RV[;,!"\
M%^@_$+Q'M&0KC@W+05S#;8`&*(H^SC2UD@B+HD#2<?+W79)^-2Y:]R**XNSL
MSNQ2L_L7U9)G,%;JKJ!I,J`$.J%+V=4%_?YM=7-'B76\*WFK.RCH*UAZ/W__
M;K;39F,;`$>0H;,%;9SKIXQ9T8#B-M$]='A2::.XPZVIF>T-\#($J99E@\$M
M4UQV-#),S34<NJJD@*466P6=BR0&6NZP?MO(WA[8E+B&3G&SV?8W0JL>*=:R
ME>XUD%*BQ/2Q[K3AZQ9UOZ0C+@[<87-!KZ0PVNK*)4C'8J&7FB=LPI!I/BLE
M*O"V$P-501_2Z6)$V7P6_/DA86?/WHEM].ZCD>5GV0&:C6WR#5AKO?'0Q])_
MPF!V$;T*#?AB2`D5W[;NJ]Y]`EDW#KN=HR"O:UJ^+L$*-!1IDBSW3$*W6``^
MB9)^,M`0_A+6G2Q=4]#A;9*/!\,4X60-UJVDIZ1$;*W3ZF<$I7NJ2)+M27#=
MDZ19DMWE:7[[;Q86*PH"E]SQ^<SH'<&AP9RVYWX$TRDR>V5#].?/RE"2CWGP
M02$4T1:[\3S/LN&,/:.%8H]91,R8DA/FB&"8_%@!9CVOX.^9/?AMYM&1-U2W
MB)AQZ.AYHN'_)/)@M.*L_'2<OTD4,:,SS`GQFT2$7"_1@PN*(D[&92?>*#%B
M)L'Z?)*<'(AIXR#'/BLP-7R`MK5$Z*T?TA3#CE_C_5G@_<F"8<<#G-^>U_#$
M32T[2UJH,'20C'%@3;P!<>-T'QJRU@XG-[PV^*,"G)-!@N!*:W?8^#MV_/7-
M?P$``/__`P!02P,$%``&``@````A`$[^2"[G!```=!0``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3<N>&ULG%A;CZLV$'ZOU/^`>#]<S&43E.1HN;5':J6J
MZN69$"=!"S@"=K/[[SO&W&Q8G.U+"/;GSS.?9^S!N^_O1:Z\X:K.2+E73<U0
M%5RFY)25E[WZ]U_QMXVJU$U2GI*<E'BO?N!:_7[X^:?=G50O]17C1@&&LMZK
MUZ:Y>;I>IU=<)+5&;KB$GC.IBJ2!U^JBU[<*)Z=V4)'KR#!<O4BR4F4,7O4(
M!SF?LQ2')'TM<-DPD@KG20/VU]?L5O=L1?H(79%4+Z^W;RDI;D!QS/*L^6A)
M5:5(O1^7DE3),0>_WTT[27ON]F5&7V1I16IR;C2@TYFA<Y^W^E8'IL/NE($'
M5':EPN>]^FQZL>FJ^F'7"O1/AN_UY+]27\G]ERH[_9:5&-2&=:(K<"3DA4)_
MG&@3#-9GH^-V!?ZHE!,^)Z]Y\R>Y_XJSR[6!Y7;`(^J8=_H(<9V"HD"C(8<R
MI20'`^!7*3(:&J!(\MX^[]FIN>Y5R]6<)\,R`:X<<=W$&:54E?2U;DCQ+P.9
M'14C01V)!=9W_4A#&\=TW"^PV!T+/'N6[==9P.K6(7C^?X?<C@2>'0ERM8WC
MV.[F22J+SB1N5RQ,FN2PJ\A=@30`$>M;0I/*]("Y7RHF[+!XGZT=+!HE>:8L
M>_5)56!9:@BXMP-"[DY_@R!).XP_QY@\(N@1-"(H;=@W3&F?^$%1C^D'Q:P!
M?@=;QGET\'IP'2)DZOIR=/8>4C#UL)_&[QO&:1!O63!'.(+Q(8-,;45HP]-$
M"QAK]*@5*E[`#"R<SY`-4Y_I<EN0W^N^TT&<[V)#(#:$K(%W;#N8U!H=+6`L
M0<-X"6,-/)QKD*)3U]9=HF#.);$A$!M"UL"Y9!F#*<RE!S!QCX%(XNR'''[<
M?@J&I9L$.;)LWAB?86"Z(1$<'A%($:$4$4D1\1J"4P#VGZD"CP4G';17(0$&
M+Y$E^.DSS)H24D0H14121,P0;KM!FJ:U,<;XX82`C70JQ'HH4[`H@+CW,LRF
MG=BVC,F\;=P&TW[:/=K5]H>L?T7`2(J(IW/P-G"^TR)0.)#D.Q0=)&H@[+4^
MPZSX$$@1H10121$Q0_1!X&Z,<3/GA-CR0JP'`06+`@@'B<\P:P)($>$<@2QQ
M7W\`$\\Q8\YR*IAP.DWC85V&%BWH8`O!['>@-2'DD+"#=.OHS),FXA!;"A`L
MB5>GX66`<^<+,E"T*,,89FU.^R8#K<H@A80=R[;=6BS-$K(NXOK1K#]>M8*7
M@!8YDYU!$@FL).+.!5NH+GR3@58ED$+"!19DCT4*JPP60<*)'2^`/DL+6AA-
MQ'CLK#19.<6+,L[0Q04#K8HBA83=5"P]%K-#RA%W',N6\+$!F*D<DMB@:#$]
MQ"/39*#ER5NE`CDD'"#TFTC8D".NTQ0,B(?>L;(9EXKWGE98DV"0>,_J,3X(
MA+3UZ><Z2+3JO102+K`@>Z:"E"=>X/E,"EIB3:1X,"]88<9+(AQK/MR82"61
M0L*.A95B:#NOQ2(.82++M;>S<V-M'A8:['*&?>H7N+K@`.=YK:3DE5Z\.+!=
M#ZW#I="S33]OA7;?].##?-X>FAY\>\_;?>3Y2SP!\N";BG[T#!/`G<\MN>#?
MD^J2E;62XS.89FCT-J-BMT;LI2&W]J+B2!JX[6G_7N%V#\,5@:$!^$Q(T[_0
M"8;[PL-_````__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL
M+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$
M;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8
MRTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;
M'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',
M3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ
M`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>
M3!<QM6)M85W?_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?
M!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;
MU69]>\W!&Y#%-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'
M3#C;+85O`'RCFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.
M1H)BS0!O$ER8L4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?
M_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY
M$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^
M%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`
M]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N
M,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7
MZ0RN=FRS=Q=U."O3>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!
M7/A%7$\J\'1`&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P
M:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:
M!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W
M1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[
M6MEX3RAC`S5GY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5
M#D*<0-]>\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.
M&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y
M:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<
ME,7*DB):#QL,^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN
M)B>+T5';:S76&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ
M-PEJ</MA[;ZDL%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'P
MKTD!=G1=2R83XJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J
M@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N
M_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!
MT0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>
M94FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3S
MS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!
MS`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4
M(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>
M,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;Q
MT7UP]`Y\-I@Q)4TPP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(
M````(0!P'O#].@L```1A```-````>&PO<W1Y;&5S+GAM;-1=;6_CN!'^7J#_
M0="VQ1W0Q+8LQW8NSF'M1.T"V_1PFZ(%>D6AV'*BBUY<6=Y-[M#_WAE2+T._
M2%1$F]L+;F/+YLPSSPR'Y)!2KKY_"0/CLY>L_3B:F+WSKFEXT3Q>^-'CQ/S;
MO7,V,HUUZD8+-X@C;V*^>FOS^^O?_N9JG;X&WJ<GSTL-$!&M)^93FJXN.YWU
M_,D+W?5YO/(B^&09)Z&;PMODL;->)9Z[6&.C,.A8W>Y%)W3]R.02+L.YC)#0
M39XWJ[-Y'*[<U'_P`S]]9;),(YQ??GB,XL1]"`#J2\]VY[EL]F9'?.C/DW@=
M+]-S$->)ETM_[NVB''?&'9!T?15M0B=,U\8\WD3IQ+2*2P;_Y,-B8EZ8!C=Y
M%B\`Q!_^LXG3[W['?[W[X[MWW7]_^]T_?_06__KIF]W/?OK6[.1JB$SP0;7,
M\VZE6/B82^YD%EQ?+>.(&`*@&4&7SU'\)7+P,P@&,`^_=GVU_L7X[`9PI8?P
MYG$0)T8*7@;[V)7(#3W^C9D;^`^)CU];NJ$?O/++%EY@@9%]+_3!37BQPS6<
M5L\#HLEM&B$,P:8^7J$VA6"2BQ>K;7)_WF.3H&M0KZL-?X(N9D6U7<IT[<;%
M#H=M=!6^(GJ2QX>)Z3B00WK=+M)*'78D9>-9%_2=3-G%X&26]9V^,U1JF1"+
MNWY#A7U')94U"IWWPYN3T:E>V2'KLC1\JAZ`'4XMBSYTW8K^/73PYQ1Q<N(!
M3:G'8`*7O@_\QX@/M^O-"F9T\\1?I<C</GJ/:BVS31AZ6`(H,_2]'WIKX\[[
M8OP8AVZ$(.G0RKXMS`R$\%<OOF"H5G2["4XS,]KIDHR)6HL;^VH?F<5HO9L^
M&LL_1*(:'2SLUA"/?A`4,_V^C7-AN')]!8N.U$LB!]X8V>O[UQ7,A"-8'V$@
M=_CW:K[]F+BO/8O-!^4:K./`7R"*QQF;?V?6SBYNG=DMTTN0R:(X(-1Q9L,C
M"+V=CF?JD<[&8]5"+0=^%`M]/\`?Q4(=^&^FC--L3+!5@2SD&:F/Z^7N^7`\
M'H]Z%Z/1:&SW>[;-2'[((MJ/%MZ+ATMH933M(A@`@G%_-+ZP`$C7'C%5)T70
M!P##P6`TZ(TM&_YG@]WQ$:CF=&#J]BI!H,FK!($FK[(E6T=!YL]Z"A2"-/=5
M@D"35PD"35X=*L[`0^U>)0@T>94@T.155FA4V%>A*JRYKQ($FKQ*$&CRJK+)
M9Y:!Q]J]2A!H\BI!<&JOYLNJV>VMP\I.NS.SP_-CMI*#M>-#G"R@`)/O$_7Z
ML&[CUZZO`F^9PBHQ\1^?\'<:K^#?ASA-80/J^FKANX]QY`;PLI.WR']7M(0M
M.MB-FYCIDS]_!F5"[87CY2J.I:'(1#;.\.VAW1W:`^N"+Z(4J0Z]A;\)=ZTK
M=.^-%:`1N:TWG'`8%4JR<"BKD!WT0N8^R1;,U<S3D@T@)O*0D&RAPL:R(B]K
M(VDA9R-I(&DC:2%K(W2=?9TK9W(1;V!W>-O!CC/J=GG9459/M4`"?$_$[`=!
MVNSR6=MD#Z.U;9K:"OEEIV],+?QA,]8]EM:TV+6SIL$>*VM:R-HHQDWN74%X
M44[`]+P'R1;?PM??!@,4\88YGJTDF.4GK*KR;1GI=">:NZ-GRQ15>J3-V,-N
M*].ST10&Y[D7!)]PN/S'LABAH1!U??6R)$<NX!P,GDG`$QWX$JJ]V4L^&O,W
MP-JA1M;!1H:[6@6O=YOPP4L<=CB&J6!7L:I<OINR:43YGNWPA!XKI9E<S`])
MG'KSE!W>897\0WCZ!_#T,D$R>-KHMP_H!YZD^6BC'THU>YT(O&C5#\$EK5]E
M/$"1(^<#7$"#N@J/2@2P(,\1@!-T(,!C55G'AO#4@0`6.CD""-`2`<"IB(HV
M_:!'LAG$0*D2]!]+)>28W$I!Y1&M/)1^07^%E8Z0?EO13/(M!'I),[RI`-!*
MY:$4JRO%$+=#3RLI@#<5%#@PZJH9\GJ'<KXV0DC2!0PE(Y`&JAA1%Y4DYX+.
M$D`U(U.%\Q`2%)B*=$,`.%H@$$?T-(V_/8I!TPA,HT'3$$PA"&/P"?L$]80P
M0FK"`'BT](IRGM`31HP3TD`@Z,J0)!HL72F28M"5(TM76+I2)(&@*T-23^A*
MD12#KAQ)7*$K11((P(B6#$D]H2M%4@RZ<F3IBKZN%$D@Z,J0Q!/](Z?(#BV;
M\B(JJ9\.NF^JGQHOR]I":N_0H@G\GC?GJR>^<@1?L+4464KCC6PNGH['VJGQ
M%"?^+[#(Q!O:YG#!2TR\`3+UY_3*E\1=W7LOL!3ENT(OR\.U7D"2US>V@U%$
M>!!3J1_JWJ;11+ER?EI@:4]$K>5L45];F-^*#+&X71LAM2"PN*,;`W*=85`>
M`HJZ"/9<W33!(*D=`W45XLEJSG!9F$.(N<(!YC#YU&2SVE@ERO&EE.Z#>>JT
MVEID(EPXR=EZ!)XM\)I2Y6V(@'F!4BPT-[#=>SIZ-AZ]<&6G%%X+JGHPF6V&
MI6+_M[DPA1U=>?0K=KKJSMG"Z<JI:I(BE0<)]1,>QA&GD@;>8<-&%794H%,U
MI]4%C1^2KD)F5>QSO6D(54>:=%P?'&#585'NP/^'P.8W.55%#Z6EOUW3JPH?
MA^W"*9V/'1O+;C`5"8`=U]OAB:QK&F#;O[H2YU62[%'$?'(!0ZQTGGJ3/T\Y
MAJLT#W=/Y>-UFFWALF*&<$9,RN>[RIH[O810,]-IQQ+04JZJX(%%E22]"1,?
M6-_6E6K0R;#Z)LQRG4GY9(BZ,J^U?37CR%L`'61HMX>("?!-7GL+0IJXQ6BK
M21A?`4)8#%:E-/T(:RAL.ZVKG[[HFOS6(SL8=RHX^WFS3OWE:ZM2PU$!\C&A
MS3KTF*L:%?3!LTH:5D=JAODFX\!7%O:8[)<:*MML$PZVW<A-#.(M#,4FG8'/
M6H(G5'9_;YP9[^<XD!13(>P(#QL_@)N'<?<--U#GT+_B<,HO9EM>5;**1&WA
M$HK(@BAN*@LD\*1OX:8ZD06E\J:R0#V7U0=KB2RXOZ.Q+(CW3!8>>2AQV;"M
MT107-,EDB=S#OJF4+'N?'W$N0G"AR3*XJ*S2C\`<E04F-Y55^A$/)I1\]<'D
MIK)*/P)"(LL&)4UEE7X$+U!9$&Y-915^M$7N!Y+<7^SUHQBKN),O@XO**OTH
MQFI?,E:IK-*/8JRBR4UQE7X$J91[^*"IK-*/8IZP)?,$M;'TH\C]0)+[[8PJ
M1KPE&?%<2ND[>$4XPFJ&#$=<2NDU,<K[DE'.I93^$N/;EHQO+J7T%,@C%MGP
M@;Q%A8_Z(KNV)+M3=Y%G73%@<)R1@0&/WYMO`GC&=(Q/J&8G5;">0`S"W2LI
M24_>_-F8P8V'A2"Q/^`P*B/H]F45N)&;QLFK@:=3"G&BTP>2XOX4QP5'H@0+
MWLH`^C,\SQL>%6X`+YPA,8;Q9$(3,45?$.G!H^I-Q$!KCD:,/SQ4W$0,M.9B
MQ*2*\R<9,1^BU:;PD)A+<>B6$?'1CYZ]A1@Y(L,X,Y:1=.=MTL0MXD_L4I8D
M,7=XNVHA0TP1_#F2^;VUV?SS#NY.S4G$DSND[^`<6@;X7S<IH1%;$2&XTRXC
MY-Y/X9[_O!,+(A"6E(@83HP5(K8RBJ2,O[M)A+U%Z+I;,7K`HO+\'<S^%R_E
MK<N,]Q2?>,]N:B[6`T#4PENZFR"]+SZ<F.7KO["G:4`P9=_ZP?\<ITS$Q"Q?
M?\3'E$`OABHYI)N/:WCT!?PV-HD_,7^]G0['-[>.=3;J3D=G=M\;G(T'TYNS
M@3V;WMPXXZ[5G?T7*,,_#W`)SY=O\?A]]F<"X`1>S[Y<!_"0_B0S-@/_J;PV
M,<D;#I]M=@!LV$K(C>BLBS]?</T_````__\#`%!+`P04``8`"````"$`4<P;
M*]<A``!\8P``%````'AL+W-H87)E9%-T<FEN9W,N>&UL[%W=<MM(=KY/5=ZA
M2^4MRU64+$JVQYZ,O451D,P,17)(RCM34[D`08C"#`AP\&-9<[47>8/<)E53
MR47N\A"S;[)/DN\[W0V``"AIUCN5FZ12B4PTND^?/N<[OXWYZH^?UJ'ZZ"=I
M$$=O][J'1WO*C[QX&42KMWM7\_.#UWLJS=QHZ89QY+_=N_/3O3^^^\=_^"I-
M,X5WH_3MWDV6;;Y\_CSU;ORUFQ[&&S_"D^LX6;L9_IFLGJ>;Q'>7Z8WO9^OP
M^?'1T:OG:S>(]I07YU'V=N_5%R_V5!X%/^5^7_]R_/)H[]U7:?#NJ^S=6>SE
M:S_*%,A03I0%V9T:1'I^D/W5\^S=5\\Y5`]_HR[C*+M),73I+^M/9_[F4)T<
M==3Q4?=%_>$H_GBHCKKM#PLR>JUDJ.][BS1+7"_[E_JT3^L_%%/-[S9^_>'3
M[M'!-_4?>V#`4IAP'KJK^M.GUVZ8-B8J5IGX21"3=4MUYF:[QYT'J>>&ZCO?
M3=0YF)XVUFEC6K&,>=VLUC[!-R?U.>>)2VE3L[OU(@[K3Y].AM_6?S,B,/57
M`1D.P1BYZ\:NGDZFXWEO./A6G0[&\_?.M#=QKN:#_JRC!J/^X8Y)^Y"S!#P8
M0'8^J:_]N_JXIT='1UT(\/'K;OU1/T\2BFF5C;MX_O3@H'M\<-*8P^SM/`C]
M1/5Q6*LX:=+0\SP?`_!XB=7P5YT4,TT_7J_C2,VRV/NQHV8W;N*G:IQGHM%@
M>OVU_GATYHQFSIG"7[/Q<'#6F^,?I[UA;]1WU.R]X\QG:O]J=J:>/*N_/(C4
M_";.4VAIVH$VAWZ:JCB[\9/;(/55NO&]X#IH:N29[T$CM=(UI*-_-9TZH[GJ
MS698^LOZFGTWO1%8\/B'_U,>?'1#G$%#<L$Q`DNJ$M_S,6@1^NI`4?8:@C,F
MR<I-4[\YS2#ZB-GC)/`;*\SC#'+C&1EH?_W\:G0V@_BIJ3.;./VY&I\KYW(R
M''_G.&HZN'@/[EY-QGP^'TR=2^R\OF-(]<29SK]3O=&9<KZY&DPXJJ-&3F/H
MF7/N@'LXS/>]Z84SJT^E*6ZGM.#7QKT39A%[7<]+<B!-XQAV\[&^YIE_[4-+
MEC@'<#)_B(UAX"Z",,A:^#T<CR[4W)E>JN&@=SH8#N8#IT5`8IQ8D@4\[RC.
MFNL-S0IW*HA@CJ+(]S(8%74;9#?X=QBZBQB*QI]@V/1?]4T]_?677W^I_UA.
M#$NE_/4FC.]\7R7!Z@9BF&\P8>)G0>(3U>LOZZ.!R5VIS$_6ZAX^F*&[&=4?
M7UX.YI22A@3T>Y,!,%)!4@;]@3/J?[>#D')V%?F9BJ^5YVX""OS2OPZ\`#Y#
M`Z5V@,EL#DP1:BC]%.;>?`"T>1RL^)\\?Y-I*%-+-W-_"]*</-HS.*GSX;=N
M9K<S,'4^.*.KIC;BF":]T7=/9X#9WM0A2O3'PV'O=*P9I'H74Z<5$OKCF2#)
MKIDOIN/93`$XS@<-C``0.;UI_[W`R1E(&XX%4)3S[826H"$R0Z+Z@5K1[J8"
MO8D?K!=YDHH@IW7&/;A`*W3-G.%P,+KHJ`MG!`$9"GF]L\O!:#";DQ\?G)T4
M&I$".@RQ[SH]YX,1;-D`4^[:83D"?L+XTMD]@WZN]NU,S\"8%AS&3T**.A]/
M%3P1!9D?C,_J\Q;#\-C(`!2$V@N#,)N/^U\W</>T-QOT]=$-AE<PU?4Y_^30
MJ,`$]#Z`C1>.&EU=GF)Z3"Q2-N-?U274%:V_R-[E!.Z2X2))-C0=P!VHK=J@
MZ[=JR_X$G@E\=N`A'-!GNZ!@ZJ=P33UM\<]@0,)X(SZQ\PDQ!WR,[R_]]<)/
M&@ZX8]%WYB<?`\_7^'&P<%-8(CA)?%LPOJ-Z81A[!N^OU=3WXE44_(QAQJWM
MQRGD_OMA$/EJD/GKM+&8N%EF;J\R=_UL+OP(]B04'>HMUT$DWFP6?/350_MY
MB+]RJN][(QA].<L&S._B\"E\ZBBB.W[JAF[D-9RC79N#+0O%'<UBQ(MP-V$M
M:30;>/"8">"E9DG@T;O5<[FW;K+L6-,#>WKM!UE.9Q:6J-MY??)"I>+<UGGL
M?/(3C]XGQAF"-'1A:E!JK7*J]H/("_,E9J1]\\UK#1]WA(=A#`2D38>\*K@$
M"*T:RT82TNS@8=4KWRFRC9,@B6:7#;)^7Z;>M_+WW8;\?R[/[UL.X51%..\;
MV5LNX3;&$11LXP;+`S"O;UR672@!GS=?YUJ,X:?"K<EV'L_4WT#\@%FP@6M&
M%DK"G>S&C=231E3W=]#7QR'DYR^TVW'Y'"&KJ&Q=5ZK:T,%9)0HA7-X`GNUA
MO3R[010&7&Y,UQ[";GN=_=[LO3H?CO^TT^NLC#B?CB^MGPISV.O#^V@/-BPZ
MU&GJ+7_(TXR6BO$G@E0&0(`?Q*)QY"%^%]`17,&O!"`)9W-:)\BMB3L`RD@N
M!1\E&FJ87#D=I2W:?5;GC(+K!=K",:B[38+,5\OX%@M=J^O@$Q9MCPG/@P@F
M(8!&^=K>:MB,UW[GF0;G?6;UPCL\]Z`(*TP;7"/>0W3@IPW0ZLN0E#N4P!+K
MVC#G3O#5HO,C8Z8+K*T056E]!$3GS/]Q>F@JD@\2MOS&.7OK&,'CSX4_L/07
MF0K2-*=M1'A(7X!,E-^72)\1"NK'7]EHY2@EOR`OVUTCR&T<*Y(C2)W"@&$;
M"+6V8V?B'ZT6(3&*HP.;?-B0Z#AJ<'P0E9.!Y8V$"'<B"9L=`E`0PW6%K&>D
M*]B=%"G>P+!BQ;:40G4K1=C;V``5[$'5:+"_5'91Y<'H@S,3S_8>59[D\#/)
M=^C$)N&Q(>E,_E!]Q>FL+\/4D%9R(W+6A5GZFS@-&E(!T8*L_&UB*MI6)Z#!
M')Y+FE$X2MRHOU3'.1/\/(QS8(KG^TO0G\3K4B7`+F#:_2F7%@>A3E:Q%RSS
M,:`:+X`)&G_NW8]S?F[S:M\B[04/6"%<=)3^&^$.HFK(0V,]A&B(YJ9.;^:H
M_3-'__5,.\^P%4RV":N8<?O0&[8E4VR6E!$51:[M'=6;JU/G8C`:,;+"R/90
M\+%3.2!KYR2SJ\ED*`F#WO0[[`31YZ6D6LB$BA)@CK935Z,Q>?)A//Q`6DM!
M:6#4H(J'`-LB$*A+`I0)"*;1*E-W4&:Z9O6S:!&/5I^]_MYL<#$:((_58[JX
MWQ]?C43))TAC([?52`0\,/R><@X8XZ@N8OT'IJ@3Z#:*#LP;_OJ+"02WAR>L
M?$T2)I6#3^HTB.?(2KL;/T>(G**$$2%IOL_\)/.5B(3O=,8R`**D^2(-EH'+
M+'5'HI2__OG?X3]MW.CNKW_^#]AJ`AE'WMY@@KL#V'YH6/':74<5"P^SY2'&
M)[Y:!/$&,=;:]80&>`%T,]P(B\!:HUB$*6!]&10M*Z$YE\+`->,P;*4TI71^
MU@NJ=,:7[-Z(MID?1*GQ9<R4AORGJ:`Q=I:YR1W)[/MAZ'S2O`//^+\3_!\B
M4"\,5A&]R;=[:0X$3[TDV&1[SU$H_%G_W#WBO\!%'<VM4>#L\I?D'!5$/60>
MK+'!D7^KIO':C?CTVET'X+=,+,.?RY+9NU__IT''[[,2*Z]?IAL<Q=L]N',I
MLAK^WCO+.KIG^)$E797>I4A2J'U(0,$LRL`A)$BA%HJ'2)B@&'KTIG;J=,'6
M.%,WTB[!#EE!H6>)"7CLH7LK`3G_!H#C3)%"8"VHD*;3PP^0)O@"]40[7W%R
MVEG$3Y?^$K%7!+;W5DPL"_7.98]T*W>S"9$DDH0\1`6.I7B06Q-<1=CZ(:I1
MOB1W(/:0F^P6F8F*9HA0)]:E@M^]I4P@'D((/\CJSZSRZB$H*4ZZ4GD>@W;W
M#@D)%I>/M>I='<X.44R-R4B47Y-\I:K)'AP1S^;\K-@=#!ZX3K5?A;D'O8`3
MXH;7KKC$0?2#KD_HR4NMN`X2%.3!'/WZDNO@[V7N95!?.JFHZ_]\MT8!PM^$
M$!S)F_&,W`T8C(K2,UF`?*3_=2!EAPQ.GL0M=(/<91X2L5&,H=\B!1*7)XFU
M*2A`G%4$3T?+``K;P,@+-T=70()GR-RE/LZDN2^\X%:UN@,22VB@%')U,@.G
MG?B+!&LLR97]B_[9,YR/*P!BC]JB#RC*4]H:2)\&B=;5;\F<,(U+WL'3(!<&
M:>+Z8:`N=6+NCD2\]]T09:%]/L>I%4/&[T4V(3!5E:((F,E.$_=GU+$HW+NG
MJPPJ)[R4A"?DZ40$R,QGM(!5K<1?,6>!,K%R=53,:AFI!;<RB8EXS#@HN)O:
M))110_\&T6<'F9'(7;JR0`^1*K*2@=O*+9P5]ZZE#7($E$0E.C39SNJY<4UC
MK@I<*L33[`)2KX"\T$\3=JS='_#OEAW=-4PGX*N7KT"L-')H=>!\Q1H/:9"(
M^P90X])1+^3Z$/(2T!S$V"E%4U3*#;%"4W1%>&0`I(TIP7*^`)DJ#5."3P5;
MA<F&WXL<P62$T,UL_X<\"5*\1G!K;+A=<Q9`J95:N\F//M.EF(WG`P#DOV89
M4K*H-18(O4#59JDB=$LH9^@,OYN-__JO_TD9G5PCEY(8KX*V0OY-H:X##32S
M9LN1LLF0R1:8(?R(NVX(02(@A!8BI0W0EA0]"8`UWL"`NJO$US@$"OC[PL]N
M?3\J[06]#WEBZ+.*9_[9LQ.04,@K=FX0D50G<;ZZV9ZK8SB%WB"]?3),:[%Q
MBB*EM;"=:5<3P[/&Z0!D*!^?E)`LU3$<@*&3X&L9T5&W<1(N;\&E@B>0->,R
MR6:K+/;;Q*X\T#HC`#B0*=25H?=8'TDRX*0I.1=;Y2(=!6ST?*,\>&2VO9^B
M1KU`8>5VFZ$*P;`^,,P*L+3M'![`LRB8/'A^T&PD\BFQE%*F95`A"&R%OS!`
ML"D(6W-LH.I)^M?0,!@>ZEE3%W'\X"+D?4M@A6S`$EH^,!O.(=\@7@5J(0<A
M%A`P^>35T>&1@DL7TF$"*]J<$U0$/+C>&(`W2'R=\W)R*9*2&20;`V`YKV%#
MN:9;IJ*?O*PLY86P!6RXJNSRP(9/H`?!.WKN+*E;\@W>F3TM@1G@)QV.^EK'
MU<4:\^W:*4`4WI*%/=EN$_C`)3)A"V<T@:52&RR@Q:A9Z)2U&NU`&#9RLHCQ
M8!)?,S#!$4LZU')#T/B1@453-B0KJ%X<_4$.Z17^/_*D`1Q3DQB4^*E#'65O
M@3@VYHDV`SB#;;H`JA7*JOJJ'5,KJELJ9U0,`$#I$/X9M,)D1F$+F#!`Q:/5
MZBL..X3%H[&W&M3"LBV\+PY#E`*+DN_6+9"'<)*@@T"BM;!='ZO-H,K!K>'1
M+LAZ^I)0(LGWK."$(=!$KY761SMGD1@FG.OT*/1E!?<7H^-PV<#-<:3^.8>0
M=U^+TWQ2"18$2>%J@EDT;((Z,V,Y,/O<]VXB1&ZK.[9Q12DR"X@7K$6QEL+`
M6O%`_#0YX7.@J/N7__[+?\5JG-ZZX3)6_23_6;OC08Q.IY^U_:,&:Q^44JHG
M%$]N_+ZS&XPP=%%:VW;,H@H:`N%I:..BM4@[6.*#&[S)RNW"/]/;Q4LIVZB0
M2G$3Z"RX0A*+4X<0R=GYGS)?<N$D8QN0KB'[!WQ=^HS$AD=(Z_DP$&`X)'L3
MPK&0:5LHT,2V/$!"$!*3(O[&V6$B"!!T`J&+'"6XEB=L*UY!?$@U1N.`-8T8
M76P0?Y_KHQ`*T'/DHBBGG87T1R!VI9XB+-XZH!4BJ232@0[W$L&SA0Q+YH/E
M#H3S^352HQI!\1<[S9#\`%I)&B6&=VT$6GL'(`=``#T`C^'$8`-(7\`'[Z@;
M='6IG]`;IR<PPF_V3/?'N#P\S`::'@)'EY#>K;/K%#NGY27$!!FY1QIL;AJ$
MA@BK3-SW*4"_-1-!3UZ4Y@S.!@*6UF65,1U<UL@;0F0M2D;H"DD2]&'TC/0W
M5%*/*DG$^57K6G\O`I&SD94.$3+;:FY8STY1>)"BV")@2VZ9-@ZUM%GCW2:Q
MB(Z"L&"ZW0+D<P>3CU\_BLM:1>HP!(7PZ(5KI:"`-`X#TI30@<!1L.NZ@9QG
M6FQY>FC8\!4:?=GTKI6H#$-MJ_NV6P3W(4Z@Y>":;L/D,F+S2RDZ.7Q9>$4"
M^ER*D,^Q6@]@J4L5;5`XJ(7#+Q!HCD>#N=/7Q(S$6.)L8`;7**K1NZ(6([<9
M)ZAA:5N*Q>86^QC8%I@)+P7^!SN*35SNT;K-).%%?8T0\'K4&+H?*.7?N/0G
M/0E/0/6*7$?B@;49_LERH9A;)A\`&O`E+4%-E2459,>#"9(,>9`4B1"BW$D]
M':)1!6X>0"3`[0A#:\MRM\`Z@FBIJ]Y-S$8F0;TB2\-_14A5ZE2-3;X4*9N"
M=5HHP?8-8V]$\<BW810H%6:94P*#X0;%H?9[+0D!30)!%>2ZB+&,T0'#=HKJ
M/%8&7;&&[,%-8,-6.OC3UEC#/,R_CD2A'&*Q",2E4W1O$"GS3+;BL#F.2&82
M(P"997!J(@@Y/6-((6/DK!S\5IZ:QZ;3GR:(@N"T'$_!6#B6:'W"H&TZ>D1P
M1#I`^8I4/9H"8SPT"74/23!:VP58>\L^&#=H<KZVW2E-]>X>U_6;O*YZE/LP
M/&SOI0TW\G[?`3QC,Y3!:T.&!(V27*-CIHGT$TCINO!"Q=;;3IU4M^=5E)RN
M^Q8O(90+_P8)49+4%JG=9VGO0ZNM56A4MBP:6(L,+&)C&$`@%D[XY1\H[Q0;
MPS-=#D7&FH>L669@'Z/)6[@[,)W4T6*?1B2%OVBZ0`<@(6B;%$AEZ80U#`D,
M%;L1,I)$UTYGS`O##6;MRJF0="%)HT'C35%XM*?#R2&OM:EJC8X:1&E;R@7H
MPL+^"I3BWXD?7]?L!`M=[?6,01DZ<W="[X8<0[Y6AR'\"?&J-B>5;*S`+1]J
MR@IO7>?)R.(BOJ6(+IATLCD;K%3D]FTUJ:V*DZP6;_?.SW$="/_S&44CDXEZ
MU)K8TF?6J-HYS?/5.4DTP,*OE01P1UWZGP(OAM766>(K%!5R*@)`L1<N4/I#
MDKAR2-LN!C3(B\M^%XW.&MRQFN"Z2>B`X_%",M4MYR,&KN$RD^!*6J7(;0MM
MU31J>JC,M2PZCI7Y30.9EDQ(@RTJI?`3X`V(2%PC!Z-54T6YU,F@\<5:1HXA
M(Y424&6QPNQ*]53RM.(N8$IA1HL=`=BQHF(SK#I-P;U2EK>2+9TBFR"'(_O6
M"E`_DA;>X63T-24$"SJ!7.`0SJ+A-L#$`]CE_A:@#VT\K+D5""/)&J:4ES:'
M3N?P8T!W3H!<V\\ZV\K[FA4)$C5O$-R0*P0U/U*)P2XRII(^(R3;7(1>%[0P
M<8$L>*T8I!5N-QF8N``)`GV#+$'R4J+:3\DFEPU$EOY$P0]D8G-AZ76N2^H(
MN"MY1N.DP>Q5MXE=`:_6)GK&[DHS2AY&O'L;VL9!.0>^CS;W)4V0I'RTRI&-
MY"'4S&>UO%I[*;"V:@E3E'M$>PO&,G)/-,0C%WR'8`T[PE58NI64%]T>2Q:B
ME"XIB0U,'02/:\KB9H\0K9L`\0AVA;@6/0T\S2)`P4T]F%[ZCZSC;MCC)G08
MB,$F45E&$(-H.$2UAISFQNS<#.0I!G@;B>\<\ERA4:)\1)@Y_%VJ6YM?T<(9
M"KHH`T'*!_4DF,AF>(->-<043$J#^T6X%K#")0V)$O=QH_H:`Y@%#PKMY&G-
M1&;OQH*//*Q2X`KI%#2I)"SITS<H$,3$`RUWN.T&DM"'ZC%=74J&T:A2Z/3U
M.V2TP3;K^`M?<4\.,,`FC`ICT&NPV7:<#+!#Q'%KPPK4=O@!)NGXW4W1KKT`
M/1MD_%`%DW7B///086I\+50SREZV!I<6C5_87G/*7"_?GX!'$'^!_+KVSZGN
M:(F4B(A\SB,7C97TXR`,T!JVM^`OA$-RH,B#LG5%NF$AZFBCP,RR2E7H2E."
M+:%.ACD@75PG64H'J1R=:8SDJALD\Q&*,:VJ'4DH%,>S44/>Y>Q;AD#RE1>]
MWD0RFQ1$T<=@72$P*"_+0SME=2Q&@XCI</P$#"B3O@%!]3'<QD^8$%DEXA$5
M"L-`60$'*-MQ90%"'"(=XS:NB$4BX?$&!0],A;-`[@T.)YD&5<6";J5%>A_/
M78MA$%'8*O(&$`/]?":GP$@*#"F%D!N'@^Y"N8KCL+O`L:-SH0S[+(.,LE'<
M*!>8KSPOPPR4'\<8!@Z`@/OGD=PZ^6B)8H^0K0+#H\"FR`,[236WKK$)ZW,7
M'`13$.I(JD5.H0-_FW"B.I6'K+*"".1"-,[]@"2)G*_V2;!X1>X?D'9C\GKZ
MZ'$E@IB,\SUG@(>O&'Q=;$@RS#JB/P-PB"]EKWPCB2Y^%J2)>[>`7=`SHP1(
MT[O(H&-[RS'09(TTGHCR\JCHONG;2[@O@T].T"8T5I7*H'AY$"6\8@H;I,`R
MH$V6.9<<'5&]`3=>XQ<"T`@D2#6+\;'4ONJG2HCR9'?+`.D6$+,]7I1\.)F)
MCDL-!T`EX\"T):X$2.:*<:B\9SAY"XM^P\G@T";0MHH3*U34X0H^!GF*`S0?
M#`!BL<LM]]43E$B/NA+@Z^*=K:]47Q#J@-<T_4(0Q5G,HM:T!G/.S&:Q,X`0
MD(7J8V'HB\[K+]YT7F%5(@_J0U^\[G9>?G%L[D!1GZJ+ZX)]>$=%K=)@;WUQ
M$NB>;<HN&;`U"4>91]+ESP8;\98`_6"BI"B-(NM?*C?+T<*.1EBP&VI1YE_9
MN5.V5CTB4WLB^V7*MUZ?)'&O.Z^[7W2.WAQ9KKQZU>UT7^_DBD44M$,@>7%_
MCGCWRLQ6H\%3]-/F`2R6T,T[$+&%%C6.F'W&H_EXVM*`6WGT4+/ML3J0CN5=
M,^%L^%4&F$I<#2^:&FWJ6UC5!`!:<R1<<&#F1*_1#!O?0H!J'<[,4+PKIOWU
MEY,CK;_,#IAVT[8$`:#D,X/U=YUBH2+$%&+L9D"+N6OV?T)+]FY?VAN7_$P"
M"I!B#\P70!IW-Z;N+:P^0@4$!8U;H4_JB/@GA'B<#WXL4H=IXX5SMM$Q8RZU
MY?K;<_D6A[V7<E=__/<IG8@[6Y9+NH>ORG()@$_N51W8>U4%+::QB+5QRIT-
M;QJ*<]X;3-6'WO#*49>XE7#5_C60]E$/J=,)FA?_3;6_6^?5O&*2UR@V2H@D
M?I:V#`0E7GR"X0&`5QZ8P=HO)@R5YE1?+Q.UK-Q]0ILLW3<]+3QV]&A0-W6,
M#\<8U0ZQO+<6>>`:ZKZ>1G6*B5#>K^JPD81W#!B_%%5E1)?VHQ_2C(S1+(8E
M\-=D#",,+&LSISKBPC2X5,4R"?U\\0*`IYHA4EUH=0C(O8I[+Y81'5"JK/E@
MKBK7$``G[/BD+X1%L&U<<\0--/`V1O4UT5^N(=/SJ/)#$,$=8(X#',-6#5W5
MB>'T,H5**X`.6KA_$F$C9KZ]"1B;(11':00=\@M,(0U@-13,W@TE)N]^J;[)
M$0<@W<,SP1U`>*/BO?M+N0XF`1H#??8DFHH2IV<8@Q0W3>H.]NE`0E^,P\'9
M4T+53WMX%>DJ^<0Z'E?QI0@/QEJF2=!J:`:4D$$-+=./C[]4XY*Y9EO"?])=
MR*%A<@0GY2?-`4C)]FYU_QW"NR26S\:0EW>&%?*YDAT4G'R)J*YYGEQ>SA0M
M0VS2R3)67U'CPQ$+>V5.QO+N1S?`IVI"MEB#%0]P"F:NG5$GNQ@UX/5#@#>2
M^?2PROFWDW,H%>*.!\Z#6JSCQHS%6W[9S8B"%*8P1HZ,3@50L&7GD'"NM:Z-
M;)-Z$6RV:J"#!*>/SB0M9)A";#Q4F[GHG'DJ:C&2($PPH&4@2,7(2'$&8I>F
MHLD@J-Q?X\!J[+6^0Y$-P-45M)EHV+-1I+:,:'DSB4O[\1SS,EQ0P(KD9'(4
M<QCS(\!E5181-8Y;P%4@[,8'0J+.G8B?*U!9(Y#^07N2OYWPIAN+@@CHTG;@
M]W<K"K^J^"B?B/,&AK^TK2_?'+XHC&NACS9+>&SQCDPW[`#AA<L$YVV.KZ<H
M?#AF-..=3WQMJ&[FFB,>,J(OQ(@VWZO/_%G.AHDH7!P^$M`\EV[WI//ZZ,A&
M*?AE*X"!RX03W?J(%:$1[:O%=S"V)GN%R;K%IS&`539[;B]*UX-$C2_N"E[9
M"MX<P-;<`VU96;)^=FFF7K$'(&+-<7IQTD$%K2;&2'FR,Q":<(PX2$=#W(A1
M%82JIS$-*?9_)FG,F`UPE!J$\DRI+WA1ACIC-T3PPA`-"KJ;"-:/<TKECS.Y
M3%I(JD)'C7S=-@*I[LLCTKF+\1A*&$'W!6C&Q_FDU<V[@4>#5!<GYTHM-.L,
M(!O$S0F)^>$+3TX.3[XH0V[->!O.\F:O8G\;B!:KKNG6@?8_R6*ZIVN;:OV:
M=JGT<^3M8$`3R>0:*C4_Z,\(NTBX+@,3^4UT+!/AR"7%8(KBIF.)Z,7KX1H"
MA49.4>D>XU4L8;/)"Z@/V(T$[II-=I.VY82>@_W<(=:4[)A$Y2[D07<*^;H)
MU+ANP$P\TI\@P`M]M$8E,8L"M$%LB3?"($X/_%(()8:1RE*^^)52G0AA0Q+1
M&'FE":Z\Z(.PF$W*&=;`[\+KI=VP1VXDR;BQPE2P>2'":Q/BIC;%"4YQ-^O'
M@QFZ>Y@#UB\?4"3(GG6\1%$$DK;`R6PCY/&;G5I4(NRQ;K*%0FUOM44L?U=5
M>G/T>%4"(3$3MKA,@3A0S*)()<J>_C4^E"1M^3B9\34^V`)UN$>?CA^I3^Q.
MK:H39:/[ZAXA/_Q_`9;BZN<(<+=S?/*J\^)-TQ`\<,M:[4]0D_'N&@F'"_U]
MK;H]9JY5C!KE"6HM7FI]T,,IVVKV:G].S[OYA1-^$D+R4O7I']S2&2\$A.G.
M+Z$->)%0+JS`AIE["S.Y50&$^4W?1.RJ2]TXZK#?KD[HJWN?(@UEO]QZ]*;^
MZL1VXIT&,6,2>QLPK?5W[OH:TZ2XDE9I!MTU&'<(#HL[!#LID1L%NZ:XV@"C
M\3%=8X<FQ<U`GB)`'MX.LP*T`(1@W$?>^7$HH<9D'X_KU.AU<%.Q)]X*O+I=
M%,U0D$=_*^JCF53M<M@@6`$1=W;"WO<1NE'1KS*K7%RNTV)XW+/7)O`QS=K]
M*)MCJ;\)Z0-3*M>3D#H)5BM6Y>I#FXM<YZSD%;DOP7/3:"_^!7<)UX!&%V6+
M^GPS?0?$8_E'7TZ6.@.8@^@827[]@55M)7>1/X2MX`<#Z0Z:AL&BH041)`-)
M]BX80LUEL1V$E"_:GDL;=6J)V?'V%-D4W''3C6SUMNKZ4O`V6)>1K^%5/I)5
M>H?U%\;ZZWM;'BPY9B>IEEK$^;&%)]9B'IWNKZ^Z!8IP8G!G2+>+%T@H#A;$
M!DDT@-M#,%?)`C-WU%C.XFLEV5H?TY[E?'CI+81]_,>LS\L49B.RKI/6C!T?
M)NOH7D!&P'18!$SUY>`/ZV!D%]Z@VV%=?PG.(V8T?F/]X>,\LEW+]<WU=`=]
M)?)IY)T#0_8+P6N6LN2]L`=_L(AS;111:>PL@]I[/J8HWQ0OPEK)+1?!&8@P
MT]9Y4=509#!L(;`>C#]BICD_^%PL5%\'_W4`B9T:RJ`UOFACO6>#!9-TJ,F1
MMH(#U-417L.;LB&:#MD:5)VT$_7T1?OOE?]\`Q.D8F`97%K((*)+I-GR'=5&
MIJ"T=;HYNRT.K1-,JVCN,MG%=^SLN'T'3A'W;<=\6CQLV<+&>R*#)0W/\5_/
M>/>_`@```/__`P!02P,$%``&``@````A`-C21H=I!0``X10``!@```!X;"]W
M;W)K<VAE971S+W-H965T,RYX;6R46%V/JS80?:_4_X!X3\!\$R6YNGQL>Z56
MJJI^/+/$2=`&B(#=[/[[CC$$S]!-LB^["7-\\/$9CR=>?WLO3]H;;]JBKC8Z
M6YJZQJN\WA758:/__=?3(M"UMLNJ77:J*[[1/WBK?]O^_-/Z4C<O[9'S3@.&
MJMWHQZX[KPRCS8^\S-IE?>851/9U4V8=?&T.1GMN>+;K!Y4GPS)-SRBSHM(E
MPZIYA*/>[XN<)W7^6O*JDR0-/V4=S+\]%N=V9"OS1^C*K'EY/2_RNCP#Q7-Q
M*KJ/GE37RGSUXU#53?9\`MWOS,GRD;O_,J,OB[RIVWK?+8'.D!.=:PZ-T`"F
M[7I7@`*Q[%K#]QO].UNEEJD;VW6_0/\4_-(JG[7V6%]^:8K=;T7%8;7!)^'`
M<UV_".B/G7@$@XW9Z*?>@3\:;<?WV>NI^[.^_,J+P[$#NUU0)(2M=A\);W-8
M4:!96JY@RNL33`#^:F4A4@-6)'OO_U^*77?<Z+:W='W39@#7GGG;/16"4M?R
MU[:KRW\EB`U4DL0:2&#$0,*LI16XS/7NLQAR1KW`).NR[;JI+QID#;RS/6<B
M!]D*F$=E<AY7K9])!8V"Y+M@Z;E`10O^O&U=9VV\P9+F`R22$%_7)HB'(?$(
M$0LH:)/QP32&X2'IB!#N@:*K+%@L*LL&V__?L%&%&$14N/A]T1QB840\1[@^
MAB1S""%)YPB%!`FUYT*=3S-S%"H&00ZJ7@1XCI&$."H$(^*[B.0N(KV%0#)A
M(JJ?MWT4X(T.:SBE6H@G'TE(T*>J98<T$U'8"D@N)VJ8,9<1@U,U'C`VL2--
M8).J26R]^SDJ!F%MGDFT28C7:V,V(ULF1F'3)QF>J&'+<LG"I3BLC$;2/"SM
MMET"3"21.4<2(B4MF!^2;(UQW`V((0F*^XX_.=(7FA3%[4")(UE0O53';LL2
M8"*+;/-(0@:G0I.L=8S"OD]&)VK8LTV2!BD*PREQS1(D2;0HI/[?3T(QB$BS
MK_3]BD82,C@6F"Z9?(SBH(V,3U#<LJV`RB,`QYL\1P)#+/"V9P),A)&]'TG(
MZ)DSO;77':MARPQ(HB5JV&,.":<H;#I30B!)#$ZRKYO6CR+BIJ20K@V8P3:/
MF0008X#KV41_@@',9S99P)0B'#;M9BQ3'.Y?SDTF6P*U^GMDF:,!,\BT3$:S
M$P.83[,OP0#?"B:K9$7!`,_TII7$(L51KXB\G9],-@9(''$@&C"CAY"$>&O&
M&.!ZSC2U?NX)!K"`T=V9$H07>M-+L#QQPC\N3_8#2-Y$/*2HQ`SR&/2_5-[8
M5(@V=`$'((XG#!'83D@KRP!P^@-TP=RI-&%IXI1_7)KL"9`TDC,1DQCY8F7S
M]\)C%+7(V`1%F4W"*0I;GW4DXC?-%R3)7D"5Y).UC'K&C7YURYSM-$DR+C:-
M)YC`MJG=Z0"0!-YG7HD#_G&O9#N`A)$LBIC$R`YR$9B,*(\QP(6F@^8A8K"8
MX\\J)4(P+U3*,4Y%<=8K\AYK)9GL$&`[7/MDVF-$`P82\XHAU2*^#TGN0]*;
M$"Q6G/R*V#L54_8)R,LI28:2(C&AW/#F<M:(,0H@!TI"`?."21@^/?-$!Z"(
M$TYZ=W^X,MDW("=),D4#YJ:3DN8&)+G/DMZ$("?AR@:)O>UDC\;]BT^='#"R
MW(16Z#.7IG1,,`[4E%G5(9C`"F;GC+AP$LWB^"[;])E2_J10>:,D+UQ*WAQX
MS$^G5LOK5W%;9$'"79_*FZR(K>`:!&XSR/,$;KCZY\8U`!=,Y^S`?\^:0U&U
MVHGO@=)<^E!0&WE%);]T];F_U'BN.[A:ZC\>X2J1PP6+N03POJZ[\8NX1KE>
M3F[_`P``__\#`%!+`P04``8`"````"$`!/%[]0P%``#*$P``&````'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;)1876^C.!1]7VG_`^*]`9OO*,EHH.KN2#O2
M:K4[\TR)DZ`&'`%MVG^_UUPWV";)0!_2@(\OYWZ=2[SZ\EX=K3?6M"6OUS99
MN+;%ZH)ORWJ_MO_[]^DAMJVVR^MM?N0U6]L?K+6_;'[_;77FS4M[8*RSP$+=
MKNU#UYV6CM,6!U;E[8*?6`TK.]Y4>0>7S=YI3PW+M_VFZNA0UPV=*B]K&RTL
MFRDV^&Y7%NR1%Z\5JSLTTK!CW@'_]E">VD]K53'%7)4W+Z^GAX)7)S#Q7![+
M[J,W:EM5L?RVKWF3/Q_![W?BY\6G[?YB9+XJBX:W?-<MP)R#1,<^)T[B@*7-
M:EN"!R+L5L-V:_LK668TLIW-J@_0CY*=6^6[U1[X^8^FW/Y5U@RB#7D2&7CF
M_$5`OVW%+=CLC'8_]1GXN[&V;)>_'KM_^/E/5NX/':0[`(^$8\OMQR-K"X@H
MF%G00%@J^!$(P*=5E:(T("+Y>___7&Z[P]KVPD40N1X!N/7,VNZI%"9MJWAM
M.U[]1!"1IM`(E48\8"_7Z8+&`0G"7UMQD%'OX&/>Y9M5P\\65`T\LSWEH@;)
M$BP+SSR(SW7/P"6QYZO8U&\%=`OI>-O0<.6\000+"4D1$MG6`-$1V15$?($X
M0._"$3R?SU%L,CA&%_.]&RE"^KKI;V3*#8T`!$8E<#\X`@Q!5#U/C`<CQ%<@
M@8[([B$T:F!D.C4!7MO@Y24IGJL_.$5(W"<UA`(U8I:IZW'H)3=2!F4]G98`
M&[2(00LA84^+)`G5ES-UF;K)L%N+53B'E``;I(RGI@A!4M0-C2QGZC+Q@R&2
M&BEHD>F1$F"#E*>'(D4(D@IC,[^9NAPEMTB)P:6HPOV"%V"#E&^00@B2B@AU
MAZK!QE/7DRAQ!Z>T6"4ZK6EB)389](QN2Q$BJRND0_D@.VTYB`;R&CD"LCD]
M:#W:H#724&%Q;4M>)/8-0":-2(`7D8&Y3LU0^?OY)*C,FDP,Q8O2*3$^-B0U
M5"33E_U;M(3>3BXS@NJLT1I2(6DA!@,2^U#@>B%FTLAG2#WXNR#TD`D%GLX-
M]1H^!V4UY"`E]S0="^TN1*<W2_?)6/A](V6IQ&!D/+7*)3>T@>L!#886UXG-
M4G[Q$F4TIU(L,J>JN!.?Q*,NT`#4C6ZE=);^D_$`\,T!(#$8DS`<MX$Z`A)/
MF1!ZS&;-`#(>`O[@L8R9*O/4]^(A6S*;&B`,DR&H.K59DX"@CJMMX!M/3B4&
MJNG2*J,F13/7(3H]8R+\0MC&H\`WGIT25>S#R`N,-LX,@.L/&J11H[/&08_6
MQ\&HVB1&=FCL*76.2=4`/HEN)94:XV#:'.UW&12'JL&ZDQ@U<[XQ.C*)03<H
M#*WK`DR-X3"1Y'A(*`F2)-4A`02,YLGZ)W^.7>J%MQ(L]'SRA*"H_O#H2]G[
M1FFE$H.1(6Y,7*,Z,QU!O"`>R.O5)]1Z.CF!UE,;F/.!(D:2\Z@?&_0S'>&[
M-!H0.KE9,T+\N#7)#34C4XJ8^W5W%Z,3G#4IZ'A2!.:DD!B,WH,?A8FABYF.
MH``8FDLG-VM:P+'(*'I#S<CH(09_]%U[:Y)&$$#(E;<F/#K!DX6*-7N6L>.Q
MM0K^*HY%*+PF7N[BD4U*EBD5YQO&_4P<Y?2',9<%.$DYY7OV/6_V9=U:1[8#
MD^XB@GPV>!:#%QT_]3_XGWD'9RC]UP.<F3$XL7`7`-YQWGU>B-.>RRG<YG\`
M``#__P,`4$L#!!0`!@`(````(0`]@X29D0,``%L,```8````>&PO=V]R:W-H
M965T<R]S:&5E=#$N>&ULE)?;CN(X$(;O1]IWB'P_!(=3@PBC)JW>'6E&&NWQ
MVB0&K$[BK&V:[K>?JCB$V(%6Y@9R^/W7Y[++%.LO;T4>O'*EA2QC0D=C$O`R
ME9DH#S'YY^_GSP\DT(:5&<MER6/RSC7YLOGMT_HLU8L^<FX"<"AU3([&5*LP
MU.F1%TR/9,5+>+.7JF`&;M4AU)7B+*L'%7D8C<?SL&"B)-9AI89XR/U>I/Q)
MIJ>"E\::*)XS`_SZ*"I]<2O2(78%4R^GZG,JBPHL=B(7YKTV)4&1KKX>2JG8
M+H=YO]$I2R_>]4W/OA"IDEKNS0CL0@O:G_,R7(;@M%EG`F:`:0\4W\?DD:X2
M.B7A9ETGZ%_!S[IS'>BC//^N1/9-E!RR#>MDV.XOGO/4\`Q6C@2X(CLI7W#H
M5W@TAB"Z%F`0_?\ES&.$4<(V3/?Z$O*Y7K8?*LCXGIUR\Z<\_\'%X6@@T@S2
M@-E89>]/7*>P#!!K%,W0-94Y6,!G4`C<3Y!&]F;I1&:.,9G,1[/%>$)!'NRX
M-L\"+4F0GK21Q7]61!LK:Q(U)O!];DSHZ&$VF\X?%L-=)HT+?#<N-!J*$MII
MU1E[8H9MUDJ>`]BO`*XKAKN?KL#X=EH@'ZA]1'%,%K!P,=&P-J^;\3I\A>RG
MC6)K%?#9*JBK2"X*7$!@:$$@-\-!4(P@N%Y(MK4/NG$C+VY?,6D5#@ADH0N"
M&V8">_7CS.`@T'7F/6W=+:%53#N*F:M(/E(XA&#2)?R8#,4Q@=FW*S)WXVZM
MHDNV<!5)7W%E=\A@,P\G0[%+]N#&W5I%EVSI*I*^X@[9_%?(4.R247^C6\FL
M+H(I75)_N]GW7?0[8%!-PU.&8@_,JZ^ME70#]]CZDCML^,LY^'!`L<=VK3!;
M`U;BL'EEDO0E=]B6O\*&8H_M:FO9K,1A\PHEZ4NN)DX94#@OAB>N5GMT7@5N
M&XV#YU5+<D-SCP\/X<$+2^V1W3U"J%>'VT;3Y8N\DDEN:.[QX6$]G,\>[5V^
MR*\*:C4.GU^R-S3W^/"H'LYG#W:'SZ\,VC_\([\T;FCN\<$\NWS#?L.@=_.K
M)+H&L%72:+IY]"38`J+-O#X:EY/Y(IK-KU.Q=6);-]N(%%P=>,+S7`>I/&$K
M1F%H^[3M+9NFKWT!75K%#OP[4P=1ZB#G>Q@Z'F%#I6R?9V^,K.HV9R<-]&?U
MY1&:>`YMPW@$XKV4YG*#34G[MV#S$P``__\#`%!+`P04``8`"````"$`"D#+
M9:0%``"D'```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R<F5EOJS@4
MQ]]'FN^`>&_`9",HZ=5-V#,CC4:S/%/B)*@A1$"W;W^/,9#:I#YM7[(<_WQL
MG[]W+W^\YB?MF9955IQ7.AF9ND;/:;'+SH>5_N\__IVM:U6=G'?)J3C3E?Y&
M*_W'_>^_+5^*\K$Z4EIKX.%<K?1C75\<PZC2(\V3:E1<Z!E2]D69)S7\+0]&
M=2EILFLRY2?#,LV9D2?96><>G/(S/HK]/DNI6Z1/.3W7W$E)3TD-]:^.V:7J
MO.7I9]SE2?GX=+E+B_P"+AZR4U:_-4YU+4^=Z'`NRN3A!.U^)9,D[7PW?P;N
M\RPMBZK8UR-P9_"*#MN\,!8&>+I?[C)H`0N[5M+]2O])G"V9Z,;]L@G0?QE]
MJ=[]UJIC\1*4V>Z/[$PAVJ`34^"A*!X9&NV8"3(;@]Q^H\!?I;:C^^3I5/]=
MO(0T.QQKD'L*+6(-<W9O+JU2B"BX&5E3YBDM3E`!^-3RC'4-B$CRVGR_9+OZ
MN-+'L]%T;HX)X-H#K6H_8RYU+7VJZB+_GT.D=<6=6*V3&=2^3;=&ECTET]D7
MO,Q;+_#]_:I`OV[:`]^M$\L>S8FY&,\_WYY%ZP2^.R?DRT$AH"4/+1/UV[$E
MO4+PHZN-/9I8T[G]"8T,KG?3?=RD3NZ79?&BP9@$;]4E82.<.*R,KN-PF?NN
M]%%/@B[$O/QD;AIGT$DJZ/[/]V0Q7QK/T&73EEES!F3MF>E,1#8=PCHH\^O*
M!J\S7)T0T8??$9V/0#:$LB'B!OCL:T86"]%M/&3DVF^'",R"O1L#(MZ''8;*
M(.QCZ""WQVL7999+CK+=%]!$;,V9]U&V1&(S)*:25.X0L4PISMX-1BS('Q)R
M00%'WD=>JFV($M$-PIR(58EO,5*#MK>8:V`$^<;?DH_E8O)U/7/-#?/>L)$-
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MNT(I6=H:1*C_&"6V*D*0"TYQWY"+Y9+EDEJYYHQ*+I1P4<)#"1\E`I0(42+J
MB&9HV-)<'7>I'ZZ<6Q4A",9.SM]0K,DF2W8=PGR+T4(JS7#$Q1$/1WP<"7`D
MQ)&H1YKSN362@A+WZ1^+IT1$]=AI^.O3([N#&`PX:=Y8MY!2/>Y'@;BX%P]'
M?!P)<"3$D:A'F'H3>=SUJ0KM5"$1M6-'X??:J;<@A)^<Q4W]]>3<CC@.*039
MM'X4B(LC7HOP)6DL=W(?]Q#@2(@C$8[$.+)5(J)H[*#]!='XN5P4[7HN;T7C
M$(\E\>ZDC<J&J-/=-EVAJ(>X\)'T`"\BQ)$(1V(<V2H142P(B2`6.XY-X#"'
MC#2635[;Y+L.>&=@T(Q?P]JS&2&V="+8"(QMD[FYD&84MT64VHDEP4WT="Z5
MY`LES>WY8B;?)`9X22&.1#@2XPA[I&'!N]UJ+B%_A.&WZ#DM#W1#3Z=*2XLG
M]L#"#G^]E3_^K(D#%]EPZR?9/>+`;?70'A`'[JB']K7EP)7AT+ZQ'+@Y'-I=
MRX$+Q*'=LQRX1QS:?<N!ZT2P&WU%X8WHDASHGTEYR,Z5=J)[:*(Y8H\H)7]E
MXG_JXM)<3#\4-;P.-3^/\!I(X0[?'`&\+XJZ^\,*Z-\7[W\!``#__P,`4$L#
M!!0`!@`(````(0#/LF\_D0<``"`C```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;*Q:VX[;1@Q]+]!_$/0>V[KXBO4&MH.T`5J@*'IYULJR+<2R#$F;
M3?Z^9RZ2AIQ99^7F9;TF.1SJD#Q#27YX_[4X>U^RJL[+R]H/1A/?RRYIN<\O
MQ[7_]U\?WRU\KVZ2RSXYEY=L[7_+:O_]X\\_/;R4U>?ZE&6-!P^7>NV?FN:Z
M&H_K])0523TJK]D%FD-9%4F#K]5Q7%^K+-G+1<5Y'$XFLW&1Y!=?>5A5;_%1
M'@YYFGTHT^<BNS3*296=DP;QUZ?\6K?>BO0M[HJD^OQ\?9>6Q14NGO)SWGR3
M3GVO2%>?CI>R2I[.N.ZO09RDK6_YQ7)?Y&E5UN6A&<'=6`5J7_-RO!S#T^/#
M/L<5"-B]*CNL_4VPVDTG_OCQ00+T3YZ]U,;_7GTJ7WZI\OUO^24#VLB3R,!3
M67X6II_V0H3%8VOU1YF!/RIOGQV2YW/S9_GR:Y8?3PW2/<45B0M;[;]]R.H4
MB,+-*)P*3VEY1@#XZQ6Y*`T@DGR5GR_YOCFM_6@VFLXG40!S[RFKFX^Y<.E[
MZ7/=E,6_RBC0KI234#O!IW8R[7W<6!?I=?AT;&XO'*O@)18?DB9Y?*C*%P\%
MAO#J:R+*-5C!60N"\M#!\AHJ@$,XV0@O:W_N>[C@&JG\\A@L@X?Q%\"?:INM
MPX9:[%H+D36$U\4(<'Y`C,*+B%%D4@2];05]T"$+J+7@`0$H'E"$^G-73HN1
M6(0:,3&*8KKA5MD$`*(#<DI-=IT)#RJV@Q+E/#"3P@MJ`5?>11`L&2Y;;70K
MS,Z$AXF03.QN8R:,931=TK0$'WU\T8QAI(UFQ&C>&9'B@M';XQ'&-!XE"<.N
MK':FA.R$]C!WDJTV6XSFB'9@DH0G&H:2(`P3ED5WQ;+@=YT1SXDXT@P2N)T3
M84PW5Q(3`U-",%C2G00&83"[!P/AB8:A)`R#)<.@,^(8!&C@MX,@K>GV6A1&
M?2D0$<%!M+BYFP!B%MV#@_3$(E%$&J('^R:))PP)O1!6%A2"]]Y<#X(K6":T
MB$"AK)2(0B$8S=A-]L4$Y@.;(M#,V+?B5HMH2<3L8-KU5A80@L6,T&XW1J`Y
MSPQ`B<S6T%9*1($0M&7L)H"(HF`TG!\$[_.4*!&#@A'[3B]T!3>()P.;*+6(
MU(2F2MDQ%`H'5]X)A<V50<>#9GM$O#TZ*ZLJ!M%E8/.E%I&J>)4Q`P=E1@LQ
MD@YN$)LRI7-0,+K-8`HVE>QZ*PY%.(@TI36E*BW2`[88RW9$1*HB=)!F$,[O
M:!#IB46B29-"P:<OO=#1(`)#LWMO<X6T9@$(!S(70%D=V-K*M9N+-&?3>PX0
M="0G"RT2VQMEP:>LWLHJBT&\*<XIQE9:I"Y<8V%2*2T+06V,-Q?+>SI$-!6/
MQ,F;_2RI@^NL+"@&\69H\Z86$2@T;\J#AD+AX,T@B.\J"YLXPXX2S;+@4V9O
M96$QB#A#FSBUB&#Q*G&&#N*<XPY],&]*1ZQ7NS'21(+/FGJA"I?D2=PMFB5[
MFRRD-0U`BTS>)"*ZFX,W[SM"(D62F.]:CMIJ$1TVIWS8[*UX442#>%-:,R@T
M;QISM[92LP:%XL?Q9F3SIA8AX4993/F\V5M96`SBS<CF32TR&X2(*!:"M!AO
MWM4@D6(_4A4=(9I(\'%3+W0UR"#:C&S:U"*P9UNI.R*B2+AH<SA11!UE&A>]
M9(/EMK5"*W6'*Q\S>ANK1`9Q:&1S:"L"@W7;!U,6Y$Y;B5G,L.H'0PH?8]KO
ML)GB3E(MFD[-%C9%9+>8<:>\7YPO[B!VZ8F2B1:Q#N;IZ:UX>F)&M;>AD-8L
M`,6PBKK4<*&M'&P6,^Z44-QWW$M7+!1-K)3-^!2H%SIZ.&9<^QTL;#J5#C`1
M&SU,1+0L&'=*+(;W<-R1JE'XR[[P94JVK=6M'NYMK"(1Y&@0[W>`451J]DNL
M1>@1HSOY4*JM6`_WXQJ%;Q#AQC;A:A$I7&7E*EP'X=[W^"ON.+?E^:T6L1[F
MPUEO9:5G$,7&-L5J$8%"6;F@$$1G%,/_Z6'%F:12-(V2'I[QZ2SNK#@6>`%'
MHKM=JM*:DH@6F3U,1*H(U4LZ]6*JR*ICMLO.Y]I+RV?Q`FX:X)52)]9O!^-X
MM8$G!,PT:,[5#LWGTLR@D6QBK9E#(]\-69H%-`NGMR4T2Y=F.FE?77)O$6+#
M1.:(+9I"(]\S6FL0-687>\TFFJ\V8$1;@R$#:YS7$R'JR!EUC*AQLCF\Q7@5
MBU/(I0FAD7<#/.HX@L896PA$<2?G\!8B-MPT.3018L,-CDN#V'!WX=(@-MP)
MN#2(#5.X0Q-BC3K*^/6$6*/:U](@I^HINJ5!3M4MFJ5!3E5/6!ID#K?0CM@"
MK,%35)<&:_!4TZ4!UGC<Z-(`:SS8<VA"8(U#PZ4!UG@"YM`$6(.W'2X-UN!5
M@TL#K!57<0P"8(VG\JXUP!I/T%T:8(W'U[8&OR/8.*M`!.:PWXH2<,E%T3CD
M&Q"1LSVW@H<<"[;(HS.-R*(SB<BA,X7(H$S@N,,/OT^X)L?L]Z0ZYI?:.V<'
MT.=$/OZIU"\<U)>FO(*F\2N%LL$O$^2_)_P2)</SUXD8I`]EV;1?@.BX^VW+
MXW\```#__P,`4$L#!!0`!@`(````(0`U$>(;"0@``.(E```8````>&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULG%I=C^(V%'VOU/^`>!_(!X&`AEEMXM!6:J6J
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MR\/OY;6`:$.>:`9>J^H+A?YVH$TP>-X9O6,9^+.>'(IC_GYN_ZH^?BW*MU,+
MZ8Y`$16V.7PG1;.'B`+-+&#3V%=GF`#\.[F4M#0@(ODW]O>C/+2G[31<SJ*5
M%_H`G[P63;LK*>5TLG]OVNKR'P?Y=%**)!`D(<Q>]`>S(([\:/D`RT*PP%_)
MXLW\A?<(!\R9R8&_@B-X6,U2<,!?.8_Q:N8\OBQ=)&_SE^>Z^IC`&H`(-K><
MKBA_`\PR3SRJ*G/W$@?!IB2?*0OC@IPT4&U?7V+O>?X5"F0O(`F'K*83!8F6
M-B25$)I#2DMD@Q[CVT,RB9!#=D;#'"0JG5`+6&<(5=U?CU(6'63+BB)[`DD7
M$MB(M(N(5C:$<(@9&T222832Z62UE$/UF\K=BBEX.P5RE:48A3SA$%@-"H)B
MD@XB"$?$K%*>@N5Z@4HADQ1*KS4B#(T06F)A6J986L[#:::#D&@4_X1#7*('
M$40BZ/+PERBLF>Q5BF4#6TUK'6-++VPH6.\"VMQ)IH.0WM"NR(1#8`IWDSR(
M(!)!!40!BF@F>Y5>WK!D-1%$4:QF9`F&/0H+'DXP'80$+Q0]VVH2#G$)'D00
MB:""%RBBF>Q4>F4#*P=/PRVYL">8<MUYI6`D4Y<-E\DA/,A/L>>C73JU^J/5
M`N]45G_@+U8HCAD'+-@Y3/?PG37"7ZX]/25+*75^QD'D5DK!2"G:01(.$4H7
M*]AC[(RG%L!?KCS$0"Q`#T/&`896:X1-:6E=/Z*5@I%6E)6$0US%.X@@@XA,
M(E0%RX:^3<+2Z\-).SZY#(T4H]TR$1B7Y&$(41"Z!G&!9*I7"58M#']GR?K4
M@HRN9(9&8O76QQ>MP#C%<M_C@!#!PE?$.HPBWUNC)V7J25HR)Y:C%O$Z]M9J
M)=E9II[$$#[N\/6YD[$L!SHK$H%QJ$N'(:0'@O>W3&%T`/C\S&<;H^P`4)."
M`C!\&OO<VE@!T*4E*D#ZH;ZEQB"IH#'GJ7=:!B$]$$,*PV0*HP/0?;8QR@X`
M//T'`D!'H26@2TP$@&,<ZE)_$$($1!P*?ARB,R%3'%H]9Y5#EDN]]]K2J7U!
MN1\V)O0K,9:.YI0(C%.Z-%-WRX/TL!A9%+GG-'274[9OC1S"3A$QWW)G)Z#>
M!@5CQ$+@CLA<".O.OB]=DYXAJO+4'X00`>%)]?TP]I#*3)'H0N"T?,P2[(#>
M.^U"H(;'T.XV,CZW1Z;F&`E*!,99`-)VW0T+Z6'I%H"DT:IEBR8V1MG"J?L9
M+YQ[)4LX,F")+PU6W_&<.GN)LS=3O5KHG6?9$JGC&2^1^R-3XKISLG$,KZIU
MN%R&WA)M`*EO8Z(H6&/?3A"FCR<3&,.OHE&(V9(>/&3A&-K>TM?X3!,85UD/
M0\@P)%,0E6S5HJM:+SI;]D-F+N!FR<QXY_6)P#AE#YLYP2)VL'@1+K0`OIFK
MYVC5II7SX<N?,<86#0+,,A]GY`(ZRLYYC,M=8)SB.8T#0A0+.X(Z;U)4MU8N
M.>F`^-Z[E."'[!L;A61W2KUKH5"Z4D'CE"U9J(KN"Q7%H&7S`;Q([K]2">"A
M/Y!N.@KI1CM7PIBW4X>H=!A"%(3J[KQ74;U:-I_9@KU)\CU=@W:1(\/F/J?I
M[P58+4IA(C!.M<-&K8?%.''%VI8T6K-LT3N:,<H63HW,Z$,LX+8'%I"RA#$^
MIP5&;D:1MT*V+46(<(4-%T&(+D<F$,;QA<98K+9DZF+&2^:>QY2,WPTD0=<7
MH7)(AR%D&)(IB$ZUZ]&V[(<<6=#CR%`>$X%QEK@T4KI@4&2(8.'U\A10`XX@
MF7J0ELUYQ2#X[A;=W<>12QMY?'7=6O?XXABG_$$(";H08ZV*%2XQ6K]LT7$U
M1EEYI]\[S7*G`1C^^L5&H0T='V0"XPK`,(3T0`PI/``*HP*@6D8$`+FV<140
M]K@W?*()C#,`P^ZMAZ4;`$FC`R!;1@2`&I[1&U[([9&YX>$%F0B,4SBG<4"(
M8%$KO_O[@7J.ELUIY<*__PM"B/R;^T1G:%3N^&`3&/D[90AW!]"+J11!/"_J
M'&T(TL.2"8AQMJ%!-J^]VB'@#^2:HN$W;7Y3@OY"DX2=IK3;1+I-6;=I9S79
MTZ0.Q2A)NB;INZ0';QK`I15LQ/`KJD1@Z+M<95J,PX)M,*D&R4HCW::LVT2O
MS;`(!NP"#+MCP*_!\'L5EZ)^*]+B?&XF^^J=7G&)P(BJ5G[])O$W<-L!'HS:
M"5S+Z6T/-G`%H(O_'"[@'@\K&\0$09`W?.:J"V[8W/*WXH^\?BNOS>1<'&%Z
MWFP%BFI^1X=_:*L;N_;P6K5PMX;]]P1WJ0JH%F\&X&-5M?(#3&JN;F>]_`\`
M`/__`P!02P,$%``&``@````A`!^WS<'&`@``'0<``!@```!X;"]W;W)K<VAE
M971S+W-H965T-BYX;6R4E5UOVC`4AN\G[3]8OF^^(($@0@5TW2IUTC3MX]HX
M3F(1QY%M2OOO=QQ#2F!T72\HB5^_><Y[G,/\]EG4Z(DIS663X=`+,&(-E3EO
MR@S__'%_,\5(&]+DI)8-R_`+T_AV\?'#?"_55E>,&00.C<YP94P[\WU-*R:(
M]F3+&E@II!+$P*4J?=TJ1O)NDZC]*`@27Q#>8.<P4^_QD$7!*;N3="=88YR)
M8C4QP*\KWNJCFZ#OL1-$;7?M#96B!8L-K[EYZ4PQ$G3V4#92D4T-=3^'8T*/
MWMW%A;W@5$DM"^.!G>]`+VM._=0'I\4\YU"!C1TI5F1X&<[6"?87\RZ?7YSM
M]<EWI"NY_ZQX_L@;!F%#FVP#-E)NK?0AM[=@LW^Q^[YKP#>%<E:076V^R_T7
MQLO*0+=C*,C6-<M?[IBF$"C8>%%LG:BL`0`^D>#V9$`@Y+G[O^>YJ3(\2KQX
M$HQ"D*,-T^:>6TN,Z$X;*7X[47BP<B;1P60$](?UR(NF<1@G_W;Q'5%7X!TQ
M9#%7<H_@T,`S=4OL$0QGX&PK&T$^CJ.O]5JI4*,U65J7#$\P@NT:VO.T2).Y
M_P21TH-D=2D)AXKU46$[`70](A1^BOCWT(\D5FQ);!,LVLK=`.\>+3I[[J4B
MGO22`0D$=$IBPQI?/09'(KL)0CT!2%_M':.3C$\D<0_0*=9O*0:(8'*.:/OY
M=FAV4X8AASZC=#H$6#E)TO4VG([&P^7U8#E)7@L<P$%6IW!O0UGQ&50Z?.K*
M25(']>EF-%Q>7UT>0"7_`V7%0Z@P"(:/73G-(:HX<']##0PKZW--X_C<.')O
MJV"J9&M6UQI1N;.C)H*J^[O]%%Q&]N2?W5_!=.QFB=\OP'1J2<F^$E7R1J.:
M%6`9>!.(3+GYYBZ,;+L9L9$&YE+WM8*?(09O5N"!N)#2'"_L>]O_L"W^````
M__\#`%!+`P04``8`"````"$`E5(M;-,%``#G%@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6RLF%UOHS@4AN]7VO^`N)\0/@():CIJPG>RTFHUNWM-
MB9.@AA`!G<[\^SW&-F"?;#75S$UI'HY?X]?'YN"'S]^JB_:5-&U97]>Z.9OK
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MSW7]0D/3`T70V$"MHWX&_FRT`SGFKY?NK_HM(>7IW,%T+V!$=&#^X7M`V@(<
M!9F9M:!*17V!!X"_6E72U`!'\F_]]:T\=.>U;EDSQUIX2Q/BM6?2=E%)-76M
M>&V[NOJ719E<BZE87`6N7,5T/J[B<!6X<A5GYIGSE>W!D[S3.]SMQP!7WLZ;
M6<N%N7#I$-YI"(N@;PC7H<-Q[.\T7/&&<!4]WNO(8&;W<Q?D7?[XT-1O&BP(
M<+.]Y71YF;X)IHE98UT.\_A_TPCS1U6>J,Q:]W0-)JB%W/OZ:*X6#\97R)>"
MQVSNQ,@16Q%!DX/*!BH(51"I(%9!HH)4!9D*=BK83X`!Q@WN@6&_PCTJ0]T3
MX]X(,-II*5:)"-$D4$&H@D@%L0H2%:0JR%2P4\%^`B2K[%]C%959Z_!W3#17
M\6;#8DR8M"%(R<7M$#+XATB(2(1(C$B"2(I(AL@.D?V42$;"GO0K<H[*P**'
MZ1I,,E>NG&4;'O2>DT/(X"0B(2(1(C$B"2(I(ADB.T3V4R(Y"5NRY.3]-Y78
MXFAT;Y@8Z(811[+0=60+MT.0:!8@$B(2(1(CDB"2(I(ALD-D/R62/^Z'_*'1
MLC^,@#]BZ%M$`D1"1")$8D021%)$,D1VB.RG1#(#WFT?2!8:+9O!R7(T`Y&`
M$1LNXYITE:TK'(*$JQ$GHW2,2#*TFDHKRST=@H1TAH1VB.P9,?ON)<MH98]K
MBQFMH;IS6;QL:A@F["UWUIT--02K+*B(["0GXW"WB`2,V*N^%+'FIK(JP^&^
M&&G$B-/7N'W/,2+)T(H6.*!JRVL]'>X+U8R3\5EWB.P9N>,?U'0_[Q\5D?WC
M9'RF+2(!(\YTXS==3QYN.`2)X4:(Q(@DB*2(9(S8XR/NID1*,A,^5"27[F03
M%-\BG?IPV0^.+)B'R;);RH/=CE%BM(%`\&R3ABNY8<BC[#DKBUUW+@=$(H!]
MR-"Z-\8H^:'.4M&0=6;9CE(;92*@[TPV$B;[(T;2<,5(CB0C/66X6UJ7T8;C
MY`8"C15PR)%M]:XI&A%N$&.48)3*LBOD#G^V_D%D=VA=^].;&2VW5-,8DK//
M,^4<V?*&$#5F'VMHVP,*>93M]*8M3-7[2`1,4XW+C"@14:-R*A!77EC*UI>)
M@#MY12O9GW>.U\-C,;$Q.9+339G2[1@U.L<:VO0]-'RNNFC=\BBW-]-=VB@)
M>?]CUL:BLQ$E'+W?62JB6&?>:J'LM9FD+&<FK6_?\_=+?8/E=O<U.]T8>9D\
M-9@ARQTR;`L'2#2!)RC`*,0HPBC&*,$HQ2C#:(<1/>L:'Y4YQLZNV/E'19H3
MV9++I=6*^I6>2YFT6A@P.S3;F(XX-5/N!"L?7ER04PK/5CZ\K#"'X[>GWELE
M?D./Y>[$;RP?OJ6QSL;VX=L0\R?'?X(AXQL;&,%=OO"A]+\3[_I0!6,>>#[4
MGIA'G@_U)N:)YT-!B7GF^5!$8AXL?2C+,(^6/I1BF"=+'PHNS+.E#T46<&-P
M&HX9;_F)_)$WI_+::A=RA.F>]X5HPPXJV8^.KY3GNH/SQ7[1G.%`F<`K>3Z#
MW>)8UYWX03L8CJ@?_P,``/__`P!02P,$%``&``@````A`,>^"BC6!0``MQ@`
M`!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6R<6=MNXS80?2_0?Q#T;DND
M+I:#.(N5@FT7Z`)%T<NS(LNV$,LR)&63_'V'&MK4C&7Y\K(;9PZ'AX><.33S
M^.6CW%H_\[HIJMW"%E/7MO)=5BV+W7IA__/WMTED6TV;[I;IMMKE"_LS;^PO
M3[_^\OA>U:_-)L];"S+LFH6]:=O]@^,TV28OTV9:[?,=1%957:8M?*S73K.O
M\W39#2JWCG3=T"G38F=CAH?ZFAS5:E5D^7.5O97YKL4D=;Y-6^#?;(I]<\A6
M9M>D*]/Z]6T_R:IR#RE>BFW1?G9);:O,'KZO=U6=OFQAW1_"3[-#[N[#2?JR
MR.JJJ5;M%-(Y2/1TS7-G[D"FI\=E`2M0LEMUOEK87\5#XOFV\_38"?1OD;\W
MO9^M9E.]_U87RS^*70YJPSZI'7BIJE<%_;Y4OX+!SLGH;]T._%E;RWR5OFW;
MOZKWW_-BO6EANP-8D5K8P_+S.6\R4!323&6@,F75%@C`OU99J*,!BJ0?W?_O
MQ;+=+&POG`8SUQ,`MU[RIOU6J)2VE;TU;57^AR"A4V$2J9-XP%['Y51&@0C"
MRUD<9-0M\#EMTZ?'NGJWX-3`G,T^56=0/$#FP\J0QW&MYY8*:U1)OJHL72Y8
M10/[\_-)N.+1^0F:9AH3(V9F6P9#$<D!H;8"Z!TYPLHY1P_V<%C]`R4UB%*2
M,SI?/`"AB.04$9@DA"-H=SM'-0C.0E\25U(*,6+\'B:@B&0,03A"DC['<?T4
M>&&#`&:[7(_.'",FZC9\(H4_\RD@(0`1SEW#G3"#*N@S4Z?0/UM?AQU6@[AZ
MC$",&*!Q7(5AT!W=9`Q!.(:4X[AZ"LS58S/'B/$[]<*(:9M@-.RBGA^8,"$%
MY<2%NUP::A`G%]*=BQ&#TTM?1#2<D'`8S8]APD[Y'VLNE]FI09R=*;INTV+$
MH'11:&;'+>U')\)WA\G-[R&G!G%R3)L8,4A.^)P<C9HS0803T-YN5ZX;Q=FQ
M^6,-0GH3:0B@=BQLC@7E-V`;EW=68(,G/468W<&MU2#DYWFL'28D+`Q[2D_U
M[9L/GL!N3]JQ.'$Q!(UU%)UG&$)YJM9].T]L^%1&IE,L$(0%/`G%C`$2"@B\
M^9D.(U0/OYVC&L6.HC`SZ*U&D#Z*P8P54M)-#4Z`_C*;FSA54;7P'L/QSJSN
M;2?,N&UH$*HG!+\Y)"0^\0+O'#5F&LK8KJB3`??H'74M7M\@)F+FF5+5E4P`
M@=^3G\K'/.2"?`/F(=C4L>C;PT3ZOLL:>,(0P;Q7:)3=71XBT`)H*3,.L08-
MUZG6\&`E0_<'RI/9R045!WR$>VPL^E:A2OCH8YH<QG6)BS`\<P@E,Y-Q:AV:
M5RXW$0W2E=EK'<B,AGW3>HAD\BX3Z48Q?I*;B`9I?D(:!IH@.M$Q;KH\9<A\
MY()R:`VD+TN3N9LYE@C2,T<G_J;CATV-/).`4KO+.B2Z`JD++DZL06-U,0JA
M/%6/[S7GZSJ@1&>@4G+[T*`^3Y_7B,:@G&$X]\Q)H31O\A#U?9M[B.0>HD&X
MTSXCGY#H659WV8<<L`]^SXLUZ!R[OG>`;.$YV9AW7+F[`QXBN8=(!!T*)3)7
M/5W"_;CPC?IT7^^R#XEMGQX_=K1B#=*5*D,W,J6J*6(:1,`%*S1MB))DWG'=
MUU\YX"'26(!N-WV/B$*O=X?2'/N`0+J>T9EP5+>6V^NX&\6;-3<3#=(U"H]B
M3.F$`.;"FQL`Y3A@*)>?$3ST`M(3>P6).FI0O]<8H5#)40CEJ3R@UQ/';<5#
MQR"'\>2NH$%8+:=^1\/1.?WN\A0//87PZ[F6U@]!H_H=(-WS87"FX\`S+]'N
MNH[3C6+GD%MOK$&C'-7L"QM?O&:FI^/VXOLQ/J^6>;W.DWR[;:RL>E-OPP*^
MQAQ_B^_6,;Q;=X^\SC$`S\;[=)W_2.MUL6NL;;Z"H>YT!HY3X\,S?FBK??>Z
M^5*U\&#<_;B!/Q#D\!KK3@&\JJKV\$&]IQ[_Y/#T/P```/__`P!02P,$%``&
M``@````A`"RS.7Z1!@``5QL``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX
M;6RLF5USJS80AN\[T__`<'^,`7\R<<[$YAMWIM,Y;:\)QC838SQ`3D[^_5DA
M"22MZSIM;D+\L+N27JW$(AZ^_BA/VO>\;HKJO-+-T5C7\G-6[8KS8:7_^<W_
MLM"UIDW/N_14G?.5_IXW^M?'7W]Y>*OJE^:8YZT&$<[-2C^V[<4QC"8[YF7:
MC*I+?H8[^ZHNTQ9^U@>CN=1YNNN<RI-AC<<SHTR+LTXC./4],:K]OLARM\I>
MR_S<TB!U?DI;Z']S+"X-CU9F]X0KT_KE]?(EJ\H+A'@N3D7[W@75M3)SHL.Y
MJM/G$XS[ASE),QZ[^X'"ET565TVU;T<0SJ`=Q6->&DL#(CT^[`H8`9%=J_/]
M2G\RG:TYUXW'ATZ@OXK\K1'^UYIC]1;4Q6Y;G'-0&^:)S,!S5;T0TVA'$#@;
MR-OO9N#W6MOE^_3UU/Y1O85Y<3BV,-U3&!$9F+-[=_,F`T4AS,B:DDA9=8(.
MP%^M+$AJ@"+IC^[Z5NS:XTJWK-'$FLX7)MAKSWG3^@6)J6O9:]-6Y=_4RF2Q
M:!2+18$KCV(*46YXVLP3KLS3M$?3^=CNFK_A.&&.<&6.D[O\8%#=@.'*_.8C
M:S$UIS,RWAL-SICCO'>\LZ>PU+H6X?JAGBZ9'US[GIJ3\;_UTX0<HE,ZS,;M
MGAHT)[H4<],V?7RHJS<-UBU,>G-)R2Y@.B9$X\E%5>K3[9^R#=*,1'DB858Z
MZ`9YU,`2^?YHSLP'XSND=<9LUE=L9(L-MR`Y3,*Z*O!4X*L@4$&H@D@%L0H2
M%6P%8(!PO7H@V&>H1\(0]?BXUQP,<EJ*5-R"N[@J\%3@JR!00:B"2`6Q"A(5
M;`4@206K_S.D(F%6.OP5$DW19DUM3)BTWFBJR->;]/HAXB'B(Q(@$B(2(1(C
MDB"R%8DD).R&GR$D"0.+'J:K%PDO669T2\G>I%<2$0\1'Y$`D1"1")$8D021
MK4@D)>%A("EY_8'*MSABW0G&![JFQ!+5,6>VDFF]$7=S$?$0\1$)$`D1B1")
M$4D0V8I$T@<>AQ_0AUC+^E`RL?I];8.(BXB'B(](@$B(2(1(C$B"R%8DDACP
M;/N`&,1:%H,2$$-<;Q,E67JC/ED0\1#Q$0D0"1&)$(D121#9BD32A[QMB(7$
M[<5$K&5]*!&3!1$7$0\1'Y$`D1"1")$8D021K4@D,:">^X`8Q%H6@Y'%L'(0
M<2FQ84*$#5QYSGF]$4\HGY$A=(!(V'N)H6=RKD:]$0\=HT`)(EM*S*YY23)2
MTTJ:T4IT-(?MJ3T6V<NZ@G'"7GLEL6RH.%D=2J+(6G:!`0TCWF#D,F0ON^+5
M&IO*TO0&`SY>GZ%)]_K6M1]@%`Z.I"R&R,H3(AH,>.28HZ'/"49;AJZ)"3I]
M@I@DBB(F0T/'-J3.(E8#<AF:P!TA-^=R`GF#%1^WCU&`48A1A%',D#WT*Y&0
MG'VD;+U_^R)EDZH,11;L"<*8%_*8-\P1K/B878Y@90B.2]G18U;VF+U<S<:R
M@<\-Z%L[>7L*,`KO:BSBCK0QRYXH%7;,#;K&9"%)W?H!(5F9.]0(:Y,A2<BY
M,MS-8#4(R1R']RB/6=E6IYH2P^<Q!H<`HQ"C2`Z[1.J('9'5(;6HJ,Y_V^18
M12N*1I&<?7/E#7QC]E:#:!39=I^0'K.R)YUH4U/5WN<&8JJQ,`,*N=40.>*(
M19Y:RE88<X,K>46JU/^O'*UU(7VY`&MRDD:W+V'YS94IW0Q6W-%ER";/I^'0
M`ZU;&MZ>=6+.%C9*0M:^F(0(A7<U%G$KVMA\.56VW)@/HVM,SDQ2^-[2]UMU
M@4W^ZN,73M7ZYR^MGR6!*;)FO>8;$R$7(P\C'Z,`HQ"C"*,8HP2CK81DQ4@I
M+"IVI3`1E:&5LZ1,7TP+&317UL0&CI9)@@J5L8N1AY&/48!1B%&$48Q1@A$Y
M!1^Z2L6BI]KTR+',ZT.^R4^G1LNJ5W)B;9&-N<?T.'T]=^`M`Y:9RA<.%-Q7
MN#F#\_<NNU0/$T)!G[`/5"@.J1GP'2@;'%(GX#MPS/_4[1NH%6CDBOW:<N`P
M#,=9VPX<[F#^-'&>KG9V/7'@#`,[K*<.O+M?X:#'-3G<I0/O`]C>7SKP#H!Y
MN'2@R,<\7CI0V&,.-;1#RF1\!RIEAY3&^`Y4QS`1U^Y`#0P3T=TQ>L7AL\8E
M/>2_I?6A.#?:*=]#$HV[=X2:?ABA/UJV63U7+7S/Z/:M(WS`RJ$J&H]@=]U7
M5<M_0*>,_I/8XT\```#__P,`4$L#!!0`!@`(````(0!\@>.ACP,``%\+```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*Q6VV[C-A!]+]!_$/2^NEF^
M";87MH6T"W2!HNCEF9%HFX@D"B0=)W_?&5&B25N;ND!>(NMD>'CFS)":U=>W
MNO)>J9",-VL_#B+?HTW!2]8<U_Y??SY]6?B>5*0I2<4;NO;?J?2_;G[^:77A
MXD6>*%4>,#1R[9^4:K,PE,6)UD0&O*4-_.?`14T4O(IC*%M!2=DMJJLPB:)9
M6!/6^)HA$X]P\,.!%33GQ;FFC=(D@E9$@7YY8JT<V.KB$;J:B)=S^Z7@=0L4
MSZQBZKTC];VZR+X=&R[(<P5YO\4I*0;N[N6.OF:%X)(?5`!TH19ZG_,R7(;`
MM%F5##)`VSU!#VM_&V=Y'/OA9M49]#>C%VG]]N2)7WX1K/R--13<ACIA!9XY
M?\'0;R5"L#B\6_W45>!WX97T0,Z5^H-??J7L>%)0[BEDA(EEY7M.90&.`DV0
M3)&IX!4(@+]>S;`UP!'RUCTOK%2GM3^)@GD<+2=S8'FF4CTQI/2]XBP5K__1
M05U&AF32D\"S)TF"-)G.%S'L^2A)VI/`<U`R"Z;S:/(`2:BSZDS*B2*;E>`7
M#SH/=,N68!_'&1`/[NA<C%\_L@M\0I(MLJS]N>^!$Q)J_+J)%]-5^`IU*?J8
MW4B,&[$?(K`(2)M;0`AZC>CD4T0C"XH>MML-P#6+Y$;A$#$LR2W`40B%_@1;
MD07ZS;%UYDK:Z1@X05?5-\[O38B1;2..;FB!3]"-+-!08,X'_=`'?23<A!CA
M-N((AV-D"Q\_W4.[8G"G;^#=:21U.WCN6KTW0<.RW$8<.;/_(P>#73D:21>F
M-_=W2&XCSMZ0A&T%'NG%$B^W']QY@RNXSI6AD32]RN@1X+I6=G+3DKE99@4M
M%L9,1RQ^9JW[Y^.Z8;"K4".V47=(;B/.WDMW;S0JF?ZG3;C*%:$1VZ8><6R:
M3HP#^G8SRVR;EB;(D1K#=^]QG[IH5V,/V4[=0[D#N0+P+K8*U9D5SP+\"'Y<
M-+R:;@SK(=NQ`7(MNSF!."@@5PJ]?^V_973CF9X%]&>NIN)(][2JI%?P,W[G
M(<?-RL!F"-DFV.4W^`Z'DS$\R>#J'XF?9/ED!-^FV1:TCRQ(L[P[7K<;3S.X
M7$;B9QD<_!%\D4&?C^!Q!!GH"<EL`>--2X[T.Q%'UDBOH@>P!88:\%[H`4F_
M*-Z"73"?<`6#3??S!(,LA4]S%$#P@7,UO,#6H1F--_\"``#__P,`4$L#!!0`
M!@`(````(0#'I@7.<0,``%`,```9````>&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;)17VVZC,!!]7VG_`?%>P.1"$H54[5;=K;0KK59[>7;`!*N`D>TT[=_O
MC)V00$A+7I(R&9\S9\8S3)>WKV7AO#"IN*ABEWB!Z[`J$2FO-K'[Y_?CS<QU
ME*952@M1L=A]8\J]77W^M-P)^:QRQK0#")6*W5SK>N'[*LE9294G:E;!+YF0
M)=7P*#>^JB6CJ3E4%GX8!%._I+QR+<)"#L$06<83]B"2;<DJ;4$D*ZB&^%7.
M:W5`*Y,A<"65S]OZ)A%E#1!K7G#]9D!=ITP63YM*2+HN0/<K&=/D@&T>SN!+
MGDBA1*8]@/-MH.>:Y_[<!Z35,N6@`-/N2);%[AU9W(?$]5=+DZ"_G.W4R=^.
MRL7NJ^3I=UXQR#;4"2NP%N(979]2-,%A_^STHZG`3^FD+*/;0O\2NV^,;W(-
MY9Z`(A2V2-\>F$H@HP#CA1-$2D0!`<"G4W*\&I`1^FJ^=SS5>>R.)EY$@ODH
M`I0U4_J1(Z3K)%NE1?G/.AE%#4BX!X'O`\C4FT3!B`#G!R"^#<CH>Z":KI92
M[!RX-$"I:HI7D"P`N%\0*$'?.W2.W<AU(%8%57A9D6B\]%\@<\G>Y][ZP.?1
MI_'P@;1A!K;AS.B,S)A:#.7>&DYIPGZ:T34TZ`RU.0T^FC2XEMGZC$]\CAXM
M@>`R7"`Z0PU`UC%O9[FU3@.HX3X,IT9G0]TD=V]IYV':Y*&E<GH-%3JWJ:PE
M-)5MX<(M.Y5@.HY,/`CM_3N*Y]H4U@(4IZF-^M7@P![<#NC<IK*6'C7S-BZJ
MB2*<%1^HP7-M"FOIJ)GUJR$PZ(;+,=YMLKVI1Q#!/C_)U&!%YF"'Q<Z,CJ;Y
M!4U7S0ULJ$X"]Z8^3=C:'4T3XN&(?O_.$3L3`+EIH;VIK6D67-!TU:@@S:PX
MLEE3GR;LY8ZFZ?CC-L*W6S=QUM211"Y(NFHND//!L#?U2>H;#4$XI$[GPX'T
M38?9A7<)N6H\&._.3;\X($C/A!A4I_,)8:!BMU.G47^=PJM&A/%N2]J;>NH4
M]HR(0>UD#G98[(@8MUY)L^/N85\==G^S^TW)Y(9]846AG$1L<3<+86-IK,W>
M>&>:MFL?+^X@"N@OO_D%]KF:;M@/*C>\4D[!,L`,S*V3=B.T#UK4$#LL9$+#
M)F?^S&%S9["U!-AWF1#Z\(`$S?\"J_\```#__P,`4$L#!!0`!@`(````(0#/
MJ&9C2`<``%LB```8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK%K;CIM(
M$'U?:?\!\9ZQ@?9E+-O1V%%V(VVDU6HOSPS&-HHQ%C"9Y._W],705=WQ#M:^
M9#*GJJN+TU6'`F;Y_EMY"K[F=5-4YU48/8S#(#]GU:XX'U;A7W]^?#</@Z9-
MS[OT5)WS5?@];\+WZY]_6KY6]9?FF.=M@`CG9A4>V_:R&(V:[)B7:?-07?(S
M+/NJ+M,6O]:'47.I\W2G%I6G43P>3T=E6IQ#'6%1OR5&M=\76?ZARE[*_-SJ
M('5^2EODWQR+2W.-5F9O"5>F]9>7R[NL*B\(\5R<BO:["AH&9;;X=#A7=?I\
MPG5_BT2:76.K7YSP99'555/MVP>$&^E$W6M^'#V.$&F]W!6X`DE[4.?[5?@4
M+;:3<3A:+Q5!?Q?Y:V/]/VB.U>LO=;'[K3CG8!OG)$_@N:J^2-=/.PEA\<A9
M_5&=P.]UL,OWZ<NI_:-Z_34O#L<6QSW!%<D+6^R^?\B;#(PBS$,\D9&RZH0$
M\&]0%K(TP$CZ3?U\+7;M<14FTX?);)Q$<`^>\Z;]6,B089"]-&U5_J.=(A-*
M!XE-$/PT040?X\:ZQ*S#3\_F[L*13EYQ\2%MT_6RKEX#%!C2:RZI+-=H@6!7
M$G2$CI8?L0(Z9)`G&645SL(`%]S@*+^NHR19CKZ"_LSX;#P^U&-[]9"GAO2Z
M'$'._Y"CC")SE"<ID]Y<@3[IF"5T]>`)@2B>4(+Z\U?.E2.Y"#5".!)TPXWV
MB4!$1^2$NFP[%YZ4<).2Y3SP)&44U`*NO,O`/4KC="O-SH6GB91L[FYS)IU5
M-MVA:22VMXX2SE'GQ#>?#ME<.M/-#2*4KM@5BLI_^T5)9QK7($C;(GW*#MXX
M(0?+:=8YD8Z1]RBKJV^3+)UI/AJ)XZY7MC9"=GJD.RG]F$</N)2!A2<#T2PT
M@BSL"YYW%ZR:>-LY\:..T)!OYT!YT^T-9+-`($*#;%E[-\E#'$T?9L.)4*%8
M*C(Z`E(J'AD59J%.F&8GA>S-]2";GQV%@>*DKP@"T=VD1%F[22ZFR5U4&+'K
M"W$3:2B&OO1M(,:<BL[+*0LI3%9RMULC,C)F)Z`A0H4-42JD$EF[J?88@]^!
MS2&%G!^)AFA-B(@3T7DY1`S2PL@50P.1_M!>O@ID"BF)2(20D]5@+ES]C#3$
MN.!W\][+X6*07D:N8!J(%(613-4RM"@\FGDO%ZYJ1ITBV@W"AK%M[\6YB`?I
MIO*F8F4@NRX(1+B0-W+>(,G\GK)0D5@F/MD4;.;:FH6>HI7U9"=W6RN4-TM`
M*ZEY?)!#Y]9X:8A2X9'-2*B'CZ$M@CKD<F$@N;VEFWQPZKV<LABDFU*>F5X9
M"`D@M+YW$XAR(66+Z^9L?L=8(06&9])IHDT%'[?,0ITO36Z0<L:N<AJ(4/%#
MY8P]RCE_O*M#7.%4P?E@(?JATIQ3)Z].50P2SM@53@,1*HQPJD*AQ'N$,XK$
M/9-%[`JG@9"*719\WNR].!?R"="NV=MJH;RI6AC(YH)`A(O$(YPSO'\8?#M5
M@5@B7MWDXZ99J-.EN0W2S42+).;)JS!L#&3K)H'H;A[=O.\6DKBR:2`Z;D[X
MN-E[.44Q2#835S8-9$\6!*)4^&1S.KFG01)7-PU$&V3")\[>R^%BD&XFKFX:
MB#3(#W4S\>CF?0WBRJ:*S65SPN?-WLMA8I!L)JYL&@@WDFO/;`E$JX+)YG\(
MDZN,B8'PHY\=)GRD-%YRUK.\^FF+Y"0&B:7RIAIE(+LO"$1W\XAE=-<X(;0T
MVF)E(-86?++JO7@QB$%JJ;P9%5I`"14V1*GPJ.6=]U#ARJ6!&!=\M.J]'"X&
MR:5PY=)`=F,0B'+!Y/)V8PA7$:\0;0P^/ADOUAC]8$%S&B22PA5)`Y%J,"+I
M/HH*CTC>]ZI&16)UV8V-MB#P,<(LU*).J1BDDL)520,1*K27ANAN4N3X(T<\
MNV.B$D8NK8'&0+0OIGR,Z+UX7^`[&$GN=J4J;WH6!K+[@D":"OVM3'\?*O/Z
MD&_STZD)LNI%?@<#G>ME!^N/=!OQN-@B;R3,+9/Q]?L=MX@8:Q0[CB6!196I
M8Q&PJ!?OCF4*B[H1.I89+.J#CV.9PS+W99U,%EN,,)[K2;`/)A"?!?O@9N^S
M8!_<F#T6`79PP_)9\-T3=PN/)0;7>/[P6!)$P[."SX)HF-1]%IP"IFJ?!:>`
MD=9GP2E@_/188JS17<6YCK$&\[-O#;C6,[ZS!ESK6G4LX!I/K;YHX!J/DQY+
MA#5X^>>S8`W>W?DLX!HOR3R6&%Q#RWT6<(VW23X+N-8*QZ\GPAJ\N/>LB;!&
MSQG.&G"-]^"^->`:[ZQ]%G"-M\@^"[C&NUS7@@_P3][ZD"E[_#?R(GVX+"</
M_B063Q`A=^.-['4?CFOP7@).T7N(.$/O$48X0GS+P<ZCCEM\VK^DA_QS6A^*
M<Q.<\CTD;ZP>G6K]QP'ZE[:Z0%KQ@;]J\5%?_?>(/^+(\7)O+&\6^ZIJK[_(
M#;H_"UG_"P``__\#`%!+`P04``8`"````"$`F8/A+C$!``!``@``$0`(`61O
M8U!R;W!S+V-O<F4N>&UL(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````G)%!2\,P&(;O@O^AY-ZF:66,T&:@LI,#P8FR6TR^;<$F#4FT
MW;\WZ[HZT9/'\+YY\GQ?JD6OF^03G%>MJ1')<I2`$:U49E>CY_4RG:/$!VXD
M;UH#-3J`1PMV?54)2T7KX-&U%EQ0X)-(,IX*6Z-]")9B[,4>-/=9;)@8;ENG
M>8A'M\.6BW>^`USD^0QK"%SRP/$1F-J)B$:D%!/2?KAF`$B!H0$-)GA,,H*_
MNP&<]G]>&)*+IE;A8.-,H^XE6XI3.+5[KZ9BUW595PX:T9_@U]7#TS!JJLQQ
M5P(0.^ZGX3ZLXBJW"N3M@?5OKDF\WU?X=U9),=A1X8`'D$E\CY[LSLE+>7>_
M7B)6Y.0F)20E^;H@M)S38K:I\+DUWF<34(\"_R:>`6SP_OGG[`L``/__`P!0
M2P,$%``&``@````A`'1IF`(\`@``%P8``!``"`%D;V-0<F]P<R]A<'`N>&UL
M(*($`2B@``$`````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````G%11;]HP
M$'Z?M/\0Y;T$*%HG9%)E(;31("!BV&/D)A>P&NS(-JCTU^]"1`EK-FF\G>^^
M^_SYLWWD\6U76`=0FDLQLGN=KFV!2&7&Q69DK^CD[KMM:<-$Q@HI8&0?0=N/
M[M<O9*%D"<IPT!92"#VRM\:40\?1Z19V3'>P++"22[5C!I=JX\@\YRF,9;K?
M@3!.O]O]YL";`9%!=E=^$-HUX_!@;B7-9%KITVMZ+%&P2[RR+'C*#)[2G?%4
M22US8P5O*13$:18)JHLAW2MNCFZ7.,TEB5-6@(_$;LX*#<2Y),@SL,JT!>-*
MN^1@A@=(C526YN]H6]^V7IB&2L[(/C#%F3`HJX+5BU-<E-HH]Y=4KWH+8#1Q
M$%`G3V$3VXSYP.T]G!`872,KAEH)%JXU4FX*T/-\P91ID=Q[:&H^J:@5UX+.
MMYC@VT@"8="O)!3U;7/95/YQ!G\>C8,H#L8)1O%\&HX]BHL?WM2+_.!_6F**
MG;-;6GHW;-._H>?^AIY!:T\</D7A)/2]B":>[\]7$0VCIV2!_OEANP5AM`XB
M.E^&0=Q*.?'"9;+VIJL@F05>O%JBEQ%MA<9T[O],Z-*+8L^G(=Y;.^R?(MM-
M;ZA,*'O!MW@#=?O=-*ECG$?9OH!$YOA`#SAX6K=I]R09@V&\^(NR3]ZTP:]^
MX!]_;LK%JUZ55(Z9@?-0N4Z2>,L49/C=SO5+@CSC/%%%1>)OF=A`=L9\+E0C
M<%W/>;<WZ'3ONSC=&CGB7":Z^QL``/__`P!02P$"+0`4``8`"````"$`4<-"
MNZ$!```8#0``$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM
M;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+`````````````````-H#
M``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0#114?/;`$``)T+```:````
M```````````````'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(M
M`!0`!@`(````(0`FEVV4;P(``&L&```/`````````````````*P)``!X;"]W
M;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`]]8ELS0#``!W"@``&```````
M``````````!(#```>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`BT`%``&
M``@````A`)]U%WL!`P``=P@``!D`````````````````L@\``'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"````"$`PYG$AED"```_!0``
M&0````````````````#J$@``>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M`0(M`!0`!@`(````(0!._D@NYP0``'04```9`````````````````'H5``!X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`/MBI6V4
M!@``IQL``!,`````````````````F!H``'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"+0`4``8`"````"$`<![P_3H+```$80``#0````````````````!=(0``
M>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0!1S!LKUR$``'QC```4````
M`````````````,(L``!X;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(
M````(0#8TD:':04``.$4```8`````````````````,M.``!X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`!/%[]0P%``#*$P``&```
M``````````````!J5```>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`
M%``&``@````A`#V#A)F1`P``6PP``!@`````````````````K%D``'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0`*0,MEI`4``*0<
M```9`````````````````'-=``!X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L!`BT`%``&``@````A`,^R;S^1!P``(",``!D`````````````````3F,`
M`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"+0`4``8`"````"$`-1'B
M&PD(``#B)0``&``````````````````6:P``>&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L!`BT`%``&``@````A`!^WS<'&`@``'0<``!@`````````````
M````57,``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(````
M(0"54BULTP4``.<6```9`````````````````%%V``!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`,>^"BC6!0``MQ@``!@`````
M````````````6WP``'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`
M!@`(````(0`LLSE^D08``%<;```8`````````````````&>"``!X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`?('CH8\#``!?"P``
M&0`````````````````NB0``>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M`0(M`!0`!@`(````(0#'I@7.<0,``%`,```9`````````````````/2,``!X
M;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`,^H9F-(
M!P``6R(``!@`````````````````G)```'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+`0(M`!0`!@`(````(0"9@^$N,0$``$`"```1````````````````
M`!J8``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0!T:9@"/`(`
M`!<&```0`````````````````(*:``!D;V-0<F]P<R]A<'`N>&UL4$L%!@``
0```:`!H`Z`8``/2=````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>NOTE 2 - INVENTORIES</strong></p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">&#160;</p>

<div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">Inventory at September 30, 2014 and December 31, 2013 consisted of the following:</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">&#160;</p>

<div class="CursorPointer">
<table align="center" cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; clear: both; margin-left: 1in; width: 85%; border-collapse: collapse;">
<tr>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"><strong>September&#160;30</strong>,</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"><strong>December&#160;31</strong>,</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
</tr>

<tr>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; width: 70%;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="2" align="center" valign="bottom" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"><strong>2014</strong></td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td colspan="2" align="center" valign="bottom" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"><strong>2013</strong></td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="6" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">(U.S. dollars in thousands)</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Raw materials</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>1,660</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>2,342</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Work in progress</td>
<td style=" font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>0</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>92</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Finished goods</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>5,170</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>5,523</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Total inventory</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>6,830</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>7,957</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>
</table>
</div>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>

</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">During the nine months ended September 30, 2014, the Company recorded approximately $<font>1.6</font> million for write-down of inventory under cost of revenues.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y-3$U
M-38P,S`X83$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y
M-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3-F
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]35$%414U%/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$
M7T-/3E-/3$E$051%1%]35$%414U%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-14%3
M55)%345.5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-43T-+7U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3E9%3E1/
M4DE%4U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244R/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y614Y43U))15-?4V-H
M961U;&5?;V9?26YV96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1D%)4E]604Q515]-14%355)%345.5%]$971A:6QS/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM?5%)!3E-!
M0U1)3TY37T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\
M>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^
M#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R
M;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@
M/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@
M/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE
M9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V
M9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-3-F-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P
M.&$Q+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O
M<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@
M,#$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1&]C=6UE;G0@06YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)
M"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M43,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)U!,6#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=04D]404Q)6"!"24]42$5205!%551)
M0U,L($E.0RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<P,#`Q,#`V,C@Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&
M:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)RTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!8V-E;&5R871E9"!&:6QE<CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#8W,BPU-C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S4S9C<V.38T7S9D
M-V9?-#!B-%]A8V4Q7SDU,34U-C`S,#AA,0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X
M83$O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4#5!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!
M3$%.0T4@4TA%1513("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($%34T544SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8P+#,Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.#8L,SDX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A
M8FQE("T@5')A9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPP-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L.#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY-3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L,C`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3<L.3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&54Y$4R!)3B!215-014-4($]&($5-4$Q/645%(%))1TA44R!5
M4$].(%)%5$E214U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!23U!%4E19($%.1"!%455)4$U%3E0L($Y%5#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L.#0V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-S$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$149%
M4E)%1"!#2$%21T53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@T+#<Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q,RPS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=',@<&%Y86)L
M92!A;F0@86-C<G5A;',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5')A9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PR-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,BPP-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,S8Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C0L,S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8L-CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ/3D<@5$5232!,24%"
M24Q)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C<L,S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C<L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,S<S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L-SDV/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6%B:6QI='D@:6X@8V]N;F5C=&EO;B!W:71H(&-O;&QA8F]R871I;VX@;W!E
M<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!F;W(@96UP;&]Y964@<FEG:'1S('5P
M;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPS-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#,V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&QO;F<@=&5R;2!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`X+#$P-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,RPU.#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,R+#0X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T,"PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0T%0251!3"!$149)0TE%3D-9/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T-RPV.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C8L.30V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S(&YE="!O
M9B!C87!I=&%L(&1E9FEC:65N8WD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@.#0L-SDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,3,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y
M-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3-F
M-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q+U=O<FMS:&5E=',O
M4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14Y)04<^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&($]0
M15)!5$E/3E,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R
M92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@3U!%
M4D%424].4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2159%3E5%4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+#,Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPR.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+#4Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PQ,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-/35!!3EDG4R!32$%212!)3B!#3TQ,04)/4D%424].($%'4D5%345.5#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,C4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPR-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-/4U0@3T8@4D5614Y515,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L-SDX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L-3@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-#<V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#<V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=23U-3(%!2
M3T9)5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<W
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPU,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)%4T5!4D-(($%.1"!$159%3$]0345.5"!%6%!%3E-%
M4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PP-3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPW,C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C,L,C@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(S+#0V-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQE<W,@+2!G<F%N=',@86YD(')E:6UB=7)S96UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DT-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPQ-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)%4T5!4D-(($%.1"!$159%3$]0345.5"!%6%!%3E-%
M4RP@3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#$P-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M+#8S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-RPQ,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3<L-#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4T5,3$E.1RP@1T5.15)!3"!!3D0@041-
M24Y)4U12051)5D4@15A014Y315,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L,#$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-S@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#<L,C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,#8U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]015)!5$E.1R!,
M3U-3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#(P."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#8T
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q."PQ,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,38L.38X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1DE.04Y#24%,($584$5.4T53/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@U,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPT.3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1DE.04Y#24%,($E.0T]-13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9)3D%.0TE!3"!)3D-/344@*$584$5.4T53*2`M
M($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX,#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,L,S4Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3D54($Q/4U,@1D]2(%1(12!015))3T0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PP,3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#<T-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(Q+#0W
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#$V+#DP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3D54($Q/4U,@4$52(%-(05)%($]&($-/
M34U/3B!35$]#2SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)!4TE#($%.1"!$24Q55$5$/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E=%24=(5$5$($%615)!1T4@3E5-0D52($]&(%-(05)%4R!/
M1B!#3TU-3TX@4U1/0TL@55-%1"!)3B!#3TU0551)3D<@3$]34R!015(@4TA!
M4D4@+2!"05-)0R!!3D0@1$E,551%1#H\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!4TE#($%.1"!$24Q55$5$/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,BPY-S$L-3<R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L-#,S
M+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDR+#@R."PX-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY,BPS,#<L,3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y
M-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3-F
M-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q+U=O<FMS:&5E=',O
M4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P159)044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&($]0
M15)!5$E/3E,@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R
M8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@
M4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@
M;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPQ.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD($%D
M;6EN:7-T<F%T:79E($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC
M92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C
M;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PR-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU
M,34U-C`S,#AA,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W
M-CDV-%\V9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X83$O5V]R:W-H965T<R]3
M:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%1UI"1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5"!/1B!#2$%.
M1T53($E.($-!4$E404P@1$5&24-)14Y#62`H55-$("0I/&)R/DEN(%1H;W5S
M86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(V+#DT-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L,S4W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S
M960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L(&YE="!O9B!F
M;W)F96ET=7)E<R!O9B`Q+#@S-"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L
M;WEE97,@*&EN8VQU9&5S(&YE="!E>&5R8VES92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@X+#`Q,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#<T-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2PT-S0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38L.3`U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W+#8Y-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPW
M,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#<L-CDT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#<P
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,L-34Q+#`Y.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDS+#0X.2PX,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O
M;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L
M(&YE="!O9B!F;W)F96ET=7)E<R!O9B`Q+#@S-"!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@
M87=A<F0L(&YE="!O9B!F;W)F96ET=7)E<R!O9B`Q+#@S-"!S:&%R97,@*&EN
M('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX
M,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV-C<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R
M8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S("AI;F-L=61E
M<R!N970@97AE<F-I<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E
M9"!T;R!E;7!L;WEE97,@*&EN8VQU9&5S(&YE="!E>&5R8VES92D@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$S+#@P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T+#<V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO
M<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#8V,RPP-C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPU-3(L
M.3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3,L-C8S+#`V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS
M+#4U,BPY,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!#87!I=&%L(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#0L,S0U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#$T-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA
M=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L(&YE="!O9B!F;W)F96ET
M=7)E<R!O9B`Q+#@S-"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@
M*&EN8VQU9&5S(&YE="!E>&5R8VES92D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@U+#`W,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,RPW,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.#4L,#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@S+#<P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C=6UU;&%T960@1&5F:6-I="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C$Q+#,X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q.#,L-3DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T
M960@=&\@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N
M(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9"P@;F5T(&]F(&9O
M<F9E:71U<F5S(&]F(#$L.#,T('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N
M<R!G<F%N=&5D('1O(&5M<&QO>65E<R`H:6YC;'5D97,@;F5T(&5X97)C:7-E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C$L-#<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$V+#DP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#(S,BPX-3DI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R,#`L-3`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C,R+#@U
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(P,"PU,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&0@8V]L<W!A;CTS1#8^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L
M:6=N/3-$=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-2!V
M86QI9VX],T1T;W`^4F5P<F5S96YT<R!A;6]U;G0@;&5S<R!T:&%N("0Q/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S4S9C<V.38T7S9D-V9?-#!B-%]A
M8V4Q7SDU,34U-C`S,#AA,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X83$O5V]R:W-H
M965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$5!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5"!/
M1B!#2$%.1T53($E.($-!4$E404P@1$5&24-)14Y#62`H4&%R96YT:&5T:6-A
M;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%
M3E0@3T8@0TA!3D=%4R!)3B!#05!)5$%,($1%1DE#245.0UD@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O(')E<W1R:6-T
M960@<W1O8VL@87=A<F0L(&9O<F9E:71U<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#@S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL('!A<B!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!3=&]C:RP@075T:&]R:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-3-F-S8Y-C1?
M-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S
M,#AA,2]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!3$%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@
M4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($92
M3TT@3U!%4D%424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,C$L-#<T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,38L.3`U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!9&IU<W1M96YT<R!R97%U:7)E9"!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD('=R:71E(&1O=VX@
M;V8@9FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#0Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&:6YA;F-I86P@97AP96YS97,@*&EN8V]M92PI+"!N
M970@*&UA:6YL>2!E>&-H86YG92!D:69F97)E;F-E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$T,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG97,@:6X@86-C<G5E
M9"!L:6%B:6QI='D@9F]R(&5M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I
M;B!O;B!A;6]U;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M<&QO>65E(')I
M9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@:7-S=6%N8V4@
M8V]S=',@86YD(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@:6X@9&5F97)R960@
M<F5V96YU97,@*&EN8VQU9&EN9R!N;VXM8W5R<F5N="!P;W)T:6]N*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ-S(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PS.3,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R
M96%S92!I;B!A8V-O=6YT<R!R96-E:79A8FQE(&%N9"!O=&AE<B!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4W."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.3@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R
M96%S92`H:6YC<F5A<V4I(&EN(&EN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3,X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@:6X@86-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5A;',@*&EN8VQU9&EN9R!L;VYG('1E
M<FTI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<S-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#0Q
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-"PT,#<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4L.3$Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#05-(($9,3U=3($923TT@24Y615-424Y'($%#5$E6251)15,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-C8X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N="!I
M;B!R97-T<FEC=&5D(&1E<&]S:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UO=6YT<R!F=6YD960@:6X@<F5S<&5C="!O9B!E
M;7!L;WEE92!R:6=H=',@=7!O;B!R971I<F5M96YT+"!N970\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$R,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E
M9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH.#,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L.#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($92
M3TT@1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R;VT@:7-S
M=6%N8V4@;V8@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPY,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F
M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPY-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5&1D5#
M5"!/1B!%6$-(04Y'12!2051%($-(04Y'15,@3TX@0T%32#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH.#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!)3D-214%312`H
M1$5#4D5!4T4I($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V+#`X,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PS-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.
M0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y44R!!5"!"14=)3DY)3D<@
M3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-BPS
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,BPP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y4
M4R!!5"!%3D0@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,"PS,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,2PS.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%262!)3D9/
M4DU!5$E/3B!/3B!)3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)5DE42453
M($Y/5"!)3E9/3%9)3D<@0T%32"!&3$]74SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&-O<W0@<F5L871E9"!T;R!C;VYV97)T:6)L
M92!N;W1E(&]F9F5R:6YG(&YO="!Y970@<&%I9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N
M=&5D('1O(&5M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S,#AA,0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W-CDV-%\V9#=F7S0P8C1?
M86-E,5\Y-3$U-38P,S`X83$O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4TE'3DE&24-!3E0@
M04-#3U5.5$E.1R!03TQ)0TE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@
M4$],24-)15,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)
M0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@:60]
M,T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z
M("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,#LG/CQS=')O;F<^3D]412`\9F]N=#XQ/"]F;VYT/B`M(%-)1TY)1DE#04Y4
M($%#0T]53E1)3D<@4$],24-)15,\+W-T<F]N9SX\+W`^#0H-"CQD:78@8VQA
M<W,],T1#=7)S;W)0;VEN=&5R/@T*/&1I=CX-"@T*/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$
M)R`[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;BUT;W`Z(#!P=#L@;6%R9VEN+6)O='1O;3H@,'!T.R<^#0H\='(@
M<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<VEZ93H@,3!P
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M;W`[)SX-"CQT9"!S='EL93TS1"<@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`V)3LG/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[)SX\<W1R
M;VYG/F$N/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G('=I
M9'1H.B`Y-"4[)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z
M(#$P<'0[)SX@)B,Q-C`[)B,Q-C`[)B,Q-C`[1V5N97)A;#PO9F]N=#X\+W-T
M<F]N9SX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H-"CPO9&EV/@T*/"]D:78^
M#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,'!X(#!P="`Q:6X[)SY0<F]T86QI>"!":6]4:&5R87!E=71I8W,L
M($EN8RX@*&-O;&QE8W1I=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L('1H
M92`F(S$T-SM#;VUP86YY)B,Q-#@[*2P@86YD(&ET<R!W:&]L;'DM;W=N960@
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M,C`P.2P@4')O=&%L:7@@3'1D+B!F;W)M960@86YO=&AE<B!W:&]L;'DM;W=N
M960@<W5B<VED:6%R>2!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@3F5T:&5R;&%N
M9',L(%!R;W1A;&EX($(N5BXL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@175R
M;W!E86X@365D:6-I;F5S($%G96YC>2`H)B,Q-#<[14U!)B,Q-#@[*2!A<'!L
M:6-A=&EO;B!P<F]C97-S(&EN('1H92!%=7)O<&5A;B!5;FEO;BX@5&AE($-O
M;7!A;GDG<R`\9F]N=#YT=V\\+V9O;G0^('-U8G-I9&EA<FEE<R!A<F4@<F5F
M97)R960@=&\@8V]L;&5C=&EV96QY(&AE<F5I;B!A<R!T:&4@)B,Q-#<[4W5B
M<VED:6%R:65S+B8C,30X.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#!P>"`P<'0@,6EN.R<^3VX@36%Y(#$L(#(P,3(L('1H92!5+E,N($9O
M;V0@86YD($1R=6<@061M:6YI<W1R871I;VX@*"8C,30W.T9$028C,30X.RD@
M87!P<F]V960@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!I;FIE8W1I;VXL('1H
M92!#;VUP86YY)W,@9FER<W0@87!P<F]V960@9')U9R!P<F]D=6-T+"!A<R!A
M;B!E;GIY;64@<F5P;&%C96UE;G0@=&AE<F%P>2`H15)4*2!F;W(@=&AE(&QO
M;F<M=&5R;2!T<F5A=&UE;G0@;V8@861U;'0@<&%T:65N=',@=VET:"!A(&-O
M;F9I<FUE9"!D:6%G;F]S:7,@;V8@='EP92`\9F]N=#XQ/"]F;VYT/B!'875C
M:&5R(&1I<V5A<V4N(%1A;&EG;'5C97)A<V4@86QF82!I<R!A('!R;W!R:65T
M87)Y+"!R96-O;6)I;F%N="!F;W)M(&]F(&=L=6-O8V5R96)R;W-I9&%S92`H
M1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#96QL
M17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B>2!T
M:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`F(S$T-SM)<W)A
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M875T:&]R:71Y+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T
M(#4V+C=P=#LG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#!P>"`P<'0@,6EN.R<^/&9O;G0@<W1Y;&4],T0G(&-O;&]R.B!R9V(H,"P@
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M;F4[)SY);B!!=6=U<W0@,C`Q-"P@=&AE($9$02!A<'!R;W9E9"!T86QI9VQU
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P
M<'0@-38N-W!T.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,'!X(#!P="`Q:6X[)SY486QI9VQU8V5R87-E(&%L9F$@:7,@8F5I;F<@
M;6%R:V5T960@:6X@=&AE(%5N:71E9"!3=&%T97,@=6YD97(@=&AE(&)R86YD
M(&YA;64@14Q%3%E33R8C,34S.R!B>2!09FEZ97(@26YC+B`H)B,Q-#<[4&9I
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M=&AE(&)R86YD(&YA;64@55!,65-/)B,Q-3,[+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^4')O=&%L:7@@3'1D+B!G
M<F%N=&5D(%!F:7IE<B!A;B!E>&-L=7-I=F4L('=O<FQD=VED92!L:6-E;G-E
M('1O(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A
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M+C`\+V9O;G0^(&UI;&QI;VX@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5C
M=71I;VX@;V8@=&AE(%!F:7IE<B!!9W)E96UE;G0@86YD('-H;W)T;'D@=&AE
M<F5A9G1E<B!A;B!A9&1I=&EO;F%L("0\9F]N=#XU+C`\+V9O;G0^(&UI;&QI
M;VX@8VQI;FEC86P@9&5V96QO<&UE;G0M<F5L871E9"!M:6QE<W1O;F4@<&%Y
M;65N="X@5&AE($-O;7!A;GD@<F5C96EV960@9'5R:6YG(#QF;VYT/C(P,3(\
M+V9O;G0^(&%N(&%D9&ET:6]N86P@)#QF;VYT/C(U+C`\+V9O;G0^(&UI;&QI
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M;&EZ871I;VX@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N(&$@/&9O;G0^-#`\
M+V9O;G0^)2!A;F0@/&9O;G0^-C`\+V9O;G0^)2!B87-I<RP@<F5S<&5C=&EV
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M+CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C<U
M:6X[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@
M,'!T(#%I;CLG/D]N($IU;F4@,3@L(#(P,3,L(%!R;W1A;&EX($QT9"X@96YT
M97)E9"!I;G1O(&$@4W5P<&QY(&%N9"!496-H;F]L;V=Y(%1R86YS9F5R($%G
M<F5E;65N="`H=&AE("8C,30W.T)R87II;"!!9W)E96UE;G0F(S$T.#LI('=I
M=&@@1G5N9&$F(S(S,3LF(S(R-SMO($]S=V%L9&\@0W)U>B`H)B,Q-#<[1FEO
M8W)U>B8C,30X.RDL(&%N(&%R;2!O9B!T:&4@0G)A>FEL:6%N($U/2"P@9F]R
M('1A;&EG;'5C97)A<V4@86QF82X@5&AE(&)R86YD(&YA;64@9F]R('1A;&EG
M;'5C97)A<V4@86QF82!I;B!"<F%Z:6P@:7,@55!,65-/+B!4:&4@9FER<W0@
M=&5R;2!O9B!T:&4@=&5C:&YO;&]G>2!T<F%N<V9E<B!I<R`\9F]N=#YS979E
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M;VYT/C(P,30\+V9O;G0^+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#!P>"`P<'0@,6EN.R<^1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(')E
M=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#QF;VYT/C,N-3PO9F]N=#X@;6EL
M;&EO;B!F<F]M('1H92!S86QE(&]F('!R;V1U8W1S('1O($9I;V-R=7HN/&)R
M+SX-"CQB<B\^#0I);B!397!T96UB97(@,C`Q-"P@0T].251%0RP@=&AE($YA
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M.B`P<'0@,"`P<'0@,6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,'!X(#!P="`Q:6X[)SY4;R!F86-I;&ET871E('1H92!A<G)A
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M97)A<V4@86QF82!T;R!&:6]C<G5Z+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^4')O=&%L:7@@3'1D+B!I<R!R97%U
M:7)E9"!T;R!P87D@82!F964@97%U86P@=&\@/&9O;G0^-3PO9F]N=#XE(&]F
M('1H92!N970@<')O8V5E9',@9V5N97)A=&5D(&EN($)R87II;"!T;R!I=',@
M86=E;G0@9F]R('-E<G9I8V5S('!R;W9I9&5D(&EN(&%S<VES=&EN9R!0<F]T
M86QI>"!,=&0N(&-O;7!L971E('1H92!"<F%Z:6P@06=R965M96YT('!U<G-U
M86YT('1O(&%N(&%G96YC>2!A9W)E96UE;G0@8F5T=V5E;B!0<F]T86QI>"!,
M=&0N(&%N9"!T:&4@86=E;G0N(%1H92!A9V5N8WD@86=R965M96YT('=I;&P@
M<F5M86EN(&EN(&5F9F5C="!W:71H(')E<W!E8W0@=&\@=&AE($)R87II;"!!
M9W)E96UE;G0@=6YT:6P@=&AE('1E<FUI;F%T:6]N('1H97)E;V8N/"]P/@T*
M#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,6EN.R<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,'!X(#!P="`Q:6X[)SY);B!A
M9&1I=&EO;B!T;R!T:&4@87!P<F]V86QS(&9R;VT@=&AE($9$02P@=&AE($ES
M<F%E;&D@34]((&%N9"!T:&4@0G)A>FEL:6%N($U/2"P@;6%R:V5T:6YG(&%P
M<')O=F%L(&AA<R!B965N(&=R86YT960@=&\@/&9O;G0@<W1Y;&4],T0G(&-O
M;&]R.B!R9V(H,"P@,"P@,"D[(&9O;G0M9F%M:6QY(#H@5&EM97,@3F5W(%)O
M;6%N.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R!D:7-P;&%Y.B!I;FQI;F4@(6EM<&]R=&%N
M=#L@9FQO870Z(&YO;F4[)SY%3$5,65-//"]F;VYT/B!I;B!#86YA9&$L($%U
M<W1R86QI82P@365X:6-O+"!#:&EL92P@57)U9W5A>2!A;F0@06QB86YI82X@
M26X@861D:71I;VXL('1H92!#;VUP86YY(&ES(&-O;W!E<F%T:6YG('=I=&@@
M4&9I>F5R(&EN(&ET<R!E9F9O<G1S('1O(&]B=&%I;B!M87)K971I;F<@87!P
M<F]V86P@9F]R('1A;&EG;'5C97)A<V4@86QF82!I;B!A9&1I=&EO;F%L(&-O
M=6YT<FEE<R!A;F0@:G5R:7-D:6-T:6]N<RX@0W5R<F5N=&QY+"!M87)K971I
M;F<@875T:&]R:7IA=&EO;B!A<'!L:6-A=&EO;G,@:&%V92!B965N(&9I;&5D
M(&EN(&$@;G5M8F5R(&]F(&-O=6YT<FEE<RX\+W`^#0H-"CQP('-T>6QE/3-$
M)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P(#!P="`Q:6X[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P<'@@,'!T(#%I;CLG/D-U<G)E;G1L>2P@<&%T:65N
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M+W`^#0H-"@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XW-6EN
M.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,'!X(#!P
M="`Q:6X[)SY);B!A9&1I=&EO;B!T;R!T:&4@87!P<F]V86P@;V8@=&%L:6=L
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M<W!E8W1I=F4@9&5V96QO<&UE;G1A;"!P97)I;V1S+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^3V)T86EN:6YG(&UA
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M('!R961I8W0@=&AE(&]U=&-O;64@;V8@=&AE<V4@86-T:79I=&EE<RX\+W`^
M#0H-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"<@;6%R9VEN.B`P<'@[
M(&-L96%R.B!L969T.R!F;VYT+69A;6EL>2`Z(%1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]P/@T*#0H\+V1I=CX-"@T*/&1I
M=CX-"@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\9&EV/@T*#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS
M1#$P,"4@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;BUT;W`Z(#!P=#L@;6%R9VEN+6)O='1O;3H@
M,'!T.R<^#0H\='(@<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O
M;G0M<VEZ93H@,3!P=#LG/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V
M)2!V86QI9VX],T1M:61D;&4@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE
M.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E
M<BUB;W1T;VTZ(&YO;F4[(&9O;G0M<VEZ93H@,3!P=#L@=VED=&@Z(#8E.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/CQS=')O;F<^8BX\+W-T<F]N9SX\+W1D/@T*
M/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT
M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE
M.R!F;VYT+7-I>F4Z(#$P<'0[('=I9'1H.B`Y-"4[)SX\<W1R;VYG/B`F(S$V
M,#LF(S$V,#M"87-I<R!O9B!0<F5S96YT871I;VX\+W-T<F]N9SX\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H-"CPO9&EV/@T*/"]D:78^#0H-"CQP('-T>6QE
M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P(#!P="`U-BXW<'0[)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@,'!T(#%I;CLG/E1H92!A8V-O;7!A
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M:&4@:6YF;W)M871I;VX@86YD(&YO=&5S(')E<75I<F5D(&)Y($=!05`@9F]R
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M92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A<BX\+W`^#0H-"CQP('-T>6QE
M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P(#!P="`U-BXW<'0[)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@,'!T(#%I;CLG/E1H97-E('5N875D
M:71E9"!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&%U
M9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN('1H
M92!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD
M960@1&5C96UB97(@,S$L(#(P,3,L(&9I;&5D(&)Y('1H92!#;VUP86YY('=I
M=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VXN(%1H
M92!C;VUP87)A=&EV92!B86QA;F-E('-H965T(&%T($1E8V5M8F5R(#,Q+"`R
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M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$
M)R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XM=&]P.B`P<'0[(&UA<F=I;BUB;W1T;VTZ(#!P=#LG/@T*/'1R('-T
M>6QE/3-$)R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-B4@=F%L:6=N/3-$;6ED
M9&QE('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT
M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE
M.R!F;VYT+7-I>F4Z(#$P<'0[('=I9'1H.B`V)3L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\<W1R;VYG/F,N/"]S=')O;F<^/"]T9#X-"CQT9"!S='EL93TS1"<@
M8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R
M+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@9F]N="US:7IE.B`Q
M,'!T.R!W:61T:#H@.30E.R<^/'-T<F]N9SX@)B,Q-C`[)B,Q-C`[3F5T(&QO
M<W,@<&5R('-H87)E/"]S=')O;F<^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M#0H\+V1I=CX-"CPO9&EV/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P
M<'0@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,'!X(#!P="`Q:6X[)SY"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!S
M:&%R92`H)B,Q-#<[3%!3)B,Q-#@[*2!A<F4@8V]M<'5T960@8GD@9&EV:61I
M;F<@;F5T(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F
M('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C:RP@<&%R('9A
M;'5E("0\9F]N=#XP+C`P,3PO9F]N=#X@<&5R('-H87)E("AT:&4@)B,Q-#<[
M0V]M;6]N(%-T;V-K)B,Q-#@[*2!O=71S=&%N9&EN9R!F;W(@96%C:"!P97)I
M;V0N/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XW-6EN
M.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,'!X(#!P
M="`Q:6X[)SY$:6QU=&5D($Q04R!D;V5S(&YO="!I;F-L=61E(#QF;VYT/C<L
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M<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N
M9"`\9F]N=#XR,#$T/"]F;VYT/BP@<F5S<&5C=&EV96QY+"!A;F0@/&9O;G0^
M."PX,3<L,#DP(#PO9F]N=#YA;F0@/&9O;G0^,3@L-C8Q+#$X,B`\+V9O;G0^
M<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,30L(')E<W!E8W1I=F5L
M>2P@8F5C875S92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N
M/"]P/@T*#0H\<"!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G(&UA<F=I;CH@
M,'!X.R!C;&5A<CH@;&5F=#L@9F]N="UF86UI;'D@.B!4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO<#X-"@T*/"]D:78^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S,#AA,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W-CDV-%\V9#=F7S0P8C1?86-E
M,5\Y-3$U-38P,S`X83$O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y614Y43U))15,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)3E9%3E1/4DE%4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@:60],T1%9&=A<E-!03$R,S0U-S@Y
M,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M86XG
M.R<^#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#LG/CQS=')O;F<^3D]412`R
M("T@24Y614Y43U))15,\+W-T<F]N9SX\+W`^#0H-"CQP('-T>6QE/3-$)R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-"@T*/&1I=CX-"@T*
M/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN.R<^26YV96YT;W)Y
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,@
M8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS
M1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[)SXF(S$V,#L\+W`^#0H-"CQD:78@
M8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&-L96%R
M.B!B;W1H.R!M87)G:6XM;&5F=#H@,6EN.R!W:61T:#H@.#4E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R<^#0H\='(^#0H\=&0@<W1Y;&4],T0G(&)O
M<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT
M;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@
M(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R
M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T
M=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P
M>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H
M=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P
M,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P=#L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/'-T<F]N9SY3
M97!T96UB97(F(S$V,#LS,#PO<W1R;VYG/BP\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT
M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P
M,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N
M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D
M97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q
M,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT
M97([)SX\<W1R;VYG/D1E8V5M8F5R)B,Q-C`[,S$\+W-T<F]N9SXL/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[
M(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R
M+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P
M=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO
M;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R
M9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*#0H\='(^#0H\=&0@<W1Y;&4]
M,T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O
M<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC
M;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[
M('=I9'1H.B`W,"4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D
M97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P
M.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P
M,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE
M.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A
M9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`Q-24[)SX\<W1R
M;VYG/C(P,30\+W-T<F]N9SX\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B
M;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S
M;VQI9#L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O
M;G0M<VEZ93H@,3!P=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA
M;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G(&)O<F1E
M<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z
M(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED.R!B;W)D
M97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q
M,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT
M97([('=I9'1H.B`Q-24[)SX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\+W1D/@T*
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@
M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M
M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N
M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D
M97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT<B!S='EL93TS1"<@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="US:7IE.B`Q,'!T.R<^#0H\=&0@
M<W1Y;&4],T0G(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO
M;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O
M<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0V('-T>6QE/3-$
M)R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N
M93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M
M<VEZ93H@,3!P=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG
M;CH@8V5N=&5R.R<^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[
M(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R
M+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P
M=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT<B!S='EL93TS1"<@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@9F]N="US:7IE.B`Q,'!T.R!B86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.R<^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T
M.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[
M(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@
M<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[)SY287<@;6%T97)I86QS
M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E
M<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O
M;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E
M<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO
M<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!P861D:6YG+7)I9VAT.B`Q,'!X
M.R!W:&ET92US<&%C93H@;F]W<F%P.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR
M:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@
M;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N=#XQ+#8V,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B
M;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O
M<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O
M='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M
M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ
M(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!P
M861D:6YG+7)I9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE
M9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N
M93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P
M.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N=#XR+#,T,CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R
M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L
M;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A
M<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT<B!S='EL
M93TS1"<@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="US:7IE.B`Q,'!T
M.R<^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M
M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ
M(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY7;W)K(&EN('!R;V=R97-S/"]T9#X-"CQT9"!S
M='EL93TS1"<@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N
M93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R
M9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U
M<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O
M<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC
M;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0^,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@
M;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B
M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"<@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E
M<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O
M;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D
M9&EN9RUL969T.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG
M:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO
M;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]W<F%P.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0^.3(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"<@
M8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R
M+71O<#H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@
M<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*#0H\='(@<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&9O;G0M<VEZ93H@,3!P=#L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CLG/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R
M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T
M=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P
M>#L@9F]N="US:7IE.B`Q,'!T.R<^1FEN:7-H960@9V]O9',\+W1D/@T*/'1D
M('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N
M;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B
M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O
M='1O;3H@(S`P,#`P,"`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B!N;VYE.R!B
M;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC
M;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W
M<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@
M8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N=#XU+#$W,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)R!B
M;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M
M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P
M861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR
M:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@
M;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D
M97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO
M;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0^-2PU,C,\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E
M<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O;&]R
M.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*#0H\='(@<W1Y;&4]
M,T0G('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M<VEZ93H@,3!P=#LG
M/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I
M9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N
M;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N
M="US:7IE.B`Q,'!T.R<^5&]T86P@:6YV96YT;W)Y/"]T9#X-"CQT9"!S='EL
M93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@
M8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R9&5R
M+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUB;W1T;VTZ
M(",P,#`P,#`@,BXX,'!T(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O
M<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O
M;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('!A9&1I;F<M<FEG:'0Z(#$P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P=#LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#(N
M.#!P="!D;W5B;&4[(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z
M(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P
M,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0^-BPX,S`\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O
M<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O
M;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O
M<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT
M;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@
M(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P
M861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M
M8F]T=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4[(&)O<F1E<BUL969T.B!N
M;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O
M<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!P861D:6YG+7)I
M9VAT.B`Q,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`R+C@P<'0@9&]U8FQE.R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R
M+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z
M(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT/C<L
M.34W/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N
M;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O
M<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX-"@T*/'`@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)R!M87)G:6XZ(#!P>#L@8VQE87(Z(&QE9G0[(&9O;G0M9F%M:6QY(#H@5&EM
M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W`^#0H-
M"CPO9&EV/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[
M)SY$=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@
M,C`Q-"P@=&AE($-O;7!A;GD@<F5C;W)D960@87!P<F]X:6UA=&5L>2`D/&9O
M;G0^,2XV/"]F;VYT/B!M:6QL:6]N(&9O<B!W<FET92UD;W=N(&]F(&EN=F5N
M=&]R>2!U;F1E<B!C;W-T(&]F(')E=F5N=65S+CPO<#X-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-3-F-S8Y-C1?
M-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S
M,#AA,2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y4/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1D%)4B!604Q512!-14%355)%345.5"!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&04E2(%9!3%5%($U%
M05-54D5-14Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQP('-T>6QE/3-$)R!F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P.R<^/'-T<F]N9SY.3U1%(#,@)B,Q-3`[($9!25(@5D%,544@345!
M4U5214U%3E0\+W-T<F]N9SX\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P(#!P="`S-2XT-7!T.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,"`P<'0@,S4N-#5P=#LG/E1H92!#;VUP86YY(&UE87-U<F5S
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P
M<'0@,S4N-#5P=#LG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#`@,'!T(#,U+C0U<'0[)SY4:&4@86-C;W5N=&EN9R!S=&%N9&%R9"!E
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M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,S4N-#5P=#LG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#,U+C0U
M<'0[)SY,979E;"`\9F]N=#XQ/"]F;VYT/CH@475O=&5D('!R:6-E<R`H=6YA
M9&IU<W1E9"D@:6X@86-T:79E(&UA<FME=',@=&AA="!A<F4@86-C97-S:6)L
M92!A="!T:&4@;65A<W5R96UE;G0@9&%T92!F;W(@87-S971S(&]R(&QI86)I
M;&ET:65S+B!4:&4@9F%I<B!V86QU92!H:65R87)C:'D@9VEV97,@=&AE(&AI
M9VAE<W0@<')I;W)I='D@=&\@3&5V96P@/&9O;G0^,3PO9F]N=#X@:6YP=71S
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#,U+C0U<'0[
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`S
M-2XT-7!T.R<^3&5V96P@/&9O;G0^,CPO9F]N=#XZ($]B<V5R=F%B;&4@<')I
M8V5S('1H870@87)E(&)A<V5D(&]N(&EN<'5T<R!N;W0@<75O=&5D(&]N(&%C
M=&EV92!M87)K971S+"!B=70@8V]R<F]B;W)A=&5D(&)Y(&UA<FME="!D871A
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#,U+C0U<'0[
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`S
M-2XT-7!T.R<^3&5V96P@/&9O;G0^,SPO9F]N=#XZ(%5N;V)S97)V86)L92!I
M;G!U=',@87)E('5S960@=VAE;B!L:71T;&4@;W(@/&9O;G0^;F\\+V9O;G0^
M(&UA<FME="!D871A(&ES(&%V86EL86)L92X@5&AE(&9A:7(@=F%L=64@:&EE
M<F%R8VAY(&=I=F5S('1H92!L;W=E<W0@<')I;W)I='D@=&\@3&5V96P@/&9O
M;G0^,SPO9F]N=#X@:6YP=71S+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#`@,'!T(#,U+C0U<'0[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P(#!P="`S-2XT-7!T.R<^26X@9&5T97)M:6YI;F<@9F%I
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M('9A;'5E+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#,U
M+C0U<'0[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
M(#!P="`S-2XT-7!T.R<^5&AE(&9A:7(@=F%L=64@;V8@=&AE(&9I;F%N8VEA
M;"!I;G-T<G5M96YT<R!I;F-L=61E9"!I;B!T:&4@=V]R:VEN9R!C87!I=&%L
M(&]F('1H92!#;VUP86YY(&ES('5S=6%L;'D@:61E;G1I8V%L(&]R(&-L;W-E
M('1O('1H96ER(&-A<G)Y:6YG('9A;'5E+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`@,'!T(#,U+C0U<'0[)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P(#!P="`S-2XT-7!T.R<^/&9O;G0@<W1Y;&4]
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M8V]N=F5R=&EB;&4@;F]T97,@87,@;V8@/"]F;VYT/E-E<'1E;6)E<B`S,"P@
M,C`Q-"!I<R!A<'!R;WAI;6%T96QY("0\9F]N=#XU.2XT/"]F;VYT/B!M:6QL
M:6]N(&)A<V5D(&]N(&$@;&5V96P@,B!M96%S=7)E;65N="X\+W`^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S4S
M9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S,#AA,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y
M-3$U-38P,S`X83$O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TL@5%)!3E-!0U1)3TY3
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4U1/0TL@5%)!3E-!0U1)3TY3(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-+(%1204Y304-4
M24].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@:60]
M,T1%9&=A<E-!03$R,S0U-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z
M("=4:6UE<R!.97<@4F]M86XG.R<^#0H\<"!S='EL93TS1"<@8V]L;W(Z(')G
M8B@P+"`P+"`P*3L@9F]N="UF86UI;'D@.B!4:6UE<R!.97<@4F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P
M="`P<'@[)SX\<W1R;VYG/DY/5$4@/&9O;G0^-#PO9F]N=#X@)B,Q-3`[(%-4
M3T-+(%1204Y304-424].4SPO<W1R;VYG/CPO<#X-"@T*/'`@<W1Y;&4],T0G
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M;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-"@T*/&1I
M=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"<@9F]N="UF86UI;'D@.B!4
M:6UE<R!.97<@4F]M86X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@
M,'!X.R<^#0H\='(@<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!T;W`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL93TS1"<@=VED=&@Z(#`N
M-6EN.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@=VED=&@Z(#`N,C5I
M;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQB<B\^#0IA+CPO=&0^#0H\=&0@<W1Y
M;&4],T0G('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX-"CQP('-T>6QE/3-$)R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6EN9&5N=#H@,&EN.R<^1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(@,S`L(#(P,30L('1H92!#;VUP86YY(&ES<W5E9"!A('1O=&%L
M(&]F(#QF;VYT/C$Q,RPX,#`\+V9O;G0^('-H87)E<R!O9B!#;VUM;VX@4W1O
M8VL@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B!A('1O=&%L
M(&]F(#QF;VYT/C$Q-BPX,#$\+V9O;G0^(&]P=&EO;G,@8GD@8V5R=&%I;B!E
M;7!L;WEE97,@;V8@=&AE($-O;7!A;GDN(%1H92!A9V=R96=A=&4@<')O8V5E
M9',@:6X@8V]N;F5C=&EO;B!W:71H('-U8V@@97AE<F-I<V5S('1O=&%L960@
M87!P<F]X:6UA=&5L>2`D/&9O;G0^-#,L,#`P/"]F;VYT/BX\+W`^#0H\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"@T*/'`@<W1Y;&4],T0G(&-O
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M9VEN.B`P<'0@,'!X(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-"@T*/&1I=B!C
M;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"<@9F]N="UF86UI;'D@.B!4:6UE
M<R!.97<@4F]M86X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X
M.R<^#0H\='(@<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SX-"CQT9"!S='EL93TS1"<@=VED=&@Z(#`N-6EN
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@=VED=&@Z(#`N,C5I;CL@
M=&5X="UA;&EG;CH@;&5F=#LG/F(N/"]T9#X-"CQT9"!S='EL93TS1"<@=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/D]N($IU;'D@,C0L(#(P,30L('1H92!#;VUP
M86YY)W,@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D+"!S=6)J96-T('1O
M(&-E<G1A:6X@=&5R;7,@86YD(&-O;F1I=&EO;G,L('1H92!G<F%N="!O9B!A
M(#QF;VYT/C$P/"]F;VYT/BUY96%R(&]P=&EO;B!T;R!P=7)C:&%S92`\9F]N
M=#XQ-3`L,#`P/"]F;VYT/B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O(&ET
M<R!N97=L>2!E;&5C=&5D(&-H86ER;6%N(&]F('1H92!";V%R9"!O9B!$:7)E
M8W1O<G,@=VET:"!A;B!E>&5R8VES92!P<FEC92!O9B`D/&9O;G0^,RXS-SPO
M9F]N=#X@<&5R('-H87)E+B!4:&4@;W!T:6]N<R!V97-T(&]V97(@82`\9F]N
M=#YT:')E93PO9F]N=#XM>65A<B!P97)I;V0[('1H92!F:7)S="`\9F]N=#XU
M,"PP,#`\+V9O;G0^('-H87)E<R!V97-T(&]N('1H92!F:7)S="!A;FYI=F5R
M<V%R>2!O9B!T:&4@9W)A;G0@9&%T92!A;F0@=&AE(')E;6%I;FEN9R!S:&%R
M97,@=F5S="!I;B`\9F]N=#YE:6=H=#PO9F]N=#X@97%U86P@<75A<G1E<FQY
M(&EN8W)E;65N=',@;W9E<B!T:&4@<W5B<V5Q=65N="`\9F]N=#YT=V\\+V9O
M;G0^('EE87(@<&5R:6]D+B!697-T:6YG(&]F('1H92!O<'1I;VYS('=I;&P@
M8F4@86-C96QE<F%T960@:6X@9G5L;"!U<&]N(&$@0V]R<&]R871E(%1R86YS
M86-T:6]N(&]R(&$@0VAA;F=E(&EN($-O;G1R;VPL(&%S('1H;W-E('1E<FUS
M(&%R92!D969I;F5D(&EN('1H92!#;VUP86YY)W,@/&9O;G0^,C`P-CPO9F]N
M=#X@4W1O8VL@26YC96YT:79E(%!L86XN(%1H92!#;VUP86YY(&5S=&EM871E
M9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@;W!T:6]N(&]N('1H92!D871E(&]F
M(&)O87)D(&%P<')O=F%L('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO
M;BUP<FEC:6YG(&UO9&5L('1O(&)E(&%P<')O>&EM871E;'D@)#QF;VYT/C(Y
M,RPP,#`\+V9O;G0^+CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*
M#0H\<"!S='EL93TS1"<@8V]L;W(Z(')G8B@P+"`P+"`P*3L@9F]N="UF86UI
M;'D@.B!4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[
M('1E>'0M:6YD96YT.B`P:6X[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R<^)B,Q
M-C`[/"]P/@T*#0H\9&EV(&-L87-S/3-$0W5R<V]R4&]I;G1E<CX-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)R!F
M;VYT+69A;6EL>2`Z(%1I;65S($YE=R!2;VUA;CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG
M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;6%R9VEN+71O<#H@,'!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)SX-"CQT<B!S='EL93TS1"<@=F5R=&EC86PM
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@9&ES<&QA>3H@:6YL:6YE("%I;7!O<G1A;G0[(&9L;V%T
M.B!N;VYE.R<^/&9O;G0@<W1Y;&4],T0G(&9O;G0M<VEZ93H@,3!P=#LG/D]N
M(%-E<'1E;6)E<B`R."P@,C`Q-"P@=&AE($-O;7!A;GDG<R!";V%R9"!O9B!$
M:7)E8W1O<G,@87!P<F]V960L('-U8FIE8W0@=&\@8V5R=&%I;B!T97)M<R!A
M;F0@8V]N9&ET:6]N<RP@=&AE(&=R86YT(&]F(&$@/"]F;VYT/CQF;VYT/CQF
M;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,#PO9F]N=#X\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G(&9O;G0M<VEZ93H@,3!P=#LG/BUY96%R(&]P
M=&EO;B!T;R!P=7)C:&%S92`\+V9O;G0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G
M(&9O;G0M<VEZ93H@,3!P=#LG/CDP,"PP,#`\+V9O;G0^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[)SX@<VAA<F5S(&]F($-O;6UO
M;B!3=&]C:R!T;R!I=',@;F5W;'D@87!P;VEN=&5D(%!R97-I9&5N="!A;F0@
M0VAI968@17AE8W5T:79E($]F9FEC97(@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!O9B`D/"]F;VYT/CQF;VYT/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z
M(#$P<'0[)SXR+C,W/"]F;VYT/CPO9F]N=#X\9F]N="!S='EL93TS1"<@9F]N
M="US:7IE.B`Q,'!T.R<^('!E<B!S:&%R92X@5&AE(&]P=&EO;G,@=F5S="!O
M=F5R(&$@/"]F;VYT/CQF;VYT/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9F]N=#YF;W5R/"]F;VYT/CPO9F]N=#X\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G(&9O;G0M<VEZ93H@,3!P=#LG/BUY96%R('!E<FEO9"!I;B`\
M+V9O;G0^/&9O;G0^/&9O;G0@<W1Y;&4],T0G(&9O;G0M<VEZ93H@,3!P=#LG
M/C$V/"]F;VYT/CPO9F]N=#X\9F]N="!S='EL93TS1"<@9F]N="US:7IE.B`Q
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M<'0[)SXR,#`V/"]F;VYT/CPO9F]N=#X\9F]N="!S='EL93TS1"<@9F]N="US
M:7IE.B`Q,'!T.R<^(%-T;V-K($EN8V5N=&EV92!0;&%N+B!4:&4@0V]M<&%N
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M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y
M-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3-F
M-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q+U=O<FMS:&5E=',O
M4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*%!O;&EC>2D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E
M;F5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&ED
M/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N="UF86UI;'D@
M.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O
M:6YT97(^#0H\9&EV/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G(#L@;6%R9VEN+6)O
M='1O;3H@,'!T.R<^#0H\='(@<W1Y;&4],T0G('9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX-"CQT9"!S='EL93TS1"<@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`V)3LG/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[)SX\<W1R
M;VYG/F$N/"]S=')O;F<^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G('=I
M9'1H.B`Y-"4[)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)R!F;VYT+7-I>F4Z
M(#$P<'0[)SX@)B,Q-C`[)B,Q-C`[)B,Q-C`[1V5N97)A;#PO9F]N=#X\+W-T
M<F]N9SX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H-"CPO9&EV/@T*/"]D:78^
M#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`Q:6X[('1E>'0M:6YD
M96YT.B`M,"XR-6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,'!X(#!P="`Q:6X[)SY0<F]T86QI>"!":6]4:&5R87!E=71I8W,L
M($EN8RX@*&-O;&QE8W1I=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L('1H
M92`F(S$T-SM#;VUP86YY)B,Q-#@[*2P@86YD(&ET<R!W:&]L;'DM;W=N960@
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M,C`P.2P@4')O=&%L:7@@3'1D+B!F;W)M960@86YO=&AE<B!W:&]L;'DM;W=N
M960@<W5B<VED:6%R>2!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@3F5T:&5R;&%N
M9',L(%!R;W1A;&EX($(N5BXL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@175R
M;W!E86X@365D:6-I;F5S($%G96YC>2`H)B,Q-#<[14U!)B,Q-#@[*2!A<'!L
M:6-A=&EO;B!P<F]C97-S(&EN('1H92!%=7)O<&5A;B!5;FEO;BX@5&AE($-O
M;7!A;GDG<R`\9F]N=#YT=V\\+V9O;G0^('-U8G-I9&EA<FEE<R!A<F4@<F5F
M97)R960@=&\@8V]L;&5C=&EV96QY(&AE<F5I;B!A<R!T:&4@)B,Q-#<[4W5B
M<VED:6%R:65S+B8C,30X.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#!P>"`P<'0@,6EN.R<^3VX@36%Y(#$L(#(P,3(L('1H92!5+E,N($9O
M;V0@86YD($1R=6<@061M:6YI<W1R871I;VX@*"8C,30W.T9$028C,30X.RD@
M87!P<F]V960@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!I;FIE8W1I;VXL('1H
M92!#;VUP86YY)W,@9FER<W0@87!P<F]V960@9')U9R!P<F]D=6-T+"!A<R!A
M;B!E;GIY;64@<F5P;&%C96UE;G0@=&AE<F%P>2`H15)4*2!F;W(@=&AE(&QO
M;F<M=&5R;2!T<F5A=&UE;G0@;V8@861U;'0@<&%T:65N=',@=VET:"!A(&-O
M;F9I<FUE9"!D:6%G;F]S:7,@;V8@='EP92`\9F]N=#XQ/"]F;VYT/B!'875C
M:&5R(&1I<V5A<V4N(%1A;&EG;'5C97)A<V4@86QF82!I<R!A('!R;W!R:65T
M87)Y+"!R96-O;6)I;F%N="!F;W)M(&]F(&=L=6-O8V5R96)R;W-I9&%S92`H
M1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#96QL
M17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B>2!T
M:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`F(S$T-SM)<W)A
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M875T:&]R:71Y+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T
M(#4V+C=P=#LG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#!P>"`P<'0@,6EN.R<^/&9O;G0@<W1Y;&4],T0G(&-O;&]R.B!R9V(H,"P@
M,"P@,"D[(&9O;G0M9F%M:6QY(#H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I
M>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B!A=71O
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!D:7-P;&%Y.B!I;FQI;F4@(6EM<&]R=&%N=#L@9FQO870Z(&YO
M;F4[)SY);B!!=6=U<W0@,C`Q-"P@=&AE($9$02!A<'!R;W9E9"!T86QI9VQU
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P
M<'0@-38N-W!T.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,'!X(#!P="`Q:6X[)SY486QI9VQU8V5R87-E(&%L9F$@:7,@8F5I;F<@
M;6%R:V5T960@:6X@=&AE(%5N:71E9"!3=&%T97,@=6YD97(@=&AE(&)R86YD
M(&YA;64@14Q%3%E33R8C,34S.R!B>2!09FEZ97(@26YC+B`H)B,Q-#<[4&9I
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M=&AE(&)R86YD(&YA;64@55!,65-/)B,Q-3,[+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^4')O=&%L:7@@3'1D+B!G
M<F%N=&5D(%!F:7IE<B!A;B!E>&-L=7-I=F4L('=O<FQD=VED92!L:6-E;G-E
M('1O(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A
M;&9A('5N9&5R('1H92!09FEZ97(@06=R965M96YT+"!B=70@<F5T86EN960@
M=&AO<V4@<FEG:'1S(&EN($ES<F%E;"!A;F0L('-I;F-E(#QF;VYT/C(P,30\
M+V9O;G0^+"!I;B!"<F%Z:6P@*'-E92!B96QO=RDN(%1H92!#;VUP86YY(&AA
M<R!A9W)E960@=&\@82!S<&5C:69I8R!A;&QO8V%T:6]N(&)E='=E96X@4')O
M=&%L:7@@3'1D+B!A;F0@4&9I>F5R(')E9V%R9&EN9R!T:&4@<F5S<&]N<VEB
M:6QI=&EE<R!F;W(@=&AE(&-O;G1I;G5E9"!D979E;&]P;65N="!E9F9O<G1S
M(&9O<B!T86QI9VQU8V5R87-E(&%L9F$N(%1O(&1A=&4L('1H92!#;VUP86YY
M(&AA<R!R96-E:79E9"!A;B!U<&9R;VYT('!A>6UE;G0@;V8@)#QF;VYT/C8P
M+C`\+V9O;G0^(&UI;&QI;VX@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5C
M=71I;VX@;V8@=&AE(%!F:7IE<B!!9W)E96UE;G0@86YD('-H;W)T;'D@=&AE
M<F5A9G1E<B!A;B!A9&1I=&EO;F%L("0\9F]N=#XU+C`\+V9O;G0^(&UI;&QI
M;VX@8VQI;FEC86P@9&5V96QO<&UE;G0M<F5L871E9"!M:6QE<W1O;F4@<&%Y
M;65N="X@5&AE($-O;7!A;GD@<F5C96EV960@9'5R:6YG(#QF;VYT/C(P,3(\
M+V9O;G0^(&%N(&%D9&ET:6]N86P@)#QF;VYT/C(U+C`\+V9O;G0^(&UI;&QI
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M;&EZ871I;VX@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N(&$@/&9O;G0^-#`\
M+V9O;G0^)2!A;F0@/&9O;G0^-C`\+V9O;G0^)2!B87-I<RP@<F5S<&5C=&EV
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M+CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C<U
M:6X[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P<'@@
M,'!T(#%I;CLG/D]N($IU;F4@,3@L(#(P,3,L(%!R;W1A;&EX($QT9"X@96YT
M97)E9"!I;G1O(&$@4W5P<&QY(&%N9"!496-H;F]L;V=Y(%1R86YS9F5R($%G
M<F5E;65N="`H=&AE("8C,30W.T)R87II;"!!9W)E96UE;G0F(S$T.#LI('=I
M=&@@1G5N9&$F(S(S,3LF(S(R-SMO($]S=V%L9&\@0W)U>B`H)B,Q-#<[1FEO
M8W)U>B8C,30X.RDL(&%N(&%R;2!O9B!T:&4@0G)A>FEL:6%N($U/2"P@9F]R
M('1A;&EG;'5C97)A<V4@86QF82X@5&AE(&)R86YD(&YA;64@9F]R('1A;&EG
M;'5C97)A<V4@86QF82!I;B!"<F%Z:6P@:7,@55!,65-/+B!4:&4@9FER<W0@
M=&5R;2!O9B!T:&4@=&5C:&YO;&]G>2!T<F%N<V9E<B!I<R`\9F]N=#YS979E
M;CPO9F]N=#X@>65A<G,@86YD('1H92!A9W)E96UE;G0@;6%Y(&)E(&5X=&5N
M9&5D(&9O<B!A;B!A9&1I=&EO;F%L(#QF;VYT/F9I=F4\+V9O;G0^+7EE87(@
M=&5R;2P@87,@;F5E9&5D+"!T;R!C;VUP;&5T92!T:&4@=&5C:&YO;&]G>2!T
M<F%N<V9E<BX@5&AE('1E8VAN;VQO9WD@=')A;G-F97(@:7,@9&5S:6=N960@
M=&\@8F4@969F96-T960@:6X@/&9O;G0^9F]U<CPO9F]N=#X@<W1A9V5S(&%N
M9"!I<R!I;G1E;F1E9"!T;R!T<F%N<V9E<B!T;R!&:6]C<G5Z('1H92!C87!A
M8VET>2!A;F0@<VMI;&QS(')E<75I<F5D(&9O<B!T:&4@0G)A>FEL:6%N(&=O
M=F5R;FUE;G0@=&\@8V]N<W1R=6-T(&ET<R!O=VX@;6%N=69A8W1U<FEN9R!F
M86-I;&ET>2P@870@:71S('-O;&4@97AP96YS92P@86YD('1O('!R;V1U8V4@
M82!S=7-T86EN86)L92P@:&EG:"!Q=6%L:71Y+"!A;F0@8V]S="!E9F9E8W1I
M=F4@<W5P<&QY(&]F('1A;&EG;'5C97)A<V4@86QF82X@56YD97(@=&AE(&%G
M<F5E;65N="P@1FEO8W)U>B!H87,@8V]M;6ET=&5D('1O('!U<F-H87-E(&%T
M(&QE87-T(&%P<')O>&EM871E;'D@)#QF;VYT/C0P/"]F;VYT/B!M:6QL:6]N
M('=O<G1H(&]F('1A;&EG;'5C97)A<V4@86QF82!D=7)I;F<@=&AE(&9I<G-T
M(#QF;VYT/G1W;SPO9F]N=#X@>65A<G,@;V8@=&AE(&%G<F5E;65N="X@26X@
M<W5B<V5Q=65N="!Y96%R<RP@1FEO8W)U>B!I<R!R97%U:7)E9"!T;R!P=7)C
M:&%S92!A="!L96%S="!A<'!R;WAI;6%T96QY("0\9F]N=#XT,#PO9F]N=#X@
M;6EL;&EO;B!W;W)T:"!O9B!T86QI9VQU8V5R87-E(&%L9F$@<&5R('EE87(N
M($%D9&ET:6]N86QL>2P@4')O=&%L:7@@3'1D+B!I<R!N;W0@<F5Q=6ER960@
M=&\@8V]M<&QE=&4@=&AE(&9I;F%L('-T86=E(&]F('1H92!T96-H;F]L;V=Y
M('1R86YS9F5R('5N=&EL($9I;V-R=7H@<'5R8VAA<V5S(&%T(&QE87-T(&%P
M<')O>&EM871E;'D@)#QF;VYT/C(X,#PO9F]N=#X@;6EL;&EO;B!W;W)T:"!O
M9B!T86QI9VQU8V5R87-E(&%L9F$N(%1H92!"<F%Z:6P@06=R965M96YT(&)E
M8V%M92!E9F9E8W1I=F4@9'5R:6YG('1H92!F:7)S="!Q=6%R=&5R(&]F(#QF
M;VYT/C(P,30\+V9O;G0^+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#!P>"`P<'0@,6EN.R<^1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(')E
M=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#QF;VYT/C,N-3PO9F]N=#X@;6EL
M;&EO;B!F<F]M('1H92!S86QE(&]F('!R;V1U8W1S('1O($9I;V-R=7HN/&)R
M+SX-"CQB<B\^#0I);B!397!T96UB97(@,C`Q-"P@0T].251%0RP@=&AE($YA
M=&EO;F%L($-O;6UI<W-I;VX@9F]R($EN8V]R<&]R871I;VX@;V8@5&5C:&YO
M;&]G:65S(&EN($)R87II;"=S(%5N:69I960@2&5A;'1H8V%R92!3>7-T96TL
M(&%N;F]U;F-E9"!T:&%T(&ET(&AA9"!D96-I9&5D('1O(&=I=F4@82!P;W-I
M=&EV92!F=6YD:6YG(')E8V]M;65N9&%T:6]N(&9O<B!T86QI9VQU8V5R87-E
M(&%L9F$@:6X@=&AE('1R96%T;65N="!O9B!A9'5L="!P871I96YT<R!W:71H
M('1Y<&5S(#$@86YD(#,@1V%U8VAE<B!D:7-E87-E+"!A;F0@97-T86)L:7-H
M960@=&AA="!T86QI9VQU8V5R87-E(&%L9F$@=VEL;"!B92!T:&4@9FER<W0@
M8VAO:6-E(&9O<B!T<F5A=&UE;G0@9F]R(&YE=R!A9'5L="!'875C:&5R('!A
M=&EE;G1S(&EN($)R87II;"X@5&AE($-O;7!A;GD@86YT:6-I<&%T97,@=&AA
M="!#3TY)5$5#)W,@<F5S;VQU=&EO;B!W:6QL(&)E(&EM<&QE;65N=&5D(&%R
M;W5N9"!T:&4@96YD(&]F(#(P,30N/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"`P<'0@,6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,'!X(#!P="`Q:6X[)SY4;R!F86-I;&ET871E('1H92!A<G)A
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M97)A<V4@86QF82!T;R!&:6]C<G5Z+CPO<#X-"@T*/'`@<W1Y;&4],T0G(&9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^4')O=&%L:7@@3'1D+B!I<R!R97%U
M:7)E9"!T;R!P87D@82!F964@97%U86P@=&\@/&9O;G0^-3PO9F]N=#XE(&]F
M('1H92!N970@<')O8V5E9',@9V5N97)A=&5D(&EN($)R87II;"!T;R!I=',@
M86=E;G0@9F]R('-E<G9I8V5S('!R;W9I9&5D(&EN(&%S<VES=&EN9R!0<F]T
M86QI>"!,=&0N(&-O;7!L971E('1H92!"<F%Z:6P@06=R965M96YT('!U<G-U
M86YT('1O(&%N(&%G96YC>2!A9W)E96UE;G0@8F5T=V5E;B!0<F]T86QI>"!,
M=&0N(&%N9"!T:&4@86=E;G0N(%1H92!A9V5N8WD@86=R965M96YT('=I;&P@
M<F5M86EN(&EN(&5F9F5C="!W:71H(')E<W!E8W0@=&\@=&AE($)R87II;"!!
M9W)E96UE;G0@=6YT:6P@=&AE('1E<FUI;F%T:6]N('1H97)E;V8N/"]P/@T*
M#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,6EN.R<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,'!X(#!P="`Q:6X[)SY);B!A
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M(&EN(&$@;G5M8F5R(&]F(&-O=6YT<FEE<RX\+W`^#0H-"CQP('-T>6QE/3-$
M)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P(#!P="`Q:6X[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P<'@@,'!T(#%I;CLG/D-U<G)E;G1L>2P@<&%T:65N
M=',@87)E(&)E:6YG('1R96%T960@=VET:"!T86QI9VQU8V5R87-E(&%L9F$@
M;VX@82!C;VUM97)C:6%L(&)A<VES(&EN('1H92!5;FET960@4W1A=&5S+"!"
M<F%Z:6PL($-H:6QE(&%N9"!)<W)A96PN($EN(&%D9&ET:6]N+"!T86QI9VQU
M8V5R87-E(&%L9F$@:7,@8W5R<F5N=&QY(&)E:6YG('!R;W9I9&5D('1O($=A
M=6-H97(@<&%T:65N=',@=6YD97(@<W!E8VEA;"!A8V-E<W,@86=R965M96YT
M<R!O<B!N86UE9"!P871I96YT('!R;W9I<VEO;G,@:6X@;W1H97(@8V]U;G1R
M:65S+CQB<B\^#0H\8G(O/@T*/&9O;G0@<W1Y;&4],T0G(&-O;&]R.B!R9V(H
M,"P@,"P@,"D[(&9O;G0M9F%M:6QY(#H@5&EM97,@3F5W(%)O;6%N.R!F;VYT
M+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B!A
M=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!D:7-P;&%Y.B!I;FQI;F4@(6EM<&]R=&%N=#L@9FQO870Z
M(&YO;F4[)SY);B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E(&%L9F$L('1H
M92!#;VUP86YY(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M96YT(&]F(&-E
M<G1A:6X@;W1H97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X+CPO9F]N=#X\
M+W`^#0H-"@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XW-6EN
M.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,'!X(#!P
M="`Q:6X[)SY);B!A9&1I=&EO;B!T;R!T:&4@87!P<F]V86P@;V8@=&%L:6=L
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M<W!E8W1I=F4@9&5V96QO<&UE;G1A;"!P97)I;V1S+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`@,'!T(#%I;CLG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,6EN.R<^3V)T86EN:6YG(&UA
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M('!R961I8W0@=&AE(&]U=&-O;64@;V8@=&AE<V4@86-T:79I=&EE<RX\+W`^
M#0H-"CQP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"<@;6%R9VEN.B`P<'@[
M(&-L96%R.B!L969T.R!F;VYT+69A;6EL>2`Z(%1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]P/@T*/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O
M9B!0<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV(&ED/3-$161G87)304$Q,C,T-3<X.3`P,#`@<W1Y;&4],T0G9F]N
M="UF86UI;'D@.B`G5&EM97,@3F5W(%)O;6%N)SLG/@T*/&1I=B!C;&%S<STS
M1$-U<G-O<E!O:6YT97(^#0H\9&EV/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;BUT;W`Z(#!P=#L@;6%R9VEN+6)O='1O;3H@,'!T.R<^#0H\='(@<W1Y;&4]
M,T0G('9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<VEZ93H@,3!P=#LG/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1M:61D;&4@
M<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO
M;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&9O
M;G0M<VEZ93H@,3!P=#L@=VED=&@Z(#8E.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/CQS=')O;F<^8BX\+W-T<F]N9SX\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D
M97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P
M.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!F;VYT+7-I>F4Z(#$P<'0[
M('=I9'1H.B`Y-"4[)SX\<W1R;VYG/B`F(S$V,#LF(S$V,#M"87-I<R!O9B!0
M<F5S96YT871I;VX\+W-T<F]N9SX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H-
M"CPO9&EV/@T*/"]D:78^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P
M="`U-BXW<'0[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P<'@@,'!T(#%I;CLG/E1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O
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M(&YO=&5S(')E<75I<F5D(&)Y($=!05`@9F]R(&%N;G5A;"!F:6YA;F-I86P@
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M(&9U;&P@>65A<BX\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P
M="`U-BXW<'0[)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P<'@@,'!T(#%I;CLG/E1H97-E('5N875D:71E9"!C;VYD96YS960@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('-H;W5L9"!B92!R96%D
M(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&%U9&ET960@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN('1H92!!;FYU86P@4F5P;W)T(&]N
M($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P
M,3,L(&9I;&5D(&)Y('1H92!#;VUP86YY('=I=&@@=&AE(%-E8W5R:71I97,@
M86YD($5X8VAA;F=E($-O;6UI<W-I;VXN(%1H92!C;VUP87)A=&EV92!B86QA
M;F-E('-H965T(&%T($1E8V5M8F5R(#,Q+"`R,#$S(&AA<R!B965N(&1E<FEV
M960@9G)O;2!T:&4@875D:71E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A="!T
M:&%T(&1A=&4N/"]P/@T*#0H\<"!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M(&UA<F=I;CH@,'!X.R!C;&5A<CH@;&5F=#L@9F]N="UF86UI;'D@.B!4:6UE
M<R!.97<@4F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO<#X-"CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=B!I9#TS1$5D9V%R4T%!,3(S-#4W.#DP,#`P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY(#H@)U1I;65S($YE=R!2;VUA;B<[)SX-"CQD
M:78@8VQA<W,],T1#=7)S;W)0;VEN=&5R/@T*/&1I=CX-"@T*/'1A8FQE(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T
M>6QE/3-$)R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XM=&]P.B`P<'0[(&UA<F=I;BUB;W1T;VTZ(#!P=#LG/@T*
M/'1R('-T>6QE/3-$)R!V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-B4@=F%L:6=N
M/3-$;6ED9&QE('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R
M+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M
M.B!N;VYE.R!F;VYT+7-I>F4Z(#$P<'0[('=I9'1H.B`V)3L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\<W1R;VYG/F,N/"]S=')O;F<^/"]T9#X-"CQT9"!S='EL
M93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@
M8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@9F]N="US
M:7IE.B`Q,'!T.R!W:61T:#H@.30E.R<^/'-T<F]N9SX@)B,Q-C`[)B,Q-C`[
M3F5T(&QO<W,@<&5R('-H87)E/"]S=')O;F<^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*#0H\+V1I=CX-"CPO9&EV/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"`P<'0@,"XW-6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,'!X(#!P="`Q:6X[)SY"87-I8R!A;F0@9&EL=71E9"!L;W-S
M('!E<B!S:&%R92`H)B,Q-#<[3%!3)B,Q-#@[*2!A<F4@8V]M<'5T960@8GD@
M9&EV:61I;F<@;F5T(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M
M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C:RP@
M<&%R('9A;'5E("0\9F]N=#XP+C`P,3PO9F]N=#X@<&5R('-H87)E("AT:&4@
M)B,Q-#<[0V]M;6]N(%-T;V-K)B,Q-#@[*2!O=71S=&%N9&EN9R!F;W(@96%C
M:"!P97)I;V0N/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@
M,"XW-6EN.R<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,'!X(#!P="`Q:6X[)SY$:6QU=&5D($Q04R!D;V5S(&YO="!I;F-L=61E(#QF
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M,3,I(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R
M,#$S(&%N9"`\9F]N=#XR,#$T/"]F;VYT/BP@<F5S<&5C=&EV96QY+"!A;F0@
M/&9O;G0^."PX,3<L,#DP(#PO9F]N=#YA;F0@/&9O;G0^,3@L-C8Q+#$X,B`\
M+V9O;G0^<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!F;W(@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,30L(')E<W!E
M8W1I=F5L>2P@8F5C875S92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL
M=71I=F4N/"]P/@T*#0H\<"!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G(&UA
M<F=I;CH@,'!X.R!C;&5A<CH@;&5F=#L@9F]N="UF86UI;'D@.B!4:6UE<R!.
M97<@4F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO<#X-"CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-3-F
M-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU
M,34U-C`S,#AA,2]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4R`H5&%B;&5S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@:60],T1%9&=A<E-!03$R,S0U
M-S@Y,#`P,"!S='EL93TS1"=F;VYT+69A;6EL>2`Z("=4:6UE<R!.97<@4F]M
M86XG.R<^#0H\<"!S='EL93TS1"<@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[)SY)
M;G9E;G1O<GD@870@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S
M,2P@,C`Q,R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP
M('-T>6QE/3-$)R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C5I;CLG/B8C,38P.SPO<#X-
M"@T*/&1I=B!C;&%S<STS1$-U<G-O<E!O:6YT97(^#0H\=&%B;&4@86QI9VX]
M,T1C96YT97(@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"<@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@8VQE87(Z(&)O=&@[(&UA<F=I;BUL969T.B`Q:6X[('=I9'1H.B`X-24[
M(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[)SX-"CQT<CX-"CQT9"!S='EL
M93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@
M8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R9&5R
M+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N
M;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O
M<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D
M9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R
M9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L
M;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([)SX\
M<W1R;VYG/E-E<'1E;6)E<B8C,38P.S,P/"]S=')O;F<^+#PO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D
M97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO
M<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C
M,38P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G(&)O<F1E<BUL
M969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO
M;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT
M+7-I>F4Z(#$P<'0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG/CQS=')O;F<^1&5C96UB97(F(S$V,#LS,3PO<W1R;VYG
M/BP\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)R!B;W)D97(M;&5F
M=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE
M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US
M:7IE.B`Q,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N
M.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M
M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N
M;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT<CX-"CQT
M9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@
M;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@
M8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ
M93H@,3!P=#L@=VED=&@Z(#<P)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O
M<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC
M;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P
M,#`P,"`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG
M:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P
M,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$U
M)3LG/CQS=')O;F<^,C`Q-#PO<W1R;VYG/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z
M(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ(",P,#`P
M,#`@,7!T('-O;&ED.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z
M(#!P>#L@9F]N="US:7IE.B`Q,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!T97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/'1D(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R
M9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q<'0@<V]L
M:60[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT
M+7-I>F4Z(#$P<'0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@=VED=&@Z(#$U)3LG/CQS=')O;F<^,C`Q,SPO<W1R;VYG
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G(&)O<F1E<BUL969T
M.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[
M(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT+7-I
M>F4Z(#$P<'0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ
M(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL
M969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO
M;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"@T*/'1R('-T>6QE
M/3-$)R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX-"CQT9"!S='EL93TS1"<@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR
M:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@
M;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@
M<W1Y;&4],T0G(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M
M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P
M>#L@9F]N="US:7IE.B`Q,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T
M97AT+6%L:6=N.B!C96YT97([)SXH52Y3+B!D;VQL87)S(&EN('1H;W5S86YD
M<RD\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)R!B;W)D97(M;&5F
M=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE
M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US
M:7IE.B`Q,'!T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N
M.B!C96YT97([)SXF(S$V,#L\+W1D/@T*/"]T<CX-"@T*/'1R('-T>6QE/3-$
M)R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-I>F4Z(#$P<'0[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX-"CQT9"!S='EL93TS1"<@8F]R
M9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O
M<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C
M,#`P,#`P.R!P861D:6YG.B`P<'@[(&9O;G0M<VEZ93H@,3!P=#LG/E)A=R!M
M871E<FEA;',\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N
M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D
M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I
M;F<Z(#!P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N
M93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R
M9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('!A9&1I;F<M<FEG
M:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P
M=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@
M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M
M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT/C$L-C8P/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z
M(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P
M,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG
M+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@
M;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B
M;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A
M9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[
M(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R
M+6)O='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG
M.B`P<'@[('!A9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R
M87`[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)R!B
M;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M
M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z
M(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT/C(L
M,S0R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N
M;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O
M<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@
M-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"@T*
M/'1R('-T>6QE/3-$)R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[
M(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R
M+6)O='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG
M.B`P<'@[(&9O;G0M<VEZ93H@,3!P=#LG/E=O<FL@:6X@<')O9W)E<W,\+W1D
M/@T*/'1D('-T>6QE/3-$)R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I
M9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N
M;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG
M+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@
M;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@
M8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N=#XP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E
M<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z
M(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT.B`U<'@[('!A9&1I
M;F<M;&5F=#H@-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N
M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D
M97(M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@
M-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O
M<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O
M='1O;3H@;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N=#XY,CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE
M.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A
M9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H
M=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT<B!S='EL93TS1"<@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@9F]N="US:7IE.B`Q,'!T.R!B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R<^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N
M;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O
M<F1E<BUB;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D
M9&EN9SH@,'!X.R!F;VYT+7-I>F4Z(#$P<'0[)SY&:6YI<VAE9"!G;V]D<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M
M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB;W1T;VTZ
M(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B
M;W)D97(M8F]T=&]M.B`C,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@
M8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T
M.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P
M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO=W)A<#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT/C4L,3<P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO;F4[
M(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D
M9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I9VAT
M.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@
M8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M
M8F]T=&]M.B!N;VYE.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X
M.R!P861D:6YG+6QE9G0Z(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R+6)O='1O;3H@(S`P,#`P,"`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B!N;VYE.R!B;W)D97(M<FEG:'0Z(&YO
M;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@
M<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@;F]W<F%P.R!P861D:6YG+7)I
M9VAT.B`U<'@[('!A9&1I;F<M;&5F=#H@-7!X.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T=&]M.B`C
M,#`P,#`P(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR
M:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O;&]R.B`C
M,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N=#XU+#4R
M,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N
M93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D
M97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z(#5P
M>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H-"CQT
M<B!S='EL93TS1"<@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="US:7IE
M.B`Q,'!T.R<^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUL969T.B!N;VYE.R!B
M;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E<BUB
M;W1T;VTZ(&YO;F4[(&)O<F1E<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@
M,'!X.R!F;VYT+7-I>F4Z(#$P<'0[)SY4;W1A;"!I;G9E;G1O<GD\+W1D/@T*
M/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@;F]N93L@8F]R9&5R+7)I9VAT
M.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B;W)D97(M8F]T=&]M.B!N;VYE
M.R!B;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R
M+6)O='1O;3H@(S`P,#`P,"`R+C@P<'0@9&]U8FQE.R!B;W)D97(M;&5F=#H@
M;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B
M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@<&%D9&EN9RUR
M:6=H=#H@,3!P>#L@=VAI=&4M<W!A8V4Z(&YO=W)A<#L@9F]N="US:7IE.B`Q
M,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G(&)O<F1E<BUB;W1T;VTZ(",P
M,#`P,#`@,BXX,'!T(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E
M<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6-O;&]R
M.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W=R87`[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N=#XV
M+#@S,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M;&5F=#H@
M;F]N93L@8F]R9&5R+7)I9VAT.B!N;VYE.R!B;W)D97(M=&]P.B!N;VYE.R!B
M;W)D97(M8V]L;W(Z(",P,#`P,#`[('!A9&1I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO=W)A<#L@<&%D9&EN9RUR:6=H=#H@-7!X.R!P861D:6YG+6QE9G0Z
M(#5P>#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"<@8F]R9&5R+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@
M8F]R9&5R+71O<#H@;F]N93L@8F]R9&5R+6)O='1O;3H@;F]N93L@8F]R9&5R
M+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN9RUL969T.B`U<'@[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M(&)O<F1E<BUB;W1T;VTZ(",P,#`P,#`@,BXX,'!T(&1O=6)L93L@8F]R9&5R
M+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@
M;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('!A
M9&1I;F<M<FEG:'0Z(#$P<'@[('=H:71E+7-P86-E.B!N;W=R87`[(&9O;G0M
M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)R!B;W)D97(M8F]T
M=&]M.B`C,#`P,#`P(#(N.#!P="!D;W5B;&4[(&)O<F1E<BUL969T.B!N;VYE
M.R!B;W)D97(M<FEG:'0Z(&YO;F4[(&)O<F1E<BUT;W`Z(&YO;F4[(&)O<F1E
M<BUC;VQO<CH@(S`P,#`P,#L@<&%D9&EN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]W<F%P.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0^-RPY-3<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"<@8F]R9&5R
M+6QE9G0Z(&YO;F4[(&)O<F1E<BUR:6=H=#H@;F]N93L@8F]R9&5R+71O<#H@
M;F]N93L@8F]R9&5R+6-O;&]R.B`C,#`P,#`P.R!P861D:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W=R87`[('!A9&1I;F<M<FEG:'0Z(#5P>#L@<&%D9&EN
M9RUL969T.B`U<'@[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*#0H\<"!A;&EG;CTS1&IU<W1I9GD@
M<W1Y;&4],T0G(&UA<F=I;CH@,'!X.R!C;&5A<CH@;&5F=#L@9F]N="UF86UI
M;'D@.B!4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-3-F-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S4S9C<V.38T7S9D-V9?
M-#!B-%]A8V4Q7SDU,34U-C`S,#AA,2]7;W)K<VAE971S+U-H965T,30N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5304)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)
M1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*$1E=&%I;',I("A54T0@)"D\
M8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^4')O=&%L:7@@0FEO(%1H97)A<&5U
M=&EC<R!);F-O<G!O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^4&9I>F5R($EN8V]R
M<&]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`Q."P@,C`Q,SQB<CY0<F]T86QI>"!,=&0N(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,#D\8G(^57!O;B!&:6QI;F<@;V8@4&5D:6%T<FEC($EN=F5S=&EG871I;VX@
M4&QA;B!T;R!%34$@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY5<&]N($9$02!!<'!R;W9A;"!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%-U8G-I9&EA<FEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G
M<F5E;65N="P@=7!F<F]N="!P87EM96YT(')E8V5I=F5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N
M92!P87EM96YT('1R:6=G97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L(&9U='5R92!R
M979E;G5E<R!A;F0@97AP96YS92!S:&%R:6YG('!E<F-E;G1A9V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=7!P;'D@8V]M;6ET;65N="!F;W(@96YT:71L960@<FEG:'1S('1O(&)E
M(')E8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQI8V5N<V4@86YD('-U<'!L>2!A9W)E96UE;G0@<&]T96YT
M:6%L(&9U='5R92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=7!P;'D@86=R965M96YT(&UA>&EM=6T@
M8V]N<VED97)A=&EO;B!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!F<F]M('-A;&4@;V8@<')O
M9'5C=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92!P97(@<VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@=&\@<'5R8VAA<V4@8V]M;6]N
M('-T;V-K(&YO="!I;F-L=61E9"!I;B!D:6QU=&5D($Q04R!B96-A=7-E('1H
M92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@L-C8Q+#$X,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.#$W+#`Y,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PW.#$L
M-3<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPX-SDL-C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S
M,#AA,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W-CDV-%\V
M9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X83$O5V]R:W-H965T<R]3:&5E=#$U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%1$A!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)
M3E9%3E1/4DE%4R`H4V-H961U;&4@;V8@26YV96YT;W)Y($-O;7!O;F5N=',I
M("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY)3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W
M(&UA=&5R:6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#8V,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,S0R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V]R:R!I;B!P<F]C97-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:6YI<VAE9"!G;V]D
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ-S`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU
M,C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@:6YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#@S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#DU-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2!W<FET
M92UD;W=N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S4S9C<V.38T7S9D-V9?-#!B-%]A8V4Q7SDU,34U-C`S,#AA,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,V8W-CDV-%\V9#=F7S0P8C1?86-E
M,5\Y-3$U-38P,S`X83$O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%4T4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^1D%)4B!604Q512!-14%3
M55)%345.5"`H1&5T86EL<RD@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9!25(@5D%,544@345!
M4U5214U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!C;VYV97)T:6)L92!N;W1E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U.2XT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V
M9#=F7S0P8C1?86-E,5\Y-3$U-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-3-F-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P
M.&$Q+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P144V044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TL@5%)!3E-!0U1)3TY3("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`R-"P@,C`Q-#QB<CY#
M:&%I<FUA;B!;365M8F5R73QB<CYI=&5M/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,C@L(#(P,30\8G(^4')E<VED96YT(&%N9"!#
M:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!;365M8F5R73QB<CYI=&5M/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^
M0V5R=&%I;B!%;7!L;WEE92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP
M;&]Y965S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$S+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!P<F]C965D<R!F<F]M(&5X97)C:7-E
M(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D
M(&EN(&-O;FYE8W1I;VX@=VET:"!E>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V+#@P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5R;2!O
M9B!O<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&=R86YT960@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXS-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXS-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E9E<W1I;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F9O<FUA=&EO;B!B>2!V97-T:6YG
M('-C:&5D=6QE(&9O<B!S:&%R92UB87-E9"!C;VUP96YS871I;VXN/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@97%U86P@<75A<G1E<FQY(&EN8W)E;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!V97-T:6YG('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%<W1I;6%T960@9F%I<B!V86QU92!O9B!O<'1I;VX@;VX@=&AE(&1A
M=&4@;V8@9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R.3,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#(S-BPT.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\U,V8W-CDV-%\V9#=F7S0P8C1?86-E,5\Y-3$U
M-38P,S`X83$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3-F-S8Y
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M=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?-3-F
E-S8Y-C1?-F0W9E\T,&(T7V%C93%?.34Q-34V,#,P.&$Q+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>NOTE <font>1</font> - SIGNIFICANT ACCOUNTING POLICIES</strong></p>

<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" ; font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;">
<tr style=" vertical-align: top; font-size: 10pt;">
<td>&#160;</td>
</tr>
</table>

</div>
</div>

<div>

<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;">
<tr style=" vertical-align: top;">
<td style=" text-align: right; width: 6%;"><font style=" font-size: 10pt;"><strong>a.</strong></font></td>
<td style=" width: 94%;"><strong><font style=" font-size: 10pt;"> &#160;&#160;&#160;General</font></strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx<sup>&#174;</sup> protein expression system (&#147;ProCellEx&#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's <font>two</font> subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type <font>1</font> Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &#147;Israeli MOH&#148;) in September 2012, by the Brazilian Ministry of Health (the &#147;Brazilian MOH&#148;) in  March 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"><font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.</font></p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&#153; by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &#147;Pfizer Agreement&#148;). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO&#153;.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since <font>2014</font>, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $<font>60.0</font> million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $<font>5.0</font> million clinical development-related milestone payment. The Company received during <font>2012</font> an additional $<font>25.0</font> million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a <font>40</font>% and <font>60</font>% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p>



<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is <font>seven</font> years and the agreement may be extended for an additional <font>five</font>-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa during the first <font>two</font> years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of <font>2014</font>.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">During the nine months ended September 30, 2014, the Company recorded revenues of approximately $<font>3.5</font> million from the sale of products to Fiocruz.<br/>
<br/>
In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil. The Company anticipates that CONITEC's resolution will be implemented around the end of 2014.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $<font>12.5</font> million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix Ltd. is required to pay a fee equal to <font>5</font>% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to <font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">ELELYSO</font> in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.<br/>
<br/>
<font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</font></p>



<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>

</div>

<div>

<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;">
<tr style=" vertical-align: top; font-size: 10pt;">
<td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"><strong>b.</strong></td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"><strong> &#160;&#160;Basis of Presentation</strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>

</div>

<div>

<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;">
<tr style=" vertical-align: top; font-size: 10pt;">
<td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"><strong>c.</strong></td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"><strong> &#160;&#160;Net loss per share</strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Diluted LPS does not include <font>7,879,601</font> and <font>18,781,572</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2013 and <font>2014</font>, respectively, and <font>8,817,090 </font>and <font>18,661,182 </font>shares of Common Stock for the three months ended September 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>

</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EP5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 60,317<span></span></td>
        <td class="nump">$ 86,398<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
        <td class="nump">1,992<span></span></td>
        <td class="nump">2,091<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other assets</a></td>
        <td class="nump">2,069<span></span></td>
        <td class="nump">1,457<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">6,830<span></span></td>
        <td class="nump">7,957<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">71,208<span></span></td>
        <td class="nump">97,903<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,621<span></span></td>
        <td class="nump">1,578<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">11,846<span></span></td>
        <td class="nump">13,711<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">DEFERRED CHARGES</a></td>
        <td class="nump">120<span></span></td>
        <td class="nump">141<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">84,795<span></span></td>
        <td class="nump">113,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">3,578<span></span></td>
        <td class="nump">5,254<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">14,186<span></span></td>
        <td class="nump">12,073<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">6,620<span></span></td>
        <td class="nump">9,369<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">24,384<span></span></td>
        <td class="nump">26,696<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
        <td class="nump">67,359<span></span></td>
        <td class="nump">67,048<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">38,373<span></span></td>
        <td class="nump">41,796<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,371<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">2,373<span></span></td>
        <td class="nump">2,368<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">108,105<span></span></td>
        <td class="nump">113,583<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">132,489<span></span></td>
        <td class="nump">140,279<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
        <td class="num">(47,694)<span></span></td>
        <td class="num">(26,946)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 84,795<span></span></td>
        <td class="nump">$ 113,333<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Share-based compensation related to restricted stock award, forfeitures</a></td>
        <td class="nump">1,834<span></span></td>
        <td class="nump">1,667<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) forfeited during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EALAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (21,474)<span></span></td>
        <td class="num">$ (16,905)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">683<span></span></td>
        <td class="nump">3,453<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">2,418<span></span></td>
        <td class="nump">2,689<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income,), net (mainly exchange differences)</a></td>
        <td class="nump">869<span></span></td>
        <td class="num">(140)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">149<span></span></td>
        <td class="nump">145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(26)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
        <td class="nump">332<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
        <td class="num">(6,172)<span></span></td>
        <td class="num">(5,393)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
        <td class="num">(578)<span></span></td>
        <td class="num">(798)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="nump">1,127<span></span></td>
        <td class="num">(3,538)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals (including long term)</a></td>
        <td class="num">(1,736)<span></span></td>
        <td class="num">(5,413)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(24,407)<span></span></td>
        <td class="num">(25,911)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(617)<span></span></td>
        <td class="num">(1,668)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Investment in restricted deposit</a></td>
        <td class="num">(93)<span></span></td>
        <td class="num">(42)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(122)<span></span></td>
        <td class="num">(121)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num">(832)<span></span></td>
        <td class="num">(1,831)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">66,930<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">43<span></span></td>
        <td class="nump">30<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">43<span></span></td>
        <td class="nump">66,960<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="num">(885)<span></span></td>
        <td class="nump">144<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(26,081)<span></span></td>
        <td class="nump">39,362<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">86,398<span></span></td>
        <td class="nump">52,035<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">60,317<span></span></td>
        <td class="nump">91,397<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">122<span></span></td>
        <td class="nump">187<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost related to convertible note offering not yet paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 73<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash due from broker assisted exercises of employee stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 2,396<span></span></td>
        <td class="nump">$ 2,284<span></span></td>
        <td class="nump">$ 11,517<span></span></td>
        <td class="nump">$ 8,116<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump">1,311<span></span></td>
        <td class="nump">1,075<span></span></td>
        <td class="nump">2,259<span></span></td>
        <td class="nump">2,275<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(1,798)<span></span></td>
        <td class="num">(1,587)<span></span></td>
        <td class="num">(7,476)<span></span></td>
        <td class="num">(3,876)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">1,909<span></span></td>
        <td class="nump">1,772<span></span></td>
        <td class="nump">6,300<span></span></td>
        <td class="nump">6,515<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(8,052)<span></span></td>
        <td class="num">(7,723)<span></span></td>
        <td class="num">(23,280)<span></span></td>
        <td class="num">(23,467)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump">1,947<span></span></td>
        <td class="nump">2,086<span></span></td>
        <td class="nump">6,146<span></span></td>
        <td class="nump">6,049<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(6,105)<span></span></td>
        <td class="num">(5,637)<span></span></td>
        <td class="num">(17,134)<span></span></td>
        <td class="num">(17,418)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(2,012)<span></span></td>
        <td class="num">(1,780)<span></span></td>
        <td class="num">(7,289)<span></span></td>
        <td class="num">(6,065)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(6,208)<span></span></td>
        <td class="num">(5,645)<span></span></td>
        <td class="num">(18,123)<span></span></td>
        <td class="num">(16,968)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
        <td class="num">(1,851)<span></span></td>
        <td class="num">(131)<span></span></td>
        <td class="num">(3,490)<span></span></td>
        <td class="num">(153)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
        <td class="nump">49<span></span></td>
        <td class="nump">29<span></span></td>
        <td class="nump">139<span></span></td>
        <td class="nump">216<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
        <td class="num">(1,802)<span></span></td>
        <td class="num">(102)<span></span></td>
        <td class="num">(3,351)<span></span></td>
        <td class="nump">63<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="num">$ (8,010)<span></span></td>
        <td class="num">$ (5,747)<span></span></td>
        <td class="num">$ (21,474)<span></span></td>
        <td class="num">$ (16,905)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE OF COMMON STOCK:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="num">$ (0.09)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.23)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">92,971,572<span></span></td>
        <td class="nump">92,433,502<span></span></td>
        <td class="nump">92,828,851<span></span></td>
        <td class="nump">92,307,170<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EE6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 24, 2014

</div>
          <div>Chairman [Member]

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Sep. 28, 2014

</div>
          <div>President and Chief Executive Officer [Member]

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Certain Employee [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">113,800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 43,000<span></span></td>
        <td class="nump">$ 30,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 43,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued in connection with exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">116,801<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.37<span></span></td>
        <td class="nump">$ 2.37<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Information by vesting schedule for share-based compensation.</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements', window );">Number of equal quarterly increments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently', window );">Subsequent vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Estimated fair value of option on the date of grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 293,000<span></span></td>
        <td class="nump">$ 1,236,490<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the estimated fair value of option on the date of grant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of equal quarterly increments for remaining shares vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfEqualQuarterlyIncrements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the subsequent vesting period of equal quarterly increments for remaining shares vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPeriodOfEqualQuarterlyIncrementsSubsequently</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Nov. 01, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,672,564<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 173<span></span></td>
        <td class="nump">$ 609<span></span></td>
        <td class="nump">$ 764<span></span></td>
        <td class="nump">$ 2,198<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="num">$ (67)<span></span></td>
        <td class="nump">$ 345<span></span></td>
        <td class="num">$ (81)<span></span></td>
        <td class="nump">$ 1,255<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" ; margin-bottom: 0pt;">
<tr style=" vertical-align: top;">
<td style=" text-align: right; width: 6%;"><font style=" font-size: 10pt;"><strong>a.</strong></font></td>
<td style=" width: 94%;"><strong><font style=" font-size: 10pt;"> &#160;&#160;&#160;General</font></strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx<sup>&#174;</sup> protein expression system (&#147;ProCellEx&#148;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's <font>two</font> subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type <font>1</font> Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the &#147;Israeli MOH&#148;) in September 2012, by the Brazilian Ministry of Health (the &#147;Brazilian MOH&#148;) in  March 2013 and by the applicable regulatory authorities of certain other countries, including Chile, Canada and Australia. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;"><font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">In August 2014, the FDA approved taliglucerase alfa for injection for pediatric patients. Prior to this approval, taliglucerase alfa was approved for pediatric indications in Australia and Canada but in no other jurisdiction.</font></p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&#153; by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &#147;Pfizer Agreement&#148;). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO&#153;.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since <font>2014</font>, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $<font>60.0</font> million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $<font>5.0</font> million clinical development-related milestone payment. The Company received during <font>2012</font> an additional $<font>25.0</font> million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a <font>40</font>% and <font>60</font>% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p>



<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO. The first term of the technology transfer is <font>seven</font> years and the agreement may be extended for an additional <font>five</font>-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa during the first <font>two</font> years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $<font>40</font> million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa. The Brazil Agreement became effective during the first quarter of <font>2014</font>.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">During the nine months ended September 30, 2014, the Company recorded revenues of approximately $<font>3.5</font> million from the sale of products to Fiocruz.<br/>
<br/>
In September 2014, CONITEC, the National Commission for Incorporation of Technologies in Brazil's Unified Healthcare System, announced that it had decided to give a positive funding recommendation for taliglucerase alfa in the treatment of adult patients with types 1 and 3 Gaucher disease, and established that taliglucerase alfa will be the first choice for treatment for new adult Gaucher patients in Brazil. The Company anticipates that CONITEC's resolution will be implemented around the end of 2014.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $<font>12.5</font> million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Protalix Ltd. is required to pay a fee equal to <font>5</font>% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to <font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">ELELYSO</font> in Canada, Australia, Mexico, Chile, Uruguay and Albania. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.<br/>
<br/>
<font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</font></p>



<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;">
<tr style=" vertical-align: top; font-size: 10pt;">
<td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"><strong>b.</strong></td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"><strong> &#160;&#160;Basis of Presentation</strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div class="CursorPointer">
<div>

<table cellpadding="0" cellspacing="0" width="100%" style=" font: 10pt times new roman, times, serif; margin-top: 0pt; margin-bottom: 0pt;">
<tr style=" vertical-align: top; font-size: 10pt;">
<td align="right" width="6%" valign="middle" style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 6%; text-align: right;"><strong>c.</strong></td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt; width: 94%;"><strong> &#160;&#160;Net loss per share</strong></td>
</tr>
</table>

</div>
</div>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px 0pt 1in;">Diluted LPS does not include <font>7,879,601</font> and <font>18,781,572</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2013 and <font>2014</font>, respectively, and <font>8,817,090 </font>and <font>18,661,182 </font>shares of Common Stock for the three months ended September 30, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accounting policy related to the nature of operations of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NatureOfOperationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><strong>NOTE <font>4</font> &#150; STOCK TRANSACTIONS</strong></p>

<p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">&#160;</p>

<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;">
<tr style=" vertical-align: top; text-align: justify;">
<td style=" width: 0.5in;">&#160;</td>
<td style=" width: 0.25in; text-align: left;"><br/>
a.</td>
<td style=" text-align: justify;">
<p style=" font: 10pt Times New Roman, Times, Serif; text-indent: 0in;">During the nine months ended September 30, 2014, the Company issued a total of <font>113,800</font> shares of Common Stock in connection with the exercise of a total of <font>116,801</font> options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $<font>43,000</font>.</p>
</td>
</tr>
</table>
</div>

<p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">&#160;</p>

<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;">
<tr style=" vertical-align: top; text-align: justify;">
<td style=" width: 0.5in;">&#160;</td>
<td style=" width: 0.25in; text-align: left;">b.</td>
<td style=" text-align: justify;">On July 24, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a <font>10</font>-year option to purchase <font>150,000</font> shares of Common Stock to its newly elected chairman of the Board of Directors with an exercise price of $<font>3.37</font> per share. The options vest over a <font>three</font>-year period; the first <font>50,000</font> shares vest on the first anniversary of the grant date and the remaining shares vest in <font>eight</font> equal quarterly increments over the subsequent <font>two</font> year period. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's <font>2006</font> Stock Incentive Plan. The Company estimated the fair value of the option on the date of board approval using the Black-Scholes option-pricing model to be approximately $<font>293,000</font>.</td>
</tr>
</table>
</div>

<p style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">&#160;</p>

<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style=" font-family : Times New Roman; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;">
<tr style=" vertical-align: top; text-align: justify;">
<td style=" width: 0.5in;">&#160;</td>
<td style=" width: 0.25in; text-align: left;">c.</td>
<td style=" text-align: justify;"><font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"><font style=" font-size: 10pt;">On September 28, 2014, the Company's Board of Directors approved, subject to certain terms and conditions, the grant of a </font><font><font style=" font-size: 10pt;">10</font></font><font style=" font-size: 10pt;">-year option to purchase </font><font><font style=" font-size: 10pt;">900,000</font></font><font style=" font-size: 10pt;"> shares of Common Stock to its newly appointed President and Chief Executive Officer with an exercise price of $</font><font><font style=" font-size: 10pt;">2.37</font></font><font style=" font-size: 10pt;"> per share. The options vest over a </font><font><font style=" font-size: 10pt;"><font>four</font></font></font><font style=" font-size: 10pt;">-year period in </font><font><font style=" font-size: 10pt;">16</font></font><font style=" font-size: 10pt;"> equal quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Company's </font><font><font style=" font-size: 10pt;">2006</font></font><font style=" font-size: 10pt;"> Stock Incentive Plan. The Company estimated the fair value of the option on the date of board approval using the Black-Scholes option-pricing model to be approximately $</font><font><font style=" font-size: 10pt;">1,236,490</font></font><font style=" font-size: 10pt;">.</font></font></td>
</tr>
</table>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory Components) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 1,660,000<span></span></td>
        <td class="nump">$ 2,342,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">92,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">5,170,000<span></span></td>
        <td class="nump">5,523,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">6,830,000<span></span></td>
        <td class="nump">7,957,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
        <td class="nump">$ 1,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcessNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">Inventory at September 30, 2014 and December 31, 2013 consisted of the following:</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in;">&#160;</p>

<div class="CursorPointer">
<table align="center" cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; clear: both; margin-left: 1in; width: 85%; border-collapse: collapse;">
<tr>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"><strong>September&#160;30</strong>,</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;"><strong>December&#160;31</strong>,</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
</tr>

<tr>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt; width: 70%;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="2" align="center" valign="bottom" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"><strong>2014</strong></td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td colspan="2" align="center" valign="bottom" style=" border-left: none; border-right: none; border-top: none; border-bottom: #000000 1pt solid; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center; width: 15%;"><strong>2013</strong></td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td colspan="6" style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">(U.S. dollars in thousands)</td>
<td colspan="2" style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; font-size: 10pt; vertical-align: bottom; text-align: center;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Raw materials</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>1,660</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>2,342</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Work in progress</td>
<td style=" font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>0</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>92</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt; background-color: #CCEEFF;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Finished goods</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>5,170</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 1pt solid; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>5,523</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>

<tr style=" vertical-align: bottom; font-size: 10pt;">
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">Total inventory</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>6,830</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-left: none; border-right: none; border-top: none; border-bottom: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; padding-right: 10px; white-space: nowrap; font-size: 10pt;">$</td>
<td style=" border-bottom: #000000 2.80pt double; border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; font-size: 10pt; text-align: right;"><font>7,957</font></td>
<td style=" border-left: none; border-right: none; border-top: none; border-color: #000000; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-size: 10pt;">&#160;</td>
</tr>
</table>
</div>

<p align="justify" style=" margin: 0px; clear: left; font-family : Times New Roman; font-size: 10pt;">&#160;</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESABG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Protalix Bio Therapeutics Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Pfizer Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 18, 2013

</div>
          <div>Protalix Ltd. [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009

</div>
          <div>Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Upon FDA Approval [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights', window );">Supply commitment for entitled rights to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">280<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits', window );">License and supply agreement potential future payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplyCommitmentPerYear', window );">Supply agreement maximum consideration payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssets1', window );">Revenue from sale of products</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="nump">18,661,182<span></span></td>
        <td class="nump">8,817,090<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,781,572<span></span></td>
        <td class="nump">7,879,601<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License And Supply Agreement Potential Future Payment Based On Net Profits</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplyCommitmentPerYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplyCommitmentPerYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from the sale of other assets as part of operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfOtherAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value convertible notes</a></td>
        <td class="nump">$ 59.4<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0001144204-14-066530-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-14-066530-xbrl.zip
M4$L#!!0````(`"*$:D67`R9`*3@``)\N`@`0`!P`<&QX+3(P,30P.3,P+GAM
M;%54"0`#$"]A5!`O851U>`L``00E#@``!#D!``#L75ESHTBV?I^(^0^,9GJ+
ML&P6@<"U3+AL5X7CEI>VW=TS3Q4I2$DYA8!.P+;ZU]^3R2*$0$)(LB2+&S=Z
MRBQYOK.?/)DIWO_[960+3YCZQ'4^M*1CL25@QW0MX@P^M$*_C7R3D);@!\BQ
MD.TZ^$-KC/W6OS_^_6_O_]%NGU.,`FP)O;'P.,3"[\0)T``+7Z@;>D?"G?N,
M:73WZO[J03A'M.<Z[39[^:5';7+*_BL`!,<_);[;D:7NA]8P"+S3DY/GY^=C
M=OO8I8,36125D_B)5OR"39SO<YYFMWO(Q\GC84!+GS9.X&[R(+MAD?39['/:
M270S^RB9A]AA@C-3#"\SF)\5_K1D&,8)OYL^ZI.B!V%8Z>0_UU\?S"$>H7:>
M@(5SP'UL'@_<IQ.X`>]*G;8HM14IE8G?'B#DI:_TD=_C9.(;!:]X]LL4+H^Z
M`;+)R['ICOCCHJ&(+="P(+QG_)SZ'.D][@N<O]-@[($1^63DV0PVOS:DN/^A
M!4.WDQ&.7WRK)9Q$XT2V8KI.@%\"@5@?6E?\.2VAE#Z#G8`$X_A:>I58['J?
M8"IP-'B*@T1$YU?_U_HH@GQ!S[(NO3_)OYR0.BF@%5/R,"6N-4.?:RGX&$G3
M:"MB.GA\9WKDS"C)I9CY>?)0]DT62EN2P;+6+8L+)N9ORO5>B`-8IL$%Q-#8
M.+K@;<DHDWNYE[!C95[)VE-R9QTR5/92ALKR,E0V)T-FA]_NL8\1-8=G,#!^
MPK;KC8"YRQ</.SZ^QJ,>IEN0\T1\>,#PI)?C&Q;`>/%L8I(@PBA8!)Z+"H4X
M/YQ>0:TPP@\!R(N-\=4U40`/G+T0O_4Q>:@"_^]/"DE.H)X487US[M:8RHZ:
MR@Y&E2_8P139(*DS:T0<X@<4!/J$#\=8*DF@B2Q19&G,97?-97>B"Y]7_2I!
M'@H0<;!UB:A#G(&_W^:1&L;EGR$@/G='GNO`GWX^^10Q_5H6L?F)$9\D@G*!
M_Y'K/`2N^?T@]#K#[Q94*F]6I6>615C$0_8=(M:5<XX\$B#[(-0[E_>WI^HF
M-&\S-&]8N=)>-%Q>21ZLO]LDJZW4'YMK4G.E-NEJ=]+5QI7=)*SMSB4VJ]Y]
M2U@;E$>GF5N]M>ERIYE;[5BRVIRJFW)S2TK=X)Z(3E-N[I@';US93;FYS7)S
M0^J]8)OT]G$_"DA#$I=;VV&O9)/<&I<"N0R_/9C80?#VX[/[1IPCX2AR"L]^
M.9WA<1L+>[NE?$G^IF64/Z1XSU=]JZA_PN565G9EMGEVN95=>$7;U,HN3Y!W
M\8[=3TP\F"(/AP$Q?;:&3CV7\I7S_3:,Q[&';_MGE")GP`UD8AC5F7\[R3.C
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MYKEJ[*OU/Y+`QK=],'_R1*P0ZN>I$/C)1=2Z[5\0BLW`I?[Y$!$Z0J^\TV#V
MMT=D94D'@%<Z:W<`;1NG@UY#[>=#@ON7+]@,V0SJMM\G)J;;U;G1EKM+!SUY
M+8O9H4,BA?_VD.]MC3#R0XH_QC_=>0I/)`,EM[*#LY'*1K[#]&&(*,Y1X`J:
M892]>!..8,(+7IFW@,JPLJ(H'C%#[@([+LRKYQ.,]</X\*M0G!TTN9OA>Z'T
MN-S\$M4L@K1P]+MP1BG38WOPSUHC7T$56C(RJS8(W*XV;N*W7UUG\(CIZ`+W
M@AO7,4-*P>,XK4<TD%I";-WW[.=()[\Q*K"1^#5FX<*+3TX=8G]H!33$Z8^4
M9F=))!CQ<MFQSF%`J(VQ8Q+L)X3DUR*DS!)2EB-RY3P!`9>.;W`JITY%^!8V
MR0C9_H=66VE]U'0%HC=4645#+R:J5F!EFF#74+L5"9[Y/@[\\VEST&JQV95D
M49\B.S7X--W;8(CI/38Q>4(]&_L`+`>B6PN$+&K&%(9R0LL"TI?6@]3)Z:$J
M&-YI&+JVE<XW$A#&TB#:LF9TM"D8L\/G@@5!/6*3`/P)_*L<C"36TI'>`0.=
M`K2(8$UX!6%MD<8D!?YO!6SGR&?+$NQ_V.TG9/,H%9PC2L<0I7Y'=HA3@`7A
M<`%`75.,:2>K1#'G]*;IAO#0Q!)GK5TJB*`5="L9ACP=`^;0JH&J(`(OD)@L
M&E)-1!G5%^3,@KA<14"B+HFEUC\ALPR2@GB]V,Y5O=3.*Z!(:=<+TY(B=W2C
MC/XJ+E40I:ND:%&1NJNZ59%XEH_7`%?N5A1->>R3ZX7F=J<+V6*I9`'EUQ.F
M`0$_*BXNY>7#L-85.[DH5T9E&LP%[F.X;-UC*'A"7`"F:@4Z#4C1E>ZTNY12
M6A90E4IU&DQ'ZAI:'3#S)P%RC=BJ=*=C:S&%:11W4<L!G(N70W>N'U`<$!IM
MEG<L=@'S=BJ[\`D[N$^".QLY_MPH*->+QW)>L6N&]SJ\+Y\!9$737X_O).?>
MH3%+N)Q"+K7+!9ED4:B4Q9SRYM"9ZY=Y+#6SB":+\_RR#I+E$XBAY*9`55!D
M=)A#H-3+)')'T3ME66Q9",MG$%G3<C%R$?F%>4RIESJTKJ(:J^2R<W"\25]C
M^70A=:1"<^#C%G4#4EKUVAVST[MHV+FDEF]R%$S5"NE,1X1'BJR\CRGU^AV*
MVM7G!9\LJ>4Q+1\-55GMK`5/4716ZD5$L#U=JQ>A"SM32HUP",5TD9F4!6.V
MKI_);M'#GUW*_HBO%V3@3KTH*6GRC',N!V!=^&OT2O+VOR+V.^IZ$!;'[%E6
M<+#)!M_8F6W`UHO!DJ3G6F#SB-6`52,J0^DLU814F!DZ]:*U5%*R%&2'N'Z8
M4,P%[<P^[P7:4'.3[63D!?2T67I*!7JZ)&ESR+$%%1Z&OB`"Q:P+-CLAV:W'
MHBS'.;]H\`ID]7J<RG)774!V4H3XP6T_ED1*UZC';K?3U7(E3F;T"H15L1[#
MBEZ=,)<'!!_F98BM&$6;AU,(4@$$]L-+\R5>L-HP2V,!D'@C<HI$KH-$4J3Y
M4&(J\WU,50HL8+$4%&.>AY42Z]02N9R;6%1W9[4H8E61K+2",ZM%86LQ4;&R
M*R\R[((85BF8Y*+F>FR[9F235*6&=?^!R6`88.L,YEMH@&]"MB'EML]W!=R&
M`?^V*[S["?G$9(=)B!VR;[HF6(NBX;3BXOT%&;`B5)RRT87B2)Z@K8=CG;QH
M10&V$B\=15'%-?-R9MOLI`:V^%OP**LW1DR!_/A&SF:T@LA<^?."\ZTJWSZJ
MA&LE7DIB^^J\:*+QVKR4Y(J*1X[F+T1HW=?FIB09K8,;I:.NS,ULY,TS4"NY
MM25=G%ZQ+26T+)Y:>:\MU82#@^@NRY`IA*+R?3$$G6VUG,*0';P*W:(LMYBN
M"G5T5;K)T8-D<V!9W%^<P[([##.(9``D'HO&!,T"DK7P=1?GI?GXM)KX'K!M
MP\,+G#N%69*"%FT]D*9MN1K1E8#6FSOP3LZ*0&^GO33K#]U:LXJVEM]05D"B
M.H9:DXVVJN5B]V(,"TK@;KU)B*[6F=\MF!MT"V+T8BR=&I/>N?5-"J=6O-9%
M5<Y-".?0J@.K5CCO=F5E65ALLO>%HFACZSTFHUY(?;X"&V]7PM9M9@-A"K!2
ME)_=JQ6GFR6IK@15KQ3P9R-IO(Q0&VHB_(SD68_5&1`'8SIQGTQ75Z\5]+5D
M>]>25%>#6BOLJYK2K0^U7IFM%Z6"97ZI8$'I)KWRM$$O2BMKXT>2U=5G#H4=
M5[U>%NKF=Y\NV>C5ZS7#5+U;E>P7"AGYCKI],O&.6FE%,G(SZLS(BTG62AD2
MY(QJ)"N6UWK%AGYY@<W.TVUR`F!4[/R7(V2_2UH+X6H=-:,H.^2!E_34=%F'
M<FZ7^H-&40*IR(TB=J6NN,T.H5&>5%;NJW6USBNG%*,\I:S,C2SE`G@==A;-
M<(R:"\,*GUBL>XYC%,UQJBPY*#6F.0N[8D;-%>6VHN0F@.OJTQDUEV0T96U]
M.J/FNG-;ECK=SDJM.I!I/?;;DF;D#G(4T*Y9STMBE>Q26$%(2N?5IQ^26"5]
M%,+M2/KJ4Y#E>F226)HN%J0".7=F9?/]/$DL30:+EH,T=9,M/9CEUO1929=R
MC9%5VGJ26'-7$/-?;<GV8D&A+XDU`SH/GW6G%Y)8-VBKDEJ-:J7.F"36C-RR
M(N=:SNMNVDGYTZF5]STH'2V_/6U3C3LI?T:ULO5(G14;8K70U@SSFM@QZJ--
MU)">8K]'S]=0LE("!"`7L$:`C^E3YMA=W=.KFE9R4K^49'V(=8Y;=>3UP/O#
MI=^O''![$_ME^.J=IRI"5TXMEQK-(;;"Z.=GXE?C7=J/?`,[0/D$LY7O$XSE
MI?W''^W@G46>V+,_75H#1!_.SB#Q=-0N3^+B3X(?C&W\H=6'`=I]-"+V6#@5
M?GHD(Y#"#7X6[MT1<GYZU_IQ$+S[^]_8>%[RCL!>.A4DT0N$W`M'T84CX0'4
MT7\GC!"%^N548(^*T7^/5>)$PZ9\"BB`%[P@^ET>13P2&"L"S)2%"W"'Z*K$
MKRJ,91\2-\S>W;X`LQ)``[.X9TA<IPSEB1<AWA#F']'(>_=/21/?S1)C`C=M
MY(,Q@.9\E]ZY!-1#,S(,>$1!-ADX'UHFYG<%$XH3#UFL+<":"OQOWT-F\G<!
M"P%GP0$6:,1"$+'@1RR8-H3L4Z'G!L.$G[:-^^QM8$1X)E8P/!5T]8=W\`RU
M,&V;($3D^?A42/Z557U`,_^V4D#QN]'(CNO@=#C*FB"Y:X'KY:X`OL`=Y2X"
M?1>P_Y,7".([(98,T\?+.RZ#MD_^PI$@"I426'N,%@8$W3NLO[<VY,N!%/CY
M+!/9;6ZGW(R`\7<"BS3)M<AV8X8`.532KC-@?Z6./.%3$3FGDV>.W@KG;UN5
M2?#-:%(Z2$UNAXE%P$Z2L+SK03I).%WQA[<=L'.)_2G^.P(RXPL)OAB+($%B
M]UV;6.]VV%L274KJ#T4A@Q5NN1#Q6A%BL3AW)ALL9R=[*9'%=J)LR4Z:3+(X
MDZ0XR[@OI###Y>%4Z]K;B.Z<Y9]_.WXX%BPV#Z2^0!R89;NA#[-Q_Y>W[Z.K
MNX+00^;W`75#QTKY.#^_O/S\N<1+=L74[]&S,$H::?OOFUM$&_^5$)#XQ><A
M"7";-78P&^R9(J^$KW_M&#N5D$\Y&X<RR?OL6?9OZ4C3HEY`<F5[.;*0J9SB
MU*PR(QSJ_EGCX7#:^%VQW\E'2D<^0+_;5%V[*PF0K2VQ`LVC[H!B?V[2WB]/
M/IR8M38G/_#$>N`6<SB<UO$-H\E^!S65_<PV]PVQ)0Q<UWI[<]FM]9:V&WIV
MB^TZ<4@]DKH'GJ=W)8T<J-4>*-OUG%65E0-TUK<^:WYT`V3#M#G>?;ACP6K]
MGB<?ZVS/H.6&/1MOVOM>H06W5?[6%EVT(UUI2H'#+@4:S]Q%S^P>&6KW`#WS
M)+N#\(1O5<_\;9&G;%7@)9N8_A?Z`>F/)VO_D_WS+^E.=(8J!I0>-LAMPZ^&
MUYM%E#GE5_$(1<FYD`OBF[;+OB=:<-BB_*#;;AZV*-IT=7/[>"G(0ENXNOG]
M\N;Q]O[J\J%H$]96CU!LE'9SY*0Y<O*VMYXT1TZ:(R?[Q9#='#G96GG9'#G9
M.>3-D9/FR$ESY*0Y<G)HF:0Y<M(<.6F.G!S8/IWFR,FZT#9;WYLC)SNNOC?)
M:>-WS9&30]H\TQPYV?^8U1PY:8Z<-+ZQ8=]HCIP<UE2V.7*R_^:[ZVPW1T[V
M.HT<J-4>*-O-D9-FUMP<.6DVMN].=&F.G#2E0..9N^B9S9$3>]>/G)1A6O-N
M_XN0?>N+GS)PB(.%$0P[]`7L6-@J.+%PQ)]D'RU$SEB@V&0:M@3D>=1](6QI
M'1C_U]2"Z+$V96@"R,8FK@,,4.&9,MU;[K/#CCJD]8H0`GDJF*X?L.LT^O2L
M?YR53U8Z!9]!*3A<L\+G6?2E/Q]CE'P\INKG6=(7DC[/%];F*8%GU/IZC"JQ
M+R\5@2RG61^D+"XM0U7-?;NL/L`_F*%=,#M+\=3Y&)3*/ELDED@MI9'['JD3
M$(M]=I4\X0=L@K\%!/N7+Z8=@NM\INZ(N5,8\$^`WO;S7]4]&[FA,_D6F5S[
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M029S"J`0/&/L,`%]QP$,PSHEQ&,?F&/'&QF]#(^"!<7`\5NU`&2:+""PTHE_
M8AM12\`^*RA97@)Y9#4_))BR3QJ.(WV!ZEP6?OZ"Y]P>2UO1D4G0?NAD+A`'
MXI$OA$SKH*Y8MMF!">0=(5ML!4.*\72YU:,N`K-BGU($#J'8-H<"!#2(E[Y)
M20\SR['=YXV=+-VFIKXRKJ<$)$T)YU3X-739.5ON3;[P<^@@BU7[V/J%.X+)
MTD5L\'ZD/28[T#Y4;X1KK=CPN8/';@W_FO)J9C^%UC$@K&!BPPUAV@/FE)C*
MF.E_$3.QO;Q)EYOE7<XI\G;B-[$R4VVE<3-V*,<-A#\CO;MY'1\)O3"`?$VI
M"Y-7]JEVH3=.(AXH%AV(>)6<>'\K"$Q,MCPX/0\A*X!U!RS9T*EQ'#<W^9M(
MDJ4T](2(S<:LY!40IA8[A7(P3G'E0!`/,&5?EH8\-!'>]"0=2EZ;YQIVCY>W
M0H#-H4/^#!,O&2&8N\,S_#U0*2L9"O0-"8K1RC]9E+18>0%/0-'+(J+G)M'2
ML:)?-X#JPA=X"L64%1)CP:38(H%`B<_W^Q%&$.*G[_.8"F0F_+U);>;L/_GE
MA[1&)`[4U6%4/1(GFK9$)U<P5(#T.S,!$WF$+?S$+R<60%@1$2(;ZCD0O,/7
MMYBC\AHU5A40-A&E8S;,VQ5R$BC2D>/6)!WT?A:/!/;_ORS5Q%,F74@V(FM@
M4IB%QM>>$"7("7)7GW'2-8TNVC@`+VC'OX>1N4X<W![F'G:I-X22_%1`8>!.
M]WJA_*1)^Y<X3-%QAY)?B:I]&"5ISN;ZKM'PS\1RG]/1P:ZL"2X^%J#O?2<P
M'!N3S?2^XW9\#I+?AZF/9Z/Q*9@FPR_\@XP\ET*)S)JCMHN2;O$<FX<`P5=A
M6<"`7,VJ:9_=FPKL!3^FPO))>1]2-8X[Q8W(M#Y`49DLR-ERKD+3<6XC8+IG
M<#[A[0+W@J(W)YV#&A^%5EL?5:.3ZU!5(!JAM#`Y?:2(==D?QJ.>:T^PS/GX
M\]W7_[P_F7EU\O'SFY#IZ;;_$/8@\!/PB2R3Y3]T-.'R#B#F.CQR]'WSHK&G
M)<Y;K=CRHQ:/#=4&J^M<FH&@ST`0C6_*]7PQ1VW`K)A+*2T-R"@&].W!Q`ZP
MZ#X^N]?<^!=8PI((F4"OB0TU%GCH'1KSS)N`4L191<G?M`PH-O>L`DM.<141
MG$"9((0*\(Q"_!IPCP0N^B3@;;D[3-FA1S3`$YQ2B==\@_<@.9*73PPK5)<>
MAM+(]*\<*/<]3L9U9O#G34]N?12/.S'VI1"NS)A<RE@?DA&MP8>V&A\/H>?9
M8Z@R1B3@CV/Z7XSH!+%2T/(7-4E/5?$UL!9:C-;ZV!&S%E-"MMS+'A#[C;9;
MR"WTC$_)I0G$\N[L7!M6U#FN-4MO(K.O,#=U?'SF6!$;9P/P&LZ%RTIEJ/0^
MAP'H*O:&3RPWW3HW.-;%)$@H:L%"P#?I>BG9LO4,6<W(=E5X^6PW&KG.0P!I
M\`[16_H0L!DUSSU)8WW"CU8IVR7O9=FXNOG,K%G,+F[\?WO/VMRVK>Q?X>3>
M3M(9R1:I=W.:&<6Q4]^36J[MG'O[J4-+E,0>F=0AI<3NK[^["X`$0%"B*/J1
ME/V06A()+!:+?6.WP-0JK+`4/Q[/+D$8(IWC(4(L@&;EST!A#M:CQ.5W&2[]
MB6]R]K>_F[)]6_Q,3>OZ_./%^=GYR>CBQAJ=G(P_7]R<7WRT+L>?SD^*U/@K
M4$9.BWNSJG*[RLB1(OKS*[O5^B$-UK_=HZH<+R1'*0R42\&_$%D?>N9??MX@
M#+$C:;!LJH*>&&!*$\A^?$I\'X0T<V)E-J=%5%_I_9!CVIES+11*Y]X\C52+
MI,3PR8<=8^F78K!8TNX;_OKH!:"D++,@;:DG<Q#15&-O4_E%Q09MMHZ<0M4E
M#P9@=9^`0),)46AI*E_#`F7IR'J#A2`]\O\"J_WJKQ?D=HHE6X*YTCC0G?Y;
M[E(17PS>_M@@IQ:^]W4!PSTTPZ\!F)/)(`\-*P$#1/)1@_FD_1#L>+"Y)P21
MNP2Q@2.C:30+)QLITC=%FS1<D3+._&=W=Z",@2CV_V+N/$J1@:]OT5E$\0BQ
M4KPVN_;\0`L>\E6\CO'W%:QS#7`BF"=PP$_OB9@W*VF[^AU.>NQ;,:SEW:_P
M4BX"$3_$8)!;;U)<I>.EV#H"S$MI16C8:/C!R,D=IA2!Z0\+R<,J3Q$BM[#[
M-1:^`]!$X*4E5G*1QGU_]*\CBFR";`X\%LVD[<973C>``\\-K%^]*8CU`'9@
M-/>"R8.\EM-?1](JT,\`*@##_HKE\@A?7#+<YP!^97[M%-]*L.ZKYAR7"8^H
M)/)F7A2Q\)]"J[!&1+\;:^0IF\%'*<"/Y5NSG^54CV&KW`>+5<MUV`FE>CYG
M83AE)76CS=P:3=%9#<R2;9.TF6<?],V,0@R;([',EYL)')\82]C.7`KC^<&?
MC&8:VN&9^5&\3E^?XJSP]W0S63=P;X`(O.`O4)1A(U=+..ITAMGQ!.HZO;KY
MD29@L8U@WD1GOK6./'<MG-[N=+/$4/O:)\<O$:V+9`QSXRF!O9X'(6BN=``>
M5MXVQ>VCNYG@D9KZL0<K!-K,+AB=:#)7:"BL!<\FSH0O`=5'WFT$DT_Q[3<?
M3S[\R,()LN^9<R\`=1.C;SEA"L;9OR+6EG&8(O7V@88[CR/76_K6KVQ+'Q"(
M7SQW">AXHQZ!Y,GQ+_(F^RK;0;KA0[^/W+_\I8\,8.?@TK.9X8$HH\F"57!&
M(N3#<U:!ZE3DS3=+EY6#WJP7(<M!PMD`!VL7QF`LC^P,)GV8IQ\1=[+PEU[#
M.G$#=^K2!*,-$C=`D[>1+("`-`K4![N'ZEN3"8(=\B*#?S@R&#'`'64PWKE_
MPF?#BAX>+7#0[1WUGR1NH#.<.FKPHJ(&H$&,-G,@?BDC&>FS,!^G3\"2?!=.
MV23AKD?`G'QDQQ@0$\&$+^ZR81J0.)684!T/L,AU`U(*DF-*AY:?7\PR@-^"
MD!^G/S>1'\-K^-915N7_GDZ3F5?=>LCD6'I`&M@$'0H_D?,FEE2^VPAQ&;@@
M6D\_G7[Z_7HL4A/;;Y%E,8\HU_(EC92^5I1W5:)G=6L,3H,=1O(<=]N7PJX>
M9H_&F#VR9&XSVN&8'&>6*SQG"`_)`YX^IVJ[^`N'5I,U_-O$`Z=HT9)6B6N(
MPLU\H=L9(FV)8PBA9L*1FRP!%WUFO'Z^5-'Z:&S]>91(=1?FL&XD-(YS5-S$
MWC:0GRVGP*W2;08.P?6:C$7FF9A%BF!]4UF^4>2A]$?.M<"(/#DXXG2_<)*&
M!>K31%7ODDK$XHN&M*EO8L]CJ7TJN5@+Y%PX/YD5KA6OO`FZ.`'49<AMFIVT
M"H+?C:;BY@C8@"O,ZA`Y;HE6B[Y0/]B@HBI9L=X,?N=)L%EL`;0AY="I:2P(
M=I+@"ANT6<TBE,DK'J<"+4J)]_9:1^K=PR3>FV,'>O?>9"/L:=->L=,-2LYZ
M24H1Z.FS-:,6])'AJV#'JT'G/!@F(.;([)?PTHR\)66<W8F0F%B<NH$)%J;L
M[HY&$FIFW#;HG%SP,A#D(0WD[NM44A+F#.S=P,S9DE(FR7EKG+4@8@H3T(Q\
M1^BRDD?O4$@$$RS#&,F#X8\G'Q5RG!C`I4P`&4\=%4L_T&@JK6D/W&(PH4'G
M0MCL#60I8(&PE?!?!*C:2CQE+5FXQ0%2.`0_^)CC"Z2IW=/B_"656$PX(/DP
M;D..&2#(">KSR8VP+)(5,>RF;(S.`SDMA"W#><P&.`,PSCL:@Q&"2Y<IDMRS
M!\Q=![$*9K/(79]'N)^8O<ZXA!C3NU\A`X[Y?L9KLIZH`@Y67IAJ0JKJ6W/]
MYW%CC@/K?S9P%NT!:Q"D>\RH["^I)<30K[D"`BBZP40_,%;F#]:-R/9/^9G1
MN#4J'(QHSV#G7?:MT[8Y#ARG_S:TQO%7=SD-K9-H\Y?B:O'#"7RE^4N!3NX$
MEU5,ZD:^3%"U$_-CDO@#E9)I,#RSE,Q@\J_P>=<I:I*+$+[JH(OQWJ'*(!\\
M+!B-8"CT+ZB8\AVGW")0.:\\\`Q.H#)N$\<E\$C1#.#@>"#RV>%?@:GGY<',
MEI>S&."G8.,Q+H+0S6;>A&O7"CCA)M(\D1CH9^OTD<WP5<F71N!OOKE,TKMH
M\*T9V<7_!CF"/.P_&S_BV%#W>@YV4Q0P?UA(*:'K",X_^='QEAX<D<W,G:R9
MA(._^.T4EST"9]T3S(!ILS`*<[UYJ-*`R07L`ITN#<JEM_ZS<?D`G'%P9"`K
MY`J[41@<@=0R<#NQ<E1*)I2(P'GU:A--%O3R&BQT5[@'S2EIG1SI"PHGG#:S
M<)JF]W4936_U*#-RY12?P$^\'IW-L#^X`_14NBA?VKFG6-(*\(L@'%FCY+@L
M];`)0H6)^S)DRMG`3-DE(]QM1QPC^,MDJ6)M<:'%.8/]5\?.I\Y:X31.D(VE
M1)C95Z#8"+5+GOB8J_-_9W99-??1Q8UQ<J'G;VC[J&O>T,P%.N[6CR6V1XB_
MC8[3@&KR08MQ(9@GXXOSF],3!N^%RX4")3&Q^!GR2"6%"Z=-Y#>E3`KA!AKW
M9\Q*@84R-_4$]:YK"L`AAPM`O9J0-4GL$KC4E+)E.`O'"Q7HY`]CGTAO!F*=
M%$&/-$V0\8F3+%^9WQFEP&!$;-G$<-MZZ('QX?3"'(?5Y&>#'4'9E1Z,R2+$
MJX\$7@($?L*L#@:)F"V!*$&=:DFY`;O!N!9V!]^EU\@!0<9LN+'#0/"1V^!L
M:(!2Q4AF-P;4IQ&W^3L[BV"'<\GK<B;KIKF!7"5D9Z&1>$[NV$E%(5W0/<8L
M.X77DVF((ZFFH5`C$F:>)(SK!A).Q!RKW)>"FLLV=1&K@.)#*ARC.+FM(IV)
MPA#PI3(0='F6NF#`Q$[0QZ[B;.ZXC;2#?]G.5@:&FR";<&]<5`EG9`GR8[QM
M9WZ4)#.';Y'$YU+HO8BB@L)$(]0(I1>O!=%EO!33H>95>HV^WP5L1YZ+89MZ
MIK/C[^?L990?124#BG&MF0?,!Q5;2[L%K-+$#X)(.2E0FJHUI^PB;@SPK8%A
MZ-K57'#49/MDS[<;8W-:'LN58%2TL8S"`YI6O'&9NH^&$<NPD)SDN1Y'IKHF
M7K#,F\2>(^\.B<\/N$IE]+)D@&+*(%,5\1H=OQV'KHQP]IT1U'EJC0I\"+==
MG.H[9Q]&#37@/OXEV07-5$]=2(G_#_G#+6ZC<*A+E%E'3U]$]%3$RQ2Q`>>&
M!28;:;BR8?WJW?N3L"%2#SY'F_G&91;^:'GK!IAY()&5JHO[*#O#%4E.(!'9
M?\NO=PHO)M!(>$NRPT!1^5JHY%M)$B8(-CF6&A]9O"4[6I32^"Q;00CK-)TK
M!AK^XC$BGL&R&<NS`KIG1*D:8J[OC#](:$K49LI4I,`L:=IXU9ND<H[//-6"
MF`/<Z/AO)'YJ(BO:,<9L=&(RQHDG`DP.6"*9@(HR:C_S5%.`"ZNL4-6&5'*0
M3QN]B5/Q!ALM%I%[+1MGB\%7\[@7Q>-T69>AI`RK$C>H#3FWF?2LQ!>@9[1M
MR=OX3B(16Y2('`4=^7?*=LT,060E</TL-=ZD1+AX0Z=WMED*15.*U*8)'/+&
M4<L@]RY.$K13TP2!9Z1I<1%%1Q[?7WE$XBQNQ>12XI@+(S@U@9+UEJA0LGX>
M`SW0C`FIT'6+P!7.33`MR0&+]$NL*;'V\#X*11-6H&<#C\,Y%6)U)PO?^T(E
MAMAM9:E`(FP.&@1KRE!`NPE."'.I)XML6/X,G9T`12-1[,38Z%'G3BX_`$ZK
MP$CN=MA[=D?9;*L9,)/D1R,E>``]57I,<6--``I_2CZ8U`GJ1U+P5-Y5'!`(
M-9Q^;_)WG)":00O2K1G<K`S^6.FN!WYJB*U-@2(G*"Q3NLY<`>"5OVC3A8>+
MVXNX;YAK+VUKO/96*K%SW0T.Z"(]#JJ?;8(^2?3=NW&(41D$'I/MV3SA9@U'
M6GCMD7'@KK-B22;$O[RJK,]YW>IE7FX3FT2^KP3RW@]I)_`[?SI=>M5W`F=?
MZL!)M\6VU4=.KU;=&J^&/4F5[SS8<RZ;&:^1T6U6/%'R?=9OX/;8\V6E\J)^
MQ+"0]VX"=S,E-04$W12=I*QT$?;W(%,H+<T3HQ[#+0JU\DYJ2P+#6[D1-R<G
M&*9R,9V/7>A(BPFN0`!._!7FO3`/'1;M0<-EE9L5*V5;?!R-+N6L#9;UC.V.
M[Y1*0JBN$T6`'D*PP-1+2B3U0%2$%&CE-89041"KDEXDU8$59TEDP>V#A0#P
MW(<`'9,F')&91WQ_Y0=<B8/=<N<\MHX3LBI\#*5OT`<NM+4(2[>2D@#*%&@B
M/R8.>@`@%5@$`BLMDTPL5@$'8K-<I]$$@2"N5N!.Q2S(D^Z>*+AT9(T3C\;V
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M`TX3IH2E#GR:0]?4P`YF%6,L*AF#/G!1E4Z)N%.5&35V(L&MYM/*`\J+`'N7
M:D939J-PBC"MX=$$_+-M]@>^Q;"1H%EZL:);RICM-P;]8:.G8U=/M;<'C?[`
M;G3[VC6'=%=EM+,(P)(4>AGMX8IY_'!T>`VO[2&0.8.P>Q_T$PCH#4D/<@^R
M2H6QY(G,UBY\@Z\PW5W)"6NG=[\+)+JU,X@P7/Y1KQOH+PP:`[O?:`U;:B%%
M`X)[/;MA#QSUN1S<)!DQ6/VMT")8/IP**Z9#8C59RJ?B`7RAW*'[L2E:-[QX
M%47^E%:C.J2XE+%,E?;\`_O74)`J6]OP40M2U<K8MZ^,U:ZOVO55N[YJUU?M
M^JI=7[7KZYGTRJUZY`[M3VM3QK(66'X7/)5V=/KH^L$G,)H_!T!%6+M@FNJ-
MV1+4V39SAI9]=D<MB[O/Y%H!7S@+3$VF0KJ7(4AO;^VSHNSO04#,_/4INP&8
M0-TQU*C>6<V7H!ZJQ7R+SUT!T(9&A,50W:T&:+W779XMT3&T'JQMB=J6J!V[
M+\N0J!V[M6.W=NS6CMW:L5N]`KY#5Y*:WI"-/IZ-D\S;7+4JO\OQMZ]6U<7@
MZV+P=3'XNAA\70R^+@;_**>Z+@9?%X.OB\'7Q>#K8O!_VZN^=3'X;_<TU<7@
MZV+PSZ]$UL7@ZV+P=3'XNAA\70R^+@;_TN-N=3'XNAA\'LQU,?BZ&'Q=#'Y1
M%X/_3NRRNAA\70R^+@;_,LYB70R^+@9?%X-_"?[)NAA\70S^\>JXUL7@_T;1
MT[H8?%T,WL0?ZF+P=3'X[X7'U<7@ZV+P=3'XNAC\MR1_ZV+PWT(Q>/6*6*%;
M7^D%L4L>;1C1:;\)WWO7\$:,CMR;\(IE=9S"85N#VGG%<X#$C;&.>F/L'./`
MK9X]^$,8S&`O_TH.YRTE!'JOWCF#%ON/0;\_2&HA@1'\)N[SI:4^3N]9`9DS
M,"M/Z(HO868\T^_2L6G3578-=1'^:/\J+8E>B^55M5Z]&PSL?FLH%4:H!*Q'
M76G/<`.PP$KM0:]GVP/G49=*MT'/Z:HK"\=<$L?]%UZAIM_&[,KMZ3UJ^[%4
M0Z33S[O8^`>[:4JOF^GT/O9_"OSESZ_6T<9[91VGYT;4#1D'#-H8$Q&\Z7EP
MQ3@BK`H85_C@>8Q$/X/HODKJ8*3`Y1?&VUIUP^DFQ^4P2`Q87H1+,%'B4V"G
MP((32(>&T_Z;_<<5S^,1F[CSP`/T37O0[@[5NB'9J0N#UFV90;-W0-%N=_M[
MP3!*BV+=A&E@^-+U`=TG[LH'KD<43!<:D,:]("8BOT+A!'H>'`=R7S+J!686
MS@,:A0@Y75%N,98_<J8M@O:!AO+'7LYS(<]0(*9()9OG00\>81KE?78443B`
MZ'+TU8VF\84'!_HLC&:>T'K%J@WWMP\G&:?;'22<Y@`P*UYKI]P.5[N:':*)
MR<KMLJEK4BYVRZ:L&#Z_.'OUKM?I]P8:-]L+KJI$;M>@2118EJFZ5)8_[P-1
M90LRZ!"''RZ[Y;R0Y1FTD$*UOUKM*A<`QPRS3>X\5&=2X')KP)74/7K#ELKH
ME7DUG-)A&4NE7018/9/2T>JU6V5.[K#=[3I#6T:E/G%A;:AGEP',@*EAIRH%
MK>?D@73(Z1FT^ZU692"V\T`L161PL+L5`F>VM-NMG:3>;_7V`R*?WKM9&#J@
M9)>D=KLU'%1"[;W]P7I<6N^;`3J(TCOM3F764F]@!K`<G=MV>[`?:$]F!_0,
M@J-SN-#NV7\'(ZI?MH;ILZ"G*L.B;["[#R>9KN.\/!NJGU]&]>D64X$)U<^M
M6U9&-"$[*Z#1/H$-U3?8N(>38J=2A?V`U1D,WR+45RW\9H.C;_*#'V!P.':G
MWSG<X.B;%(OR!D</WNQUJE#!^B:%XGD-CK[!6=TYW.#HMOH&AT0Y$`<&^[%S
M@,'1=@;=846Z_L!D0I;5]3N#X:`UK(+0!B8SLH2N;^`A)??09#0>JNNW](KJ
M>0`>*(&O><59L99<GVJ9;0?3L]<_6$E@@^^C*ACGXB-*XF>0ZW<MH"+0RJH`
MIUJ%;I`OMDK&.<4:I=?9ND8\4U7&:)YT*H#0;A+^+S!C51K((#?R6I`!;\?9
MDQEJ@WPK]YM:QS#7X#PD3%_%P1KF&X558%A:W:4;C2/*0&04+!(B4E#R'*GJ
ME.*]S%&C\O+&8Y8W=1&%>9@?>GSNK2LGU%[4N2@7(BRPA)S-S(_=[:76'"Y2
MA@:1HA/[(XB4I]O9W*A;)7REO&@<'AIQ*T%W3NNE\G^`XSG0D>N>J^(85FHZ
M.*U*77"8'-9YL::#T\KURQ5@2[2RZDR'I.<6OT'+,BN3#B$?O-MU"G=AC]MV
M<BTT5ZX,V6[\]GIDF\O=Q/)GDR@9;V-[+!-_/)MYB$OL:RSPBXW[3J@P5P)@
M;C['#NN\FZ8I%YXU!?3$C1=++TY8[G@F,^(4NI+I&/UV`MSVF=0=!>Z#6?"`
M5/;_<^F$X3@I7"6[\774-)==\QF\5)F#D,!DEXQ3]0::%\@XS7Z@E.R@U^YT
MB\."F_O!6T5X?1"_'=V%<"38G5&@OE$<@SBY6[E8BCW-,W;LDM$>IV.G&7/%
MYST,UEQS8@>LO<&P-*R'M*ET["(RP>2U'?14E^W^?2JKRT5W[").,2/>'R47
M7=XU$.VL=6HP5QFYG>OTVG'FVBI/VC;9+F[Y@7?$N&(WWE+8<B\>[*"*GMW?
MQ3&U.4N#6%+2-+MMS8M^,(B\F6S,+OA0;X($REP7UXY0=7^P`\;LI`>`Z1A$
M42&Q/:P>S'-0E8)U2/4'$OAR_5B[TLALI[\#0FF^4J"53-EO=]N[<+<'9`+-
ME^X#XAA%Q60".O#TD^\F9:03D//[I>W`9K_=*[C?VP"I=C$E$^J;W8Z]BP_L
MOQBPY5`/O.1E%-X_?(Y1AB2-WT?)74PP";"6-WR77G5,%U4RQZ#I=#HME>`/
M@^AQ5E?2QFHZW:%M/]KJ+EEM;G2=3>@^[B6VGHK6#Y?8[@4V'R.8*T7O<$K*
M21"3JJU8>.K#02Z;,-_K#2J!N;#-YI24G3O%^S:;3:P*U%G9@*>&X,B/8Y6J
M$F#;99,.'<>(U8+S5P1\V0;JCET=\#E'V?#>5N;2+FDN-@>:7GT8/(^SMI+F
M)?HE"_'-4HN3MWJK=]YIES0VM=2YG1,60GYB*15%?C5Y?X=!HZ[LE(KS@65Z
M/UE@(=$K=^V-`QP>V"_^#UGP%W?)BK:*=92T.YL#+5M^G]FK@+NLX[/3J0AL
M\S/,]:U+F13LDM?DFTZO-5`/[3[S5P%Y29\IV-<]YU$!'\$1BB)L7:Z$)9U.
MN=OT7:?5[A8`6)OV($CS;KKM4&WL]K!?%E+T<@ELGP>2"</$]0Z]L5-2KMI2
MTOW>LU<">$FA:0_ZAP*^ES]0KTFS5V"GC#NPN-PV%I(IP@GR(V)/)[=-M6$*
M1O1ZK4<3W24BJ.F*\LO""!]U\4LC8-5):54EP"H2:!JEA<[?/Z2/<'N!PN#T
MS[^8]LDFM=,%:S+TI-=Z]>ZR\_NNN%.Y:;4\@TRN3';46WU43M@XKC>]H&*G
MH'!@<>G?6!^*Y0.QE#M%P]'KU)S@_?%D!\_7WEUF_P92ML&C`UJ6?>A%;HK0
MJW8@6V6-@&?81KT"#E+KCFVT>T^_C_E9*@6.#9_O(]:ECL\#=G+HTP=0I\]<
M/U+U';VPC8J3[&;;8*9TAEOOZE4'9=64PN;)Q_]UTBMH^9!BJ)T]_.\NG=^K
M)(Q]`*N(K1NW(%UT9QM9Y-W+T:L35`J;8=UE\'YZO_*9X->7W#7ML]W2A5D5
MD^ZYA_%>B/I?*GGL34=?0,.9>X+O7D;83B99;6_'N3?E>SNOWCE'[?X>.UP=
MY%5=[G5,=7=**VD5W^Q]#!U-+\3#Z+K]J#K:(YY2714CC?-%G-)RG%:O^:/J
MEEMST9^0TSXQ=]+K#:E(R>=.[1?"G2K5%K7,:+WP42&",=%+Q0`^@_*J%UC*
MD(FFO#K#-)OU:737J>?_1'6%'ZZ\N8\=1X+U!79$3):0'WEY=WDUOAE].O\_
MZ_WY^.:7TZO1Y>GGF_.3ZX9U?G%R](_CO,'UJ4\`],A=G@=3[_Z?7JK9ZN67
MY+D!3W:KU7,&MCR/-E(ZT8=PLD$,W3RLI+7E!S3>V:WF;VQD^=7L@`R]I\'T
M`U7^%B/GA_??X9_-UK#9;JGC*R.E$XU$_[6SI3M/)\@/#KR;`3EY;&SEY71,
MWF/DS(\G[O)WSXTR\.='T-\UF[;3;'.TYXVD;_&9O_2B$_AACL7+Q31;"NZ\
M&TTFWI*WQJ*WY7U6ALN0DW[KR7#=W]&KWIR@&E*@@D0?--..0G);9LN22XJH
M,_@F99I;*M,0P:BDHHV2-PVC*&VB_!2N=[^U3=-(H^PJ$G`1KKT/\-(RC#>1
M=^/QRNOIY%N8"59TG_I?\-G7I].Y&UV/1F#,=[I]RG!NO1;UY=4B\J^U*O*O
M6=5XO3G`H7U@L!Q]W0=&Z@/#<1%YZ\DB'5;KK,`K^,-.X`C!'#]=C&].E2YY
M:AM=T0>]VWIK7=^,3_YIW5R-+JY')S?GXXMK>C0=:UL[B.]^Q_W@!>XX;XM3
MJ"L.GO;)THV!NX(8B</H,J3V+-(!7E.R,0B"Y0K[W01S5)/H,X>=/LL=0+;L
M;MYNF!!?Y%Q5A-"RQ&7>CPP)&VF-[5IS':XX+/R+VW"]#N]^2L\NWX8HP3'=
M1@.I($@3AE!IE;<#45Z?)J^+]>=2R'JZ_3VGF]`]GY!:BR2,)FD%YAYM&V\'
MQ&6ZRF1.Y^%]M'URU5C87G7-.CLI76?M=F/0TEJAQ\P8@T>98F*1E,[K$^1Q
M&Y'ZV^;-TH-9;'66D-_>NWU(>G)YW#<5:\V@1+?0>>3-4<5,.I\:0*+>-0*F
MF,&#Z]_2Y[[=:&DH.,KTB9%IX'@=R1^0OV0[RM32I)8FM33YFTN3VW("9!Q8
M_[,!DG$Z!H[^.K;>AVY$C>H_4$^P,(IYMRYOBMWU;O_DK<62/MY>Q%OG`;=D
M11!B-B;U]F6<6V'8*CML8N-PSK"I9S7O-*6^TVUE^&B>*.'=J0/O*ZP23'1,
MA[=@2!^((>D$:%@E<7AX(I$Y*W*IPC,*1T<7J0H'=C\G6)@H$;('$XXM0%ND
MK7^]B#S/@`+6KNXMZR#H1_"RTJL['P%LHD!ZT0T"'R:FGFQ\P6PSJ/V;Z.;'
M>F&C])<'@BV5YZ6CI$[+>HG_1T19L06@R!2@Y;)F["+@JJ[]:ZB.):W\R.*1
M$`&R0"0U[K[UJ"^K\+@`E+,-?$W=%UT@@&@5XB^6=#T7V[;"3Y0+2YV+8=(H
MQ':&(+H78>P)VHT\O=U]>AQDZ)U6JZ>"SRCN/)C`0K$!(:;+J2WM<$EW!#)M
M#U"A]85\L,HBDWZBN`3XY9;(,VGKQQJ($MTNW<F_F]>31;A$TJ>7FTBHU!`P
MG'K4G?W6VZ:3.,,\I:161&I%I%9$:D5D/T5D4DX1J;`7]LOD%"^Z]74&^\;F
MIJ`LICX`9_#$&J/2(UO_>SO@FI)I'&W["%OUT@,@&[:RFEP)\`IIO[`-Q-NG
MUB4\ZU-?7\3[R<+W9M;IO3>A=J#6>#8#53?:I0(?L&I'UYK+++F@HGT`F/(;
MLW`3;0>Y%$6M>/I*<#")]PY&:+XF_W*5\4.(4-??R^#LFU+Y#R&OAM/N-3K#
M@SG5T8Y#5,+H4+MK[QWO96%BD)'__FD6ANL`GOH$'ZQ[^FK]L(*UP+/D`W_%
MOP5:A6\7Z_7JI^/CKU^_'MW?1LNC,)H?`U6UC_'G8WSP%0TNAH?9E%'A,[9'
M%X,NW5MO^?,KHHZ!^'(18>CYOT2;Y&-E0`&O,BKP=N!5$P]&N%O"H*B?>T'S
M\[4VCWAYL,^BQ$NOWEUA^:Z8['R7=:G&:G9`HR`Q_MO^Q[$"H!'J4:2BPXTF
M`I19%-[IF%B'!ICAG1U@\R>.9\!YF@GXP("`,'Y^-4BJ)QYG*`"^_\<Q#N;_
MA/_"Q_\'4$L#!!0````(`"*$:D4TG.!6OPH``)^-```4`!P`<&QX+3(P,30P
M.3,P7V-A;"YX;6Q55`D``Q`O8500+V%4=7@+``$$)0X```0Y`0``Y5W=;^,V
M$G\_X/X'UWT]Q\FF[36+S179?"%`N@F<;*]O!UD:V\3*HDO22=R__DA9CB6*
MI$A)CNCL2V)+,\.9X8_#X:<__?8RCWM/0"C"R6G_Z."PWX,DQ!%*IJ?])1T$
M-$2HWZ,L2*(@Q@F<]E=`^[_]YY__^/3#8'!.(&`0]<:KWN,,>G^@A`53Z%T3
MO%S\JW>/GX&LW]Z,;AYZYP$9XV0P$,PQ2KY]%'_&`84>UR*AZ=?3_HRQQ<?A
M\/GY^>!E3.(#3*;##X>'Q\,-=3\C%V\C]LJ0)_YYN'Z9)T4&T2@1%H9;T;&!
M^,];KLB64E;Z^3@E/3HY.1FF;U])::0BY#*/AG_^?OL0SF`>;(E1-?$@IS=%
M'VGZ\!:'`4NKL]*3/2V%^#;8D`W$H\'1A\'QT0$WHL_KK]=;UR#!,8Q@TA/_
MOXYN"F4N"&9!C%X.0CP?"H+A(GX9A.&8<G53;K9:<$!1-%_$L'DV(S`Y[0O*
M#X='/QV>'!^*,G_<L@X;%D\QKEU^RMM<@7#20`/!W$P%1#$*HYHJ;)CS*H1!
M'"[C%'6B;10$PPN#)(+7XH06MC!)B]@4$N.P(#@6.,>DJ'(^%DP".DX1S>/8
M-`@60V'+$&)&-T]2ZP:'1QFP?\P>_^^,4F"O*(V#,<1I-%2\9(@)>^27PVY5
M/U\2`@DS6B#1*`UYI2G:DZOO,U(T+2#A1B+_6*KL8I3)*(9T.9^GT@:(P7S#
M/R%XKG4[MC/G?*MI[V.OR-%CN*>1@4D$A/>'_=XSH.F,I1\[J],+F*`$HL^0
M\`_L/@Z2M;I7F(@OV7/Z!2>AL=YKRY&P44..S_AIZA9;C-4H)\/AL1\X/`_H
M["R)Q+_+OY;H*8BYDO2,\;R.K'C&^$<0+T&#/2=>"6^6O+Y@3(Y$N)D73/#*
MBLJCS+((OR+<61CB)5=S!"%PE<<Q?`%6T8E9L,A]FI%E#^#C8+,C:LR2,[!\
M\`,L]P0O@+"5")J,0UW`?#'GBG*5-6"Q89'`8F;Q!2PJE#@8:]MUF45F\/C)
M#WCP;A8X;J-S3+4YO)*FG.7D:7RN<9,Y#ME)7H9?3?Z.S8!L8Q.M[!VJ&:3:
M-C'X4O6&GL':7L=^P237K^3T)GGB6F&RTO<"*A()!D62/:AX@TV.55V4Y%=,
MOT7!&,6((:B8VM`32A6M(NP\_;T/5J*5/9(@`KOLU\"A27Z5'-T#W5!QB@2X
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MX&3Z"&1^`6-6W2R,Q'*[T!#O$4BL[*V)$)ULOQ*P>TC$1E4>V].1]CVFC`!#
M!$3(YT_%`Y@O8KP2#W(;+:A+N-U1*?+Z8MNE[!&2=^OAFDV@=:4LIM`[KJ6*
M[+Z^AS4IO6/'X[=W:LX3:5SCZ:PASZ&?@#`TCL&J3ZZD+PUXM/1>8<$<SVRM
MKAF9#.(-:/DTE!UWR[_O>M>VV"'?%5BO":;TGF`>ES7P5%!(@"Q0=-;LLD1=
M-[$@OY9LV+[NO@VI/(XK+5$WE)RL?//8RFAK,*,Z^+#>"G$=(-[?<S5*=6,B
MR:Q2DWA;1Q866=636HYO_1QE=Y,,2=J^34%3ZL\*--[6K8U-3HU0$E0>-PZZ
MK-XOP&X2WE.!0)^F>I4T4O5*--WMAUL`"<3D9J55!DIY!YR*LGL`JZL%NUBH
M!G)!<&'/FTJ@7_-D/`7$12TO7Q9\_*H+797T,L[U]'N`"%MK'7%A$.M79Y9V
MMGEMS>"H(E?ME%62>P"-RIJ7]\Q6VZU!B:ZDTNY990GE<%+N'[MPH"F88IMQ
ME-I;"K%Y/Q7$[32)'P$%[H_9!4]48KS(IO8NDRE*`,BVALJ;B&MRYU)_)V[O
MH=#,'TXP<2[*L^QSHSM7.*>^.2A;\93&_4:>[B!5%RNXGC^*X'(LO#BS8"QT
MIY'JF@3K;0PC0//QDM!T'2([H`?17>Y4AB)2U>#.12HG[KV$53,?-0:8<_'E
M!+/3B/8`,9<YO8:$!^R8VW`6S5&"*!/A^ZEB,.+&+&^IM&3VOO]LY(U:699M
M29YAK91$KZVS'<P4J:O&,AOJ[N'3;"BCM+K-D<RF``\7H,))9RM0ZLL7[GD/
M@"/N,0(!A0M8_]?-,M<0875?ADY$9PW[<C*!D-U-+E_"69!,810PN$O4RFN<
M54>$Y"PW$=W'A5KXP*VX3!T_7!3*AQ0W13R;?P4F-+PG^`GQ(/5Y]94"-_8*
M)4$2\NAX%O(>=;VO(]V$O.3/LMX9)X8%B!:$EE<L&@G=?\"WZM9VFT!3U?R:
M=M98\YJ5MMDH'(7:-0IKH>][';.C-9TVJAG;N4&[\--`!ZE=^[MV^#`+"'SF
MD2@ZQW.1Z*?ZZ\;J1F)Y;*XA?H_PLG+,KG&F4V(O^@5QWPAMNU]P%&K7+U@+
M[1[H.TJ6ZKGU39(E:]4LCK*\HQJKER"]28U9J];6'43*]94+6!`(T;JRYY@P
M]/?Z<Q*E5R3=S!<!(O/R5O=ZS+G5%1?F[O'97M?9R'&[ZDI=E?+K0-P5)ER+
M9'UX)%P]DH#G`*'07>RU%=GGUX0WRQC]O9U)E3K2.B*D;M--Q'N"=`M.W'6.
MZ*9:.>1VNO9C/).7'<$S+S;6D.!R4%.6\![!7=^%N\:VDV89M'_V(W+G^YF[
MR>N,G^G26AL6^0HW(\M[!*N#DW:-3K,J&1Q_\0..<AI_DTAW1F@P:<U7NF>U
MDN\]HM/57;N&J(4^&4[_[2M.RS?76T-5SUJ)5A7K]P'82J>]/695*F6P_=63
M1+:L].:Z9?WU858\E4@M\'P?$-6[Z>VQ6=`E`^6)MZ"4[K,5$R!A2)8055]]
MV$R8=<`U"_L^\%W#L=T%9;.2FZ710S_2"^Z)$""B5[Q.TZL&[Q:IJ9<O0$)$
MM9-HUGSE'YFIXO,6TJX;:'!]=SFAUU(OZ>=MJO39`-6317S>JM+3`H_X+/QK
MB0AH?Z%'AUAG`3)T'01XBV'7=4W<@@.=P&RI8`',#HK9'$/M`-7B%Q%S33*=
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MS_EBE#]&:1#OU[&*5XW_B\FWFR0-+]0-2=6<.BB9./<(2]8.J`DFDWR_SDR\
MJGPE;FB8072-<>2&IFI.'9I,G'N$)FL'U$232;YAF[`V8\A>B#]CGB#S)_\'
M4$L#!!0````(`"*$:D57MG!.R@\```'F```4`!P`<&QX+3(P,30P.3,P7V1E
M9BYX;6Q55`D``Q`O8500+V%4=7@+``$$)0X```0Y`0``[5U9<^,V$G[?JOT/
M6N=U9=DSF4D\E=F4?$S*59Z1UW:.?4K1)&1A0Q$*0/K(KU^`I"R*Q$F"()C-
MB\J6&NANX.M&HW%]]_WS.IX\`DP@2CX>'!\>'4Q`$J(()@\?#S(R#4@(X<&$
MI$$2!3%*P,>#%T`.OO_7W__VW3^FTS,,@A1$D_N7R=T*3'Z"21H\@,D/&&6;
M?TZNT1/`Q:^7-Y>WD[,`WZ-D.F6%8YC\]H%]W`<$3*@4"<G__7BP2M/-A]GL
MZ>GI\/D>QX<(/\S>'!V]G6VI#TIR]FN4OA:H$K^;%3]62:&D:I@P#<-=U;&$
M^)<K*LB.LB[TT]N<]/CDY&26__I*2B(>(:WS>/;+YZO;<`76P8X8JHFG%;D)
M_$#R+Z]0&*1Y=RI;<B*D8/]-MV13]M7T^,WT[?$A5>*`]M]D4O1@@$.,8G`#
MEI/RSQ]O+IM=0G$QB^!Z5M+,@CBF(N<UI"\;"BH"UYL8;+];8;`4BK_M6R;5
M.R;/5WEML^Y216@=P&2Z!NM[@"W*5ZO7AJ1P#1)FL],(+(,L3FU*VZS;KL1Y
M:_0C<%FU!7E75"X<9O=@^EJ]19&YM5>EWHI<EY=5O<$H#6+X?!BB]2P7=A,_
M3\.0(+11R\AHWQP=?WUT\O8HEZ5:N+L((20@C#J(L:V@FR@DV$3'+:4HRW84
M(&W;"'G)CLQ!:^:@QISZ`)A`-IZP46^O4O"<@B3:L6+L]8&:\]ARB5&X5W7,
MQC"$N=:56]8R(/>Y>=$8Y2$(-C.FR0S$*=E^D^LV/3HN!ZVORJ]_O:`M@5X`
MN`7X$8;@=A5@<$H'N>@,K3?4%/.Q<Q['Y2BZ6-Z`$#TD\`\070,,$:4C*:&-
M`2Y3L"9;$>/@'L1YR-0GEQ2FK(U[XS(;JE=8/!-E,5@L[>AT%]SO\%[KFUYY
MU7JH)U[[_;2ST3G>]E@YCAF%8DN,UOU#&+GMB?/7QIE\F/2DVR1%$S<ZY79(
MN^Y@@G`$,)VRT9_RX.)#&"-:]\>#%&=@]R5*4NJG+V)`PPPZ5R+@@?TQH*67
M"H.(WQX7S^Q/D>F:%:[9HFYAB\;%G5$X-[-6K>;:;@R%;!C"FX8A+(.XV9T.
MD7Z9T+@'W*94*69SVWGY_!F*H@:-$C5,2TOXIOGYWLQ/3_?],GK:G^]-`^T8
MLFC"O6_,.AV(VNG,M4<)OZIMZ?'1&%L\-:GVP/KUV"=H[:G1'[(:2@^`+?_<
M]0T@@$JXFB?1.7@$,=HP?<IQY_/>"%Y#F$')&LJT2KJ-1_3Z$W71W@1N!=\J
MX$SXC<"E_0`2@(.8:C./UK192(JIXH]`!WA&96O0TRSK.?C:M$`W^)EQ;.OW
M.C6T)'>]W]S]SE75PQ$GL.5V3B]R:@QB>_(U?<GA.^^\"5-OL;P-8D"DGD-(
M5_,2'#K//8)*LV[6+ZZ]`8^W<G!\-^/DUWM/O)>K*X,EWW_/8/K";!4EM)VE
M<;N4MIX(Y],.:(;K-4IN4Q3^IC!#`5W##!MTCK-4TLY`^AKQTTJ\VO?-3E3K
M""*\>13E"@?Q=0"CR^0LV$!JGE)@:)6IYS?E93P%C(FF[<"CQV$4,]24J@:B
MBP`G,'F0C_!RXL8\E$_L*6:T=&L'%D75IJ/\$$NIVRA&N@;*):HO7M:(AE>I
MUGU$DDO7*B-2F%]FD"D:OZ-0.T7YLZL]%GMKF5I5CV`(WD7VBGT;8D(15*Y$
MNR?Z6967",C#A/:*>+->+A#^;*O1>4BY0C&5GA0@%P)#1-@`1I/0[3"J"Q&%
M0JU@(JQS!.%5GDPBBRS-=[O3P5\$!1%='0E-.B^!H%"G#0Z$58XB?J(@OB0D
M`]%YAJGP1>+PIR#.P!?PE/\B'CX,RO(<A[JLEQ!JH79;]Z+-I@&UK\<"M<)\
M6F)-4%@/;(W"(T*;7'%[<!/Q:>#-O]4!F0'EORTVK(7(Q3.=G,#*+G(#-R>M
MQ\#E">H9$2"UF\.R*Y2S;,#TV['`M#`\"SC5J,C$78X?J?H-8MN-&F+UQ#NL
M?@%IL7AXA8AHI.;2U!!6H_$1/#(U6N""7UTSI>#?#&$>_3<C*5.,W"'!ZD(.
M[_OZSH0;0&?%!*;;_0N%*91[%!A![L"%:T)NV#:6E?IFZR/8'3=V"_MQ)F'#
M)-];M$C>*<1?^=MZ;@!),0S9$0$V:LR?`AS1.#Q=+#\AO`0PS7!CLF2IMK*7
M.M?F$]+M-HT!@&TQ;N)2=T.6@_W:>DLG%8>CL]U%WL@\3E6'(><P@E6<SKN'
MA+O]M?8/N3A`8@<V>AO\^P*.S<R^[>&AF'78'23VZ[0S5&SK_!,-&-QF<C=L
MU-@W4/N-:O!POV&SN(ABL%D.QD'RD/<#F2?1%QI<[KZYHW^1(,SG[?*-;.UJ
MJ<]!3&NQY6JNRXXYA>AN!7"P`5D*0\(FKGB#<`X_KO[M"E><ATEAMUZB;9>B
MCJW"]16&PFP=20LA>@V0^.!;PC\`UL2:BK8*+3'MN)"DJ;-5X"AYCF"GPSQ)
M803CC)U;N@5AAFGC`/(E6`-I3*U;K.Z\E<6L!8:5;#+MTTI<D`_^0N,Q*E<-
M\/3*.38JW5Y"[97G6Y2"\6L09\1P!/-2ON(7SV&<T:#O$^T=%JUF:7DD;;NU
M^!K@(IY]X5<@V=SJ@*.6$5OBZ#P[XZ+]4&O':6!=5D3>RRKKBCI:N^P\S`FS
M2*8#G8N$DF=(U\M,>8_UWE-<V_G)51HIIY<-&LXLLD(SKA!?H6,?<\(FKS'L
M6@T!U1*B'Q.R`2%<0A!)G9R2OG&1H9#>6O1>LKA[0N)(7413C<J;-([3J,JV
M17K:""Y#$-3^&E\+:QT@55_*LDCX-YE(:3A]6J'QO$]%VG3KTV:M[M-2K_BB
M-.I>Y5#Q;+5*Y7G/BC7J:*^<>GL=>:2]^PEE6-FY32).WU:)/.]:H3[=>I93
M[2A.)Y3+<%LU=$[;\FA%1R?W:8?;HL&5&9G'2O+%S"J7_0N#5;6/8*IM+?P4
M3JZU`U"GVS1:0\=PBX9%\/BW''%'&2R6E5F;Q-%(:6N0$="ZAXM<:-1]MBR!
M$)?W7A:D)<\1>*5!MC"(TX/=-C$X&!'[PJF>LW.'U/ZGO?`AH<XX#*@288BR
M)&7G7E`,0PBX;U.8%:H&V1J%7-Y;8J@([\X*20BYAQL]5MQK++@LVCHT7QO4
MW2)AQVYQ(:AG/N!*<`^->4%=7W#EYIZ:%@J@EN[/#'57C;VD^OR&O.>&BZTO
M&1O@%LO;[)Y0Y%-7QMW4+".KX(9/YB95TQXO&LIU1(B4PPC6A*XQ"@&(2.%!
M8PH,MF,-8='<2DE?"V@E]#Z#QU3=#BC29]5K/I#K0S[#&)`4)>`Z>"F\4\-_
MB$@JOJ-)XG/7:RC5T6<(:^_U>A!N!^^`1L.BRMR)@G$)TSQTHB$4C839F\V<
MWF]5O@(-P_*^XZ9+<W0$53O6S:C%OPQ-Y6+GZP`O<#Y#*ZXQV8;W@L'*H*3X
M,FUQ29_1V+X)+`QE)DR;"/0O^=QQ\CE?LT8390YMUFUW0^ZV[C'@O(]FM&`)
M=L5J??&)K^DGG96:CHDC.8OF#,W#!ULJ"M]FFTW,CEFO87ZMQPU@]D3U_TP_
MU]FZ`$SQ>RJ^\ZISA?6%UPX5CL&[6&LP"R[%@BSN;VNY@B%[^6J>1(7,\P<,
MBO`4I?03!O&GC!W!+F=$^?'M1?(%E.$K+W%EJ\K*;*1[E3Z#N8=&ZSAGL29-
M\Z1^WX"^SG"XHO(4)G:'3L$M'<,)VUQQAVY`"-AS;TG>3-$-?%AQ(=R^DNKV
M_1:5^`[3S@W3$9@=^(]@+TTUT\B>*5LL%^D*X#DA("7'@IA!KY`D^\LKY#,.
M6REN.0\LX=?K':W\Q<I:M$$G*?\!`7?KKYRRNAPIHO09&?HJ=EU^5#!I+@@<
MOG_W_HU_E]2DPSTG>!8'A"R6>3*JT9OU?*&,MIXAY-,.N+MV^_YI+M+I2RZ@
M]'TG=8G&_EI)"1<OV\@["+71C;O-C,MG?T^MNOX_R<LW?UVR;72>1!^BO=RS
MK4:NQ:NV;<ZR>@AM#0"J74X6X(X*?J8:MT.;/I?1OSG`O7:PE3^4UF3D$`4U
M>0K)[JW2ATN4\S6_(W(`X!9&=TDC]V>6P,A5W;Z^5GQ*3M.8%:[!4[>PETW#
MEHZD)]3,"ALT3;6P\Q,>AAV..K8'UV;U9*@:L2'O$9Q,<@!-X3FD8<$I.R?7
M-SKUSB&YQV?O9Q$NUIL8O0!0G)H"Y7_"X_TZY)5$GYS<;4!BV!7(6&%CR.RX
M;E-_6MS<W^MQH0L+)1#&V/5]=[:E,XF.7AW72(%I>E]A&"FX4D/(6-?A<AB.
M("#@O]13V=IT^K(C*=?,\XON+YXWL+B'N)C9B&:EMNOG/79LIWY?9[`]M6#+
M>:UU:79&DA'Z%\I-+(AW#NK;H<VC,5-OJGM:5[?,2?U`"5-RJ6$CUIGP#,4B
M$Y^MI:^V[&`R]D52V<U;K^V&*)3>)G-?]?X9L#TQ()H_`AP\@.WOUQB&PL7(
M080PM3O+0HS5+OOLBY[LMA^157;]M==V+6J2_.,G0-+75+AH4U@?+&R-A5P6
M8[6X]NWH>!R4":2REG?MK(6_6:UM[%OZ`Z8"B+:G^^E\,8C_G04X!3A^N4Q"
M7#@5WMXWIXSK+\DY8.R9"0W6YF:&-8"8*G-[;]O<K,7-^7_G00H^!1#SGKMV
MR5+Y6*--EKX:E[MV;FE6+@14&=2WWHU?A4IB7\%NK0&_9_3/^*6WL:R-$-;'
M-3,A?#7#(?MBJ/&NE<@J4_UF\(F9M3B`^URQ"U:VLOM25IY9HL-V=9SSUQ%,
M954G0UK5'6NVQ?(RB>`CC*BOD-T0+:.MWQ#-IQW!DJN.EEU66.7UJ\!RW$C'
M#`F6GV&ZN@%Q;BUD!3=W*#_?^2+=9-6R%A7`5+6XO_-9VM$RQ!DU"/_&9QYO
M*0HU>2KQ>30@/D\1<\G+<XA!R.X`/%O1V<@ZX+_M;%:HACY5(;<#<-O.1"U;
M00]R<B&J8-1D[C7VSE80+"^>09C?6K18+F$(^,_\&)2HGYZ4E1@=Y/3UMXTW
M'<[*31M#@FV0@5BX[=F3H5CZ3DA/8['F^PM#C<:#@K3SZO)^BG&([1'F$MC>
M&V$B@<^S_D%Z8:!=$2WD58<VKTF"`2ZB`,-=1+'+4UX\T@_E"1XE?=U`Q?3#
M.<Y]F:1!I)16KNM`+T<J.PB9:<?/Q8BX[!FZM':O9QL<_61O2,JIU28QU#N2
M"KG%2#$[-RG@(\&*].S9"/`BN^!&0JI`BOM'L;2$EL-$.[W+8:%`B%EFUR-\
M-.(Y.4::X9\4)U<^7/STUVJBIZN)2FQYL*`HDM&;-<5OVCF3OS;5_)]OJM$Q
M/B^ZP]@L/=]:<](PV'[N`C3RKNI(L+UWE-6MD]8<V9V`MM(8XE?<=1,93EYQ
MMS!QTWS'W<74;9=&%R7?RN_9!W,>])O_`5!+`P04````"``BA&I%P`[_PG!4
M``#&Y00`%``<`'!L>"TR,#$T,#DS,%]L86(N>&UL550)``,0+V%4$"]A5'5X
M"P`!!"4.```$.0$``.V];6_C2)(N^OT"]S_D[?-AN@%7][3KX.+,8%<'*EFN
M%M8E:255S0X:BP$MI6V>EDD-2;G*\^M/9I*42.8[&4FF[0(:71:9$9%2/D]$
MY/N__>]OCWOTA),TC*-__^'7G__\`\+1-MZ%T?V__W!,WP7I-@Q_0&D61+M@
M'T?XWW]XQND/_WOT__X___;_O7LW27"0X1VZ?4:;!XR^A%$6W&/T,8F/APNT
MC+_B)'\[6\W6:!(DMW'T[AT5WH?1'W^E_[L-4HQ(+:*4??SW'QZR[/#77W[Y
M^O7KS]]ND_W/<7+_R^6?__S^E[+T#T5Q^C94E`\C6NWMN3RG_^M[5OK7O_SE
M+[^PMZ>B:2@J2-3^^LM_?;I9;Q_P8_"N8B`-_YJRAS?Q-LC8CZG]'DA:@GYZ
M5Q9[1Q^]^_7RW?M??_Z6[GX@OQY"^>^7Q'N\PG>(_OMY-9/:_,LOM,0O$;ZG
MK743W.(]J3-3D3T?2)NFX>-AC\MG#PF^$^O:)TE-%:W;7VC=?OW_:=W^1]W"
M+YVKNHFS8.^^OE4SU4KOZ:,;\E?-./Z6X6B'=Z5Y:D#1W,P^`Q?3?-(=;VM:
M]Q0X<2+\3DSA79#>,JV$EO=!<"#:?_V?O^!]EI9/WM$G[_[\:X&4_U$\_L<D
M2!_&T8[^,_WG,7P*]CC*TG%&^)@\$Z9_"?;'TX_)OC/COKUL%F;TI["4_:7^
MNU#[M5\FP6E\3+;-&K)__M&JGB8MEA&GB.O0R[]=.[N/>U)OZE1Q].[S^@<4
M[MII&M'WB'ACM*5_X'/)?_OE_.OPO^@XJ<,M2+;E]R)_:GZ0HL0OVYAXNT/V
M;E_]6>Z2^+$M7N).S5@T"&LD]%=DI0-E,6IENC^T_N-7*P\#`U5F%`BL1-<9
MKNR/2MD+%&2H+(Y8^;>#X'/3#H!A:KQ'%%_:H/B`DS#>K;,@R8!\+[,/!>C+
M'T8?QC?C^62*%M=H,E[_AL;SJ_R/Z7]^GGT9WTSGFS4:;]"'Z<?9?#Z;?Z0E
ME]/5;''UAO!].22^+WO%]WM[?$^C'12ZWP.B^[TYNJ?D^5O$]?LA<?V>PW5_
M?8CQ=AL?29U6>(M)_6[W>(ZSR3%)2$4E70<3D4:/02T"0FJ36@'V#S3F]-15
M*AB5;U%R>HW>H4T2[#S)IHQ`P)'1`CI-!JI$>>(-##CH%%]KJQO>:$)_0MRY
MP`4B12Y04>BUXDZ;L\,A3Y"A]^?I%]D#3LZU2K5^7B_0\/(J`1#*Z6L$0S>E
M'3W5%.(C]J["L=1'DAFT/$<Q8[0TZ247Y,DU(,+L7+IA%J$QUP5JU*?G8`O2
M%/LRC`B++*WKAL'6H&Y[%CV1*L3),ZF/Q%&+BC1<<[T("%5$5@&IT5"OIT)-
M8%1^"K$GR!<V$H=U15,VL5TMRJ/9<8-#)[B<;KOVIL[N])E%U)?:Z%J79M[L
M8./!-:56P[X9/\^K;7VS<=V&R(A-]:*P?/IBFU\WP&K1_/QP:8_#2BSGT(PC
MB<HT!X[J96`Z[B*[0/WTAFJ#;GE-8I1_]*P[(&XHOI.M:$^N3UTM*^A$NVYV
MRVS>S(WQ%BS;GX:QW)%MBU_&I]R]#0ST@RL60!@T#[_"=V&$=Q]P1/[(EJ19
M\[I=QPG]4#Q/Y^1W5'J]UGH:GK&%'A`:M:X_8-^@31WT5+37.KK^/+]:H]D<
MK:;KY72RH7-GTT_+F\7?IU.TFGW\;;-&GY<+^GXS6TT_3><;/[C<'H4<W[L"
MNND1K/7Q7N/%<`.Z&]6N`@ZH02-9(82*MXB6O$"Y(+J+$_:@?$O'04_2WSFB
MC9M#L&30^+M,X@-.LF=:M6P<[>A\^N&1U$H^+F8BTHBJ:A$0)V%2*\!8J3&G
MY[Y2P6BY6BRGJ\W?V8H2NIAD28,<(?/4DTAG!`*.L!;0:3)3)<J3<&#`00<@
MK:UN>*-AI7Q_P>)'QA:AGLIX-/8'#SQM4("#WM!=+4P"SFX2IUDJ[T;Q9?@N
M4K4,5(K'VP5+WFJJC=*RBL2H_(C89R\3*D&;B9(E:=,*TJ!S66&*XQ8!3F:%
M>0N64&#9]_1ZNEI-K]#DM_'JXW3]<B%@D@L;@V!0QY;GU\KA<.4X..A(J(N1
M;XLASW*LVP]<-GY\R:"FT5BF;!`3M/$<CE];#5R?1ZS]&ZG6M:;AV+2L/0?U
M)#=Q=+_!R>,5OLVT0\[JP@U/(RL,`EYU36`\D=2&'M,2T1%]_HX$[T=$WUR@
MZ;?M_DCWTI?S=.A3D!V3,/-FM8FFR3E&&$&DR0^Q$,^7`2#E)"]3F&J++>H_
M;\+@-MR'V3,*(T3:-L);>M(`^AIF#^3SGNB)$W;X`*(=-O;7:T*9U@]WP]F@
M?GH2/SZ&&>U4IW0?4!QEQ&O@:$L<A<19&T@TM^.K)&`VS.GK!+GU7FG-8%.<
M0GXT67SZ--O0,4I/>D0F[<UO:C,&29-+"DG!]K4AD06^35YCJA.PV);X\^M\
M9WRUP.L$FWZ_.Q#<ANVV%UMZEL$S71G.=N&9;9%42$AV2`HE0/>K*>KD8'^D
MV)KY=C61_,C#?9"JEI9N1]/#@^N2RB7E6]$&P92K+9`R4YT@5=L`6;R_R+?;
M^K86$QAOQKL?NR+.)P_.MOI8>7"1A-J#UR5<L$U4)W<>O&'-FFXU^7QGFI>,
M$K:TCE$*>&CX5)74\JE?3#GVX)RI3I`2>W!6PF\/WAEOMAZ\->*\6!.PPD\X
M.FK2;W5AR2J!9F'0R6)Q31S,&7.&S*>.&Z+GY01)_L*3/JRF<:5SR4HP-#DC
M%I+/+?<('@=KAF56VF*G6/V;HZ=XY9D7AD&1\=*$=C@:=HJQF)8(L68?G[Q@
M<VI14!!F#DA:`Z`I19%^@RD?7FQ4>>89(Q3-R$_DZ)J<F\+A!`33-_W!P\GR
M"8F9-CCA-P+NSV5>`UST<WZM`#/P7%_TA),L)&FST;(,;7ENGD]:'F@N1E,?
MJ'D8N1F3.1B9]*CRJEBGX=L"6'V+"R9?S$#"3[Q(Y$33+@/ARLDB#;6U#@#+
MI_C.$(OBS!=?#(DK@RF][LCR:2C!9,>VNKQZ0,'%+E-U?=P-*]COJ)9(OY#!
M!<.]G4;PT'0--3LUAT&4X[&&-ON0I?*"$0??XC\DNFR''EKA:]@=OSBBUU>-
MHQT;A5[&:9;@+$PP72%"GM('^/&PCY_I@\HVYK32,=!Z=T=6FON*H:W`[`QU
M\]V!MI*"5\Y@[RFPS5&AD*T'RT_CK.MD+^I:4?6\A/0"U4:,?/-HKMC#[XMU
M2M.F[P2V)MA[^Q;\@9/^G8LZ]NX8ZLO^Z5DHN3#&*`GO'[(4'0_$:YQ-?&<[
M#!!?"=]]F1C2;SVSR)%<>K8>\I7V68<D=_`Z\%L2NDT0-J16[[!Q/7EDO[5,
M%F+R*:1]'-TCMGO1YTFDUBBRF4JRQI$OCE;O7O5.%9X3SARH+>QKSM([:!L!
MVAS$2NC"-[)K=V?OY"JN[:6WNHWS4K;[H(YJG<7;/Q[B_8YTX>@I4MFSQ%_)
M"S;<EJ@@"+#E-0#LHPJ-Z"$N$!M-QLO99GR#KJ;7L\EL.I_\W0^@*UJ2P[NV
MU9N@YP5X[/>($.A9$(F%-@"AKK#Z]$^H^+W&69:$M\>,W1Q(?KQEX$_?H1MV
MM"ZS'7K`;LL0J'9W5;+$6"LHT4N0\7T81?1@DP\!4;#U9)-E1\#H[M1H"1BH
MZX@%JEW=/2PQU0HN[W\8$9NO#2NZBX!;8F7(*WXK6>(XVAGG:J9B\@ZG1`RZ
M@Z*L'7C75&;-J@<C5E+MQ)Z.M<T\N<O(&`ZJ[HX)D!0](*&XLELT)`1==YSE
M1KMC4=C%1A'.4'R'ML$AI*]V^"[<ACC:OGJ(VG33@4`Z:(>^6`@D&W9LOFZ$
M@/-K$)XUK0%VU"NJ]9PY%1ZMIE^F\\^^G*G+M08';TE[-4%<%N/!ZJA%H3O6
M-;WF#4J=W<JK9:CF3:KU3/I&'7C33)HM[HJJ2-R-L`RW.:96!FCC@L`NU":8
MNFJ3?0E5B1']2&-Q\<`/V(H;2K#W0-Z>3?C6RHIV&*B:O3\8?TSB-%TF\5TH
M6PDA*-&`<*T$"(`%-@%3T;IV/8*KY4<?5XOU&BU7B^N9)Q?%B!J(@ZZ\%9O`
MK93D8>NTJ:&C:E.U54O3V,H^HOSSRVQK;90U;>V!L_H4DQ_I@?0WKHC'W,?L
MMI?IMP..4EGL-9+A\G^E#%`*:5`OJ*Q2;<HDT51I&)6OV9A/I0`J2OC!&3,D
M"!)5<P#QN:M"5I30VN"NQ^EQO"<Z[S_B""?!GM1NO'L,HS#-Z%G>3UA-0#OA
MYC2ZH3#,/(9538&F4DUM&DQQF*D:%>4N4%&2L;9>UB_B6B*(GR5I@T!NWL1(
MB6`NI1V"^R/W(C^2/[J?1=OX$=^04"]ALJ)D@[;"DB`<5=0!AI!B`WKVB>1&
MIX<H?XI^I,]_\H-6JN;D.*1O^R9A!!(\.WH%BI/Y#)F=5HBAG0UZ'>EX,YM_
M1#>DA_DZH*+M?K0%RZ#=$;839AY'<5DO=2*D*][TH=+B,/S0U`;(F\JM&!!$
M)IR?OHNJK_S*6+1-S9/&#!P<;R1B`O*8PFE`_N2\-J5/O;2./65I-^2IU\41
M=TY&6E"GD!4Q)W_E*7$:C:SGC1`56MH4Z9F>-7W`R,FV8Y6MUGBB^<KU;#Z>
M3V;C&S2;3Q:?IJ\+2/K,I2.4!LU@^.JH4QAM^8875I0'(9"V/C">6&5&SQVY
M]$C@A]&/Q5M/>HGZ)N>H9(J2)I6D<CR9!@.6DSZDVEH'A(G\,P'8?RVG\_5T
M_1-ZA^933V8O(7&F==H02!O6<>-,.UPG+--TT/4R,-P1V05RQ`W5!M2H28S(
MQ_I0G-?[C,0MR/-`T=`<\JME!6AWC0<[_WF(TY".DANX4,Z()3:HJZ3HV)._
M7V[KZSV?1?N#[2BK:[7:3/:$D]O8I'_#V[`%P.49`.Q$(Y*OHWQKT@O&@V[K
MF!4>H#:,U;5:[14SS:@X"[9H>$_0,-VP,7ATO5BAS6]3M)RN9HNK%XP&W>8P
M*S0,N25L&B1TEV>ZQ,GZ@43L#T$:;NFRB7!_S/!.DA$92C5R)*T4""<,ZP:3
M1^F-Z>FBTS$J"R!2`K$B%X@5RI<)Y<7\(),I,#AZV2&J23>--$]`+Z#H9'C2
MQ&9G3-(<[\-X/9N@\?P*7<UN/F^FGKAS5PC4)H30&!RT6_PW3`^?Q+LQ21N#
M>SP_/M[B9'''ZKDX9FD6L`W?9M&BF[)&$&FK#(30W;X)(,M;5T1/_9:J??4'
M'<''N0D0,#=]1SNEO$MY@>2`WJ/0H1:NN$&C92F)"E&4R]*-6TPZ115Y;],[
M/\BD#<7#TFG8^\WW3#G>E2D%WDWB1SK.'F1A'*EG)>V$F[>>&PK#7%9M55,8
MSV)LT^#Z:C-5HU.YW$F\NZ4E4;6H7\NU+`'$7V[=!H!-]ILI$5QX[1^`G?00
M+4Q#(9D=3E=!\+92Y"TA5W]#NU/L#AJ9\@'/=49J23=CW5!+]"#\;Z%LWM5`
MHA&#E!(@O#6H$TRT41O2$U,E/RIF;D]O4?D:_4X+_+<?G#1I?XZ(YJ!I<D\A
MR1/.!FF>[.O]A&GZ*N&:A:3-'M]2TOU.WWH=>]CO>S+8<==OH4>[]Q?]GI?T
MA)PV@+';"BQ$6Y.L!AHLMP5+H-KCR2'JG8U*^EK)-D\;,9.%.9S"IIY`AU88
MFC0XS,)(TTB_&]@S*MN!AS\=HP7VFG0VTB$X3Z,5=/L\#K_(#_*3_&A*'D?D
M8ZK(>HUDN$/RE3)`AQ,;U`OJ6'2U*9-3BE4:1L51C.?'7N6]9@@0G&%L#IPF
M_Y2RHG.-;?#69_Z;!6&$=^74JB;E517FLEQQ8:#$5E43T%,N)89,<EBAZ&B\
MW1X?CWLV2'G%CH'-/`MOFG86)*<&N.#S49&0*`7M'4?P9VM*K;2%47[N9OX&
MG98[O488&9S2V05(PU[^PR8R*Q-CL@Q'5JZ9U?#E8#(9F7VCE?16EW((+!DD
M+YP4?QT'^C&,4,H*>K*_3=ZJ?*:B`0"7G33+"S*2OK!BN>_"XD8.H:46:*'.
MM'X?Q^L"B_[:GQ9P@;OTA]-LM4W#H',D--`&)Y?%I%QZ45U\\@H`HKWFIPU`
M^#T;/:[JV/V?8YK1#E>ZB<>[74CG&H+],@AWLVB27\+`:GS;G/E;8=)#2\,,
MKW'R%&[QDCFD%=[&]Q'3\B782X_;[LML<R6)<[,P4_@]_3I`JU?<U]9@M8#K
M2HPJ%BBISS80-8)('"S,7$B7U%R@DS%46$.Y.52QYX>;[(VA_(*'?GT#MU#"
ML7G!$HOO7HE6TR[_-=YUVDNUAW=0JH50*,'Y,!J!7DIO`4+Q@3[W9!?UZW4U
M^E59K\[9#'])]"Q-CWAW=4Q(;IW7,4^YV<M%#OSI-YQLPU2ZL:B](M$ETY:*
MX&[\;/4-`&<%6E7"\*90.[6C\D^Z+Z+P?N@^":+"+>+'PSY^QCBE(QK;_7%7
M7$6'"[&?/!SI:(]1\2VE7?#.3_O9*I3<<?HRN./D^F[[&KB@3C.QJ.T1&">$
M0O?Y2L_;YUK'9QD\L\?CKT&RNT"%V@M4*DYIEVGIT>$=P_+)[,KQWAGE8SAG
M>09`--?K,0OF*CTN_9&^_NY#N;(.K=V10FOG0.ZULS&`I*FO,4:WH:.1ZS/V
M,_X1I:>XK:F``YZPJ,VZ^KD4RL6*@'N!F.0%RHL4PJ?0['=`[H4C;<.Q4Y8,
M?(OJXV,<L7HI%[])RW&WJ7+E@&Y4E=B'8;A(O<G-JDVI4?ZH8*!?"Y+D32BX
M9U7=VDW:<.5%]ZWJ@-'G]*AP@$Q)`",9;F)2*0,T?F]0+\C=P!I[)F/F*@VC
MRA3<@;Q_=YZ"\XQ/9H@0C$Z;`XD?6%;(BD:%!\8?="*F-]81?C3!:LP!ORT`
M&LQMP$'0E\QG&22+A.U1R-.T\H0U?2ZDDY1G1W))Z'Q)5T?0>5DSNU:IE51/
M+=FZ(-$B04^T@!_LM$&)*@$SA)@B)9-I4"9IP^,3.GB8F@0!)PTD=7B2DBA.
M\C,4=GE/_7Q`Z]N`K#:XN`(MV&I=$UM6ZW<-LVY3NS#8O3QA-VVX5GHN>SY?
M^D80JUL:[`RQ0RX?KM0OGT0:'[.'.`G_)9V+,9"0IT*\!#17975RE?H([%DQ
MDY-OQ)+S&^]H*&U^%?TTF%&0KBFI)%O_0'.8PPA-=4(9G[/D)5X]W&SRDDZ`
M&WZ[)7?4FVQR75E8M/%24!AN@Y2T)H![I$0V#+=)\:+2Q35^,$C3O.(]4SHX
M<)-I0B')WJE^X>/DH$R%J;8X.BW30KX>A`F#)+,]FJVQ-*C?O8X3'-Y'DV.2
MX&C[O$D"4JLMK=;'((SHC3Z?HP0'>T5ZW49%PT?;J0"A7IM:P_AS2\MZ=EHI
M'!6E45D<5<HC*E#<@7B!SE)^L+D5T#B.=X!KD_<VJGAOT`GT_7F()?%3I$[C
M:,?NJE[&:9;@+$S8"MP/.,)W8=8X4;CA(%IH:/@'*PT@[J%%G6&\@YUAO7.P
MT3<J"K/3_EAQ5"^/"@&_#FIO@R_.+;0':=,K6&CBG8+72'>2F-K:!X4\&U5X
MH/L)V-Z`8+M-Z,K%?1C<AGMZJAZ]\K-<WXL2>H-&BHX'MK^QU/@V2:!-BONB
MP;`WE#S&21;^B^7QB[OK,`JB;1C=3TA]94=BFH@TEVHI16!6RAC4"FB9C-J2
MP1H9E8)1]2U=KW]ZCU@!/\AJA`%^;8PY<IID5(D*UL4,BS<W%X7H#'8#'EN;
MU8#>#M]F*$S3(SNV:LM^:YI9L>>[,-W&1U^B!SP@]6NUP"`Y]$T@I).6XBN<
M_SN+KO`=)EVZW0H_X4AZ')&Q''\KB$X.ZFX0L_H!<M3$IM%E(1HMH_(5S?EV
MQ4N2T;&WIUU<-&9$<?1NRSKH&3I0!,:1)[NYS/$CNE7$"GI-YFKEA3>,^(%:
MZ#E/,X,`H*4!IBR$?BR+_4017)9$1='7#U!M<'$!4<_"S'C+\H=TA;<X?`IN
M]^:11BZJ#38B44?,E=?2%76%%MMP5Z!(1MZR*#J7]96_"M@84%@+.CV'>14F
M-#:`[)`\GD7$NQ!K(59<':>7T3*W)N.(LH)ZN>)JW50;DE8UR-A9*>,K*T58
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MNXA;MA;66D%S*:R%`ICU@=8U!EH(:V/78%&@N;I1699=NI*71F7Q"\0$+EA'
MY23CAW]I`2Y^"6!;@#:]AKDBP?*_]B`?<D!QA=,L";<9WE'_9CQT*!;3#A(V
MQ1R-88AKYVJL@K/69DRBH40V]G`NQI)Z/SAL#`^#P00EL/2#!G5QD^$!#23[
MC]/7<4)<QQ;C77I-?F:VF)A.1Z3U/$,3K"VU2"*VL1;0L&U9=]C8;6[</(";
MZCQ'<;J&_\=2!E&Z_53L;CG)53KL?KB!MM"3QO-V&)8%=4-M\LC>E@R#CR0*
M*ME])-%2J=E(HK%2EP,8EM_,Z4BB>5U:CUN8FM"-)(H<TTL<2;0%MNG01CO"
M&`YL&"HW'MAX243L<R31IDJN&2D<20Q/+'PA(XD#TZWM2.)`A!MV)+&2_=A<
M+&0LU^R%Z.5@^AVF]0,]WL[$JD$70ZM%=!60'Q[!'!=\%\$24ERG0"<OZ`;X
M@D;HU3=F!@&@2`-6K4_K]\4Z+N&IWXKN`*!@I_;J+;DXL]?,*@1.Z7F]-*DZ
MU,"*WZ(?U1[8ZP2H0Q[6*TG03OMW(0=1+)6:#:(8*W79=[/\9DX'4<SKTKK+
M9FI"-XAR/OKA90^BV`+;M%?7CC"&?3I#Y<9]NI=$Q#X'46RJY)J1M4&40X63
M=R<FOI"!E($IUW8@92#2#3J0,KV[P]ML<3?]MF4'>:V"#"\B^FW&$9N&IFM%
MGH(]G762)!1M5#32!SL5(#ZJ3:T!>Q"6YO6^QTKA:'I]/9ULT.(:3?]K\MMX
M_G&*5N/-%.5_K]%BCB;C]6]^>)E6`.-\2@>8-OV'C2K>6W@.=N@Q'6O;L%BG
M434O3SO+I02B(BB.\@28+D9D?U3DWBKTM<&S/_`/>X>@L$KYA<_-I5N2P-A&
M1?,J'2L5,%>>M*@U8*)N:=[@5A0;A:/Y=(-F\\EJ.EY/T8]7T_ROG\@S%A#1
M>'Z5_S']S\^S+^.;Z7RS]L-5M$(;?Y5*>\PV'86-*L%5*WXC'_SV'UO;L,!G
M)_G*0N$%RH608"7P6\6^_EZAWM`_:)C\$*1ANKA;$H*1&K(.+:GW.KR/PKMP
M2[<;Y'N>28]W&>_#+>D#;_"W[`.ITA^2L`FALA%&NZD$<2X0WPJP_]FQ.GKO
MT\G`:#W[.)]=SR;C^0:-)Y/%Y_EF-O^(EHN;V60V]23B@@"5\T*`\&_ZI"ZJ
M>1_UPDD%'<$[U\4MIVB$9_*T&US5P$)^10<Z*T&E%O0[U8.8HO_^3CX=H+RG
MGP\I0Z-ZS_G_#9,#0V%Q&J`5AO1-AC4%]4%ZF\:^1J?J[%/.)2]RO_&,?B_^
M]=5YF*)(YB;L4"AQ!QHE4N+[A&(G=PY8F(:"LS1(OB78FL8Q1\`==CHT2")2
ML;2\J]TL*!E*-2<]=5(P4S]F=8.<VM1:-)CAT>A@"R7V<9JB`TY02HOX05%3
M*/!S-%88XB9EU-*">1@?P`<^U6A@KC/VV(1B480.C")6R/^<QQ4R]1.&P-CT
M9N/1)-Z3BL<)M24]!$%77K'1J%$>?+V\L#Z.5LDW;=FMC:]+CY9WX;\(\<;W
M"697VEV@XX&`G=XRDV^01PD[K=['[1MB$"A7PZMPTR2;5$Z]]KU7J+G<-<0;
MZH`T?I=0[?7K`Y?57J"V\/+&?Z^#/5[<L<,SQFF*L_17`R<N%U)M&14(P6]_
MDM;,P>8\D2W+_4Z\BN:6/%*"=L3STV;R0OYQ3@$(]1XG'9!4W..%-7N;A@&@
MFRN/]2:[(I$Z_O*J*P;%M(#B(8EWQ^WKAJ'=AM#.0!SV!N(H"W?A_IB19'&-
MM\>$K=*??J/74>!='KH>#\>LN#FSV3,9/]*1+$G4`-7=O-,81C?,9;20WQ,F
M5$%5R>!66Q!+HZH:=-:#2D5E]GE2Q18S"T8A<H5^N"=8`O#WYSK@5]/5@=@0
MW,?[VNCKYM)IL)KUQ&.:-I0G2)`V/Y#?_H$N[]O&CX^$LBD[8B**,Y3?=Y0?
MD\2LTNM:EFMTB[?!D:X'?,`(YYL6OL;'_8Z\0`&IX;NRBM\);H_,%TCQ07.C
M-:D;&UY;;W$4)&$\_A;*ACF591NYBZ0LB#-3U@,FMY"9T/L8L>2H_(1^IY\]
MF2U0-RA'59/V;Q)/*,,3R0PN_=%B0PPL[L9)0K<OT7HI:*$LVZ"%I"P(+93U
M@*&%S(2>%F+)$7W,UA6=7["EBO,X>A=4GFW(GRG=&$^CKD\44C<^1R$3K#0I
M))3A*60&K3[/_L^O-'V^"M/M/DZ/"=8ML3`1X<[\5XD`G?>OKQ746?]*2R;G
M_"L4C$YOT?FUAXM^C5`@.-K?&#M-@JE$14?Z#XHX)YTPK<%NT&.76\Z_3.>;
MQ<J;C1WP,#.X=!(*:,/V&;8/>'>D0[RG*DZ.24+^VM`;+W5>WE:\V;,P%H?I
M;%C6%JC_86[5H$MBJFQ4EJ0IV:GL!2I*DUC![I_U+F)8(XKOVK3#)-?;,50C
MZ`#YB6HGT<;*.!R\\RN6BQ)O#;C:V.0>NH/&K%/55L'73P$!:ACLTSG.%G<K
MG.+D27K!D;F@K&>B$(3-%K4U!.ZEJ.Q9)(QR-:-*#"*ET*G8!:)+PTF0*HOZ
M06<+K,@32U.<29-+J0)%BCD\1MWV:]1F(<#*5I,0C#Z6;]\"),U[/*"@]".2
M_"U._IA%;-U+:A=*])*R6**2A"6JOH[`T41IT(*A"CW5>$*+T9G9HJ#O$<4`
M,G+^&N--2E^Y!@5_?0"KV["BL0N"6AI82K`>\O=O`YOFP048G7Z$E^LP"E/2
ML_H8QSN[\**7E(47E20L8_5U!`XO2H,61%7HJ8:7LAABY7R/+@:(D3/8&&Y2
M_LHU*/CK`U;=1A>-71#0TNARPNH]??TVH&D>7(#!Z4=P^5L29O@J_AIINRK-
M@M*>R;D@<&[7K($)U8QOQ1.:L<G;3F*5Z?6O].&['7GJ&9GXUE0D9I*6EV=A
MI8`JZ7*.$NA]IQ(+;2!2FX!`?WM5(+%(UFU@,JBWO`["Y$NP/^+S!+SV7%,C
MF88/U<B`$,6H7C",T9G24T>M841?(_:^LI#)Q^,+S<#`L<L&0TV:*65YQ@T.
M/2<9M-YB1PRRK'D\6Z$OXYO/4_1I.EY_7DT_3>>;UPL\K8>'A-[`>R)(#1[B
M_8Z@C1[,G3W/XPPKEHDU8H"U/+=WPE@>:#^%97TAUX)8V#;9?&&J;;3>+";_
M@3:K\7P]GFQFB[DGRQ+MP2/8I]$.?TU"&^L1[>?P%,+0W0,[PX`(IB&H6OA/
M*"^.:'F_%WCW"7']NJ<>0#Y\-)NEZ1'OKHX)/9"373#!-B"F[/\?@A3OZ$9%
M'*5LIZ(JKK73)(IPMIK@'$6[[P`=]:QK8>@]+/6.)M6-RR$3IG.-A,@19CNN
MT-<P>_#W.O(NL!0[EDX8%SH8.XT25_-2".,DQK:H@A.^G.(NRN50+EC<GG21
M']&1%O^^NZ7BJ"I_F@J\CI,['&:TV_.=1W78>,:D0<-W?M3$+-H1_[O;Q*SF
M9;J1_U^Q-=E.N!&D385!W(Q=36'\BK%-O2,Q5%4<'(**@A2=>=$_I67Z[M/F
M9DOX<$Z@%?R:K#=3PA.])7QMF9WB[<_W\=,O.QSFI"9_-+E,'OUC_(BC'=V6
M?;T/[AM4D+XO?A+!^TZDD]KKQBN16CEU^-*CTT=$/P_+`7F;Q-J?L8%DKMP9
MK/J6=87'8HO.->FM!ON_XR"91KNK(&L"QJ1H!:7RHIT!JZM%=^PJ+*AA+!4<
ME3LG\U>(OD/D):)OA\>WMF%CFP80H%XF4B>`,6A<<>$JWAXI`?-44$X$9;D*
M"R3E.E-`:;\[_F7JU>`72XW*Q^6ULOZ@7MV*L?$/+L"[L'P=[&;8Z/%PU/.!
M,>DXVLWCJ'+N3O78G4_X\18G#6QVU-(\\-16"\S9B.WJ#G2(J;5Q@V,.+76.
MJ@(&QR]=Q8]!&'G21VF+//X@PDX0;O9:++4)CA;LR`57L9*8WH71_?KY\3;>
M"V*D\'TE-C;>=XZ)0GO=8V%3K3H&UDN/BH\H_SQ\Q!.W2:S]&041KE:N'MG4
M+>L*C].(U/+Y.MSC9$(BZ7V</`M0J2A5P::P5&>$*FQWQZE8N1JM(IE1_A"Q
MIZA\/#QT50T7&_[*`A@+2M?!;`(%MY!>X?LPS8BCS^;!HZ@WHBK&@;I9#`C5
M8NM0L.:TF^"Z(50"^_P8T>>^(%O2?`)H*QN:QW:]N`C<&DBX1?>$9#%)L&?#
ML_^!Y2Y;4H[#-U<.".`2^U`(Y]6;0+PI56*\>)Y/+R#RQA>4RUI1`'-U@_,X
M;Y07`5V'#<=(9\LKV+1C/LFX.&9I1GI9)%>2P]Y`B.>`4@B*$`8U`V.'VI81
M550J3KS)5\"P4N4,/JH4](9&)J@0<<H<30*"*82%;+-!H>L1W?.8\C5YTIPF
M-R@I&-7E2H*-ZTKJ`#>RRQLP&]MMRIU'=ZL3&^S=\%S1M:APA%?=_*(QWH:$
M>)17AY5^\)^/-9LQ0%!6RH%:66`6".H!S8.Z"1LF5"4Y+A03'EZR0=2Z"C[(
MP2!G1$5&Q0D5=ERS@AZ5KR!"];4`^_EK,+A7K<$AO-!J!FI6^(QC^M$?X-9:
M0XA507N)X,GNFA`B4MBB/4[!;;?T'B"Z%I%>@A[B='Q+.^9;Z:6#6H'FQ)I"
M`&8.35LCH.DRE1V#F3&Y^&@]^SB?7<\FX_D&C2>3Q>?Y9C;_B):+F]ED-EVC
MW\NBODQ\Z4'`SW&9`H>;SI(*"F:NS,'6.\?29?!,#R4>1SOR)#GBW4T8W(9[
M=F]7L0[%C'QM-(E9::<)DJYMO@/@+IAVM3!FN97>42F$#KD4FP</J%RP3__J
M%>5;04_F"SK@6.(D;#1*O<?+(`7T3I>V57#"";K3Y<2*9845A22JB%;NB/`S
M3`[&&?W5E`.Q9M@KN7?_YYAF;''+)EYAVH[A'L]Q-HNV\2.^B5/R?!*D#\LD
M?@IW>/?A^7.*=[-H<<!)0'.+\38+G]CWTL5KAZ::`=V)*1CGYO!7@$P)W%33
MP#^Z,#RJ:$4)_N<Q3/)-/TEI`$4X0WNBG#ZE?V^)">(:\BVX<:D;!2?EOJ0B
M+EG%^UWW'.;<L@.3`K_]MCP&>+[DJH[#.`R6<55<!H'+23/;-ISK1C]2[3_1
MU]0`*BV@VV?TX^?<=_R$3G;0V9!_V=F+=R/Z_.[%.A)_,L3Q;A?2Q<[!?AF$
MI-*3X!!FP;ZREYO^/R!PF\1I)ML-#:%2E?%9JX3WTRV_E0-O;%\32Y]K:Z#I
M6<_RB"J@^5:AX@)5#WBX0*4>Q!1YZ#C;8EGM(+LQ1.D&+55KW-W+XYV34R\[
M5\@M`6ER(SIJZ"Y.6*_G@CU@/-M^YYD)=KQGVK`)1)2%NW!_)%D-7N/M,6&Y
MS?3;=G\DZ<\U:65ZQLLQ8T>\+.ZF01*1+"A=XB0_!>99K$!QVDH/%IOIATN+
M,%[2_6\"E+PXK:B!:W5H?U1]A\XOO3ILI@_V\(ZX-\IR7MJ=98$3[]%/#.WA
MZ6:6?(>RE9OFQ8Q\;57,H</D:^?2Z]6LM75=%24R_W/!MF+YMJ'<%!Z&SD0*
M+#./<!8WI;4"DCUR,TUQ9KJB1E6VR4)Q61CJJ>H!Q#>)"0.2"25'^6./I]^5
M;<M3R``*'&]$,@*R](T<-YU\J:66$&+=\L^KU90N>UROIYNU+S.,`,C1]Y4[
M8&?8WBVKD9%C-?*H3@CA<J%`TX`I_"NNDZ'=)[";HMS*,>I0[;3EP2=\>>VV
M#<\F6=D33X.E+0H,G9PI#@9U:Y-]D*:+.S:@>!-&>);A1]EPF[)LP\E)RH(@
M7ED/&-C+3.BQ+Y8<L<?T%/)\INMW^@JQ=YY00=VX'"-,L-"DA5"&9X<9='JD
M2)QFI#K!'JN/Y).6:U*#+P=#"YE]P"Q`9,.`$YS4B#[*[^=^PM$1H]_S%[Z0
M0=J4/!$TK<Z1H%E>0("^``*=+(@-M,!'/G69(X0]?D7XT&8/;1`R:`YQA6\S
MMO/L67=1GZ)DPTD*2X*P0%$'0$<IMJ*G@DB.4"%ZPDD6TOT@49SY<G^)JC4Y
M'NB;OLD#@03/A%YQ`NTO929:P83Z3/KX`N4OT._%O]Y=1]<5-UH/VA8Y@WI1
M;@XP2,/M.-I=T?D&O%MD#SBIW-RJ&8GJJ*WAC5MK`V%BQ^\"P]7VE="SN:WN
M42E(CT#)C]&Z0$R8;1LLQ"\04U"_NMNS@9BN<.7<!@S^FXZEI5;>^;Q(0CF9
M7^E2%V?,HK'T;]/9Q]\VTRLT_C)=C3].T?SSIP_3%5I<H_5OX]5T3?^:+#Y]
M6LQ1?K?QYS4I/9O3A\O/["R+F\5ZC99$B$F@=^C#>#V;H/'\"EW-;CX3[9[,
M_?C"/VUH'YJ!7J4(ECF`99!W['3Z"=.=XK`JT'H?0NTYVC((FG.L)T3U$J<Z
M!J)JI)E/-\U(T0@MGD:)]A"S]O/V(!O64S\>]O$SQFN</(5;++[F=+QG-6`K
M0.D.POLH_!?>Y>?TL>7\W,1*T\&[L=*,"]!68,COYKL#12'PRAEX&&";HU(A
M*C0J;E@^J\WG=$K%Y=&<^587_R8]71&(]X-.F<HY3UAK`I_KV"7TZ*C9Q;2T
MVG&$HTRYCEU9MNDTQ65A7)^J'D`.3&+"P`T))4?%9<NGYYZM05<W+4]G`R1P
MI!3)"*AE!)S^"'(=A,F78'_$YF//)B(-NJA%0%AC4BL8\F@LZ3FD5#"Z'L]6
MZ,OXYO,4?9J.UY]7TT]T+;%O_5$C%'#,LL!.DV`J49YG5HCKCV[YZ2'K+,C8
MO8,:IFE*-T@F+0W"+TU=8*@E-Z)GE4QV-%G,KZ9S.GA+_EHO;F978SKNN]Z0
M?RBUV$CO@G3.QYL9*>`=TW0HX$AF!ILFOR12/+5,<388JVZ*O%29[1G)J!G6
ME''!,W&]G+"-,V7-N8:&47&\UND]*@MXEAZ:84'',R6$-&RKRVHYIT%>K\Q+
M,.D97N'\W\KY5\59%OH09ZF`YZ2Q`BB"6M88<)C:RK@1?TW5C28/]+;DM'&.
M9K[Q@RY'V)]/QO5D/+L%MD0<;X=/`>$-%0G9[RO&H=?,65J&A#B=JRE+HQ_+
M\C]1P)_/?BQD?$P2>\2Z=GZG'[0/.@<TBYY()(Z3YW,/4QOKM!)<<%-(`#%=
M6R<H8JL,F?!8+C^:S;^0CMQBY>.],B:M+J"B*51XYDDE150SQU=_S+*^0L;Z
MIACG=U_T>N]+Q^M=5+>XE"<9W,S&'V8WLPTAF"?)79OK)EK?Q&)S=<2`V().
MQCK?DJ*^#.5%W'<"BS-MX@2#M$$3HTJUYN3WM?7@<AFY$Q?)0'--7B]PL@E-
M6;%-H*%.MW,!GQFGP(**=%H(*5C'RRJ)-PSRG"R!U%OL"$'F\Q?SCV@S77WR
M.Z4``YZ-P^\,/5_<_CC:L>,='N+]CF`O7_-@'@&,Q.7!0",.S4ZCVH*'")U5
M*ZJJE54#!QOI+1;[>!PWS!"D8K(-!A645JI1LMLG%+L.-WKC<'!F0>@<>A!=
MG4^7XX^7L\WX!EU-K^GUQ//)W]\:J&TBE2-8#QJ_YC@3W>=S'49!M+6Y(+&]
MHD9,:Z,(Q"^T_P:`_J%5)?1^HH7:T62\_@U=WRS^MD;7J\4G=#V;C^<3N@-T
M/-G,OOB4PW8`'^<Y.@.YZ4'L%?*^Y`61`GHXKF4-7'""[6O#F>J^O).TS_?E
M#4L7;<@=AC`^AF$Z4Y5:W5/<7I%9&%8J<NEQ#+Z!^S"LKD1KEZ-2RX5A.NN[
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M/\B-&?'&][EDF<!ONB<U[W,=V!3YZSY\R!"^GJTH^O#,;A8S\]A2":G?%4@`
M>T]IG:!]H,B0C2?CY6O^*+\"[_89Y9?B>>I-Y`A0^`0=;.3,YB15_-1CK4>6
MA83X=^$VB++U\7#8T[/K'L.,GD*RPC3;"Z/[3^3_C\?'\6-\C++\?89W,A)V
M5MCD:`>%,!3N_(V`&-ZE'@8.H+WZ42Z`SA(7Z"2#"B&42Z&3F"<NHSM>>8\"
MQ0'.X;16+/!'+Y=73A:L=ZR.2X+1"8A-3,\E27.B;4^2WTFD@H?7-!ITYN%T
MUI@RH186:L;G1B$8WR"T#!1'F[H-J%L7&9V/O/,K_16W%T\M5;MR9*D5%A!`
MW?X#0/I&<_&"O*`,VC?`UQ_(:P`,\1NK2P@$8E6HW_AV`8"B(>68ES6Z%/<W
M\I/T#0`R`/Z+'J;-]EPK61E+U+*PQ#&I)S"7-"8MZ*74I#W0F.UG_&T\_SA=
ML_OJN*V-WBT\L4.7G+H6X)2R6:5#07`K;`_">;KNY7H??]6MV#01D3-<(`)-
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MHB@O6RSYN<A7"]$3`?'7O$3ZEJ"LGPIP"N:!A_B%56379K4,8F)9LQC6E'5)
M<W$]W4<PSFYKEC<TM8I?7A-=`B53GBN1:$CRN@YCC@\'Y)["E<`H$(YUP8J5
M?C&Q"A3";2,5"(B'CU.U@=5YG.DNVS`3$D4FA1`<D[4U`R2PRI8A;^4J1NO-
M8O(?:+,:S]=T_[>/-R@:8D',2U,,">DH%9;PT!Q[/=*/KEIA@S'!OAQ2G44D
MMW@,3$8O[:2;A#25AF&F75TATT5CRP:$-=0U6G]>+F_8G,-X]7<TFU\O5I_8
M':B(_%<Y7&E^)3SQ$,T7&UIL<?.%OCA/67AR^(,M\GCZMX(NYP?,M`@<@H_8
M!\\P+<R"09]EF:[`[U_TZXD'^@35,1-:)JF'_3<6^O[\E_=_9H&///@'-;/'
M:3K]AI-MF):;,O+MY,U!$7.!XI<Q$>C$:O,:=:.QD1TY;PW$1^5[5!9`BW*/
M45%F6)I9-'YLWSP-*ND%S^SQ`&1VT6(7;X^,Y%2V)=PT@<)(`8,<VATQHBV,
M;I/X#YS0JV[#E*[PQH5<2D?4<+GY-A]XBW,E/[]&2$K].RPH!5X<'):7@"F\
MH;E.F+S\873R?@1T!<K0?1)$Q9Z#$H>OTAF>V\LM\BX!\X=X3\S&]%"I)SQ.
M$GIW-O5MRR2^"S,V"[0D=:#>[KX)X];RU>S"3KX[X=K4%R#WL#2K8:&5ME&M
M.*J41[E`/K6*SB(><+,5K.+.+2WBK8V>!HU]!K>3G,>Z`H!`9QE1#>I!!>J'
M'.IT%0R=J#F<Q'S(@7I&NSI#Z@GO,/F3E47P=,K:.B3<2;*UO`O_15+^\7V"
M<;Y;_>Z8'8DO3_`3CH[%/6CX&STL!0NP_P:AKTS1^H(^8`)WA0\)WH;Y`--C
MG&3AO_*_H]TX37$V>SP$84*K(LC>[(4KJ9N-<&>BV]>T>])F95/-;`M5HVI9
M5"V,2&G$BJ-S^>$IW`)$<;>F%5#77$F=MYZ"V$5R9FD="M#LS(<'DHS=DRAU
M'V3X%(^2\[EN]-Q&4J:\ZOF0'_.6/009"O+SO>B2D(=\01@=6LA(U4*ZC3N@
MUO(X%T;-IZ2I<U5IKNL61YAF@6R\[)@/4E"M>?&?T7B?QD3-=G_<E?:(Y[ZG
ME0_"B%C&04+/04A)W=/CGIV3S731HE^3D'RY7?R5'5I7U*!\&](5;DGR3"6>
MZ)(56K?\^1WYH?)G'J2B_9%9F82ZIS-(^FEA#CKWM#0-QN;+1H"BQ*LC_RZD
MAT;G^']3@%:EECT`&C*I+`(*L3*-R+=YUJ^CL16K)I)&8MW):E$[@.31S)J&
MER9*1F4IEA_FY5"EH#<3_=80B=LVGXB`!N(-ZK6!96O*E6>=$FOS."JG23[A
MQUN<"*AF4KQ",77QSM0RJ4UW2FFLJ*FD%!Z=SB:F%*J\1[_G)3Q@CE&+Q[:M
M(F"*2JS.D`%1Y:*#I+77'F&T$Z3%F`?I/RS(E"D^#,Q`TGBE`>C$76NL`\I(
M<C[!24:O02C+Y5UC4O3=:>K]U3HU908.A#?`+'LJ_+J"(*\-Z^`NUU7HM@S6
M7'CV#[DF6#4.N2HT.FICEX'4.G0*@J6'P=&\R8T"H+[108.<X[!F'<CDH>M%
ML]TH%ADT/6"\^4A^W)LX31=1?H!O>GV,=O16P16F-R-EYPLW5N']0Y9^/L3D
M518F6#)]"*.P$L^Z*NQ,$IAOU#U>=JZ'FGL=U8^H/*(*T"(JCL-/4:X#S2)4
M:*$+X$]<SA4AJ@F=50W/;"`,Q_`H$OB-;HKK?N:%<\U%W@)0(Y>\HWD18]Z/
M>Z+C)T1G7PKNW>7<(^^2@GO5-?])SKTCY5YR4N=!1N4?^909FS_T@]Q"]I&N
MSD])9W>%P\?;(\GTJ(5TA;<X?,*[19+_)3A>OZ5T->#;2'?W./9U!0CE5D8U
M_L-"UR@OS$8;Z\5161XM$G26\,`=M,!2W+&!130WU]+@M*]H=A(L+<V#(9N%
MP1S;=&@SJ6,[*;$=)\7?K)W8.IS[^`DG4;X_%]'U/&%VS'??4$7;\Q).$B</
M09)%I-O+#J<B;8$)AA]8N1U^POOXP%QZL90II8N&Z-JEG0]!M4<6J<-E#SP"
M&1JQL0<];F)K&XY&ES^,;NA^Y7?Y_CP1F]X8F%5#-KV`&7"P9Q9M$QRD>!;=
MA,%MN`^S$*?7<;),X@-.LN<E01%;VO#/8WB0C.^TUE')\%KHZ,SGUO7NGNVU
M,:VFM+W&42E"QV(J0HA(H5(,,;E\R5`I.3S=VR,N!@&`@/C6NNKT?Q'X=Y$?
MMJL$,!=HKGAB0QBA?84--+$[%((7I*DI'=AVJ5+8@UQN*#XH\[J^&0&2X]E;
MA<[TVM4`FA!TUR#YH1Z"?/=#28`Z\M\P\%4Y8._`!\P';\(M[:D2]?GMGJ<]
MH\LX(_\/@_TUVSJZ#)[ITP^DGKM%-,?%#D;145)0*BO98G>5G1T%U+?JGDL"
MU$3M/3H;&!4:6!I9W)U]4H).6E"N!A5Z$%-$IPZ)JN(,"@^ZFF!PCEW`2>".
MNJJN>Z=70#T7:2Q(G=S2D":YWXGHFHC*E-@O*H(DS)TK`9T_@U3(,1,OSTRD
M"75QRWUP8N+AQ,3BH(Y#KND[Z70@\I]T@,GZIW"/TRR.2F."Y%M6I)),\T4Z
M.P69U>[)KD"SFJN<P.CTI(QOP[-*VDJQR:\JP'RS:!W#/;2XBQQ+:,.N]6D.
M=&[_PJMZ,(#7#@#*7,,.`B"Y`*<4.K8+#5@BX%*``)0EX?T]3O#NQ4)!%0$M
MH0`8H>8!C86+N\4!YPLFTF6\#[?/&_PM^T#4_"$(6<8RE1AF(-,9W<;UZA[E
M3$RI8:_7,,J+T-77YT+H][P8HN40*^C!M@IS1,2M&DQ`&:ULG4->X,]%S#4S
MVA&+I[.?MENZQI4=/IC#,,'[H#@2FIZ=%.6096=&GR!;',Z$V>$+'L1R5VA5
M1GMHO(+D`WHKT`F"F<6N<"4IQ$<<D;?[5XPV54(!CC;(E.-(-\0M[M;'VS3<
MA4$2<K>^ZHI5$PMAL>[,4%@'2!_$VC6P%PF-\J?LCI+*<P]@KVJ^V/2G%D%;
M4+R!YOX@X22BR^S8PX/&[0(@)`BGE3<^A.%."%$'VU88@0FI(L7@451FI`5$
M+JL0>4T^1!T@VR$$,`PN2$Z<T-UC*=T^)@R!LB*5\,<7Z8Q@F=7N84^@60U8
M3F#$GB#V".7/AH>IM)EBDY]5`,YFT3HP>VAR%V%-:,.N^<MNZ"1^/`31\Y]2
M=A0^6Q!:W_1SFJCS(,RU0X<RO-GA`R2L<4JA0YK0@"4\Z-DCBT_+\?SO?UJC
M]6_CU13-YFBRN+D9?UBL\MLVQQ]74W8-YXM%ABJL62(#,)SE5UC,HFV<'`H:
M2L_#TI:M!#A%V<Z@UM:C>\A3F5"C6RY97A=2>^?1(3OZYHVM6D&`<ZE,'?"#
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M`V@0/FNUBK5/.+F-3:-MW88M&B[K:/CY-<#!)-X9PP$R>A5G2.2'EV[B#WA-
M")_>A7BWB8NSK:81J_0N/\!4%-Y:*ZG&OQ9*NI.B=<T!(F@;VQHNV:L\GR*2
M"Z%-C#Y@=)*CGPM)5(H6AX![0,?VP(MA8""BL[6R!M]?!A&<9!/M:@%-BG*=
MP=T^IF=+E03)#^G.;R"F>Y/(N\<XH;<=IUG\2,\8K:UT1X_D.4J9K6>Z1B%.
M=KEOORV*[/.%\]OBOHSR>.^(%2-Z2/_VD2G=A>EV'],]_L'Y2GH?UO`-1T!U
M@M4[!6%2-'NSX.,E[:H`SD"2`Q;'7VSCQ\<P8[OBZ$EO)^(DIW:[Q:?3@M\T
M(Y0Y9O^,`,Q25\6YS5?G(YO9;:[W881Q$D;WT_S\YCD6;;%O(5W)2ZVD.[N`
M%G7MGHG:&55SW4;7J"R,*J6+VX]/Y5$A0,^V&9[>;;`4=VQ@`9TMM-1Y["V:
M7:23MN;!D$T3R)7NK/D+%&$?%JCV"6EEUM8'J"$O7%EO<10D87Q-2"`=^I<7
MJL084:'.Y)-;[AXQA+K5]!&(C,IGB#[T:)A/T6BQV4\L@#=?N([BGD#@PM%*
MK-@"@KK-UP<)I<^S!P5(3U.@%KHG*3%AC0G2$V27#<Z)BT<;G#RB"3$8;H-]
M+6L\'9+BT[78'4"CZLRU``U@9ZS4OHCD-UY+RPB"7J4,&*XYNW`AKZK:#,QG
MB;-W(\\\Q"G?7$*8REI5A-%363%$G3:^RU!7-V()A%J@JT+!@^Y`6RP8A3E3
M-(`&N;-65S&N;L$6#&6$PP'I+5Y?C5F/<7JDI\D'$?J$=^&6=&30^!Y'VV<4
M'`Y)_$2BW\MW'T9!SA@R#D+<AI31!SE!*4&8JY4"P[;`-ERHJRLW@W55YNSC
MV%,/$2MJ.B%FY6TLPFREM!BUSL'@,O0US5@#HQ;^7A,TC&*@#3A`XV!5KZM(
MV+1ACXTR&M)`./8WUK6"ATF\LX*'BYCW-=9'O&894;P[EX%#<-,N8*RKJ#8$
M[4FBXLR^QCYBE6LN,5(EK2I$:5E6@E&7C>\TMM6,6`*A'M<J4/"H6V>+!;.0
M9H@&V'!VTNHLF-4LV(+A%,C"/9W&CN_0DG3E@BP)MV@6/>$T"^_S'4#TPC#Z
MRTT_C5^!]S"+<J:(@8QP]+`@=M\#/4`(1RG[]5>D(4B39'BWSN+M'^.O0;)+
MYSA;W%W'R1T.Z<F8HD7/`-JJ4;.+MNZ4ZOY=`")QITIHV-E!]X@)%W<L5<71
M61XQ!2C7P&YA6MRABA(/V`P`UQ@8,R+_T%YKPY.\5$(YR6XZ5L<9N6C&5.P[
M(/$QP=OX/@K_A?,K3+/G=[>,=-LJZ79'MBJ,KH\^8!(J=FQ9:'*F8LJH&#![
M/B1>'A%/G<QY0#V8!+&#??!4LF-=W#'OL@AL(HY53O47$XNM7:.4O:N`@'S\
M]>)_O?^?^:F,WV.>!%F^4L^/3)N)`N?;=9TP67>I<TAO5?]>@V;@IZHX<UB%
M!8AL'*U?OH-J8!K*30FI`N2J<MU@#LL?!GJ6LE<JY9B-;,#S.Q^=\]%5WNZ$
MD4/G\$4M/,KD*S5R34CG63WZ,8R*/W_Z3E@]^EX"82$S__`^"N_";1!EX]-E
M<>PRJ1"G-V&$9QE^%*;W5H+5'-Y0L+M+LJHA0#9N:D_C4\S4C"KET+D@*DNB
MWVE9Q`K[,#EE!Y>X?4.*"&RDH,'2=C!U0\1-<+MO`MU.R)2`A9!;\M5JYIAX
MI:T.I,M5Z`G'ROG.M3HJS'DF0I,QQYBP!;_Z0Z&3KJ"9U:Z(9)TY,TSZ,*WB
M#)3JSA8X+$%W)--4;W%@-WB.HUTE!V2)GGQ=GXU<U?6;R77GG4W]``*`H3D-
MXXRTC/*QD:(<._RB.G"2Y_L>+0JR0DK<NA%%U#.1;[#/)WPZ"0W&A@&PR@*$
M!5I]B!*.X:J.%8X`"S/`9F0)?!#-V"H$7B]_&)5(#=ZX7U4/2+D"*N3`$CL-
M;G(Z#&Z)D[_C0)C,J$M6TQ=9R>[L4M<!($61&M`01R)7GK9W?H/(*T3?>4`.
M38O&%C^]"/YBB0;@^\:*DW1!8:H5;ER<E'H@N-L&>QSM2!L\%PU!)S((/+^&
MV<,+.1H5`K3J]*(#;&%2"(EN\*1!8:<=:L^GBYYN"D:/P;?P\?A(D!:EX0X7
ME[,<@F?Z]I7`29D$=(%3NT!?_";L][@+TEOVHQS3=_=!</B%9@"_X'V6ED]8
M3O#NS[^^>_\KRPJ*QWDJ,DO3(]Y=L;7!2[8L.$]$Q)-CQ108WC6P#:FR^(EA
M5';B*N2WZI:Y`-5$3GH0`T4G-Q='N3S*%5P4/8?BWV*6O:KF`IT4#>LT0+$<
MN\!2PPE!J#Y[JU?".[LL4!-,P2KDEH"G564M%[%45J]\IZ`.5MZ3L.7\"$QN
M,8FC)YQDX>T>7^';[#H(DR_!_HBO\EZ'8&MH"\E&IF`D">*8+.H($_?-#.J]
MBXF>4:40HJ5(9";E$"N(*B7]\!$V>.%<@3W8FGPWT,#3VBND.HF4IG9!($OC
M'H/H$X/HMH+?*,[>"E"UH<D55`<--.OC;8K_>21=ZND3'<`:WY+<)M@VK[,P
M+=[L?$J+PR2XFMH`=1KE5@SR49GP:/WYPWKZGY^G\PV:?B'_7Z/?RY<#SPL9
M-S:?&IK!@TOZ)&*"A,X44,,Q:(._91^(O3\,*<25UW"H4MX)B;CZN&%1U8P]
MC<[2H_,KE+]#O].WB+WVE$E\FVNI)(.)CDLG.3V9>D.6F\$%I;4.$&/#`DUG
M_?IPI>^:`R"K\_S/.:]*L\7="A/U1\O%K\8I>-."2;)=EQE-%NL-6ERC%47-
MYZDGL*E54Y4T"W]C:7I<*2U*A!O*0&"P*F[@&4>[RJ4,Q;4[3F"AMZB'B4['
M:#5=3\>KR6]H/+]"5P0[-XOE)^9\_FLYG:]]P9'R>\AQ9=AH$IPII7G<:8WU
M>MD8]!2UK6VXF\8N#5!Z@>;3S?!3V!9?2SRMW:J%A[IHC)\2;YF]X3UY>?\1
M1S@)]L3<>/<81B'M;V7TTDV'/M;"M$%>9ZILM)[>W,SF'R_0Q^E\NAK?,%R/
MKS[-YK/U9C7>S+Y,/7/`9M]-D0Q:MK$L,S12(T@3C<V#('J1/>!D'D?Q@:VR
M.;'&"8:5QO2H58B/KF?S\7PR(P#U"XVR.LOQIV\1">)D@CS&5"9`4'4=)SB\
MCR;')*'WI&R2($J#+9U*_!B$T4V<II^C!`=[>KR@$Z195T"//DN5H^LP"J)M
M&.S+2T;I:0W;^!'_E!_M\.,C$=L_D[?;![I6$NW"NSM,=0]^FD.;KRP'=#LP
M2$!NHXP'OFU5.N?!I=I%E)^LF5X?HQW>S>B1$`>\);V_Z>-A'S]CG%_430^I
M7N$L3-@Z2/#4&*`ZZFRYLX$1U8#BJ%BVG*([I@"%=+4)4T$7&N-"27GQ_/'`
M5J.4>H9/K[O]#N*,&PI+@B2\F^IZ7MZ]FB`A:!9M"9-3?(7S?V=1L><W7>$M
M#I_L-X@;AAYCP_J08ZAJ5):C+`F*$O0`WZ((VW`5TYB/@C3%F2>3UR;?3AY5
M[-I7$DU,E/!1Q-2T(QS3^PJB+$Y"1^LL]!;;(+>N8U2^8$D1^^LGBM[P7,I7
MD%:^B`TZA:UF#,N*M`D>&\9`@+C,=U^DFWB\_>>1N.LEO10QR9[IC1ELZ(4\
M9<,P3E!I:5X/42N%HV6YG8ID'X>B(/.KN"SE!U[-OY4<O&U:6H)D<U4\K.VJ
MX<C9GC?33H+TH2=_*S#:QN5R:D;Y53?LY\X3ZG+-]@X?XC3T!,.Z;V+C=F7M
M9^QYZPI,G"]O$M3_DCXL(<(6XUUZ37XV-I937&$4W8])9_8IS%RE!FWJ8.Z)
MS;46]U2TZQVRX1<_D&[YS?4NVQH<&K]MJ$_NO"TJY&`-A-GXR5]R#D3XGNYF
MT;.`MV&["N+R5:V"D(TLM%H%T?-4G1N$6!@'FZR[_#Y9IV_E82;KH#`MG;=Q
M@V*EN0[3=9=O8KI.ASF`Z3HH7%E-B[C!FG45@"?L+@43=FDY8W?Q?<K.!!##
M3]EU)03`_,5[4'H`5<CII-W[[Y-VSB;MWDNXY=FDW?L^)^W<!"!CTT#3=I??
MI^WT+=S_M)V[Z>?JG$Q?$&[:[#IQ=_G&)^[L@=EAX@X*BA;S*&YP:5D!T*F[
MR^]3=[JV'G;JSIW#;<S#].5S!68!)N\NOT_>M?"^G2?OH'VPZ72(6T=L4POX
MZ;O+[]-W8/#P9?H.BB?JG8EN6*&WV77WJLF^0#\0[63WJ@ZMH+M7(88`;;86
MMAGOV\19L%</^ME6`6X3Z_OOFUC5#3W4)E9^D*W'`WV$YT*.SZ>\?W@^%RF"
M![OFM+B6XB,IF*6S*#]K4GODLUMKS<.$7%F#6<?@]K<`.LC(624-ED<XLET[
M]K9VF7I%-[I]KIT^7>C/KU>_*.]FND"Y$9KHEF=7GT]H_?$*'Q*\92?I$OI=
MYO3S9#[1-17Y%1V]<+^9@CBR*E@QTI.SZ3DTW.J_T6WS&Y'0%N8W.^1?1A4,
M(/6+W#^,?CB'#_E]`5T\4+4,G3J(-0@W?E9:N&^/?#,H,\3>V`'YA/X7PH[$
MXSKA]TM-OWO)NGM)MKW,L7U.K0?(J%TGTK1/'=^5^;0_A\@[HI/CA+G7/-EU
M>NRSQTXUWV3Z#2?;,,6G+_,W3*=#\&[\A)/@'I?OETG(>;=A*V'K\8$KT4]$
M</++]10QH.L.$%%@JV04<5+3D'.R78TZI7U45.!4"K$JO)`0Y(;_]B'*I1^R
M#F&@E6D1XMSZ0X]"H.Q[LO]]R>>8\V_X*W2716$"JL,B-#%L=T7QK0?NK(AK
MYK"K(C((T5%A_Z!"L7^C1=!<@>N-Z!D)UA<1F`+LB9CP_@6,SA?!AGX1O)L?
M'V]QLKC++PF$'J@W,`4U9J\T->SPO<&O,/!(OKJ&#@?U589!1Y=R"Q<HMT&'
ME7(K'GEP5P2#&_HWIS/8+(#")."$@(WS,/'PA_TWYK;__)?W?V9.F]WJ#EJ[
MZ3^/P?X_CT&2X63_S)8[LRY&PX7U;[A`0)^&.R\+[/<7ZN;L>ZVO>O%A3]48
MG97HXX`@#)11H`@"E1C`3**3370V.OP2R)Y9&P_'!\&RRWXJ4%^Q^=U;U2H*
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M'GX5H%$$MS4UB#`N*Y"/$*`/9D,$13GQ&$%SGV#^`%%[B!I$S*(GP:4/4O*A
MI#]7P(4-AZ8%0>)M.R`W_7;7%1[6$]$^^92DKX_L4)X[ZB^>&+A(%ALS%?2V
M`YKP[JA#(4_OJ8[O[L0UA%^]0X'K9;NLI*L^M>LZ#^Q5^/XRMG<ROO2(7Y^7
MT?9V7X^7`;MEL6TGO'FXCI/K:F%KU^.I533_V.#D\>P*7O@.E`%.G-+><0MF
MR>&94V#WXL)Z%'=LA:UBWV<=4=[F+_)834_W#*-B//M5GNCI8">P!G&OXF2B
M_G@->IK$,+R'_PJ^G5C#QAO*`V0.[-P0ZC=V\7X?)"F=0LM]R$MQ(:_R7)GN
M+NA5G2PS?&HB.&G!K\1$5L%^SS6ASN6+1ZN*7NZ!).Z2D-Z/)(%E;^=I^/IN
M>K\&`W05'>;@"\KJ6707)X_Y#.GM\VG%3;I]P+OC'K-5-2QO*(Z]V%:L#SR,
M^'K.M'`WSC#XJ18")]'CR46GE3=3>B?JIGJO<.&)3(HV3PX2%H7QA(I:`)W<
M([9@X(!$@M55Q^PQ^IV]^&]//(.J47EFZR'`\5(@(N"5"6"&8P6Q-_X62H_D
M4I?6<.-4V@D]&G5QPY"S$7N2E+(\3^@K]#M]Z2E7FNVLI8L8&#K&%%)ZTLB0
M-"AOKF*ZWMB<.?7R>NZ4Y5VQIUX?9_PYF6G%H$):QJ'\M;\L:K2Y"8^$,#%@
M4BYGQ"4)L@9CTR=,LT8S)M7+JEE4EG7!H'H]G+#G9,*:.86D($/+W_A)F$;3
MZL@B1(*&*+F,EB02X`Q&D)LPPK,,/QKF:5QQ-4TJQ5TPA:N-$[)4K5CSY2PL
MH`Q]B=A;/VG#M[:..3)\:,AS$M/RQS&B<GJZ&>636FKIA!O;<]F;]!7Z8?TP
M5@=/##?:+,%I'UBJ&VOOHR2(>L5NRA9;+1S5H$.5RR3>8KQ+K\GO-XFC)YQD
MX>T>7^';3!+P#20:,5\I`<(M@SK!1'ZU(3VQ5/*C\B6B8$:5UXB^]X-9)JW/
MD<L<,DUV*21Y@MG@K#^&4?.S-#T&Y+>=Q"E=2+4])@G>71V3,+J?D]\\2!\6
MR3(@U0WVQ>=-$D1IL*WN.VCP$$QO@ZT`>D$X#?;]8)@/41V]?^AN9<2X4>I`
M3`DJM:!<#2KD4)R@0M/I4467'QX'#N><7X*F4--[==;/^SA?V*GPM4X26IV]
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M--DEE.$)9(:<`1GRMS![6-%<A[+X(3QLXFE$OO*S<FE-2RTZ5NFTN.&;6=T=
M,5%KO`5'-3I'U7<4L?E;SU;RM(68GMQ66-727JW-P"%8@KX_5_$AIDO+[Z["
M!&^)B73R$(3)8Q`IEPJ9"34<@4X(A/=F-8.AN=:6GM4:%2/VGH;@4PE4%O%L
M:ML0$AQQK:#4Y*E:F*>E)03[8^'D(<1W)+O>'K/PB3B.NW"+$R4%#20:_%-*
M@)#/H$XPS%,;TM-.)3]B+]'I+2I>>\8WD_;GR&8.FB;3%)(\S=PC34UD)Z.<
M!B:[^GLZ/OFFW+MVK!#6P8.-\BD`[@1[.GN=/!Y%W9)\[7!'5SD%T0Z]30^H
M!2.4#VRY!$I\//GQ<-BS;:/!?E%,6(RCW6E$[S0BWL!S*]GJ@>'FLMU/R;2M
M)\`1WA8F-6=5&FL:58NBLBPBA1$KW5CFX,'IDM;XB3LUJ^BT1U,=C6,;?40O
M_/G/5I:!8/SBYUC[1+;ZO&3'V![VT("N1R#5CVDS.9:JT8$>H`;-W4%]UL"/
M0^SL?S.@/4R]5KR'4^LLZI-?UE&<+".[K",]W=91%*S=UG%17M=QP=W7<8%*
MXZBPCDYS_<R^'YV%(=@.?PQ>:Y?#K1KHKR8.CK][S7[/SY,[+>OOE0-\:V=V
MOC!/Y?ZTSA?BJV!N%#'._EU<#6)E'*K#>=D8.3GU*>E09LI&3L)JAS3UX6*.
MOCJ8RJLR7'<P3XL$JS_X#?F+/"P?D?_1A),\^;]02P,$%`````@`(H1J18Q&
MQQ-F(```&1<"`!0`'`!P;'@M,C`Q-#`Y,S!?<')E+GAM;%54"0`#$"]A5!`O
M851U>`L``00E#@``!#D!``#M75ES&SF2?M^(_0]:S^O*LNQNM]TQW@F=#L6J
M18VD=L\^=92J0`K3Q0(;593%_O4+U$'6@1L@4:#]XD/*`YGX,@MGXN__>)FG
M!\\`YQ!EGUX=OW[SZ@!D,4I@-OOT:ID?1GD,X:N#O(BR)$I1!CZ]6H'\U3_^
MYS__X^__=7AXAD%4@.3@<77P\`0.OL"LB&;@X#-&R\5_']RBKP!7O[VZN[H_
M.(OP(\H.#RES"K,_?J9_/$8Y.""MR/+ROY]>/17%XN>CHZ]?O[Y^><3I:X1G
M1V_?O'EWU%"_JLGI;Y-BS=`F_O&H^F6;%`I$PXQ:&&]$IP+B?UV3AFPH^XW^
M^JXD/?[X\>-1^=LU:9ZP"(G,XZ-__7)]'S^!>;0AAG+BPU:[<_AS7O[P&L51
M47:GU),'7`KZO\.&[)#^Z/#X[>&[X]?$B%>D_PX.JA[$*`5W8'I`__[U[JJC
M<X%1$:7PY76,YD>4X&B1OAPF$2"`*AWS<[%:$$#E<+Y(0?.S)PRFGUY1RK=O
MCG]X\_'=&ZKS;QO6(ROU>;1(C@WUU[S6#5B8ZU\X4&^NW59Y'#_FAMHK5EOU
M.8JGQ@VHF"W=7R2F[J><]O8C"_.1DP:8XJ]A=H`!F(/8M!_:`NR:,GV>FS:B
M8K56;Z[=5CG,$33N@H;9L@FFVJT5%Z::"W?HMXG"M03;7&B<"JU5`U/5P%ZU
M\1<`:&"^/9S[6&G/P(P.UJ^C1Y#*F\"2E6+<$44'AA_IP/#X?=G*K@;[ICY0
M!VZ_O6TU[48O,,@!F='0T30=\W?:`%X*D"6;SJ1Z5(>_I8Y&2XKBCN"4CM\1
ME@/B]W,4+^>D@2=9<I$5L%A=95.$YV5[3Q[S`D?Q.L12:EXI1XN-_)J:I<YV
MI&];>_Y&$LOK&7H^2@`\HO;2?Y2&'[XYKJ<??R,_^OV$M"2AK;E,HUG/1N[O
M:V,8O^^VNMWO)[AK083C1ASYYZ#3N[.HFN)H$6$B[S!^@ND:+U.,Y@;]@>3V
MW;::?_#S@:J*@P(=,$0CG`#\Z=7;G77MV1)3;UW"/([2_P,1OLB2<Q*FC%Z6
MD;8ZG$\:7-\K6FT)`[Z6&A$?=X:(IMFW`$.4\.$@I&MA@4,7'!!4[+5$`4=%
M#8%W.X/``X[HFN3]:OZ(4D;7,W_?ZO+>[X/K:I%]EEW<$UUW[?N==6W5P$N8
M`GQ&P#5#>,7H8`%5JYN95,%UMMQ6RRYG*J@[_OC-CGO^#LP@;5Y6W$1S5EH7
MD0WZOD\6:.<+K772^WT-=??_M./>/R.-QE%Z1:92+_\+^)'/H1OT_X`N4`"(
M[76"@(&*&@(?=@T!-)^C[+Y`\1_W3\2=^619E!N.Y*O$QX,"TQ`<0J90D:+N
M"3>P$>IKOB+'.Y\=;&8JE^0G.0,Y$DK&#&%`&1Q&U&QV-$L8**G1\(,G,%2S
M%C4X,&BY@.C0!@X)OMU.0=%14\/BQYW#XH&(%2"A_6M&YU>_#K:_&=8YZN)*
M<I/ZUXOH1P,/79,?;'F!O3JDX6B%_1[.,CB%,1DEG\0Q6A*'9+-;E,(8@IRT
M&%P58-[/+?J,K55V54:#P&%:>+.</P(\F=XO'W.8P`@3-0Q[1&2MUK/)O$:,
M9D\@97L9L:.FBT8/7\<FBHBCI@#C>C]-X(C2"P7`.>AL8MF#XQ>8@KQ`&;B-
M5C3.&<#@D;1`,20)$!`2.ZW!,)2_66/U#X0SE)(^1YC8]PQ.,(ZR&2B7A3&:
MPJ*<!I`/?`S*XY\,E!CQMR"DR1\@OFP\9`T^3>6;4;U_9-XO%XNTG)/"HMZH
MH/,/UB=93-G^!O,H`\25FM76".*J:;#R^OV/[]_^.`;$W"YQ_!3EX&1.C7I`
MI^">V)U/(3T(<@=B0&*@'/FF(+F#LZ>"-1XR%]+"F8F0`"%H[2MK=)JT8`W<
M']\=CP.XUY!D8&)$EE31=C+#H$K3B,R4"ABEE\MBB9L1Q"DQ.)ED-Z!.XRP8
MNQ+9`K6]R``A[MB/UH"W;\\&_KM/V^T5GFF4/Y;2E_GA+(H6U3(/2(N\^4E_
MO:?^\>\GQ,X$IDLZIKD'\1+#@KCJXB5.EPE(+DF/D\_58EEY>3*]B'!&7)J3
M+U<YX*ER12]FMB*[[G3'L@.+HFUZUBJ<'#=L<[PBP)!J;?W<1GB"[PMZ?/9+
ME"Y!8R<G8#0X>^&@Q!DHV/6]X@3*2FHW:_0!`I5\QF(`DIR&Y7V4@LET4CP!
M?)+GH,B/.1A58^K!4\84*#*U?.$$E#*-FXGDAY_"!^5FQ07A_L!<F5X`Q1[]
M'J!0Y`'G`.PIVYR!#Q!V+4_T5VGNP#R"=)CR"_ESOIQ7@Y3J]\5FYZV'2WN!
M/>#:"`P4V<Y\Z`3Z-JW93!3'L$8BM/TA>DQ9NQ/J3*H;M373>,'9M0H9P=D,
M@*7F];*QHD9GYXB\+2><KM@"3EX@[_N_`XUNEQ[$&@,*AMWW@'$4[:2ISNX`
M6HQBZ!R5?I#N8Y!%&")!X`AI^V,/-FV`8%6QVAIF'"7]HU\>`$+/H$VFK<UK
M`4"$M#V`<&@#!(B*U=8`X2AI#K.\MC_S:?$)W[0J/\F2&T00O/[)`_E7'L74
M\/P70$]F\3[+9E+ZGUI=*<ZVO^M3DZ<0/3P!'"T`2?EQ?I7%""_*(R`H8]IO
MQMS>[M9@]A9>MKV,+!W5"T##YJPWOC6:,::#A[=3^!?`BIB4T;8AR*<-'G&*
M;G`,,+Y63XMFPJ1W7232W#:@8:2P%DWPN)&8O9V$U-)F>L[U&>!'Y']Y=3@F
MXI3>46?H#Q4$#/[1)[=&976)M<K&0QY7H]*J4JUI!#,6]HR;WL8^1W3156M9
M:,BFM+;39O./I1TLMTA7=[B.Y,%Q>XV6K^^T&VN%:/9B.CTA,%F4:9SD^#M`
MP@S&!4BJ>[_<+ZD67WM)78UOI#AE``>9^T,+;1O5ZQ2HIM+3F-_1DF"]!/5K
MEB]`#.EI7F'BE-+WEP;Y],XBK%;Q\!7QHXE'TXZ<(8WW*)&[&ZD9R`D%KOQU
M#`SECFE.LFX>H0'RWA]2L?J_314@`KA&6F.@+7E,-^N:!EZB)9:"8$C$P$";
M*#P(<$VT14!;\*@NL-7MFV3R)#"@871_BR:\WN<9:-OY+;GNASP^'"O<ZT/Z
M8QZ>@UEZ.ON!?/F\^8@'=XEWOI"KO1V.$YG:.W,[7:VCJ;2Q,"BTL7_+;A;5
M-R)Z"VLRG2Q`M7B>E[I6#Z1+3HF8/Q@?`V6>=ET..8_W(%5?2=3U@/%"HH*B
MH&?0IU$.<Y*:NHY8B3%HQMP++E7F0%!IY1,C>.IJ#/H(^SEX+-1`*:#L(9!)
M&1C<Y-9:88LIWM/<R0V0^JOO:J!2Y.H!3,H5&-CTO&`%/*DJ=RLXWH;.WT?.
M7L8Z;5S2\@C"K6*U$9"52/:XR%!D8!G%H?]<C*$,V^%N!N`G%Y4O:WI.1OEM
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M%>)R3+-)QKGT\RAGZ.%&Q!`.BI3--L642(&G`WPNAYI*8TREP>481I5E0X2F
M"$T8#?"%@T&6'4)T,\=[M13C)#EXJSX`IXGG2H8^'`@->DS2L4EEXJDRX0P/
M(DZA83%_XD;93D\]5"T^0SDWN3)I!B<=.C0!0$)DE38D>L+:E4@"S!/$&IB!
MY!1DY!_%;1IEE>67"-/_U#_/;U`6"W.)L9PAN'3EA`%`*^^8@%1789/;`@7R
M+48+@(L5-:]\;/#/)5S0`\_\2;D*R[`FKH`E`"1JV*P-.K'LH"=9VMO'VKO$
MZIO!'G!EM:UDL'7.@9[1KI*:^J`'^\V0Y`X\@VPIV:X7$W/&>GWBP!"I9+,5
MZ'@:@MYQ&9JNG.V4LUQP6)+::H4CEG3C+^<89ITM@S:C3?6/)Y^'CRP6C\<W
M;K)G,BB"Y$M$S[]+)U)2^L%[-ESZ,066H!^1OO'R$!OJZ[Y8P]73#`0"G0;U
MOD,J\W8QO7A`$#;<5(VWA9M`SQIN@3Y"<XVRV0/`<Z7<)B;N)W0.<7@P4S+;
M%F,\)4$/0&]!EE>GY\OMVUM$[`8%Q-6U]RRA/P#S18JJ9R<WJUTYTV^\=:#M
M:.DO';G6$EX@;-?1MA'DO'7[LN)%+Z_0^F]/*"4&Y719KUBI#^&5V/FC>0F[
MU\<KJS>-:!/)B)+>YP$9O<W#'=I+.1B/57(YQA3_:GV,3'PA#VNA\OY#E5RE
M0;^D*O.&890:1F?@V-3TBD.`RC77*/VP/VM!.FM`.FL_^P-"BQ&/"?(80YBP
MCY4YZ@;;+2N3OMBO?:J68?*HE\?Z_D!K)UBR>(-[#Z-9NK&P[>0ZB.DPYXG*
M8TWET>7>C2=W.8(4C!E_"A1?=<G0R?029A&9K$7I+<IAV??B-0@=5MXSCD)6
M[ZC4LG!P1EHO\:GH&AZ=WN;()2"'&RZ'.>H*=>WN=@M\%9_)43SU5WXF^?<R
MKQ:8'M`=B,G''I8WL.F+9G-PC7+R<WH7]A:C9TC,.UW]FH/D*JLK@F:SD[B`
MSU5/26YT;5%5_P[(5E2YJGE[#@B02`24X)\C7,"_FI)+90JZFB\BB.?#E08S
MYE857!UF[YEKJWA!EM[D'37>0IN;6KPZ;1W3,Q^?(YA1PR>TU?28Z^62YLFK
M[`[0DNGDDW!1[E$!<`=G3T7^ZP*17S7;6(P0<".P%1:V`K^)4''J=0_A8]M^
M[=V6CU5(96!&QCZ)[UE).V.L!V'93'2U3H6E_^$5LNQ]G!AX;L>1H-;"H.??
MEP@#.,NJA>AX];!Y/J))`;]F&)"1^%^;P7H/^28B>I&@)^*;B0P+SWJ*%+T6
M:Z^,CNLK(3Q15!\@NGA9$"I>W2H#"3K'SOH2OIG`,?>KI[C1:G#0%9.J9VRC
MG-ZPGU.#2E?SEGB%Q/U%70[Q-X-Z)6]Y`CBO;4%O>!/?D(]9#LY!]7?+&V?1
M`A91*EGETQ<PJ"JG+F!$;AJ6L51V$)]5ZAH6J_?D8``!9.4?3@)0;T>WE)^*
M?NT%MG&-\_A&BNZ@:R-:19@RQL7"]A;U&C[<41R(6Q3T4&YH=.\FG'((</BD
M:!_P[1VPQ9[9,H8'RO=LM-84HM7)U@P>*4P[/'L'4;Y'M@S/CN+`UY)HO5K&
M[&J]UJQ\<,!<4`_&)H)\E@>+`4CR2X+TWNU_WM*;G&-8'(S/X3VJ+?H=F7B%
M$]OZS>B5&..K7^9$+5I0A5%*PQR2T"]6GUZ]"?T:=,OJ\O36I#0ROW@!.(8Y
M=^-%F4\`9`[?'L)9Q4-;!S6G$<VX2AN_)$(>D7\$<QQ$/]"YUK$W<T%J7R^A
MH!&-3.](*S&,R<"$6J$\.&6S2<>G?;:Q1K\*#(1#5:%_]()?T!;QJ+7?AG6)
MF`\:-6+&-7B]C<J:"67YV5:R*[>R&'[B?<[,I/0_;KI2]@3L=M[;"O:UF[2N
M4?PN^%!X0"?QGTN(`;=JKB0*U`5P`D!%P)YA7]MG6X6]2FNT%]3&A7:.H_2O
M.Y@+4AOWN;ZJX,Q]F^UUOF>&-$.CVS1CC6K-XPPBR_4"5_&,0D^AZ6+WHKRJ
M]>Q]4M:Z1D:=<IFBK[(P5&'A7Z5DL'B'HI)%[</(V[]W);_U-VAIYS#R5EH8
M]`(:^Q7*6X`A2OH3,`[R340H/23*$Q%<9%AXR!+Q>IJ;M/TFR!I*WU_!W05J
MC1[#M8,K]TU<[92[*(%_D7D?_6\=J[\??T>K@E=VBU?]\7")5](:7/A&[,5T
M6EU>?(F?HFP&[HB')AG;`1S@FHCHH5=/1'`@MO"0)9+U-->`_K@O%4N4.L?X
MQ+EEU^CH=5\P*X".L3ZW8]E!)OJ#OOFJOE9451)>DI_5OT298+7.@5#C-4VV
MT'V)!3,O;B<NE-O2G/`V>'!F#/-1];1@'R6:0HW/*^YWE)AY<6=?#V&4?'`9
M)>%VH?IQI^UTFU"_<979/1R=[6S1WT1_T)<UU)%I_]W1%&I\TG"_OSMF7MQ9
M`A-^=]X'.CJ[7RX6:>FG*&W\=)5-$9Y'*@5T];C[&[^JW,$!W,POEDA65MJD
M]5W7$V>6*VR6=:ZRUK76ZKR?TJDW*QFMHH0&,OS#4A-FR(V[>#A5:TU3(-"@
M%9[&(TS<4@M3D*_O8$RF[9L9#)"J,;00*6,(%7Y:CG"#-9G*YNS**#)BV[;)
ME#2&CD+JJMQ7>;XD\V'`JB-IQ-O"FP9OJ-`S=8\;%&IH5[BIZ.+S[:<&>UXD
MW@JPGZ51GM?A3^P!5V1HQ7V.443;/T_`IG66$VCQJ\=^\:L3C.DF95GA;;4A
MJ8^/GWR-<%*GN"]D,@.2F^7\$>#)E'Q2H_2?RP@31*2K\D,\9VQ8[UYQ.QOM
M2+'W5"9&&?+8#9RLQVSP.L?MJ*$*"?(G_3<0M_$U=^*0ZJ@BWR'WR\<<_+DD
M_TS[SROY;83SB-9KQ+<4W1;=XR_2]1JM$/4?QA/U@V*50^><<ISSF1`6^556
MN:?\WWE4@,L(8M:9R%VJ[$?T5E4&%+^[<[UQM&ZUB0JQ^7'7L?F]NHJWN#!U
M@BZX-?0$?=C,[<"Z).7->[>IBE5QV[FJ<*)C!ZXV#:CM-$WA*_$^S*^$L;\N
M7A:PVDZN/JZNHY(GWU4H#N5_`_$G<>K.@V[8'I4EY(`C3326S;4&L[\!^@`9
M2$Z>`8YFH!DPW&(8\^Z>>6B!TE,56VI!8/'LI6.L(GY7+5;("3_L:4[@>;'\
MXTMUUJMRX;%IT!NHT(UJ+15[%+;FKMU:7&HU22'P?OS&`H^9OER'GE")J^#C
M*/D&PD_%O3L/0$ZC5(H_!QJ"S0$2D)PO\3KM5%-NO=?2S"4-BCH92`HH8JP=
M91P6)IJ;E4^#0^KC![C&BKRY("UXA[YF;^VF[8!;N*JO_E#XN`J?5P9=90EX
M`<D#*HW'.3WT7*RJ/T]>(&^E7H^YAV%5YE&ZYH$H/T?S"/(^97K,&JYI,WL/
M:4T`($O_<.):K17M0%?5;GKB/W5[G.-BODC1"H!?`-W-8!R^8!.TCDKT"4:-
M'$;_(P4[#="QT=0<5.AK\%164@B#DRRY01E0!86(G`$1-GG@@%'P@5/XL/4%
M?:'Y/GX"R3)M+J^<KLKAU(/@[5L%COZX5L3A'8(J]B#5\:[X9@=?4Z?P'5N#
M\0T-YF=K_(XV&H;:>5Y5Y>X'$&Z"_8$Z:3(E!L)GF"RC5#`+$-+V`IQ#&QKB
M5$RV`QA'@\(JHINHW_7RRA-*DW4$W:`"2`N]JS"QEDT$3/YAJ&85,OG&<J_W
MBU1V5D=$JO8FT?T&BZ<[D%;U-9[@X@%=9,2#*^%LWU"*+#G*I'C'JS@/BA*F
MEH,XT&5J%R91F5:50TO:9=E]0_P4T5VIZ3G$("8J\K.G".)YE#$GCGI,/0#+
MF,:'5T48(D/'J`)7W(PVI&7JMX+@4<P_SYX@F%Z\@'A)WZ:93*<P!EB(806.
M_C5J$<<^H%?=)>ZA*]2MLCWN`+=^*@[$<8Z0MYH#%Q'.8#:C[XTT&[0P/LF2
M<Y@N"Y"4KQF>PSQ.4;[$TH?.+*7U*\F;2O.6AGHG'#L7#";+(B\B$AK9K&<(
MQYEVPGJ^-!7F/:_90@HY=B@G]1DVLYT"39OGOJ"\Q_RCF6`T,\@(4H0$*&:)
MU2R!CC"ZA2]O:/E`,4Z9#VW(%*T?M0[SR%+UE-ZZ=*,DY"34P^?7V=2N]CG+
M3/J9C!YS^A;@X)ZHB*2UGSDD\1X*,C\C)>,XL.<(;W8FAT+'M+5=G98E`7@'
MX/QQ2124=T_N0`S(7"&9X.I?C,U&0^X64+2X0\&0N4O,X*6ES_3,W#:0=T>L
M)=Y_.@?/($5EI4]:]3.;P0R4)?(N7NA)5OH^*0-Y!MPMY&EQAX(\<Y>8(4]+
MGW8-ANYSY0]CJ)E-:S1.IG?$W(S_.B&+IK_8U:4)`5\JYNFCB"-5>]*E\+3]
MN-WJ9FW'O`.,]3>C];#?]+#HJ:UWQ=#7/P0Y,?J,R>CW%J,IY$V&&!2]Q-FA
M"`DU?-/,@=*1V5SB#O(MBLX+]!QP,&F&[ZFT:4("B,@\<XCTI!J_PSL.E*`,
M-8\655;5XTL>8F3T??3PZ8-"DJ+9%JCB:UAO=+_^^/[#3V&^C#/IVB;(20+*
MP;TB!F5(J)*;:HXGIFSC)Y9'`2$Z7FZ'B3A3R<C[8.*2!X4H-:,M8,55L,E2
M.CE*89+I$V*51U01UJ66`:RA#AI?3),=PJN1W_H&OC/X!(YAKM:L[-$5@,WB
MGCB)*?'T@";A"0EN.N:;@TZB1?N!U7'EM'H!D#?<ZO]Z`*;FUV'AAFF4#40:
M@6%?>@0ID3G[##*27E."]Y-D#C-([:6'&,6Y2(^Y?U=%D3DDE!DYQ!R#JNH,
MWNX69"R/1TP7_LZ8UC>=[P%^AC'@%,]*RQ:0?]%=EAC-,OA7\P1'^?#8M>1%
MK"UIZ1^I<JW%6_:J&PD2M@WB[*7'W/.A*K/W[+4M2"%+1_+.MKEM;CM;JC8S
MZ.]Y*.?B7)=L<(,;M6(/6]#%+1/A5)?W9*0SE-J!NRU&7MMIW2;UC"6!7-?M
M%I1'4.`0)Y(NQ]@L%]Z+5N)1LWXT=YY5^A.9N4`MX-H:VT$GT32"X*D.6-U'
M*<C%%S=Y=,P3;!VZL<)#<"538JP>*!C7+H?R@[Y.))G."X&EQ=L_]:/&&QX`
M39QB"TI%G9LK"N/<A!""38-39T,B7*#I.\069DH:>1]&KV6HMC&J1[M:29.6
MOG)H7>?0JFNK>/EGGZ&A/E_QU<W"%K8O;OI>D*<EPN/$WZ)\6<Z+^AIEQ#SA
M3$U(VU\@9]/Z6^9.$E@5#KF-8'*5G44+2'I$^'%6XNDO:HMYO*<(<1\B,^-Y
M"]$L79WE9+$.3Y=/7<UCYW.4E57P)/-8#MU@'CN@"P=,,B--`<20&VJ1P3M0
M$.-`TERJD4P;1,2#F0*;.!SX*)EKBB&>\*`70-8#'^%V#)-H4`^U2^3?I,&,
M@F<6;^HA(O0>%)Q.01KV<:NXMB5WW[092C3]^/K.HVM;>H&?"[9?E'AXX&'S
MA(0C!:O-(<46/I)'4]BSS3N0%QC&])@#'5F4+_;E-Z"83"\1G@)8T(O%/2@Y
MDM8J_&`E;3SP&R8IY-I;,G!>MX^R6*MN"I/LO.J3:P173Y:YQ7%7IALT-S+W
M&]-,S^T2V4T#`G^(\23Y]S(ORL)"#XBSP%":^CCT$OE4Y;!HEB*KY<5ZN9$2
M?(E2;C&57:D=+#=M6^W(H\Z3_[4"<W=M;&HKZ,?N2)Z:W-?Z"FH@-BBM($8<
MIZJ"=I'LD:"C^D2UBN#RYG,\.M9SZEVZ0)`BL]`(+0RA#6*TEP$698:ZR+S?
MU#/&S._'^X^:@8V.<6,(&Z(.%]Z!PW[HN?S2.GC06RY'[3UOD9Q08&GI(3/0
MZBMM[@`&.2_Z_D"]?T1;OTYO!&F5I^GUB]>,'M,WX&OY*_ZBOPZS#G9;S/N`
M5YXOW&.TI<FX2N"(<5E^6PQAR>;5&"+L#2B%GG`^%!A",M0#`?TG/$7X8Q)*
M'TH-"UDB&\UAU)-J7,=R//-G<^#P9]#[!!U'<V@!>(*>1-=&UP\"=RR4/M^L
MP<L[G2'F'0_HE&QD'=[0>L9901GS$$?W;K6;,T$^O2T\\=*^`J-PXEWF;):N
MSH44M@XG)V3\7&N8/L_]76BXC"`N1V[JSU6JL/3RBYC%XZ'S[!G@`I)H/0>/
M!:N5'!]H<`X.IBMP>@]]I3Y&-O[@Y`&1XNY1=@6%.WJYV5O:^)XUQF+\`^G$
M4Z+S#PWK!SP*YK=X@LL1.CZPS`X25>[J;?D)?9@CZ/$2Y!5)O1F1O=IX5UKU
M2\HQ*%DCX/!8L*=NU?#I.A$)S[:Q/$(G[QRD9""WM@!70?<.<ENP=L7C,3T3
ML#;EDA;B>`+)9X3J(Z2T?@)^Y@XL-3AYJ!)Q!@LV97<XPJ!(7]";+6L+[Z*O
MOY`Y-X91JH=,*2,/F`+&8'&IZ@Q'L!2H"_YY[=K$W\@4#9RCK_P">#Q"'NY:
MA,'BC&>L(URUQ)N^)#R20Z\;DQ#^XRJ[Q2@&N5Z"DW-RD2;@#!=ZJNYPA46!
MOF9)W462\S1W^SYM&X/EL@4;%1:Y[6-:KC$-?[D#',4]4U'P2S7%]WCW6*1]
MW;ZS)<;-SJPL]G79N:749>RAY01#Q]CE!W6EH>>*37T[?Z_.!'4"96SWI#<'
M(^F?41:#LMHBQUTN1)K<;^:*])Z.C(_W.'2EJ\-`=DTR?]![#&LYK3ISMQ&>
MX-)YU0'A6X#+P^O<<Q7*G/R"?WS.<!&N[QA70%;2;'SQ=22K1BTCJ[L5)\OB
M"6%:-E>.5!X''Z%#CKU`IL016T#D4&.#1.U[!R-!HOA6&K->35V5QO`*HII(
MK<N(,I'A@MVA*]V=.K9IDLH1N5#G4[F_M9=AU]V@0K;\HL8DO1S291K131C:
M,/456&U^)<>,<VU6L>>%%VO4O,/-.J(&B&_><!4'GS^`O_RQ?,S!GTMBT05=
M\Y(=KI61]T.#2^XO6_2:),T.,GJ)R:.*?EGO(7V[>7'.4=6)<+Z*O3Y03PL\
MC`7^WUJ\"^NN"TC%AH[E$5J+`->YKZ@?V[5TA;#^^&8\8+F65;27D(M!<SVF
MZO8B,/!!P[-8#3C#XN1<Z0K`>>O@>^`?<@]$GZ@BOIA:DJ76U*'BC6.O&[AM
MA"N./IS6"A_4ECW!.,IFY0K-Z6I#<ANMRI>[::WHNFS4%Y`7S:MKDRF9*T7I
M/Y<1)O!.5U=9C$L9^<;:M%\JPF\C^M7(=]R(L<7",*>BD?206IA=,VN?[[C=
M"A'\(=#OA1-OWBSI8TJ3*?.M@5VH8M5N=:XJB-#>H;<-`GB[K5,(T_>!ANEP
M;"%\PU-*+Q_:>7_+L]<FX4MY0EJQK:-Y)T_>9_R1K,Y3>5P]@L%L(W]'"VGC
MZ@5>V2#5(%/OAW[1(($&K4D%?V&R_@W]@^9:\I/_!U!+`P04````"``BA&I%
MZ&B"J!4)```"20``$``<`'!L>"TR,#$T,#DS,"YX<V155`D``Q`O8500+V%4
M=7@+``$$)0X```0Y`0``[5S=<^*V%G_OS/T??'G:SI00\K&=9#;;<<!D/25`
M@>2V3SO"/@9-C>65Y`3ZU]\C&0<;;`,)VY(I+QM+.D<ZYW<^],E^^F4V]8TG
MX(*RX*92/SFM&!`XS*7!^*82B2H1#J450T@2N,1G`=Q4YB`JOWS^SP^?_ENM
M-C@0":XQFAO#"1B/-)!D#,8=9U'XD]%CS\#C5KMO#XP&X2,65*N*>2;<:^%,
M8$H,%"$0US.?!G_>5"92AM>UVO/S\\GS^0GCXUK]ZNJJIELK":EP\PC/3D_K
MM=_OVP/=[9*8;B:NTD"IZ$#"M2;,;,3]A/&\III'1+R0JU97OC"DB2]K<6-"
MRL$K[/AC#5L3PH`%033-IW4EK\EY"#4DJB(5<.J\\&UF6F&`L3)BH517-<Y\
MY(K)TBK3$HA6$9WY)<2_MU/F#?U9AC3D3!*?SDX<-D7R^L7IU?EI0NP"S<(N
MP#D9LZ<:-FCBZFF]>EY/R-&EQX2$+RP>$2,MQJ(APT*DY'0426@Q/FV"1R(?
M;1P%WR(4QZ,*"_!A"H',$*2:)>%CD!TR!1$2![90"V/#,'1TD"!``HF!J>N2
MVC"D@<<655BI7/$Z\<<^>(8.E6MEZ)N*H-/05R;0=1/M>PAO-1GN:\CA!)%)
M*)2A2\RD_0!9!*JL)6LOQTVZ(-Q9ZV4MDK$3%@*7%$0JEFK[TLHA_JY:(8L3
M^8>LE`O>KDHA"PWH`>ODD]&N.B$+^-]7'=7/$!4PU,=#WRX.VS@@4".7`$Z3
MU(WUTZ673I-NE];XC)./436:S(E4]DA_XCQK6(&D$N=,C',^U2[YJ;;:PVKG
MD0"W&WS6WZL1NN!>D)1QKD3!]HQ93\OG6]0FZ+X==,<9B27HNE0.^ADB/4!<
M8(%ZH]MI6IV!U51?@V[;;II#+-R:;;/3L(S!%\L:#H[8YV,O&$N#KXKEZ)]O
MA_Y@B'_NK<YP8'1;1K=G]<VAC01'.Q3:(5PQ1+C!$A=OLX3QH4<X<DY`4D3K
MQZ-EBBSC4%R.NEGK+.K*+72YHX64@1I?S,Z=-3#LCM$P>_;0;!M-JV4W;*O3
M^.-HHW(;A7E&VA1''_=MI6-D;6TU;\5@W@9;_?R:G-<P!U^,5KO[O^/LDVL)
M05)QHPIE-JC'BUXJ')^)B(,RB'W7L='Y38P-L]'H/G2&=N?.Z*$Y,"".H.>"
MGMIHE.\RZGK!FP'<[CRB;W?[1W`+P/6>IDMX5:$<X/-5@%NFW3<>S?:#9=Q;
MYN"AKY/)$>O<["%3R4-N0/IB+7<,NXU?C6'?[`S,QG&'4):CLTFZ/$N?[9RE
M<='"?.K,CZN5_'2=\G):[N7GI0G;^#`D(Q_$$><B/W?K&4?'8AG:%Z>[KTB,
M#TV0A/I'(Q0XNV`TO>%=E,O-D)-R,FZO[NC<R`>#>88=/"&.C,^-!IN&+,""
M^/%HE4T3K9N>:3?9XR(G+-8FVR/F&Q>2;F8EN0GU\W74\Q>31^0W>#NDG!TV
M+"LOUSS]X79@_?:@<+94#CJN*@M`3J<4V.3<ESDI917H?X5??ZJMWN(O:K*W
M_?JNG^($QZ41Y#X?*'J0$C^J:3-'=U;"HDK5A*^JJJKUL^IY_02'3NY$R\7(
M?^:RI0`)@QKY<OLQ"Y[,;#FHIE8C?JR>GE7/?G[EN/G/;[:1(<W9B1F5.%<*
M^OK'-XOS.E'V)4?.6Z%M!/$YSW#M19#T`Z3=0B+A>U5(%#YMVEX&__6Q6/3V
MJ6#P7![U45TR;R]!Z5.J,@ER&6O@2Y'4E,FS>(&E!;JI=.4$^!U!&[:9$+!\
M'O!UO25^HZ+?L5U/<2<A"9_;$J8J6Z/$T4A(*B,EKW[/F)!2)*D8`?5]M1N_
MJ4@>(3E!:DX<>5/QB*\?!FKB$?&5+]U4'`ZN.@F(JT,,..8.M0!NQ#4H)5K=
M<8+;'#-P^T"GHX@+W2CZX`!]PDF'QU]*GJ7".S&]'RSZ.-D3[DR:\`0^"U4+
MZF@%8QH`]A2,K5D(@8`.+,]=ON[$]+=BX<+HU5`,)H3#+<[>KMH+H_R:`765
MF,XQD0XD<_XTGPEW!2K6]5J,>X"B\W1<O*F3]^,V;U!3L^X'L:2K-&Y"U^T;
MM1WA:0*NHAVJR<PI)GCZ5_P=N"9F2VE/0T*Y8ECBL`O/NXDI-4.H":*K5(HP
M7[:BP`775O8-P4%S6M/09W.`/AU/I'@(E>DEY9`%YZW]O)_(L@-DQVBP<2]$
M1M2GZG4E^GPO?FHY[^$@.MM^BVB8!>D5K.\'EP81$Q^$L&;`U7.2KJ<30S=4
M?*ETLHGNW81.AZ@<U_6ZR*=I17PO-(29O/51I:7.6Y#&:L<_@KB62?T_G"9Q
MRS8"CA;"P:E+":?IB2&_-6T_&D@8`_^'M;BGZ&\27:E'YMF`7&]Y-][78&HL
MINB>P.2X^!WK9LPE'I5ZXNUA@('^A5(J^G9C6W@ENF08UWY/4\8[45FVJHG"
MT)_C,F1*I98:^!^XT$VM58H(#B2/;E:Q%^&Z'>>(>!H=LEL8H*V$^GW-D"TV
M,_K!O`]N/)4NM7\-[[L!IDT=M67!Z3$VLCGF$+LND_@O)7XK4EEV$<IZP=H-
M<$4:NW8*IK?W]&ZRQ``UQ;S,AL_L'E2V3H7*>E-F#G+9%-=T>]`J+K]-_`E:
MJ%"!=./!J=!;7"?<*D%Q]@\!AW<$+@49#UG,OJK9+CR'I[!'_\(IOU2_8I+#
M4V=AB[9TB\R4:CHX\9-=UZKLJ_4')WCR"S%];J5^'Y;Z>9BY&""U-]^*.G,,
M(=4YV&$8!Z7NX"RRP53Y5`=GN"0MMUC$BU)VNNU@%>@&A5-.JNGPQ*?C@'K4
M44<)CJ,6@NCG>KN)V[,V#4")ES[>VY+^T(*G5.YA]FY@&]I7Z.?*Z\E<;8RB
MD4;I>VF:.A_1]QLO)Z_Z*'7-2;<C/SS'5>*-5L^94WO4V_F29+$VU\?."UT?
M45%PDT,)2_VW!+]%A$O@_ER?O.G[H)5S[;]AO,,[$-F/YCT]:+'FZE@(OD7X
MZ<_WC?IN8Z<MD,!S""98NU19A^&V`(;XMM,.8B!TJ4DDM`CEC\2/8-/US3Y'
M.I`CA&U05_M]74'\KN?IJU!U#*`RIBU$I(9H,)')$MNS'"0.\7.K^#T"%O\/
M4$L!`AX#%`````@`(H1J19<#)D`I.```GRX"`!``&````````0```*2!````
M`'!L>"TR,#$T,#DS,"YX;6Q55`4``Q`O851U>`L``00E#@``!#D!``!02P$"
M'@,4````"``BA&I%-)S@5K\*``"?C0``%``8```````!````I(%S.```<&QX
M+3(P,30P.3,P7V-A;"YX;6Q55`4``Q`O851U>`L``00E#@``!#D!``!02P$"
M'@,4````"``BA&I%5[9P3LH/```!Y@``%``8```````!````I(&`0P``<&QX
M+3(P,30P.3,P7V1E9BYX;6Q55`4``Q`O851U>`L``00E#@``!#D!``!02P$"
M'@,4````"``BA&I%P`[_PG!4``#&Y00`%``8```````!````I(&84P``<&QX
M+3(P,30P.3,P7VQA8BYX;6Q55`4``Q`O851U>`L``00E#@``!#D!``!02P$"
M'@,4````"``BA&I%C$;'$V8@```9%P(`%``8```````!````I(%6J```<&QX
M+3(P,30P.3,P7W!R92YX;6Q55`4``Q`O851U>`L``00E#@``!#D!``!02P$"
M'@,4````"``BA&I%Z&B"J!4)```"20``$``8```````!````I($*R0``<&QX
M+3(P,30P.3,P+GAS9%54!0`#$"]A5'5X"P`!!"4.```$.0$``%!+!08`````
..!@`&`!0"``!IT@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGZBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (26,946)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (3,357)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">161<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">895<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">522<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,558<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">43<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">103<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="num">(8,010)<span></span></td>
        <td class="num">(5,747)<span></span></td>
        <td class="num">(21,474)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(16,905)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">(47,694)<span></span></td>
        <td class="num">(16,706)<span></span></td>
        <td class="num">(47,694)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(16,706)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,551,098<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93,489,809<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,834)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(1,667)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">113,800<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">64,768<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">94<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares)</a></td>
        <td class="nump">93,663,064<span></span></td>
        <td class="nump">93,552,910<span></span></td>
        <td class="nump">93,663,064<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93,552,910<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Additional paid-in Capital [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">184,345<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">180,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">161<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">895<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">522<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,558<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">43<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">102<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">185,071<span></span></td>
        <td class="nump">183,700<span></span></td>
        <td class="nump">185,071<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">183,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Accumulated Deficit [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(211,385)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(183,595)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures of 1,834 shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees (includes net exercise)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(21,474)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(16,905)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">$ (232,859)<span></span></td>
        <td class="num">$ (200,500)<span></span></td>
        <td class="num">$ (232,859)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (200,500)<span></span></td>
      </tr>
      <tr>
        <td colspan="6"></td>
      </tr>
      <tr>
        <td colspan="6">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents amount less than $1</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
        <td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>NOTE 3 &#150; FAIR VALUE MEASUREMENT</strong></p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into <font>three</font> broad levels, which are described below:</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">Level <font>1</font>: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level <font>1</font> inputs.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">Level <font>2</font>: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">Level <font>3</font>: Unobservable inputs are used when little or <font>no</font> market data is available. The fair value hierarchy gives the lowest priority to Level <font>3</font> inputs.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;">&#160;</p>

<p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt;"><font style=" color: rgb(0, 0, 0); font-family : Times New Roman; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The fair value of the convertible notes as of </font>September 30, 2014 is approximately $<font>59.4</font> million based on a level 2 measurement.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>45</ContextCount>
  <ElementCount>112</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>13</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-daei</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccbs</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsoo</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsoop</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocisecd</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocisecdp</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-ccsocf</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-i</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvm</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-st</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapp</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-it</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-sapd1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-isoicd</Role>
      <ShortName>INVENTORIES (Schedule of Inventory Components) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-fvmd</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/plx-std</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20140930.xml</File>
    <File>plx-20140930.xsd</File>
    <File>plx-20140930_cal.xml</File>
    <File>plx-20140930_def.xml</File>
    <File>plx-20140930_lab.xml</File>
    <File>plx-20140930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
